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a different interpretation of this secosteroid hormone is needed. Today the term 
“vitamin” may be considered outdated. This compound may be correctly be called 
a vitamin only when it is administered to humans or animals that suffer from its 
deficiency. This book attempts to clarify the role of Vitamin D deficiency in many 
pathological processes in the whole organism. Chapters in this book cover such issues 
as the earliest clinical and preclinical investigations of the consequences of Vitamin D 
deficiency for cognitive, cardiovascular, metabolic, immune, and renal disorders.
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Preface
Vitamin D is one the first hormones, or even the very first hormone that was
produced more than 500 million years ago. During evolution, compound D progres-
sively participated in several biological processes. It is now widely accepted that
Vitamin D is a steroid (more precisely, a secosteroid) hormone. Many preclinical 
research and clinical studies demonstrated that hormone D plays several physiologi-
cal key roles in different areas, and that its essential function is not limited to bone
growth and maintenance, as believed in the past. It was demonstrated that its defi-
ciency causes several detrimental effects on our health and these problems can be
addressed by means of Vitamin D administration. Thanks to the anti-inflammatory, 
antiproliferative, and antibacterial activities exerted by hormone D, it is very
effective in the treatment of several systemic illnesses in the field of endocrinology, 
immunology, oncology, hematology, neurology, and reproductive medicine.
This book is organized into four sections: Section 1 “Vitamin D Deficiency in Children
and Adults”; Section 2 “Vitamin D Deficiency and Brain Functions”; Section 3
“Vitamin D Deficiency and Metabolic Diseases”; and Section 4 “Vitamin D Deficiency
and Chronic Diseases”. Chapters in these sections cover the earliest investigations of
hypovitaminosis D in children and adults, the consequences of Vitamin D deficiency
for the cognitive functions of the brain, and the implication of Vitamin D deficiency in
the pathogenesis of cardiovascular, metabolic, immune, and renal disorders.
An important theme developed in Section 1 is Vitamin D status in children, adults, 
and pregnant women. The different ways to improve the status of Vitamin D 
deficiency and distinct strategies for it in young and old humans are discussed in
several chapters of this section. The exciting role of Vitamin D deficiency in brain
disturbances is discussed in the chapters of Section 2. An important future direction
for study of Vitamin D deficiency implication in the metabolic processes is a section
on the beneficial effects of Vitamin D in obesity and diabetes mellitus. Finally, the
last section of this book promotes the understanding of implications of Vitamin D 
deficiency in the pathology of renal, autoimmune, and cardiovascular diseases that
may help to find the best strategy of therapy for the patients with such diseases.
The book summarizes the meaning of Vitamin D deficiency in the development of
various chronic diseases in humans. However, many questions still remain and will 
likely fuel ongoing investigation and debate. These questions will likely keep the
story open on pleiotropic effects of Vitamin D for the future.
Julia Fedotova, Ph.D. habil.
Professor,
Laboratory of Neuroendocrinology,
I.P. Pavlov Institute of Physiology,
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Vitamin D and Its Deficiency in 
Saudi Arabia
Fawzi F. Bokhari and Mai Albaik
Abstract
Vitamin D is a hot topic that has attracted attention over the past 10 years, 
especially since a large proportion of people suffer from this nutrient deficiency. 
Vitamin D deficiency is estimated to be about 1 billion people all over the world 
and 50% in Asia and the Middle East. Saudi Arabia has also demonstrated a high 
prevalence of vitamin D deficiency among healthy Saudi individuals. This chapter 
provides, in detail, a clear and understandable identification of vitamin D, its 
function, source, synthesis, metabolism, status, and deficiency. The chapter also 
focuses on studying vitamin D deficiency in Saudi Arabia based on PubMed’s initial 
research criteria.
Keywords: vitamin D, function, synthesis, deficiency, Saudi Arabia
1. Introduction
Vitamin D, “sunshine” vitamin, is a vital topic that has attracted great attention 
of many researchers and the public over the past decades, because a large propor-
tion of the world’s population is deficient in this nutritious element [1]. Vitamin 
D was first discovered at the beginning of the twentieth century in children with 
rickets [2].
Vitamin D is a prohormone steroid and belongs to the fat-soluble vitamins. It is 
responsible for endocrine, paracrine, and autocrine functions [1]. Vitamin D is also 
essential for calcium absorption, bone mineralization, calcium and phosphorus 
homeostasis, hormonal release, nerve conduction, and neuromuscular function [3, 4].
2. Function of vitamin D
Vitamin D is known for its crucial role in bone health about a century ago. 
However, it has also demonstrated its role and effectiveness in extra-skeletal roles of 
vitamin D during the past two decades [5].
2.1 Vitamin D and bone health
Vitamin D regulates physiological functions by controlling the metabolism of 
calcium and phosphates, stimulates growth, and promotes the necessary remodel-
ing of bones and teeth [6]. Vitamin D deficiency is often associated with bone 
disorders (such as rickets, osteomalacia, and osteoporosis); when serum calcium 
decreases, the thyroid gland immediately releases parathyroid hormone (PTH), 
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which acts by stimulating bone reabsorption and reduction of calcium urinary 
excretion [7].
Vitamin D levels are positively correlated with bone mineral density (BMD) [4]. 
Many observational studies have reported relations between chronic lower vitamin 
D concentrations and poorer lower-extremity function, lower muscle strength, 
lower contraction speed, and lower appendicular muscle mass [8]. Vitamin D 
deficiency can put people at risk because of low bone mineral density, osteopenia, 
osteoporosis, and tooth loss [6].
2.2 Vitamin D and non-skeletal diseases
Observational studies have shown associations between the low concentration 
of serum vitamin D and increased risk of cancer, cardiovascular diseases, disorders 
of glucose metabolism, neurodegenerative diseases, and mortality [3]. Vitamin D 
modulates a variety of processes and regulatory systems including host defense, 
inflammation, and immunity and repair, especially patients with lung diseases 
often have low vitamin D serum level [9].
The biological effect of vitamin D on cardiac function is through reduced remod-
eling and fibrosis secondary to negative regulation of renin by vitamin D receptor 
(VDR)-linked gene regulation and through reduced cardiac metalloproteinase 
activities [10]. In addition, many indications support a relation between hypovita-
minosis D and slower nerve conduction and poorer executive functions [8]. VDR are 
also expressed on immune cells (T and B cells, monocytes/macrophages, mast cells, 
and antigen-presenting cells) [10]. Moreover, vitamin D may exert positive effects 
on oral health by affecting the production of antimicrobial peptides [6].
Furthermore, many studies have demonstrated that vitamin D supplementation 
has a beneficial effect in decreasing the mortality rate under multiple factors, by 
influencing the cardiovascular system, immune system, tumor progression, and 
others [11].
3. Source of vitamin D
The main sources of vitamin D are our diet, supplementation, and sun  
exposure [2].
Two dominant forms of dietary vitamin D are vitamins D2 (ergocalciferol) and 
D3 (cholecalciferol) [12]. Vitamin D2 is produced by plants and invertebrates after 
ultraviolet radiation exposure [13]. Vitamin D3 is naturally found in many foods 
(such as oily fish, egg yolks, cod liver oil, cheese, mackerel, salmon, tuna fish, and 
beef liver), fortified foods (margarine, breakfast cereals, dairy products, orange 
juice), and vitamin supplements (both vitamins D2 and D3 are available) [1, 14, 15]. 
Dietary vitamin D provides only 10–20% of circulating levels of vitamin D [13].
The chemical structure of these vitamins (D2 and D3) is similar but differs only 
in their side chains (Figure 1). This structural difference modifies their binding 
to carrier protein vitamin D binding protein (DBP) and their metabolism [16]. 
Vitamin D3 is significantly demonstrated more effective than D2 in increasing serum 
25-hydroxyvitamin D [25(OH)D] concentrations due to several reasons including 
reduced vitamin D2 binding and metabolites to DBP in plasma, a non-physiological 
metabolism, and a shorter shelf life of vitamin D2 [13]; therefore vitamin D3 is 
considered the preferred choice for supplementation [14].
Sun exposure is the chief source of vitamin D via the synthesis in the skin through 
the action of ultraviolet B (UVB) radiation on the precursor of vitamin D3 [4, 17]. The 
Commission Internationale de l’Eclairage (CIE) described the efficiency of vitamin D 
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radiation as the efficiency of each wavelength to synthesize vitamin D in the skin. 
The CIE suggests the efficiency of UVB radiation that covers the spectral range 
(255–330 nm) with a maximum at about 295 nm [1]. A whole-body exposure to UVB 
radiation inducing the light pink color of the minimal erythema dose for 15–20 min is 
able to induce the production of up to 250 μg vitamin D (10,000 IU) [1, 6].
4. Synthesis and metabolism
Vitamin D, either endogenously produced (vitamin D3) or ingested (vitamin D2 
or vitamin D3), must be activated in order to produce its effects [5]. This biological 
activation is performed in a multi-step process (Figure 2).
Firstly, UVB radiation penetrates the epidermis and stimulates the conversion of 
7-dehydrocholesterol (7-DHC) into pre-vitamin D3 [18] which undergoes thermal 
isomerization through a sigmatropic hydride shift into vitamin D3 [13].
Secondly, vitamin D2 or D3 is specifically translocated by DBP into circulation 
and then to the liver for hydroxylation at carbon-25 to form 25-hydroxyvitamin D 
[25(OH)D] mainly by two cytochrome P-450 enzymes (CYP2R1 and CYP27A1) [5]. 
Figure 1. 
The structure of vitamins (D2 and D3).
Figure 2. 
A diagram illustrating the different sources and synthesis of vitamin D.
Vitamin D Deficiency
4
which acts by stimulating bone reabsorption and reduction of calcium urinary 
excretion [7].
Vitamin D levels are positively correlated with bone mineral density (BMD) [4]. 
Many observational studies have reported relations between chronic lower vitamin 
D concentrations and poorer lower-extremity function, lower muscle strength, 
lower contraction speed, and lower appendicular muscle mass [8]. Vitamin D 
deficiency can put people at risk because of low bone mineral density, osteopenia, 
osteoporosis, and tooth loss [6].
2.2 Vitamin D and non-skeletal diseases
Observational studies have shown associations between the low concentration 
of serum vitamin D and increased risk of cancer, cardiovascular diseases, disorders 
of glucose metabolism, neurodegenerative diseases, and mortality [3]. Vitamin D 
modulates a variety of processes and regulatory systems including host defense, 
inflammation, and immunity and repair, especially patients with lung diseases 
often have low vitamin D serum level [9].
The biological effect of vitamin D on cardiac function is through reduced remod-
eling and fibrosis secondary to negative regulation of renin by vitamin D receptor 
(VDR)-linked gene regulation and through reduced cardiac metalloproteinase 
activities [10]. In addition, many indications support a relation between hypovita-
minosis D and slower nerve conduction and poorer executive functions [8]. VDR are 
also expressed on immune cells (T and B cells, monocytes/macrophages, mast cells, 
and antigen-presenting cells) [10]. Moreover, vitamin D may exert positive effects 
on oral health by affecting the production of antimicrobial peptides [6].
Furthermore, many studies have demonstrated that vitamin D supplementation 
has a beneficial effect in decreasing the mortality rate under multiple factors, by 
influencing the cardiovascular system, immune system, tumor progression, and 
others [11].
3. Source of vitamin D
The main sources of vitamin D are our diet, supplementation, and sun  
exposure [2].
Two dominant forms of dietary vitamin D are vitamins D2 (ergocalciferol) and 
D3 (cholecalciferol) [12]. Vitamin D2 is produced by plants and invertebrates after 
ultraviolet radiation exposure [13]. Vitamin D3 is naturally found in many foods 
(such as oily fish, egg yolks, cod liver oil, cheese, mackerel, salmon, tuna fish, and 
beef liver), fortified foods (margarine, breakfast cereals, dairy products, orange 
juice), and vitamin supplements (both vitamins D2 and D3 are available) [1, 14, 15]. 
Dietary vitamin D provides only 10–20% of circulating levels of vitamin D [13].
The chemical structure of these vitamins (D2 and D3) is similar but differs only 
in their side chains (Figure 1). This structural difference modifies their binding 
to carrier protein vitamin D binding protein (DBP) and their metabolism [16]. 
Vitamin D3 is significantly demonstrated more effective than D2 in increasing serum 
25-hydroxyvitamin D [25(OH)D] concentrations due to several reasons including 
reduced vitamin D2 binding and metabolites to DBP in plasma, a non-physiological 
metabolism, and a shorter shelf life of vitamin D2 [13]; therefore vitamin D3 is 
considered the preferred choice for supplementation [14].
Sun exposure is the chief source of vitamin D via the synthesis in the skin through 
the action of ultraviolet B (UVB) radiation on the precursor of vitamin D3 [4, 17]. The 
Commission Internationale de l’Eclairage (CIE) described the efficiency of vitamin D 
5
Vitamin D and Its Deficiency in Saudi Arabia
DOI: http://dx.doi.org/10.5772/intechopen.88745
radiation as the efficiency of each wavelength to synthesize vitamin D in the skin. 
The CIE suggests the efficiency of UVB radiation that covers the spectral range 
(255–330 nm) with a maximum at about 295 nm [1]. A whole-body exposure to UVB 
radiation inducing the light pink color of the minimal erythema dose for 15–20 min is 
able to induce the production of up to 250 μg vitamin D (10,000 IU) [1, 6].
4. Synthesis and metabolism
Vitamin D, either endogenously produced (vitamin D3) or ingested (vitamin D2 
or vitamin D3), must be activated in order to produce its effects [5]. This biological 
activation is performed in a multi-step process (Figure 2).
Firstly, UVB radiation penetrates the epidermis and stimulates the conversion of 
7-dehydrocholesterol (7-DHC) into pre-vitamin D3 [18] which undergoes thermal 
isomerization through a sigmatropic hydride shift into vitamin D3 [13].
Secondly, vitamin D2 or D3 is specifically translocated by DBP into circulation 
and then to the liver for hydroxylation at carbon-25 to form 25-hydroxyvitamin D 
[25(OH)D] mainly by two cytochrome P-450 enzymes (CYP2R1 and CYP27A1) [5]. 
Figure 1. 
The structure of vitamins (D2 and D3).
Figure 2. 
A diagram illustrating the different sources and synthesis of vitamin D.
Vitamin D Deficiency
6
[25(OH)D] is an inactive and the most abundant circulating form of vitamin D, and 
it is generally measured when assessing vitamin D status which has a circulating 
half-life of about 15 days [2].
Thirdly, 1,25-dihydroxyvitamin D [1,25(OH)2D], the biologically active form of 
vitamin D, is generated through second hydroxylation that takes place in the kidney 
[6] by the enzyme cytochrome P-450 (CYP27B1) monooxygenase 25(OH)D-1-α-
hydroxylase [13] [1,25(OH)2D], which serves as a hormone to regulate a variety of 
cellular functions in other organs or acts inside the kidneys in an autocrine and/or 
paracrine fashion [5]. Several factors regulate the levels of [1,25(OH)2D], 25(OH)
D-1-α-hydroxylase (whose hydroxylation is activated by PTH), calcitonin (which is 
inhibited by serum levels of calcium), phosphorus, and [1,25(OH)2D] itself [19].
Finally, [1,25(OH)2D] enters the cell by diffusion and binds and activates the 
VDR [20].
5. Vitamin D receptor (VDR)
VDR is a member of the nuclear hormone receptor superfamily and acts as a 
ligand-inducible transcription factor as well as its non-genomic actions outside of 
the nucleus [18, 20]. VDRs are present mostly in body organs such as the colon, 
small intestine, bone, breast, brain, pancreas, pituitary, and muscles [12].
The widespread distribution of VDRs and production of calcitriol may interpret 
the increasing number of diseases related to vitamin D deficiency [12]. Binding of 
calcitriol to VDR prompts the transcription of vitamin D-responsive genes (at least 
913 genes) involved in cell proliferation, differentiation, function, and the renin-
angiotensin system [2, 21].
VDR forms a heterodimer complex with the retinoid X receptor (RXR) capable 
of binding to a vitamin D response element (VDRE) in the promoter region of a 
target gene and thereby regulates transcription of more than thousand genes [20].
6. Factors affecting vitamin D synthesis
Many factors affect vitamin D synthesis and its concentration [1, 3, 6, 11, 
17, 19, 20]: aging (age decreases the capacity of the skin to produce vitamin D 
due to lower availability of 7-DHC), season of the year (autumn and winter), 
weather conditions (cloudiness), geographical locations (higher latitude), sun 
exposure, sunscreen (with a protection factor of 30 reduces above 95% of vitamin 
D synthesis in the skin), skin pigmentation (darker skin needs 3–5 times longer 
sun exposure to synthesize the same amount of vitamin D than light skin since 
melanin absorbs UVB radiation), genetic factors (SNPs and mutations), skin 
damage (burns decrease its production), adiposity (obesity has reduced vitamin 
D levels), workplace (indoor vs. outdoor), lifestyle, physical activity, clothing 
habits, air pollution, smoking, diet and calcium intake, vitamin D supplements, 
and individual height.
7. Vitamin D status
Vitamin D status is best determined by measuring serum 25-hydroxyvitamin D 
[25(OH)D]; a level higher than 50 nmol/L (30 ng/mL) contributes to the optimal 
calcium absorption, fall prevention, and prevention of the fracture [4, 22]. Below 
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this level, PTH levels increase blood circulation, causing secondary hyperparathy-
roidism, and increase the risk of osteoporosis and fractures leading to bone loss. 
In addition, moderate increase of PTH may also enhance insulin resistance, weight 
gain, hypertension, left ventricular hypertrophy, and acute phase response, increas-
ing the risk of ischemic arrhythmias and cardiovascular mortality [4].
According to the Committee of the Institute of Medicine (IOM, USA) and 
the Endocrine Society [19, 23], vitamin D status defined the values lower than 
50 nmol/L (20 ng/mL) as vitamin D deficiency (VDD), while values between 50 
and 75 nmol/L are indicated to vitamin D insufficiency (VDI), and values equal or 
above 75 nmol/L (30 ng/mL) is described as adequate or sufficient vitamin D. The 
IOM adds extra criterion which is severe VDD with 25 nmol/L (10 ng/mL).
Serum [25(OH)D] test is detected by using high-performance liquid chromatog-
raphy/mass-spectrometry (LC/MS) methodology [4, 19] which is recommended by 
the National Diet and Nutrition Survey [19]. The high cost for vitamin D detection 
hampers the diagnosis of vitamin D deficiency. There is a great need to develop a 
specific and cheap testing method [4].
8. Vitamin D deficiency
Most studies have identified the vitamin D insufficiency (VDI) at concentra-
tions of [25(OH)D] less than 75 nmol/L (30 ng/mL) and vitamin D deficiency 
(VDD) at concentrations below 50 nmol/L (20 ng/mL) [1, 4, 10, 17].
Vitamin D deficiency is still a highly prevalent disorder. It is estimated that ~1 
billion people are deficient or have insufficient levels of vitamin, in spite of foods 
fortified with vitamin D and wide supplement intake [2].
VDD is widespread in the whole world as well as predominant in Asia and in the 
Middle East (more than 50% of the population is VDD and about 75% is VDI) [4]. 
VDD is found in 30–50% of otherwise healthy middle-aged to elderly adults [11].
Deficiency of vitamin D can result from many reasons such as dietary inad-
equacy of vitamin D, poor absorption and use, increased requirement, increased 
excretion and catabolism, limited sunlight exposure, and inefficient production 
in the skin. Dietary deficiency of vitamin D is associated with milk allergy, lactose 
intolerance, ovo-vegetarianism, and veganism [1, 4]. In addition, various diseases 
affect the bioavailability of vitamin D, such as gastrointestinal disorders which limit 
its absorption; kidney and liver diseases can prevent the activation of the parenteral 
vitamin D or impair the conversion of vitamin D into its active metabolites [4].
Severe VDD in adults leads to osteomalacia while in children leads to rickets, 
defective bone mineralization, increased bone turnover, increased risk of fractures 
[4], impaired reproductive function, and production of gonadal hormone that 
may affect other organs, e.g., gastrointestinal and renal calcium handling, renal 
CYP27B1 activity, and bone function [20].
In the critical care condition, VDD has been associated with adverse outcomes 
such as infections, longer length of stay, acute kidney injury, and higher  
mortality [10].
9. Vitamin D deficiency in Saudi Arabia
A total of 132 articles studying the deficiency of vitamin D in Saudi Arabia were 
identified based on the initial PubMed search criteria. About 20 studies have inves-
tigated the vitamin D deficiency in healthy individuals living in Saudi Arabia during 
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City of Saudi Arabia Year of 
study
Ref.
Men 66.7% 20–40 Tabuk 2018 [24]
59% >21 Riyadh 2017 [25]
74.4% 18–50 Riyadh 2015 [27]
92% 20–23 Riyadh 2013 [35]
87.8% 20–74 Jeddah 2012 [36]
92.6% 18–22 Dammam 2009 [30]
32.5% ≥25 Eastern Province 2009 [37]
Newborns 90% Neonates Riyadh 2013 [38]





63% 1–6 Makkah 2015 [39]
92.5% girls
79.3% boys
13–17 Riyadh 2015 [27]
97.8% girls
92.8% boys
6–15 Western, central, and 







≤15 Different regions 2013 [41]
86.27% 4–15 Jeddah 2010 [42]
To convert (nmol/L) into (ng/ml), divide the value by 2.496.
Table 2. 
Prevalence reports on vitamin D deficiency in healthy men, newborns, children, and adolescents living in 
Saudi Arabia.











Premenopausal 80.5% 20–40 Tabuk 2018 [24]
62% >21 Riyadh 2017 [25]
67.8% 19–25 Tabuk 2016 [26]
74.8% 18–50 Riyadh 2015 [27]
100% 19–40 Riyadh 2012 [28]
78.2% 20–50 Jeddah 2011 [29]
99.03% 18–22 Dammam 2009 [30]
41.2% ≥18 Riyadh 2008 [23]
Postmenopausal 85% 50–79 Jeddah 2011 [29]
86.2% >60 Riyadh 2006–
2011
[31]
Pregnant women 88% >16 Riyadh 2011–
2012
[32]
64.2% 20–40 Al Khafji 2011 [33]
50% 20–49 Riyadh 2010 [34]
To convert (nmol/L) into (ng/ml), divide the value by 2.496.
Table 1. 
Prevalence reports on vitamin D deficiency in Saudi healthy women.
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the past 10 years. These studies have demonstrated a noticeably high prevalence of 
VDD in Saudi women (41.2–100%, Table 1) compared to Saudi men (32.5–92.6%, 
Table 2). Deficiency of vitamin D was not only limited to adults but also included 
newborns (88–90%), children, and adolescents (40.6–97.8%) (Table 2).
10. Vitamin D toxicity and safety limits
Excessive oral supplementation and food fortification of vitamin D may lead 
to toxicity because it raises plasma [25(OH)D] concentrations that exceed DBP 
binding capacity, and free [25(OH)D] concentrations have direct effects on gene 
expression once it enters the target cells [13].
Upper safe limit is 5000 IU a day (and some considered it to be 10,000 IU), 
and the toxicity does not manifest serum levels below 120 ng/mL (300 nmol/L). To 
reach the latter levels, one must ingest vitamin D in excess of 50,000 IU daily for 
several months. Thus, the safety of doses to 5000 IU a day is assured [4].
11. Conclusion
In conclusion, this chapter summarizes that vitamin D is a fat-soluble prohor-
mone and has skeletal and extra-skeletal functions. The main sources of vitamin 
D are sun exposure and diet. Two common types of vitamin D are vitamins D2 
(ergocalciferol) and D3 (cholecalciferol). Vitamins D2 or D3 must be activated to 
produce its effects in a multi-step process. Vitamin D status is determined by serum 
25-hydroxyvitamin D [25(OH)D]; the value lower than 50 nmol/L (30 ng/mL) con-
tributes to vitamin D deficiency. Severe vitamin D deficiency leads to osteomalacia 
in adults, rickets in children, and an increased risk of fractures.
Like other countries in the world, Saudi Arabia suffers from vitamin D defi-
ciency. This chapter illustrates the terrible deficiency of vitamin D for the Saudi 
population for both genders and for different age groups.
To improve the status of vitamin D deficiency, distinct strategies should be 
applied to raise the vitamin D stored as a routine measurement through sunlight 
exposure by increasing daily outdoor activity. Moreover, nutritionists should 
emphasize increased dairy intake, vitamin D supplementation, calcium supplemen-
tation, and vitamin D-fortified foods. Finally, effective educational programs are 










City of Saudi Arabia Year of 
study
Ref.
Men 66.7% 20–40 Tabuk 2018 [24]
59% >21 Riyadh 2017 [25]
74.4% 18–50 Riyadh 2015 [27]
92% 20–23 Riyadh 2013 [35]
87.8% 20–74 Jeddah 2012 [36]
92.6% 18–22 Dammam 2009 [30]
32.5% ≥25 Eastern Province 2009 [37]
Newborns 90% Neonates Riyadh 2013 [38]





63% 1–6 Makkah 2015 [39]
92.5% girls
79.3% boys
13–17 Riyadh 2015 [27]
97.8% girls
92.8% boys
6–15 Western, central, and 







≤15 Different regions 2013 [41]
86.27% 4–15 Jeddah 2010 [42]
To convert (nmol/L) into (ng/ml), divide the value by 2.496.
Table 2. 
Prevalence reports on vitamin D deficiency in healthy men, newborns, children, and adolescents living in 
Saudi Arabia.











Premenopausal 80.5% 20–40 Tabuk 2018 [24]
62% >21 Riyadh 2017 [25]
67.8% 19–25 Tabuk 2016 [26]
74.8% 18–50 Riyadh 2015 [27]
100% 19–40 Riyadh 2012 [28]
78.2% 20–50 Jeddah 2011 [29]
99.03% 18–22 Dammam 2009 [30]
41.2% ≥18 Riyadh 2008 [23]
Postmenopausal 85% 50–79 Jeddah 2011 [29]
86.2% >60 Riyadh 2006–
2011
[31]
Pregnant women 88% >16 Riyadh 2011–
2012
[32]
64.2% 20–40 Al Khafji 2011 [33]
50% 20–49 Riyadh 2010 [34]
To convert (nmol/L) into (ng/ml), divide the value by 2.496.
Table 1. 
Prevalence reports on vitamin D deficiency in Saudi healthy women.
9
Vitamin D and Its Deficiency in Saudi Arabia
DOI: http://dx.doi.org/10.5772/intechopen.88745
the past 10 years. These studies have demonstrated a noticeably high prevalence of 
VDD in Saudi women (41.2–100%, Table 1) compared to Saudi men (32.5–92.6%, 
Table 2). Deficiency of vitamin D was not only limited to adults but also included 
newborns (88–90%), children, and adolescents (40.6–97.8%) (Table 2).
10. Vitamin D toxicity and safety limits
Excessive oral supplementation and food fortification of vitamin D may lead 
to toxicity because it raises plasma [25(OH)D] concentrations that exceed DBP 
binding capacity, and free [25(OH)D] concentrations have direct effects on gene 
expression once it enters the target cells [13].
Upper safe limit is 5000 IU a day (and some considered it to be 10,000 IU), 
and the toxicity does not manifest serum levels below 120 ng/mL (300 nmol/L). To 
reach the latter levels, one must ingest vitamin D in excess of 50,000 IU daily for 
several months. Thus, the safety of doses to 5000 IU a day is assured [4].
11. Conclusion
In conclusion, this chapter summarizes that vitamin D is a fat-soluble prohor-
mone and has skeletal and extra-skeletal functions. The main sources of vitamin 
D are sun exposure and diet. Two common types of vitamin D are vitamins D2 
(ergocalciferol) and D3 (cholecalciferol). Vitamins D2 or D3 must be activated to 
produce its effects in a multi-step process. Vitamin D status is determined by serum 
25-hydroxyvitamin D [25(OH)D]; the value lower than 50 nmol/L (30 ng/mL) con-
tributes to vitamin D deficiency. Severe vitamin D deficiency leads to osteomalacia 
in adults, rickets in children, and an increased risk of fractures.
Like other countries in the world, Saudi Arabia suffers from vitamin D defi-
ciency. This chapter illustrates the terrible deficiency of vitamin D for the Saudi 
population for both genders and for different age groups.
To improve the status of vitamin D deficiency, distinct strategies should be 
applied to raise the vitamin D stored as a routine measurement through sunlight 
exposure by increasing daily outdoor activity. Moreover, nutritionists should 
emphasize increased dairy intake, vitamin D supplementation, calcium supplemen-
tation, and vitamin D-fortified foods. Finally, effective educational programs are 
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In addition to its contribution to bone metabolism, vitamin D seems to fulfill a 
broad spectrum of biological functions which justifies the interest in monitoring 
its body content. The aim of this study is to analyze the prevalence of hypovi-
taminosis D and associated factors in schoolchildren and adolescents living in a 
region of northern Spain. A cross-sectional clinical and analytical study (calcium, 
phosphorus, calcidiol, and parathyroid hormone) was accomplished in a group of 
602 Caucasian individuals (aged 3.1–15.4 years). Gender, age, body mass index, 
residence, and season of the year were recorded, and their association with vitamin 
D deficiency was analyzed by multiple regression. Vitamin D status was defined 
according to the US Endocrine Society criteria. The prevalence of hypovitaminosis 
D was 60.4% (insufficiency: 44.6%; deficiency: 15.8%). The female sex, adoles-
cence, season of blood sample collection (autumn, winter, and spring), an urban 
residence, and severe obesity showed an association with an increased risk of 
hypovitaminosis D.
Keywords: associated factors, calcidiol, children, deficiency, insufficiency, 
prevalence, sufficiency, vitamin D
1. Introduction
Vitamin D (cholecalciferol) is a hormone that is basically synthesized in the skin 
after exposure to sunlight. This substance undergoes initial hepatic (25-OH-D or 
calcidiol) and subsequent renal [1, 25-(OH)2-D or calcitriol] hydroxylation before 
the definitive functional activation. The stimulation of ultraviolet radiation (type 
B) promotes the endogenous synthesis of vitamin D from epidermal 7-dehydrocho-
lesterol, which is the main source of vitamin D, whereas dietary sources account for 
less than 10% of the total. The function in bone metabolism and calcium homeosta-
sis has been long considered and known. Vitamin D deficiency causes a reduction in 
the absorption of dietary calcium and an increase in parathyroid hormone (PTH) 
secretion with the aim to keep steady levels of serum calcium. A deficiency in vita-
min D produces osteoclastic activity and causes loss of bone mineral density [1–6].
Recent studies have shown the presence of vitamin D receptors in the majority 
of organs (blood vessels, B and T lymphocytes, heart, muscles, skin, brain, mam-
mary gland, colon, prostate, gonads, etc.) and the activity of specific enzymes that 
are not regulated by PTH and induce calcitriol synthesis. All these findings reveal 
the biological significance of vitamin D. In fact, several observational studies have 
suggested that vitamin D deficiency could be related to a higher cardiovascular risk, 
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as well as a risk to present autoimmune, endocrine, infectious, psychiatric, and/or 
neurological diseases and several types of cancer [1, 4, 7–13]. Additional studies are 
needed to evaluate the underlying mechanisms.
In other words, in addition to its contribution to bone metabolism, vitamin D 
seems to fulfill a broad spectrum of biological functions related to cell prolifera-
tion, differentiation, and metabolism, which justifies the interest in monitoring its 
body content. Gender, age, race, season of the year in which serum is collected, sun 
exposure, and nutritional status have been associated with lower levels of serum 
calcidiol, but there are disparities among the different authors in the interpretation 
of these findings [7, 9, 14–20].
The aim of this study is to determine the prevalence of hypovitaminosis D and 
associated factors among children in northern Spain.
2. Materials and methods
2.1 Participants
The present work is a cross-sectional study conducted in a sample of 602 indi-
viduals from ages 3.1 to 15.4 years after the completion of a clinical examination and 
blood testing in the period January 2014 to December 2014. Tests were carried out 
in the Pediatric Endocrinology Unit of our hospital. Tanner’s criteria were evaluated 
in every individual and were used in the assignment of individuals in two different 
groups: school group (Tanner stage I) and adolescent group (Tanner stages II–V). 
The characteristics of the place of residence were recorded as urban or rural (< 
or > 10,000 inhabitants, respectively).
All individuals were healthy Caucasian children living in Navarra, Spain. They 
were selected from the external consultations of the different pediatric subspecial-
ties and were not affected by any chronic pathology with potential interference in 
growth, body composition, food ingestion, or physical activity. Any participant 
under treatment with concrete medications (antiepileptic drugs or glucocorticoids), 
vitamin D, or calcium supplements was put aside from our sample.
2.2 Clinical examination
Body measurements (weight and height) were taken in specific conditions 
(underwear, barefoot). An Año-Sayol scale (reading interval 0–120 kg and a 
precision of 100 g) was used for weight registration and a Holtain wall stadiometer 
(reading interval 60–210 cm, precision 0.1 cm) for height registration. The program 
Aplicación Nutricional, from the Spanish Society of Pediatric Gastroenterology, 
Hepatology and Nutrition (Sociedad Española de Gastroenterología, Hepatología y 
Nutrición Pediátrica, available at http://www.gastroinf.es/nutritional/), provided 
the estimates of the Z-score values of BMI. The reference charts used for compari-
son were the graphics from Ferrández et al. (Centro Andrea Prader, Zaragoza 2002).
The values of Z-score enabled the assignment of individuals in the following groups:
• Normal: Z-score between −1.0 (15th percentile) and + 1.0 (85th percentile)
• Overweight: Z-score > 1.0 (85th percentile)
• Obesity: Z-score > 2.0 (97th percentile)
• Severe obesity: Z-score > 3.0 (99th percentile)
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2.3 Blood testing
The plasma levels of calcium and phosphorous were determined in a fasting 
sample of blood using colorimetric methods in a cobas 8000 analyzer (Roche 
Diagnostic, Mannheim, Germany). The determination of calcidiol levels required 
a high-specific chemiluminescence immunoassay (LIAISON Assay, Diasorin, 
Dietzenbach, Germany) and the determination of PTH levels a highly specific 
solid-phase, two-site chemiluminescent enzyme-labeled immunometric assay in an 
Immulite analyzer (DPC Biermann, Bad Nauheim, Germany).
The distribution of individuals according to Vitamin D plasma levels followed 
the criteria of the US Endocrine Society [21, 22]. Calcidiol plasma levels lower 
than 20 ng/ml (<50 nmol/L) corresponded to Vitamin D deficiency, calcidiol 
levels between 20 and 29 ng/ml (50–75 nmol/L) to Vitamin D insufficiency, and 
concentrations equal to or higher than 30 ng/ml (>75 nmol/L) to Vitamin D suf-
ficiency. PTH serum levels higher than 65 pg/ml [14, 17] determined secondary 
hyperparathyroidism.
2.4 Statistical analysis
The figures resulting from the data collection are shown as percentages (%) and 
means (M) including the respective standard deviations (SD) or confidence inter-
vals (95% CI). The subsequent statistical analysis (descriptive statistics, Student’s 
t-test, analysis of variance, χ2 test, Pearson’s correlation, and multiple logistic 
regression analysis) was performed using the software package Statistical Packages 
for the Social Sciences version 20.0 (Chicago, IL, USA). A probability value (p-value) 
<0.05 was established as the level of statistical significance.
Adequate information of the proceedings and potential implications was 
delivered to the parents and/or legal guardians, and the corresponding consent was 
required prior to the inclusion in this study in all cases. The study was presented 
and approved after the evaluation of the Ethics Committee for Human Investigation 
at our institution (in line with the ethical standards stated in the Declaration of 
Helsinki, 1964, and later amendments).
3. Results
The average values for calcidiol and PTH plasma levels from the totality of the 
collections were 27.4 ± 7.7 ng/mL and 33.2 ± 17.3 pg/mL, respectively. Calcidiol levels 
overtook 30 ng/mL (Vitamin D sufficiency) in 236 individuals (39.6%), oscillated 
between 20 and 29 ng/mL (Vitamin D insufficiency) in 266 (44.6%), and were lower 
than 20 ng/mL (Vitamin D deficiency) in 94 (15.8%). The average values for calcium 
and phosphorus were 9.9 ± 0.5 and 4.6 ± 0.5 mg/dL, respectively. No values for 
hypo-/hypercalcemia or hypo-/hyperphosphatemia were detected. The frequency of 
hyperparathyroidism was significantly higher in the deficient vitamin D (11.6%) and 
insufficient vitamin D (6.6%) groups, whereas the prevalence of hyperparathyroid-
ism was lowest in the sufficient vitamin D (2.3%) group (p = 0.005).
Table 1 shows the distribution of the presumed risk factors for hypovitaminosis 
D (sex, age group, place of residence, season of blood sample collection, and nutri-
tion status).
Table 2 shows and compares the mean values for the clinical characteristics and 
biochemical determinations according to the risk factors for hypovitaminosis D. Mean 
PTH values were significantly higher (p < 0.05) in females. The average phosphorous 
values were significantly higher in males (p < 0.05). No significant differences were 
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detected in age, nutrition situation, calcium, and calcidiol after the comparison 
between sexes. Calcidiol and phosphorus levels were significantly higher (p < 0.05) 
in the school group, whereas the average values for PTH were significantly higher in 
adolescents (p < 0.05). There were not any significant differences in Calcium levels 
between the age groups. Those individuals whose residence was in rural areas showed 
mean values for calcium and calcidiol significantly higher, whereas those individuals 
living in urban areas had PTH mean values significantly higher. There were no signifi-
cant differences regarding age, BMI (Z-score), and phosphorous among individuals 
living in both areas. The lowest calcidiol levels corresponded to spring (26.1 ± 6.2 ng/
mL), and they reached a maximum in the summer (34.5 ± 8.0 ng/mL); meanwhile, 
the lowest parathyroid hormone levels corresponded to summer (26.6 ± 10.1 pg./mL) 
and reached a maximum value in autumn (37.8 ± 17.2 pg./mL). There were not any 
significant differences in calcium and phosphorus levels in each season. Mean values 
of calcidiol and PTH were significantly lower and higher (p < 0.05), respectively, in 
the group of severe obesity than in other groups with different nutritional situations 
(normal, overweight, and obesity). There were no significant differences in calcidiol 
and phosphorous mean values among the different groups.
Table 3 exposes and compares the prevalence of the different calcidiol levels 
in relation to analyzed associated factors in hypovitaminosis D. We did not detect 
significant differences in the prevalence of the different levels in calcidiol status in 
relation to sex. However, the prevalence of vitamin D deficiency was significantly 
higher in the group of adolescents with respect to school children and rural environ-
ment. In the same way, individuals with severe obesity showed a prevalence of vita-

















Normal weight 393 (67.3%)
Overweight 69 (11.8%)
Obesity 68 (11.6%)
Severe obesity 54 (9.2%)
Table 1. 
Demographics and clinical characteristics of the participants in the study.
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Figure 1 presents the prevalence of hypovitaminosis D (deficiency and insuf-
ficiency) according to the seasons of the year in healthy pediatric population. The 
levels of vitamin D during summer was sufficient in 80% of the individuals; this 
level substantially decreased in autumn and winter (hypovitaminosis was detected 
in 65.6% and 62.7% during autumn and winter, respectively) and got to the lowest 









Females 56 (16.7%) 161 (47.9%) 119 (35.4%) 5.65 (0.059)
Males 38 (14.6%) 105 (40.4%) 117 (45%)
Age group
School 31 (11.1%) 131 (44.3%) 132 (44.6%) 11.696 (0.003)
Adolescent 61 (20.3%) 135 (45%) 104 (34.7%)
Residence
Urban 75 (19.3%) 175 (45%) 139 (35.7%) 12.671 (0.002)
Rural 19 (9.2%) 91 (44.2%) 96 (46.6%)
Season
Winter 40 (21.1%) 79 (41.6%) 71 (37.4%)
Spring 17 (13.3%) 76 (59.4%) 35 (27.3%) 69.12 (<0.001)
Summer 4 (5.3%) 11 (14.7%) 60 (80%)
Autumn 33 (16.3%) 100 (49.3%) 70 (34.5%)
Nutritional status
Normal 46 (11.8%) 176 (45.1%) 168 (43.1%)
Overweight 11 (15.9%) 27 (39.1%) 31 (44.9%) 30.135 (<0.001)
Obesity 12 (18.2%) 33 (50%) 21 (31.8%)
Severe obesity 20 (37.7%) 23 (43.4%) 10 (18.9%)
Table 3. 
Prevalence of the different calcidiol levels in relation to the presumed risk factors for hypovitaminosis D.
Figure 1. 
Prevalence of vitamin D status according to seasons.
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Figure 2 states the average values for calcidiol levels along the months of the 
year (ANOVA, p < 0.001), showing the highest levels during the summer months 
(July: 32.6 ng/mL, CI 95%: 29.7–35.5; August: 33.6 ng/mL, CI 95%: 31.2–36; and 
September: 33.5 ng/mL, CI 95%: 31.4–35.6); in contrast, these levels were lower 
during the winter and spring months.
Figure 3 presents the PTH levels (average) in the different months of the year 
(ANOVA, p < 0.001). The autumn months show the highest PTH levels (October: 
39.8 pg/mL, CI 95%: 35.4–43.6; November: 37.1 pg/mL, CI 95%: 34.1–34.1; and 
December: 36.0, CI 95%: 31.7–40.3) and the end of spring (May: 32.8 pg/mL, CI 
95%: 29.0–36.6 and June: 33.0 pg/mL, CI 95%: 29.0–37.0); in contrast, these levels 
were lower in the summer months (July: 25.1 pg/mL, CI 95%: 21.9–28.3 and August: 
26.1 pg/mL, CI 95%: 23.0–29.2).
A significant correlation (p < 0.001) between calcidiol and parathyroid hor-
mone levels (r = −0.24) was observed; calcium and PTH plasma levels (r = −0.20) 
are also correlated. A significant correlation was detected between age and calcidiol 
levels (r = −0.15) and also between age and PTH levels (r = 0.18).
Table 4 illustrates the multiple logistic regression analysis for the presumed pre-
dictors of vitamin D status. The female sex, adolescence, season of blood sample col-
lection (autumn, winter, and spring), an urban residence, and severe obesity showed 
an association with an increased risk of vitamin D insufficiency. Adolescence, season 
of blood sample collection (autumn and winter), urban residence, and severe obesity 
revealed an association with an increased risk of vitamin D deficiency.
Figure 2. 
Calcidiol levels (ng/ml ± CI 95%) throughout the year (ANOVA, p < 0.001).
Figure 3. 
PTH levels (pg/ml ± CI 95%) in the different months of the year (ANOVA, p < 0.001).
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There is a high prevalence of hypovitaminosis D in the pediatric population in 
our environment, which potentially represents a serious public health problem. The 
criteria from the US Endocrine Society have been used for the comparison of the 
results with the previous published data. According to these criteria, calcidiol has a 
long half-life (2 to 3 weeks) and is the best indicator of body vitamin D content; they 
consider normal serum levels when they reach 30 ng/mL or higher and hypovitamin-
osis D below this level. In this way, hypovitaminosis is classified into insufficiency 
(between 21 and 29 ng/mL) and deficiency (lower than 20 ng/mL) [4, 21, 22].
The blood sample analysis shows the following prevalence: vitamin D suf-
ficiency in 39.6% of the individuals, insufficiency 44.6% and deficiency 15.8%, 
respectively. These results might seem to show a high prevalence of hypovitaminosis 
for a healthy population, but are indeed relatively moderate in comparison to other 
studies published in different areas or latitudes of our planet (Table 5); this may 
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Multiple logistic regression analysis for the presumed risk factor for hypovitaminosis (deficiency and 
insufficiency).
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be due to the fact that in this study their participants were exclusively of Caucasian 
origin, since, as is well known, the difference in skin pigmentation in different 
ethnic groups implies a higher risk of hypovitaminosis D [14, 17, 18, 28, 32, 34–37].
Calcidiol measurements—even though they were not significant—were higher 
in males, whereas PTH levels were significantly higher in females, but there were 
no significant differences in the prevalence of hypovitaminosis D among sexes. 
Previously published data are inconsistent [9, 34, 38, 39]. Nevertheless, the logistic 
regression analysis revealed that hypovitaminosis D, and more specifically the level 
of insufficiency, was significantly associated with females. Adolescents (pubertal 
group) had significantly lower calcidiol levels than school children, but the mean 
values for PTH and the prevalence of hypovitaminosis D were significantly higher 
in that group, and these results match those provided by other authors [17, 40]. 
Furthermore, the logistic regression analysis showed that hypovitaminosis D, as 
insufficiency and deficiency, was significantly associated to the older group. These 
findings could be somehow disturbing, since adolescence is a key period for grow-
ing, development, and bone formation, when vitamin D requirements are increased 
and deficiency may affect normal bone mass acquisition. Individuals living in 
urban areas had calcidiol values significantly lower than those living in rural areas, 
whereas PTH values and prevalence of vitamin D deficiency were significantly 
higher in those individuals from urban areas. These findings might be related to the 
different lifestyles inherent to the different environment, since residents in rural 
areas are likely to experience longer periods of sun exposure, as several authors have 
highlighted [17, 19].
The characteristics of sun exposure depend considerably on the location. In this 
way, it has been found how the axial tilt (obliquity) of our planet in the northern 
hemisphere (beyond 37th parallel—north), mainly in the colder months of the 
year, causes a change in the density of incident rays and, therefore, the ultraviolet 
radiation (type B) decreases up to 80–100%. That is the reason why sun radiation 
is not able to lead to efficient vitamin D synthesis [14, 17, 29, 41]. Hence the main 
reasons of vitamin D deficiency are usually in direct relation either to any physical 
agents that obstruct sun radiation (cutaneous pigmentation, sunscreens, etc.) or to 
Authors Deficiency Insufficiency Sufficiency
Cheng et al., 2003 (Jyväskylä, Finland) [23] 32% 46% 22%
Weng et al., 2007 (Philadelphia, USA) [14] 26% 29% 45%
Gordon et al., 2008 (Boston, USA) [24] 12% 40% 48%
Kelly et al., 2011 (Filadelfia, USA) [25] 47% 27% 26%
Andiran et al., 2012 (Ankara, Turkey) [26] 40% — —
Tolppanen et al., 2012 (England, UK) [27] 29% 46% 25%
González-Cross et al., 2012 (Europe) [28] 19% 39% 42%
Vierucci et al., 2013 (Toscana, Italy) [17] 46% 34% 20%
Karagüzel et al., 2014 (Trabzon, Turkey) [29] 71% 23% 6%
Durá-Travé et al., 2015 (Navarra, Spain) [30] 13% 45% 42%
Kaddam et al., 2017 (Saudi Arabia) [31] 49% 46% 5%
Fernández-Bustillo et al., 2018 (Galicia, Spain) [32] 5.9% 60.1% 34%
Guo et al., 2018 (China) [33] 10.8% 39% 50.2%
Table 5. 
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Table 5. 
Prevalence of hypovitaminosis D according to different authors.
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geographical features, such as sunlight exposure, atmospheric pollution, altitude, 
latitude, and the season of the year [1, 3].
The negative correlation between calcidiol and parathyroid hormone plasma 
levels has been previously described by different authors [14, 17, 33, 42]; nonetheless, 
the discussion about the combined oscillations existing among both hormones along 
a natural year has not been that intense [43, 44]. The analysis of our data has shown 
simultaneous and asynchronous changes in parathyroid hormone levels with respect 
to calcidiol, simultaneously with monthly and/or seasonal modifications in calcidiol 
levels. These adjustments presumably would take place in order to maintain constant 
calcium levels along the year, as we have noticed in this study. In point of fact, the 
highest body vitamin D levels are detected in the summer months—there is a more 
intense sunlight exposure. The levels decrease gradually in the autumn and winter 
months—except for some biological variability—and they reach the lowest point in 
springtime. By comparison to the findings of other authors [3, 17, 29], only 18.2% of 
the 602 individuals classified in the status of vitamin D insufficiency of deficiency 
presented with PTH levels within the range of hyperparathyroidism; since no 
diagnosis of hypercalcemia or hypocalcaemia or any bone semiology was previously 
described, a potential conclusion is that seasonal changes in calcidiol and parathy-
roid hormone levels would be related to a physiological phenomenon of adaptation 
to the geographical and climatic conditions endemic to this region. Navarre is a 
Spanish region located on a high latitude (between 41°55″22 N and 43°16″42 N) with 
frequent cloudy and rainy days, and this characteristic is important enough to take 
into consideration that cyclical variation in calcidiol levels in relation to the season 
of the year could be explained by a possible inefficient vitamin synthesis induced by 
sun radiation, as several authors have noted [14, 17, 24, 29, 42, 45–47]. Admittedly, 
the results confirm that vitamin D levels in the summer months were sufficient in 
80% of the individuals. They moderately decrease in the months of autumn and 
winter (the percentage of individual in a situation of hypovitaminosis D gets to 66.6 
and 62.7% in autumn and winter, respectively) and fall to the lowest point in spring 
months, when the prevalence of hypovitaminosis gets to 72.7%.
Because geographical and climatic conditions significantly influence body 
vitamin D content and, secondarily, PTH plasma levels, a comparison of the differ-
ent results obtained in the published works from different countries and/or climatic 
conditions would be unwise and faulty, since the place of residence, latitude, and 
especially the month of the year when the blood sample is collected always have to 
be considered. In other words, it is not possible to establish a vitamin D status in a 
concrete population without considering the seasonal variations because, as this 
work has shown, a potential condition of hypovitaminosis D is related to the season 
of the year in which the determination has been made [48, 49].
As BMI (Z-score) increases, calcidiol values decrease and PTH significantly 
rises, in a way that individuals with severe obesity showed minimum values of cal-
cidiol and maximum values of PTH with respect to the individuals of the remaining 
nutritional situations. This means, there seems to be a noticeable tendency to pres-
ent with vitamin D deficiency in the individuals with severe obesity [9, 20, 40, 50]; 
this eventuality has been outlined as a cardiovascular and/or metabolic risk factor 
[4, 8–10, 15, 19]. Even though there is not a conclusive explanation in this respect, 
it has been suggested that this circumstance in obese individuals may be related to 
environmental factors (decreased sun exposure as a consequence of a sedentary life-
style, inadequate diet, etc.), although, at present, some authors postulate a hypo-
thetical “sequestration” or excessive accretion of vitamin D in the adipose tissue 
[2, 4, 7, 8, 16, 18, 21, 42]. Previous reports did not distinguish between obesity and 
severe obesity, as we did in this work, and this special feature could be of practical 
relevance, since the logistic regression analysis has verified that hypovitaminosis 
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D, in levels of insufficiency as well as deficiency, is significantly associated to the 
nutritional situation of severe obesity.
The development of this study unveiled several limitations. The main weak-
nesses are the cross-sectional nature of the study and the absence of data on 
exercise, sun exposure, and the use of sunscreens. There have been some dif-
ficulties to get adequate and accurate data, and it restrained us from completing 
the registration. A nutritional survey (including dietary vitamin D intake, daily 
supplementation, etc.) was not incorporated in the study. Our experience reflects 
that dairy product intake in our social context is below the recommended amount 
and particularly fish intake is quite low in the pediatric population [51]; in this way, 
only the dietary supplementation of vitamin D could condition the results achieved, 
but, at present, it is not a widespread practice in our society.
Given the difficulties in maintaining a sufficient body vitamin D content in 
the pediatric age group throughout the year, the prevention, detection, and, when 
required, treatment and follow-up of hypovitaminosis should be fully integrated in 
the programs of health promotion and disease prevention in child and adolescent 
population corresponding to primary health care. In other words, primary care teams 
and, more specifically, pediatricians should include a series of preventive measures—
in addition to the mandatory vitamin D daily supplementation during the first year 
of life, 400 UI per day [4, 52, 53], such as promoting adequate sun exposure, in the 
service portfolio. Around 10–15 minutes of midday sun exposure (between 10 in the 
morning and 3 in the afternoon) on at least 20% of total body surface (uncovered 
head and extremities) during spring, summer, and autumn is considered enough to 
get an adequate vitamin D synthesis [2]. In addition, in case any of the hypovitamino-
sis D-associated factors is present, especially in those individuals at risk of limited sun 
exposure (disabled and/or undergoing long stay in the hospital, etc.), the need for 
additional vitamin D supplementation should be considered, either as pharmacologi-
cal supplements (600 IU per day), an increase of the ingestion of higher amounts 
from its natural dietary sources (herring, salmon, sardines, tuna, etc.), or vitamin D 
fortified foods (dairy products, cereals, etc.) during the months of winter and spring, 
as several authors have suggested [6, 12, 14, 15, 18, 21, 28, 34, 54].
5. Conclusion
There is a high prevalence of hypovitaminosis D in the pediatric population in 
our environment, being female sex, pubertal age, the seasons of autumn, winter and 
spring, living in urban area, and severe obesity considered as associated factors in 
hypovitaminosis D. Consideration should be given to the administration of vitamin 
supplements and/or the increase in the ingestion of natural vitamin D dietary sources.
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months—except for some biological variability—and they reach the lowest point in 
springtime. By comparison to the findings of other authors [3, 17, 29], only 18.2% of 
the 602 individuals classified in the status of vitamin D insufficiency of deficiency 
presented with PTH levels within the range of hyperparathyroidism; since no 
diagnosis of hypercalcemia or hypocalcaemia or any bone semiology was previously 
described, a potential conclusion is that seasonal changes in calcidiol and parathy-
roid hormone levels would be related to a physiological phenomenon of adaptation 
to the geographical and climatic conditions endemic to this region. Navarre is a 
Spanish region located on a high latitude (between 41°55″22 N and 43°16″42 N) with 
frequent cloudy and rainy days, and this characteristic is important enough to take 
into consideration that cyclical variation in calcidiol levels in relation to the season 
of the year could be explained by a possible inefficient vitamin synthesis induced by 
sun radiation, as several authors have noted [14, 17, 24, 29, 42, 45–47]. Admittedly, 
the results confirm that vitamin D levels in the summer months were sufficient in 
80% of the individuals. They moderately decrease in the months of autumn and 
winter (the percentage of individual in a situation of hypovitaminosis D gets to 66.6 
and 62.7% in autumn and winter, respectively) and fall to the lowest point in spring 
months, when the prevalence of hypovitaminosis gets to 72.7%.
Because geographical and climatic conditions significantly influence body 
vitamin D content and, secondarily, PTH plasma levels, a comparison of the differ-
ent results obtained in the published works from different countries and/or climatic 
conditions would be unwise and faulty, since the place of residence, latitude, and 
especially the month of the year when the blood sample is collected always have to 
be considered. In other words, it is not possible to establish a vitamin D status in a 
concrete population without considering the seasonal variations because, as this 
work has shown, a potential condition of hypovitaminosis D is related to the season 
of the year in which the determination has been made [48, 49].
As BMI (Z-score) increases, calcidiol values decrease and PTH significantly 
rises, in a way that individuals with severe obesity showed minimum values of cal-
cidiol and maximum values of PTH with respect to the individuals of the remaining 
nutritional situations. This means, there seems to be a noticeable tendency to pres-
ent with vitamin D deficiency in the individuals with severe obesity [9, 20, 40, 50]; 
this eventuality has been outlined as a cardiovascular and/or metabolic risk factor 
[4, 8–10, 15, 19]. Even though there is not a conclusive explanation in this respect, 
it has been suggested that this circumstance in obese individuals may be related to 
environmental factors (decreased sun exposure as a consequence of a sedentary life-
style, inadequate diet, etc.), although, at present, some authors postulate a hypo-
thetical “sequestration” or excessive accretion of vitamin D in the adipose tissue 
[2, 4, 7, 8, 16, 18, 21, 42]. Previous reports did not distinguish between obesity and 
severe obesity, as we did in this work, and this special feature could be of practical 
relevance, since the logistic regression analysis has verified that hypovitaminosis 
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D, in levels of insufficiency as well as deficiency, is significantly associated to the 
nutritional situation of severe obesity.
The development of this study unveiled several limitations. The main weak-
nesses are the cross-sectional nature of the study and the absence of data on 
exercise, sun exposure, and the use of sunscreens. There have been some dif-
ficulties to get adequate and accurate data, and it restrained us from completing 
the registration. A nutritional survey (including dietary vitamin D intake, daily 
supplementation, etc.) was not incorporated in the study. Our experience reflects 
that dairy product intake in our social context is below the recommended amount 
and particularly fish intake is quite low in the pediatric population [51]; in this way, 
only the dietary supplementation of vitamin D could condition the results achieved, 
but, at present, it is not a widespread practice in our society.
Given the difficulties in maintaining a sufficient body vitamin D content in 
the pediatric age group throughout the year, the prevention, detection, and, when 
required, treatment and follow-up of hypovitaminosis should be fully integrated in 
the programs of health promotion and disease prevention in child and adolescent 
population corresponding to primary health care. In other words, primary care teams 
and, more specifically, pediatricians should include a series of preventive measures—
in addition to the mandatory vitamin D daily supplementation during the first year 
of life, 400 UI per day [4, 52, 53], such as promoting adequate sun exposure, in the 
service portfolio. Around 10–15 minutes of midday sun exposure (between 10 in the 
morning and 3 in the afternoon) on at least 20% of total body surface (uncovered 
head and extremities) during spring, summer, and autumn is considered enough to 
get an adequate vitamin D synthesis [2]. In addition, in case any of the hypovitamino-
sis D-associated factors is present, especially in those individuals at risk of limited sun 
exposure (disabled and/or undergoing long stay in the hospital, etc.), the need for 
additional vitamin D supplementation should be considered, either as pharmacologi-
cal supplements (600 IU per day), an increase of the ingestion of higher amounts 
from its natural dietary sources (herring, salmon, sardines, tuna, etc.), or vitamin D 
fortified foods (dairy products, cereals, etc.) during the months of winter and spring, 
as several authors have suggested [6, 12, 14, 15, 18, 21, 28, 34, 54].
5. Conclusion
There is a high prevalence of hypovitaminosis D in the pediatric population in 
our environment, being female sex, pubertal age, the seasons of autumn, winter and 
spring, living in urban area, and severe obesity considered as associated factors in 
hypovitaminosis D. Consideration should be given to the administration of vitamin 
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Pregnancy and Child Outcomes
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Abstract
Maternal vitamin D deficiency in pregnancy is a widespread public health con-
cern. Race and ethnicity as biological and cultural factors, respectively, can affect 
vitamin D status through differences in skin color, sunlight exposure, and dietary 
intake. Low maternal vitamin D status in pregnancy may affect both mother and 
fetus adversely. Vitamin D deficiency and insufficiency are linked to a wide variety 
of adverse pregnancy outcomes such as gestational diabetes, preeclampsia, and 
preterm delivery. Furthermore, maternal vitamin D deficiency has been linked to 
several adverse health outcomes in infants and children. The examples include, but 
not limited to, impaired growth, skeletal problems, and autoimmune diseases such 
as type 1 diabetes and asthma. This chapter reviews the vitamin D status during 
pregnancy across different ethnic groups, looking into the adverse pregnancy and 
child outcomes, followed by a discussion on the association between maternal and 
child vitamin D status and successful interventions. Strong evidence exists about 
the association between vitamin D and some health outcomes during pregnancy, 
while more studies are needed to confirm the other claim. The existing body of 
evidence justifies the need for well-designed policies and systematic interventions 
to ensure optimal vitamin D status of pregnant women and their offsprings across 
different ethnic and racial groups.
Keywords: vitamin D, pregnancy, ethnicity, child, deficiency
1. Introduction
The calciotropic role of vitamin D is well known from the early twentieth cen-
tury. The recent advances in research opened a new perspective about vitamin D as 
prohormone with receptors in most tissues of the human body [1, 2]. This indicates 
additional non-calciotropic effects of vitamin D, such as its role in autoimmunity, 
chronic disease, infectious diseases, mental health issues, etc. [2]. However, the 
current dietary recommendations are based on only calciotropic effects of vitamin 
D although recent studies suggest that higher intakes are required to achieve the 
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Pregnancy is a unique stage of life for women when the normal physiology of 
mother is changing in order to provide the nutritional needs for the growing fetus 
[3]. Those changes influence the vitamin D hemostasis and availability for the 
mother and the fetus. In this chapter, we provide an overview of the evidence about 
vitamin D metabolism during pregnancy, the association between maternal vitamin 
D status and pregnancy, fetal and postnatal outcomes. Further, we provide insight 
into the current recommendation for vitamin D intake to achieve optimal vitamin D 
status and the associated factors, particularly race and ethnicity. Finally, we review 
the existing policies and practices to assure optimal vitamin status in pregnant 
women and their offsprings.
2. Vitamin D metabolism during pregnancy
Vitamin D homeostasis is altered during pregnancy in order to provide a suc-
cessful delivery and optimal environment for the growth of the fetus. This section 
focuses on adaptive changes of vitamin D during pregnancy as a background for 
developing pregnancy and fetal related disorders.
Major vitamin D adaptations in pregnancy include: (1) maternal increase of 
calcitriol; (2) availability of maternal 25(OH)D for optimal neonatal 25(OH)D;  
(3) increased concentration of maternal vitamin D-binding protein (VDBP) 
and placental vitamin D receptor (VDR); and (4) increased activity of renal and 
placental 25(OH)D-1-α-hydroxylase (CYP27B1) [4, 5]. The first change is started 
in the first trimester, increasing the level of calcitriol in systemic circulation and 
placenta to 100–200% by the end of the third trimester [6]. It is originated mostly 
from the kidneys for the purpose of increased intestinal calcium absorption during 
pregnancy [7]. In fact, the activity of 1α hydroxylase increases while catabolism 
of calcitriol decreases leading to more intestinal calcium absorption and immune 
adaptation [8]. The additional contributors of increased maternal and placental cal-
citriol are prolactin, calcitonin, PTH-related peptide (PTH-rP), estradiol, placental 
lactogen [9], IGF-1 [10], and FGF23 [11]. Any dysregulation causing activation 
decrease and catabolism increase of 25(OH)D may lead to preeclamptic mothers, 
which will be discussed in this chapter [12].
The second adaptation is likely that the levels of 25(OH)D in cord blood are 
reduced on average 25% in comparison with maternal 25(OH)D [13]. Maternal 
25(OH)D concentration remains constant during pregnancy, meaning that the 
increased level of calcitriol is not related to its precursor synthesis. Maternal 
25(OH)D crosses the placenta barrier as the main source of vitamin D in the fetus 
[14]. Therefore, vitamin D insufficiency in pregnant mothers could affect the fetus. 
Other factors, including lifestyle, place of living, skin pigmentation, sunshine 
exposure, and obesity, contribute significantly to maternal vitamin D status during 
pregnancy [4]. Consequently, a low level of maternal vitamin D leads to impaired 
fetal 25(OH)D at birth.
The third adaptation is a 40–50% increase in the concentration of VDBP in 
both systemic circulation and placenta level compared to the non-pregnant woman 
reaching to a maximum level at the beginning of the third trimester, before start-
ing to decrease by the end of gestation. This leads to a consistent decrease of free 
25(OH)D from 15 to 36 weeks, since there is an inverse relationship between free 
25(OH)D and VDBP concentration [15]. The mechanism has not fully understood, 
although studies suggested the high turnover rate of trophoblasts that are in contact 
with maternal blood directly leads to the increased expression of VDBP on the 
cell-surface of human placental trophoblasts during normal human pregnancy [16]. 
Studies conducted by Ma et al. and Liong et al. indicated that VDBP impairment, 
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either increase or decrease of its concentration, can contribute to the pathogenesis 
of preeclampsia (PET) and preterm birth [16, 17].
The placenta is an important organ playing a pivotal role in the optimal embry-
onic improvement and healthy pregnancy. Placenta regulates vitamin D metabolism 
by its own mechanism [18]. In fact, 1-α-hydroxylase, 24-hydroxylase, VDBP, and 
VDR have all been detected in trophoblast cultures and in placenta tissue, result-
ing in local synthesis of 1,25(OH)2D in the maternal-fetal interface as extrarenal 
calcitriol. Moreover, in the placenta, VDR gene expression is higher within the 
first and second trimester compared to term placentas [19] and positively asso-
ciated with transferring of calcium from mother-to-fetal. This indicates that 
VDR-dependent mechanisms in the placenta can affect fetal skeletal growth [20]. 
Vitamin D2 is metabolized in the placenta as well [21]. Thus, the placenta has its 
own mechanism in the regulation of vitamin D metabolism.
Increased 1, 25(OH)D is attributed to the higher activity of CYP27B1 in 
maternal, kidney, placental trophoblasts, and decidua during pregnancy [22]. The 
mechanism by which CYP27B1 activity increases in pregnancy remains unclear. 
However, it has been suggested that PTH analog PTH-related peptide (PTH-rP), 
synthesized by fetal parathyroid and placenta, could be a potential regulatory factor 
for CYP27B1 and augments during pregnancy [23].
Vitamin D metabolism manifests significant changes in pregnant women 
compared to the non-pregnant state. In an optimal ongoing pregnancy, there are 
three striking alternation within a gestation; two-fold increase of calcitriol in the 
first trimester, versus about 25% reduction in the levels of 25(OH)D in cord blood 
as it crosses the placenta barrier and increase the expression of vitamin D receptor 
and regulatory metabolic enzymes in the placenta. Also, maternal increase of serum 
calcitriol and VDBP without changes in 25(OH)D and calcium concentration of 
mother indicates that neonatal vitamin D stores are dependent on maternal vitamin 
D status.
3.  Current vitamin D intake recommendation guideline during 
pregnancy
The role of vitamin D intake in pregnancy and its consequences for fetal growth 
is the focus of current attention. The previous Dietary Reference Intake (DRI) 
review of vitamin D and Institute of Medicine (IOM) workshop on DRI research 
needs requested for research to evaluate the intake requirements for vitamin D as 
related to optimal circulating 25(OH)D concentrations across different life cycles 
and among different ethnic groups of Canadian and US populations [1]. Table 1 
summarizes different recommendations from various agencies which represents in 
population and individual level.
Health Canada [28] and IOM [1] have recommended dietary allowance of 
600 IU/day and tolerable upper intake level of 4000 IU/day for pregnant women 
in the US and Canada would meet the daily need in 97.5% of the population. There 
is no consensus on the cut-off point for vitamin D insufficiency. To prevent rickets 
and osteomalacia, IOM recommended >50 nmol/L concentration of 25(OH)D. 
While, the Endocrine Society and Osteoporosis Canada suggested a target serum 
concentration >75 nmol/L based on the available evidence with the daily intake of 
1500–2000 IU in order to achieve optimal benefits for skeletal and non-skeletal 
health [29, 30]. Accordingly, the Canadian Pediatric Society suggested 75 nmol/L as 
“sufficient” for pregnant and lactating women [31]. Moreover, several pilot stud-
ies have recommended that daily intake of 2000 [32], 4000 [33], or even 6400 IU 
[34] vitamin D would reduce vitamin D inadequacy without any toxicity sign in 
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maternal, kidney, placental trophoblasts, and decidua during pregnancy [22]. The 
mechanism by which CYP27B1 activity increases in pregnancy remains unclear. 
However, it has been suggested that PTH analog PTH-related peptide (PTH-rP), 
synthesized by fetal parathyroid and placenta, could be a potential regulatory factor 
for CYP27B1 and augments during pregnancy [23].
Vitamin D metabolism manifests significant changes in pregnant women 
compared to the non-pregnant state. In an optimal ongoing pregnancy, there are 
three striking alternation within a gestation; two-fold increase of calcitriol in the 
first trimester, versus about 25% reduction in the levels of 25(OH)D in cord blood 
as it crosses the placenta barrier and increase the expression of vitamin D receptor 
and regulatory metabolic enzymes in the placenta. Also, maternal increase of serum 
calcitriol and VDBP without changes in 25(OH)D and calcium concentration of 
mother indicates that neonatal vitamin D stores are dependent on maternal vitamin 
D status.
3.  Current vitamin D intake recommendation guideline during 
pregnancy
The role of vitamin D intake in pregnancy and its consequences for fetal growth 
is the focus of current attention. The previous Dietary Reference Intake (DRI) 
review of vitamin D and Institute of Medicine (IOM) workshop on DRI research 
needs requested for research to evaluate the intake requirements for vitamin D as 
related to optimal circulating 25(OH)D concentrations across different life cycles 
and among different ethnic groups of Canadian and US populations [1]. Table 1 
summarizes different recommendations from various agencies which represents in 
population and individual level.
Health Canada [28] and IOM [1] have recommended dietary allowance of 
600 IU/day and tolerable upper intake level of 4000 IU/day for pregnant women 
in the US and Canada would meet the daily need in 97.5% of the population. There 
is no consensus on the cut-off point for vitamin D insufficiency. To prevent rickets 
and osteomalacia, IOM recommended >50 nmol/L concentration of 25(OH)D. 
While, the Endocrine Society and Osteoporosis Canada suggested a target serum 
concentration >75 nmol/L based on the available evidence with the daily intake of 
1500–2000 IU in order to achieve optimal benefits for skeletal and non-skeletal 
health [29, 30]. Accordingly, the Canadian Pediatric Society suggested 75 nmol/L as 
“sufficient” for pregnant and lactating women [31]. Moreover, several pilot stud-
ies have recommended that daily intake of 2000 [32], 4000 [33], or even 6400 IU 
[34] vitamin D would reduce vitamin D inadequacy without any toxicity sign in 
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pregnant women and their infants. The discrepancies in some factors, including 
different measurement tools of vitamin D levels, various patient populations and 
different sample sizes that were used in studies, might explain the differences in 
the recommendations. Because of conflicting evidences, identifying sufficient and 
upper-limit amount of vitamin D for pregnant women requires further research to 
be performed.
4. Maternal vitamin D status and adverse pregnancy outcomes
Numerous studies have reported pleiotropic role of vitamin D in pregnancy. 
Maternal Hypovitaminosis D during pregnancy is related to pregnancy related 
disorders. Complications caused by low serum measurement of 25(OH)D include 
gestational hypertension (GHT), PET, gestational diabetes mellitus (GDM), timing 
and mode of delivery, postpartum depression or anxiety, bacterial vaginosis, and 
other outcomes such as anemia and lipid disorders, which are discussed in this 
section.
It should be noted that, there is not enough evidence to support a recommenda-
tion for screening all pregnant women for vitamin D deficiency but must be at least 
20 ng/ml (50 nmol/L) for bone health [35]. Although some experts suggest vitamin 
D serum level of at least 32 ng/ml (80 nmol/L) for optimal state in pregnancy 
[36], some adverse effects have been reported at levels exceeding 70 nmol/L [37]. 
Consequently, due to the lack of standardized measurement procedures, there is no 
consensus on the optimal vitamin D status during pregnancy.
4.1 Gestational hypertension and preeclampsia
Elevated blood pressure that appears after 20 weeks without proteinuria or other 
findings is called gestational hypertension (GHT). This problem is confirmed by 
systolic blood pressure (SBP) ≥160 or diastolic blood pressure (DBP) ≥110 mmHg 
for anyone (confirmed over a few minutes) or SBP ≥140 or DBP ≥90 mmHg after 
20 weeks (confirmed over 4 hours) observing for the first time [38]. At least 25% 
of women with GHT is predisposed to PET [38]. PET is diagnosed by high blood 
pressure (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg) 
after 20 weeks of gestation along with proteinuria (>300 mg/day) and other organ 
dysfunction including liver involvement, hematological disturbance, neurological 
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or renal complications [39]. The pathogenesis of PET involves releasing the angio-
genic factors to the maternal circulation which causes insufficient remodeling 
and trophoblastic invasion of spiral arteries. It leads to shallow implantation and 
hypoxia, and even release of inflammatory mediators [40]. PET is a multifacto-
rial outcome that has not been fully understood yet; however, maternal calcium 
status is suggested to be an important factor. Therefore, vitamin D due to its role 
in calcium hemostasis might have an impact on PET [41]. In addition, vitamin D 
can be protective of placental vasoconstriction and consequently, PET because of 
its immunomodulatory effect. Also, vitamin D is a regulator of endothelial and 
vascular smooth muscle cell proliferation through which regulates blood pressure 
via Renin-Angiotensin-Aldosterone system (RAAS) [42].
Systematic reviews and meta-analysis, including cross-sectional, longitudinal, 
cohort, ecological, and observational studies, indicate inconsistent results regard-
ing the association between vitamin D deficiency and PET. Some studies reported 
an increased risk of PET women with vitamin D deficiency in pregnancy in contrast 
with others [43–45]. This contradiction of finding can be explained by different 
vitamin D assessment methods, criteria applied to define vitamin D deficiency, dif-
ferent season and trimester in studies [44]. Therefore, associations are inconclusive, 
often contradictory, confounded, and lack causality. In addition, supplementation 
helps to raise the level of maternal vitamin D; however, there is no significant 
reduction of PET risk with a higher level of vitamin D status [22, 46]. In this regard, 
more observational and interventional studies with different designs are needed.
4.2 Gestational diabetes mellitus (GDM)
Gestational diabetes mellitus (GDM) is glucose intolerance developed or first 
diagnosed during pregnancy. Criteria for recognition GDM are controversial [47]; 
according to World Health Organization (WHO), fasting blood glucose above 
92–125 mg/dl and/or 2-h glucose greater than 153–199 mg/dl after glucose intake of 
75 g are considered as diabetes mellitus in pregnancy as is a random plasma value of 
above 200 mg/dl with diabetes symptoms [48, 49]. Vitamin D plays a crucial role in 
glucose homeostasis through several mechanisms. The first is regulating calcium, 
which is a regulator for the production and secretion of insulin by the endocrine 
pancreas. Its second role involves enhancing insulin sensitivity of the target cells in 
adipose tissues, liver, and skeletal muscles. Moreover, the immune cell regulation 
role of vitamin D protects β-cells from damaging and improves its function [50, 51]. 
Although vitamin D deficiency can be associated with the pathogenesis of diabetes 
mellitus type 1 and type 2, its role in GDM is not conclusive [43]. Conflicting results 
have been found in case-control, prospective cohort studies, and reviews looking 
into the risk of GDM with vitamin D status [46]. Some review studies indicate that 
pregnant women with significant lower 25(OH)D had a higher risk of GDM by 
40–60% [45, 52], while in systematic and critical reviews, most studies failed to 
support the association between vitamin D status and GDM prevention [43, 44]. 
Thus, more large-scale prospective studies are needed to evaluate this association.
4.3 Postpartum depression (PPD) or anxiety
Depression after delivery is a common psychiatric condition which is called 
postpartum depression (PPD) [53]. Vitamin D as a neurosteroid suggested having 
a role in various brain functions and depression by several potential mechanisms. 
Firstly, Vitamin D plays as a neurotransmitter, neuro-immunomodulation, and 
neuroprotection in the brain [54]. Secondly, vitamin D has a role in synthesiz-
ing norepinephrine and dopamine, which are involved in mood disorders. 
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different measurement tools of vitamin D levels, various patient populations and 
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tion for screening all pregnant women for vitamin D deficiency but must be at least 
20 ng/ml (50 nmol/L) for bone health [35]. Although some experts suggest vitamin 
D serum level of at least 32 ng/ml (80 nmol/L) for optimal state in pregnancy 
[36], some adverse effects have been reported at levels exceeding 70 nmol/L [37]. 
Consequently, due to the lack of standardized measurement procedures, there is no 
consensus on the optimal vitamin D status during pregnancy.
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Elevated blood pressure that appears after 20 weeks without proteinuria or other 
findings is called gestational hypertension (GHT). This problem is confirmed by 
systolic blood pressure (SBP) ≥160 or diastolic blood pressure (DBP) ≥110 mmHg 
for anyone (confirmed over a few minutes) or SBP ≥140 or DBP ≥90 mmHg after 
20 weeks (confirmed over 4 hours) observing for the first time [38]. At least 25% 
of women with GHT is predisposed to PET [38]. PET is diagnosed by high blood 
pressure (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg) 
after 20 weeks of gestation along with proteinuria (>300 mg/day) and other organ 
dysfunction including liver involvement, hematological disturbance, neurological 
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or renal complications [39]. The pathogenesis of PET involves releasing the angio-
genic factors to the maternal circulation which causes insufficient remodeling 
and trophoblastic invasion of spiral arteries. It leads to shallow implantation and 
hypoxia, and even release of inflammatory mediators [40]. PET is a multifacto-
rial outcome that has not been fully understood yet; however, maternal calcium 
status is suggested to be an important factor. Therefore, vitamin D due to its role 
in calcium hemostasis might have an impact on PET [41]. In addition, vitamin D 
can be protective of placental vasoconstriction and consequently, PET because of 
its immunomodulatory effect. Also, vitamin D is a regulator of endothelial and 
vascular smooth muscle cell proliferation through which regulates blood pressure 
via Renin-Angiotensin-Aldosterone system (RAAS) [42].
Systematic reviews and meta-analysis, including cross-sectional, longitudinal, 
cohort, ecological, and observational studies, indicate inconsistent results regard-
ing the association between vitamin D deficiency and PET. Some studies reported 
an increased risk of PET women with vitamin D deficiency in pregnancy in contrast 
with others [43–45]. This contradiction of finding can be explained by different 
vitamin D assessment methods, criteria applied to define vitamin D deficiency, dif-
ferent season and trimester in studies [44]. Therefore, associations are inconclusive, 
often contradictory, confounded, and lack causality. In addition, supplementation 
helps to raise the level of maternal vitamin D; however, there is no significant 
reduction of PET risk with a higher level of vitamin D status [22, 46]. In this regard, 
more observational and interventional studies with different designs are needed.
4.2 Gestational diabetes mellitus (GDM)
Gestational diabetes mellitus (GDM) is glucose intolerance developed or first 
diagnosed during pregnancy. Criteria for recognition GDM are controversial [47]; 
according to World Health Organization (WHO), fasting blood glucose above 
92–125 mg/dl and/or 2-h glucose greater than 153–199 mg/dl after glucose intake of 
75 g are considered as diabetes mellitus in pregnancy as is a random plasma value of 
above 200 mg/dl with diabetes symptoms [48, 49]. Vitamin D plays a crucial role in 
glucose homeostasis through several mechanisms. The first is regulating calcium, 
which is a regulator for the production and secretion of insulin by the endocrine 
pancreas. Its second role involves enhancing insulin sensitivity of the target cells in 
adipose tissues, liver, and skeletal muscles. Moreover, the immune cell regulation 
role of vitamin D protects β-cells from damaging and improves its function [50, 51]. 
Although vitamin D deficiency can be associated with the pathogenesis of diabetes 
mellitus type 1 and type 2, its role in GDM is not conclusive [43]. Conflicting results 
have been found in case-control, prospective cohort studies, and reviews looking 
into the risk of GDM with vitamin D status [46]. Some review studies indicate that 
pregnant women with significant lower 25(OH)D had a higher risk of GDM by 
40–60% [45, 52], while in systematic and critical reviews, most studies failed to 
support the association between vitamin D status and GDM prevention [43, 44]. 
Thus, more large-scale prospective studies are needed to evaluate this association.
4.3 Postpartum depression (PPD) or anxiety
Depression after delivery is a common psychiatric condition which is called 
postpartum depression (PPD) [53]. Vitamin D as a neurosteroid suggested having 
a role in various brain functions and depression by several potential mechanisms. 
Firstly, Vitamin D plays as a neurotransmitter, neuro-immunomodulation, and 
neuroprotection in the brain [54]. Secondly, vitamin D has a role in synthesiz-
ing norepinephrine and dopamine, which are involved in mood disorders. 
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Furthermore, vitamin D protects the brain from oxidative stress by preserving the 
antioxidant glutathione in the brain [55, 56]. Most studies suggested there is an 
inverse association between vitamin D serum in different stages of gestation and 
postpartum depression [57–59]. In contrast, some studies indicate no association 
[60, 61], and even increased risk of PPD with sufficient vitamin D concentrations 
(≥50 nmol/L) [62]. However, in a systematic review study, a few studies reported 
the role of vitamin D in this pregnancy outcome [44]. Thus, although postpartum 
depression might be associated with vitamin D deficiency, inconsistent results need 
for more extensive studies in this regard.
4.4 Bacterial vaginosis (BV)
Bacterial vaginosis (BV) is a common vaginal infection in women in reproduc-
tive ages caused by the replacement of normal vaginal flora for mixed anaerobic 
bacteria [63]. Women diagnosed with BV are more likely to have preterm delivery 
[64]. Evidence indicates that vitamin D deficiency is an independent risk factor for 
bacterial vaginosis in pregnancy [65], and in several systematic reviews and meta-
analysis articles, this association has been reported [5, 52, 55, 66]. The risk of BV 
increases from 3- to 5-fold for serum 25(OH)D values <75 to <30 nmol/L, respec-
tively [67–69]. Therefore, several cross-sectional and observational studies con-
sistently stated the plausible inverse association between vitamin D status and BV 
during pregnancy. A possible mechanism is related to immune responses regulated 
by calcitriol. In fact, as mentioned above, vitamin D activates potent antimicrobial 
peptide hCTD, an active peptide with broad-spectrum antimicrobial activity, in the 
placenta, macrophages and dendritic cells, inducing the innate immune responses 
[70]. These findings indicate that adequate vitamin D levels are crucial to enhance 
immunity, especially in pregnancy.
4.5 Preterm delivery
Preterm delivery is defined as birth completed before 37 weeks gestation [71]. 
Infection is the most common factor in preterm delivery [72]. Vitamin D plays as 
an anti-inflammatory and immunomodulatory factor, enabling to reduce the risk 
of preterm delivery in several plausible ways. One mechanism involves response 
reduction to microbial pathogens via cancelation of IL-1, IL-6, and TNF-alpha 
production by macrophages [73]. Uterine immune cells, such as dendritic cells, 
macrophages, and natural killer cells are modulated by vitamin D [74], and vitamin 
D receptors are expressed in the ovary, endometrium, and myometrium to maintain 
reproductive health [75].
There are conflicting findings regarding the effect of Vitamin D on preterm 
delivery. Some articles including critical and narrative reviews, reported no asso-
ciation between vitamin D deficiency and preterm delivery [43, 46, 76, 77], while 
single studies, systematic review, and meta-analysis showed significant relationship 
between them [45, 78–81]. Inconsistent findings can be explained by different 
designs of each study including the timing of 25(OH)D assessment, and different 
definition of preterm delivery. For instance, in two studies, ≤35 weeks gestation for 
preterm delivery was considered [78, 82], while in another study it was <37 weeks 
gestation [77].
Ethnicity appears to be an important factor regarding preterm birth. Bodnar 
et al. reported that the risk of preterm delivery increased only in non-white mothers 
compared to white women [82]. In a cohort study by Wagner et al., Hispanic women 
with serum 25(OH)D > 40 ng/ml had 79% reduced risk of preterm birth in com-
parison with those with serum 25(OH)D ≤ 20 ng/ml, while the reduced risk was 
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45% among black women [83]. Also, an increased risk of preterm birth associated 
with Vitamin D insufficiency in ethnic minority women in Canada [84] suggests 
the stratification of women based on their ethnicity in further studies. Another 
important thing should be considered in study design is the association of vitamin 
D status in different gestational age with pregnancy outcome. For instance, one 
study suggested that maternal vitamin D status closest to delivery time was the best 
indicator for preterm birth because of the more significant reduced risk in the third 
semester compared to serum concentrations of vitamin D in the first and second 
semesters [85]. Thus, vitamin D deficiency is likely to be associated with preterm 
birth, nevertheless, to investigate the explicit relationship between vitamin D 
status and preterm delivery several factors should be noted including the timing of 
25(OH)D assessment (first, second, or third trimester), ethnicity, precise definition 
of preterm birth, different study design such as human interventional and cohort 
studies.
4.6 Cesarean delivery
Uterine muscle and skeletal muscle cells have VDR, which is a regulator of the 
contractile proteins of uterine myometrial cells [86]. Therefore, the strength of the 
contractile muscles is decreased with vitamin D deficiency as well as malformation 
of the pelvis, which are indications for C-section [87]. The indication of C-section 
can be related to vitamin D deficiency, but there is a mixture of results regard-
ing this association. For example, prospective cohort studies suggested there was 
an inverse association with having a cesarean section and serum 25(OH)D levels 
[88–90], whereas others did not support this relationship [76, 87, 91]. Regarding 
ethnicity, in a cohort multi-ethnic Asian study, vitamin D deficiency was related 
to a higher risk of C-sections in Chinese and Indian women compared to Malay 
women [86]. Factors such as the different definition of C-section in terms of indica-
tion, primary or secondary, emergency or elective might be the reason of inconclu-
sive findings [91]. Although observational studies mentioned above investigated 
a possible relationship between vitamin D and cesarean delivery, more studies are 
needed to verify this association along with biological and geographical factors.
4.7 Recurrent pregnancy losses (RPL)
Recurrent pregnancy losses (RPL) and repeated implantation failures (RIF) are 
two auto- and cellular immune abnormalities, and vitamin D deficiency is prevalent in 
women with RPL and RIF. Vitamin D plays a pivotal role in the regulation of auto- and 
cellular immune disorders [92]. Studies reported that 45% of RPL patients had vitamin 
D deficiency in one study, and increased risk of first-trimester miscarriage and recur-
rent pregnancy losses (RPL) was found with vitamin D insufficiency [93, 94]. Even 
this association has been found in early spontaneous pregnancy loss [95]. Studies show 
an inverse association between vitamin D deficiency and RPL; however, no conclu-
sion can be drawn based on the findings of a few studies and more observational and 
interventional studies are necessary to confirm such association [43].
4.8 Other related outcomes
Other outcomes including spontaneous abortion [77, 96, 97] and stillbirth 
[77, 96], short gestational length [98], and low Apgar score [76, 96, 98] were not 
associated with vitamin D insufficiency, according to a systematic review and meta-
analysis of longitudinal studies [99]. However, more studies with different designs 
such as clinical trials are necessary. Anemia, lipid disorders, periodontal disease, 
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45% among black women [83]. Also, an increased risk of preterm birth associated 
with Vitamin D insufficiency in ethnic minority women in Canada [84] suggests 
the stratification of women based on their ethnicity in further studies. Another 
important thing should be considered in study design is the association of vitamin 
D status in different gestational age with pregnancy outcome. For instance, one 
study suggested that maternal vitamin D status closest to delivery time was the best 
indicator for preterm birth because of the more significant reduced risk in the third 
semester compared to serum concentrations of vitamin D in the first and second 
semesters [85]. Thus, vitamin D deficiency is likely to be associated with preterm 
birth, nevertheless, to investigate the explicit relationship between vitamin D 
status and preterm delivery several factors should be noted including the timing of 
25(OH)D assessment (first, second, or third trimester), ethnicity, precise definition 
of preterm birth, different study design such as human interventional and cohort 
studies.
4.6 Cesarean delivery
Uterine muscle and skeletal muscle cells have VDR, which is a regulator of the 
contractile proteins of uterine myometrial cells [86]. Therefore, the strength of the 
contractile muscles is decreased with vitamin D deficiency as well as malformation 
of the pelvis, which are indications for C-section [87]. The indication of C-section 
can be related to vitamin D deficiency, but there is a mixture of results regard-
ing this association. For example, prospective cohort studies suggested there was 
an inverse association with having a cesarean section and serum 25(OH)D levels 
[88–90], whereas others did not support this relationship [76, 87, 91]. Regarding 
ethnicity, in a cohort multi-ethnic Asian study, vitamin D deficiency was related 
to a higher risk of C-sections in Chinese and Indian women compared to Malay 
women [86]. Factors such as the different definition of C-section in terms of indica-
tion, primary or secondary, emergency or elective might be the reason of inconclu-
sive findings [91]. Although observational studies mentioned above investigated 
a possible relationship between vitamin D and cesarean delivery, more studies are 
needed to verify this association along with biological and geographical factors.
4.7 Recurrent pregnancy losses (RPL)
Recurrent pregnancy losses (RPL) and repeated implantation failures (RIF) are 
two auto- and cellular immune abnormalities, and vitamin D deficiency is prevalent in 
women with RPL and RIF. Vitamin D plays a pivotal role in the regulation of auto- and 
cellular immune disorders [92]. Studies reported that 45% of RPL patients had vitamin 
D deficiency in one study, and increased risk of first-trimester miscarriage and recur-
rent pregnancy losses (RPL) was found with vitamin D insufficiency [93, 94]. Even 
this association has been found in early spontaneous pregnancy loss [95]. Studies show 
an inverse association between vitamin D deficiency and RPL; however, no conclu-
sion can be drawn based on the findings of a few studies and more observational and 
interventional studies are necessary to confirm such association [43].
4.8 Other related outcomes
Other outcomes including spontaneous abortion [77, 96, 97] and stillbirth 
[77, 96], short gestational length [98], and low Apgar score [76, 96, 98] were not 
associated with vitamin D insufficiency, according to a systematic review and meta-
analysis of longitudinal studies [99]. However, more studies with different designs 
such as clinical trials are necessary. Anemia, lipid disorders, periodontal disease, 
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and HIV-related mortality are other pregnancy implications related to vitamin D 
deficiency. There is a mixture of results with regard to the vitamin D deficiency 
and anemia in pregnancy. Some studies indicated this relationship [100], while 
other studies failed to support it [76, 101]. The findings show a positive correlation 
between serum vitamin D and atherogenic factors such as total cholesterol and 
triglycerides [102, 103]. As vitamin D has immunomodulatory effects, it may have a 
protective role against mother-to-child transmission (MTCT) of the human immu-
nodeficiency virus (HIV). A study on HIV-infected pregnant women conducted 
in Tanzania found that low maternal vitamin D level (<32 ng/mL) at 12–27 weeks 
gestation was associated with a 50% higher risk of MTCT of HIV [104]. Moreover, 
vitamin D insufficiency (serum 25[OH]D < 75 nmol/l) was associated with mater-
nal periodontal disease during pregnancy, as reported by Boggess et al. [105].
Almost all the pregnancy complications related to vitamin D deficiency were 
discussed in this section. However, the results were contradictory due to small study 
samples in some studies, cross-sectional design, lack of adjustment for seasonal 
variation, race and ethnicity, various study design in terms of the trimester (first, 
second, or third trimester), different definition of some outcomes and even cut 
points to categorize vitamin D status. These inconsistencies justify the need for 
more large-scale prospective studies and interventional studies to evaluate these 
associations comprehensively.
5. Maternal vitamin D status across different ethnic groups
Vitamin D deficiency has been reported among pregnant women globally, 
particularly among ethnic minorities and white women residents at high latitude 
[106]. Ethnic variety in vitamin D status of pregnant women can be relevant to large 
disparities in skin color, vitamin D intake, religion, culture, sun exposure (seasonal 
variation), and geographical location [107]. In ethnic minorities, the prevention 
of vitamin D deficiency on a population basis is challenging due to the shortage of 
clarity surrounding the metabolism and transport of vitamin D [108]. Due to lack 
of enough evidence regarding the nutritional requirements for vitamin D during 
pregnancy, there is no pregnancy-specific dietary recommendation for vitamin 
D. In addition, the question of specific dietary reference setting specifically for each 
ethnicity (for pregnant women) has not been addressed to date [109].
The best indicator of vitamin D status is the serum 25(OH)D concentration, 
because it is not regulated, and reflects both dietary intake and synthesis form of 
vitamin D [110]. However, there is no absolute agreement on normal range of vitamin 
D, although most authors have consensus that serum 25(OH)D concentration should 
be ≥50 nmol/L [110–112]. Ethnic differences in vitamin D status are in accordance 
with the ethnic differences in circulating vitamin D, where a mean value of 57 nmol/L 
has been reported for Caucasian pregnant women in Canada [113], a median value 
of 53 nmol/L has been reported for Belgian women [114], 57 nmol/L has been 
reported for pregnant women in Australia [115]. A cohort study in 2011 indicated 
that the mean 25(OH)D level in African-Americans was 38.75 nmol/L, Hispanics was 
60.25 nmol/L, and Caucasians was 72.5 nmol/L [116]. African-American pregnant 
women had the lowest serum 25(OH)D in this study. However, in Southern Europe, 
Morales et al. demonstrated a median plasma value of 25(OH)D in pregnancy of 
73.88 nmol/L [117]. Furthermore, a recent systematic review reported that mean 
25(OH)D levels in the general populations were higher in America (North America) 
(75 nmol/L) than in the Middle East (50 nmol /L) or Europe (52 nmol/L) [118].
The absence of race- and pregnancy-specific dietary recommendations 
places pregnant women of the ethnic minority among the most vulnerable and 
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under-investigated population groups concerning vitamin D [106]. A review study 
indicated that pregnant women in Latin America, Asia, the Middle East, and Africa 
are at the danger of vitamin D deficiency and these are known as the topmost 
universally locations for occurrence of vitamin D deficiency and reported that 
incidence of vitamin D deficiency varied from 51.3 to 100% [119]. Recent studies 
in the United States, Canada, Australia, Iran, Sweden, and Pakistan reported that 
the range of vitamin D deficiency and insufficiency were 24–95.8% and 54–100% 
among pregnant women [116, 120–125]. The evidence for racial differences in 
vitamin D deficiency (Table 2) indicated that the global prevalence of 25(OH)D 
concentrations <50 nmol/L is 54% among pregnant women and 75% among new-
borns [106]. In other words, one in five pregnant women (18%) and one in three 
newborns (20%) had serum vitamin D concentration <25 nmol/L, which is a public 
health concern [106]. Vitamin D status is poorly defined in the South-East Asian, 
African, and Eastern Mediterranean regions and the non-European population in 
the Western Pacific region (Table 2) [106].
Maternal vitamin D deficiency is also investigated for each trimester across 
different regions and ethnicities. For instance, in Thai pregnant women, high 
prevalence of vitamin D deficiency and inadequacy were reported in the first 
trimester: 26.7% (<50 nmol/l) and 56.7% (<75 nmol/l), respectively. Then, vitamin 
D inadequacy decreased to 30.9% (1.8% deficiency) in the second trimester and 
27.4% (2.8% deficiency) in the third trimester [120]. Pregnant women were studied 
in the first trimester of pregnancy (gestational week 11–14) living in Mediterranean 
seacoast at latitude 36°N, therefore at a high sun exposure area, were classified as 
Spanish Caucasians and Arab immigrants [121]. The median serum 25(OH)D  
concentration for the whole sample was 68.39 nmol/L. Only 35.9% of the par-
ticipants had adequate serum 25(OH)D concentrations (75 nmol/L), while these 
concentrations were found to be inadequate (50–75 nmol/L) in 41.4% and deficient 
(<50 nmol/L) in 22.7% of respondents. Vitamin D status was lower in Arab women 
in comparison to Caucasian women [121]. Another study reported that in second 
trimester 40.7% (<50 nmol/L) of Chinese pregnant women who lived at their urban 
locations had vitamin D deficiency [122]. According to a cross-sectional study in 
China, 74.9% of Chinese pregnant women had vitamin D shortage (25-hydroxyvi-
tamin D < 50 nmol/L) [123]. In one of the National Health and Nutrition 
Examination Survey (NHANES) studies reported that among different factors, the 
largest magnitude of association was observed between race and 25(OH)D status. 
Those who were non-Hispanic whites in third trimester had a higher vitamin D 
levels (93 nmol/L) than non-Hispanic black (45 nmol/L) or Hispanic (69 nmol/L). 
WHO regions Percentage of 25-hydroxyvitamin D deficiency
% < 25*(nmol/L) % <50** (nmol/L)
Americas 64 9
European 57 23
Eastern Mediterranean 46 79
South-East Asian 87 N/A***
Western pacific 83 13
Adopted by Saraf et al. [106]. 
*Vitamin D deficiency.
**Severe vitamin D deficiency.
***Not available.
Table 2. 
Prevalence of maternal vitamin D deficiency classified by WHO region.
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and HIV-related mortality are other pregnancy implications related to vitamin D 
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concentrations were found to be inadequate (50–75 nmol/L) in 41.4% and deficient 
(<50 nmol/L) in 22.7% of respondents. Vitamin D status was lower in Arab women 
in comparison to Caucasian women [121]. Another study reported that in second 
trimester 40.7% (<50 nmol/L) of Chinese pregnant women who lived at their urban 
locations had vitamin D deficiency [122]. According to a cross-sectional study in 
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Vitamin D insufficiency in this study was 13%, 54% among whites, 80%, 95% 
among blacks, and 45%, 83% among Hispanics for 25(OH)D concentrations <50 
and <75 nmol/L, respectively [124]. A recent cohort study reported that 44% of 
non-European pregnant women in the Netherland had vitamin D deficiency com-
pared to European ones either with maternal serum or cord blood [125]. While from 
one of the Persian Gulf countries (United Arab Emirates (UAE)), 69% of vitamin D 
deficiency was reported among pregnant women [126].
Generally, previous recommendations have indicated that winter, higher 
latitude, dark pigmentation, season, limited sun exposure, and dressing style as 
risk factors for vitamin D deficiency. It can be difficult to describe the prevalence 
of pregnant women at risk to vitamin D deficiency because vitamin D status varies 
according to how deficiency is defined, as well as aforementioned risk factors 
[127–129]. These studies indicated that despite the geographical location of each 
region, vitamin D deficiency is highly prevalent among pregnant women because of 
the lifestyle and nutrition status of mothers. Future studies are required to investi-
gate vitamin D deficiency of pregnant women among different ethnic groups based 
on similar cut-off values for vitamin D deficiency.
As we discussed in Section 4, vitamin D deficiency has a key role in the develop-
ment of PET and GDM. In this section, we elaborate on the differences that the 
occurrence of these two diseases might have among different ethnic groups.
5.1 PET and GDM among ethnic disparities
Pregnant minorities have been the least studied in vitamin D-related diseases 
such as PET and GDM. According to a meta-analysis, the occurrence of PET is 
seen at lower vitamin D levels due to the immunomodulation properties of vita-
min D [52]. A recent study examined the evidence linking vitamin D deficiency 
in pregnancy to PET among different ethnic groups. Although prevalence of 
vitamin D deficiency differed significantly among African-Americans (72.3%), 
Hispanics (10.6%), and Caucasians (2.1%), there were no direct associations 
between low 25(OH)D levels and risk for PET among different ethnic groups 
[130]. While another recent study in UK indicated a greater prevalence of white 
British women developed GHT (12.0%) and PET (3.4%), compared to Pakistani 
women (the proportion of GHT and PET were 5.4 and 1.7%, respectively) [131]. 
The heterogeneity that exists among studies in terms of sun exposure (naturally 
occurring vitamin D synthesized from), geographical locations, considering 
different ethnic groups with divergent cultures, may lead to the differences in 
results.
It has been shown that maternal vitamin D concentration has inversely been 
linked to impaired glucose metabolism in pregnancy [132]. A few studies consid-
ered the effect of ethnicity on this relationship in pregnancy such as Clifton et al. 
study in Australia, which examined the association between serum 25(OH) D 
with GDM among five different ethnic groups including European (European 
Australian, English, German, Spanish), South-East Asian (Chinese, Japanese, 
Korean, Indonesian, Thai, Malaysian), Asian (Indian, Pakistani, Bangladeshi, Sri 
Lankan), Middle Eastern (Iranian, Iraqi, Lebanese, Syrian), and Other (Aboriginal 
Australian, Samoan, Papua New Guinean). They found no significant association 
between 25(OH)D and GDM in any ethnic group [132]. Generally, ethnicity was not 
an independent predictor of insulin resistance.
Overall, well-designed prospective cohort studies are needed to inform and 
update our knowledge regarding vitamin D deficiency and its association with PET 
and GDM among different ethnic minorities.
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5.2 Latitude
Sun exposure decreases dramatically, with increasing latitude [129]. It seems 
logical that higher latitudes would report a higher proportion of vitamin D defi-
ciency like Northern European countries, in comparison to the European South. 
In addition, almost all European Mediterranean countries are located at a high 
latitude (37–38°N), and previtamin D3 photosynthesis is lower during winter. 
Similar or even smaller proportion of vitamin D deficiency among pregnant women 
was reported from countries with higher latitudes in Western and Central Europe 
(latitudes 46–81°N) [133]; Slovenia with 46.5°N latitude, showed a high prevalence 
of severe vitamin D deficiency (23.6% with the threshold of <25 nmol/l) among 
pregnant women [134]. Even if in lower latitudes, the prevalence of maternal 
vitamin D deficiency is still high such as a study in China demonstrated that over 
90% of pregnant women in urban northern China (39.9°N), had vitamin D defi-
ciency (<50 nmol/l) and none had normal 25(OH)D concentrations (≥75 nmol/L) 
[135]. Although the Goulburn Valley in Northern Victoria (Australia) experiences 
abundant sunshine and located at 36° South of the equator, a place where vitamin 
D synthesis is possible during the year, 49.4% of pregnant women (<75 nmol/l) 
had vitamin D inadequacy and 12.2% (25–50 nmol/L) of pregnant women had a 
mild deficiency and 3.2% (<25 nmol/l) suffered a moderate/severe deficiency in 
summer [136]. A recent study from Bangkok, Thailand also revealed that 23.3% 
of Thai pregnant women had vitamin D deficiency in fall and 44.6% in winter 
(<50 nmol/L), despite the fact that this city is located at 13.45 N latitude and 
benefits sunlight throughout the year [137].
Over the past few decades, several studies have reported a high prevalence of 
maternal vitamin D deficiency in countries where women wear concealing cloth-
ing such as India (31%) [138], Saudi Arabia (14.2%) [139], and Iran (5.7%) [140] 
and countries in northern latitudes such as the United Kingdom (21.2%) [141] and 
Norway (33% deficiency and 18% severe deficiency across three ethnic groups) 
[142]. Due to less sunlight exposure, these pregnant women are at high risk of 
vitamin D deficiency. The duration of sun exposure is directly associated with the 
concentration of 25(OH)D [135, 138]. Mothers with less than 0.5 h/day of sun expo-
sure had a higher prevalence of vitamin D deficiency (38.4%) in China, which would 
worsen the situation in winter that the tendency toward outdoor physical activity 
decrease among pregnant women [135]. However, in sunny regions like Turkey, 
vitamin D deficiency among pregnant women is still a serious problem with the 
prevalence of 90% [143]. In addition, the prevalence of vitamin D deficiency (48%) 
was noted among pregnant women in South Carolina at latitude 32°N, where women 
lived in a sun-rich climate for most of the year [144]. Despite the longer duration 
of sunlight in UAE (ranges from 9 to 11 h), 69% of pregnant women suffer from 
vitamin D deficiency. It can be due to the decrease in time spent on outdoor activities 
and to the dressing style, which limits the surface area exposed to the sun [126].
Overall, latitude is an important factor but the other factors such as culture, 
belief, indoor lifestyle, etc., would play key roles in vitamin D deficiency in sun-rich 
countries.
5.3 Skin pigmentation
Skin pigmentation is the main determinant of ultraviolet B-rays (UV-B) absorp-
tion in humans [129]. The absorption of UV-B would be more when the skin is 
pale compared with the darker skin. In other words, the probability of vitamin D 
deficiency would be higher when skin pigmentation increases in critical periods 
Vitamin D Deficiency
42
Vitamin D insufficiency in this study was 13%, 54% among whites, 80%, 95% 
among blacks, and 45%, 83% among Hispanics for 25(OH)D concentrations <50 
and <75 nmol/L, respectively [124]. A recent cohort study reported that 44% of 
non-European pregnant women in the Netherland had vitamin D deficiency com-
pared to European ones either with maternal serum or cord blood [125]. While from 
one of the Persian Gulf countries (United Arab Emirates (UAE)), 69% of vitamin D 
deficiency was reported among pregnant women [126].
Generally, previous recommendations have indicated that winter, higher 
latitude, dark pigmentation, season, limited sun exposure, and dressing style as 
risk factors for vitamin D deficiency. It can be difficult to describe the prevalence 
of pregnant women at risk to vitamin D deficiency because vitamin D status varies 
according to how deficiency is defined, as well as aforementioned risk factors 
[127–129]. These studies indicated that despite the geographical location of each 
region, vitamin D deficiency is highly prevalent among pregnant women because of 
the lifestyle and nutrition status of mothers. Future studies are required to investi-
gate vitamin D deficiency of pregnant women among different ethnic groups based 
on similar cut-off values for vitamin D deficiency.
As we discussed in Section 4, vitamin D deficiency has a key role in the develop-
ment of PET and GDM. In this section, we elaborate on the differences that the 
occurrence of these two diseases might have among different ethnic groups.
5.1 PET and GDM among ethnic disparities
Pregnant minorities have been the least studied in vitamin D-related diseases 
such as PET and GDM. According to a meta-analysis, the occurrence of PET is 
seen at lower vitamin D levels due to the immunomodulation properties of vita-
min D [52]. A recent study examined the evidence linking vitamin D deficiency 
in pregnancy to PET among different ethnic groups. Although prevalence of 
vitamin D deficiency differed significantly among African-Americans (72.3%), 
Hispanics (10.6%), and Caucasians (2.1%), there were no direct associations 
between low 25(OH)D levels and risk for PET among different ethnic groups 
[130]. While another recent study in UK indicated a greater prevalence of white 
British women developed GHT (12.0%) and PET (3.4%), compared to Pakistani 
women (the proportion of GHT and PET were 5.4 and 1.7%, respectively) [131]. 
The heterogeneity that exists among studies in terms of sun exposure (naturally 
occurring vitamin D synthesized from), geographical locations, considering 
different ethnic groups with divergent cultures, may lead to the differences in 
results.
It has been shown that maternal vitamin D concentration has inversely been 
linked to impaired glucose metabolism in pregnancy [132]. A few studies consid-
ered the effect of ethnicity on this relationship in pregnancy such as Clifton et al. 
study in Australia, which examined the association between serum 25(OH) D 
with GDM among five different ethnic groups including European (European 
Australian, English, German, Spanish), South-East Asian (Chinese, Japanese, 
Korean, Indonesian, Thai, Malaysian), Asian (Indian, Pakistani, Bangladeshi, Sri 
Lankan), Middle Eastern (Iranian, Iraqi, Lebanese, Syrian), and Other (Aboriginal 
Australian, Samoan, Papua New Guinean). They found no significant association 
between 25(OH)D and GDM in any ethnic group [132]. Generally, ethnicity was not 
an independent predictor of insulin resistance.
Overall, well-designed prospective cohort studies are needed to inform and 
update our knowledge regarding vitamin D deficiency and its association with PET 
and GDM among different ethnic minorities.
43
Maternal Vitamin D Status among Different Ethnic Groups and Its Potential Contribution…
DOI: http://dx.doi.org/10.5772/intechopen.90766
5.2 Latitude
Sun exposure decreases dramatically, with increasing latitude [129]. It seems 
logical that higher latitudes would report a higher proportion of vitamin D defi-
ciency like Northern European countries, in comparison to the European South. 
In addition, almost all European Mediterranean countries are located at a high 
latitude (37–38°N), and previtamin D3 photosynthesis is lower during winter. 
Similar or even smaller proportion of vitamin D deficiency among pregnant women 
was reported from countries with higher latitudes in Western and Central Europe 
(latitudes 46–81°N) [133]; Slovenia with 46.5°N latitude, showed a high prevalence 
of severe vitamin D deficiency (23.6% with the threshold of <25 nmol/l) among 
pregnant women [134]. Even if in lower latitudes, the prevalence of maternal 
vitamin D deficiency is still high such as a study in China demonstrated that over 
90% of pregnant women in urban northern China (39.9°N), had vitamin D defi-
ciency (<50 nmol/l) and none had normal 25(OH)D concentrations (≥75 nmol/L) 
[135]. Although the Goulburn Valley in Northern Victoria (Australia) experiences 
abundant sunshine and located at 36° South of the equator, a place where vitamin 
D synthesis is possible during the year, 49.4% of pregnant women (<75 nmol/l) 
had vitamin D inadequacy and 12.2% (25–50 nmol/L) of pregnant women had a 
mild deficiency and 3.2% (<25 nmol/l) suffered a moderate/severe deficiency in 
summer [136]. A recent study from Bangkok, Thailand also revealed that 23.3% 
of Thai pregnant women had vitamin D deficiency in fall and 44.6% in winter 
(<50 nmol/L), despite the fact that this city is located at 13.45 N latitude and 
benefits sunlight throughout the year [137].
Over the past few decades, several studies have reported a high prevalence of 
maternal vitamin D deficiency in countries where women wear concealing cloth-
ing such as India (31%) [138], Saudi Arabia (14.2%) [139], and Iran (5.7%) [140] 
and countries in northern latitudes such as the United Kingdom (21.2%) [141] and 
Norway (33% deficiency and 18% severe deficiency across three ethnic groups) 
[142]. Due to less sunlight exposure, these pregnant women are at high risk of 
vitamin D deficiency. The duration of sun exposure is directly associated with the 
concentration of 25(OH)D [135, 138]. Mothers with less than 0.5 h/day of sun expo-
sure had a higher prevalence of vitamin D deficiency (38.4%) in China, which would 
worsen the situation in winter that the tendency toward outdoor physical activity 
decrease among pregnant women [135]. However, in sunny regions like Turkey, 
vitamin D deficiency among pregnant women is still a serious problem with the 
prevalence of 90% [143]. In addition, the prevalence of vitamin D deficiency (48%) 
was noted among pregnant women in South Carolina at latitude 32°N, where women 
lived in a sun-rich climate for most of the year [144]. Despite the longer duration 
of sunlight in UAE (ranges from 9 to 11 h), 69% of pregnant women suffer from 
vitamin D deficiency. It can be due to the decrease in time spent on outdoor activities 
and to the dressing style, which limits the surface area exposed to the sun [126].
Overall, latitude is an important factor but the other factors such as culture, 
belief, indoor lifestyle, etc., would play key roles in vitamin D deficiency in sun-rich 
countries.
5.3 Skin pigmentation
Skin pigmentation is the main determinant of ultraviolet B-rays (UV-B) absorp-
tion in humans [129]. The absorption of UV-B would be more when the skin is 
pale compared with the darker skin. In other words, the probability of vitamin D 
deficiency would be higher when skin pigmentation increases in critical periods 
Vitamin D Deficiency
44
like pregnancy [126]. Pregnant women who live in southern Europe have more 
pigmented skin, probably with less efficient vitamin D synthesis [145]. In Italy, 
vitamin D deficiency of pregnant women (with different ethnic groups) was 
examined based on their skin color (fair, black, light brown). It was found that 22% 
had severe vitamin D deficiency (<25 nmol/L) in total and fair-skinned mothers 
had higher 25(OH)D concentrations [146]. Another study in Netherland observed 
several ethnic backgrounds who reside in The Hague in the Netherlands (52°N), 
that vitamin D deficiency is more common among most non-Western participants 
(dark-skinned) (59–84%) compare to western women (fair-skinned) (8%) [147]. In 
southwestern Sweden, vitamin D deficiency was examined among pregnant women 
from different backgrounds with various skin colors. The prevalence of vitamin D 
deficiency was 10% overall, and 2% among mothers born in north Europe, while 
vitamin D deficiency among women born in Africa was 50% (<30 nmol/L) and 
deficiency was common among Asian mothers as well [148]. A recent US study 
reported in the multi-ethnic population of pregnant women in the southeastern 
USA, non-Hispanic black pregnant women are most at risk for vitamin D insuf-
ficiency (91%) compare to non-Hispanic white women (47%) and Hispanic women 
(75%) [149]. The concentration of melanin in the skin determines vitamin D 
production. Melanin, which absorbs UV-B in the 290–320 nm range, functions as 
a light filter and therefore regulates the proportion of the vitamin D production 
[150]. Thus, skin pigmentation is a dominant variable controlling the production 
of vitamin D under circumstances of low levels of sun exposures because melanin 
absorbs UV photons in competition with 7-dehydrocholesterol [151, 152]. Overall, 
darker-skinned pregnant women need a greater duration of sun exposure (4–5 
times) (they are more at risk in higher latitudes) in comparison to light-skinned 
ones to provide a comparable amount of vitamin D [153].
6. Maternal vitamin D status and fetal and postnatal outcomes
A growing body of evidence suggests that maternal vitamin D deficiency is 
associated with not only pregnancy outcomes, but also later physical and mental 
health of the offspring. In this section, we aim to review the existing literature 
investigating the impact of maternal vitamin D status during pregnancy on a range 
of fetal and postnatal outcomes.
6.1 Fetal skeletal development
During pregnancy, the fetus relies on maternal supply and placental delivery of 
vitamin D and calcium for optimal development and function, particularly of the 
skeletal system [154]. Maternal vitamin D deficiency during pregnancy predisposes 
breast-fed infants to neonatal hypocalcemia and infantile rickets [155, 156]. It has 
been reported that maternal UV-B exposure in pregnancy is related to bone mineral 
content (BMC) and bone mineral density (BMD) at age 9.9 years independently of 
height and lean mass [157]. Further, winter newborns in Korea were found to have 
6% lower total body BMC, lower cord serum 25(OH)D and 1,25-dihydroxyvitamin 
D than summer newborns [158]. These results suggest that low maternal vitamin D 
concentrations due to limited UV-B exposure may exert direct effects on offspring 
bone mineral accrual.
The influence of maternal vitamin D status on bone outcomes has been investi-
gated in several observational studies at fetal [159–161], postnatal [162–164], and 
adult stages [115, 165–167]. Using data from a prospective longitudinal study, Mahon 
et al. observed that lower maternal 25(OH)D concentration was associated with the 
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greater femoral metaphyseal cross-sectional area at 19 weeks gestation and 34 weeks 
gestation. However, lower maternal 25(OH)D concentration was not related to fetal 
femur length [159]. In another prospective longitudinal study, Young et al. found a 
significant positive association between maternal 25(OH)D levels and fetal femur 
and humerus z-scores only when maternal calcium intake was <1050 mg/d [160]. It 
has also been reported that maternal serum 25(OH)D concentration, together with 
maternal height and adiposity, was significant predictors of femoral size [161]. In a 
cross-sectional study with a longitudinal follow-up, tibia BMC was 0.047 g/cm higher, 
and cross-sectional area was 12.3 mm2 larger in newborns with the first trimester and 
cord serum 25(OH)D above the median (42.6 nmol/L) compared with below median 
newborns [162]. In another study, Morley et al. found smaller knee-heel length in 
infants of mothers with low 25(OH)D levels (<28 nmol/L) in late pregnancy (28–
32 weeks of gestation) compared to babies whose mothers had higher concentrations 
[163]. Dror et al. reported no association between feto-maternal vitamin D status and 
early infant whole-body BMC. However, a large percentage of mothers in their study 
had adequate vitamin D status, which may have affected the results [164]. These 
observations suggest that maternal vitamin D status during pregnancy can influence 
fetal bone growth as early as the second trimester of pregnancy.
Emerging evidence suggests that the relationships between maternal vitamin 
D status and bone outcomes persist into childhood and beyond [115, 165, 166]. 
In a longitudinal study by Javaid et al., it was found that reduced concentration 
of maternal 25(OH)D during late pregnancy was associated with reduced whole-
body and lumbar-spine BMC in children at age 9 years. Besides, childhood bone 
mass was predicted by maternal use of vitamin D supplements and the estimated 
exposure to UV-B radiation during late pregnancy [165]. Zhu et al., in a study of 
341 mother and offspring pairs, found a positive association between maternal 
25(OH)D concentration and total body BMC and BMD in offspring at 20 years of 
age [115]. These results were confirmed in another study where maternal vitamin 
D deficiency (25(OH)D < 50 nmol/L) during pregnancy was associated with lower 
peak bone mass at 20 years [166]. In contrast to these studies, Lawlor and colleagues 
observed no relevant association between vitamin D deficiency in pregnant women 
and offspring’s BMC in late childhood [167]. In another study, compared to children 
born to mothers with high vitamin D status, tibial BMC was lower at birth in chil-
dren with low maternal vitamin D status, while BMC gain was greater, resulting in 
similar BMC at 14 months [168]. The evidence derived from observational studies, 
although conflicting, tends to suggest an association between vitamin D deficiency 
in pregnant women and reduced bone mineral accrual in the offspring, which may 
increase fracture risk in later life.
6.2  Birth anthropometry, small-for-gestational-age (SGA), and childhood 
growth
There is controversy regarding the relationship between maternal vitamin D sta-
tus and neonatal birth weight, with some studies reporting an association between 
reduced maternal vitamin D levels and lower neonatal birth weight [169–174], and 
others showing no association [175–178]. While some studies found no association 
between maternal vitamin D levels and other anthropometric birth outcomes such 
as length and head circumference [176–179], others suggested a nonlinear relation 
between 25(OH)D levels and head circumference [171, 174].
Inconsistencies in the literature have led several researchers to conduct 
meta-analyses to further clarify the association between maternal vitamin D 
concentrations and anthropometric outcomes in offspring. Four meta-analyses 
of observational studies have been published in recent years [45, 52, 180, 181]. In 
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like pregnancy [126]. Pregnant women who live in southern Europe have more 
pigmented skin, probably with less efficient vitamin D synthesis [145]. In Italy, 
vitamin D deficiency of pregnant women (with different ethnic groups) was 
examined based on their skin color (fair, black, light brown). It was found that 22% 
had severe vitamin D deficiency (<25 nmol/L) in total and fair-skinned mothers 
had higher 25(OH)D concentrations [146]. Another study in Netherland observed 
several ethnic backgrounds who reside in The Hague in the Netherlands (52°N), 
that vitamin D deficiency is more common among most non-Western participants 
(dark-skinned) (59–84%) compare to western women (fair-skinned) (8%) [147]. In 
southwestern Sweden, vitamin D deficiency was examined among pregnant women 
from different backgrounds with various skin colors. The prevalence of vitamin D 
deficiency was 10% overall, and 2% among mothers born in north Europe, while 
vitamin D deficiency among women born in Africa was 50% (<30 nmol/L) and 
deficiency was common among Asian mothers as well [148]. A recent US study 
reported in the multi-ethnic population of pregnant women in the southeastern 
USA, non-Hispanic black pregnant women are most at risk for vitamin D insuf-
ficiency (91%) compare to non-Hispanic white women (47%) and Hispanic women 
(75%) [149]. The concentration of melanin in the skin determines vitamin D 
production. Melanin, which absorbs UV-B in the 290–320 nm range, functions as 
a light filter and therefore regulates the proportion of the vitamin D production 
[150]. Thus, skin pigmentation is a dominant variable controlling the production 
of vitamin D under circumstances of low levels of sun exposures because melanin 
absorbs UV photons in competition with 7-dehydrocholesterol [151, 152]. Overall, 
darker-skinned pregnant women need a greater duration of sun exposure (4–5 
times) (they are more at risk in higher latitudes) in comparison to light-skinned 
ones to provide a comparable amount of vitamin D [153].
6. Maternal vitamin D status and fetal and postnatal outcomes
A growing body of evidence suggests that maternal vitamin D deficiency is 
associated with not only pregnancy outcomes, but also later physical and mental 
health of the offspring. In this section, we aim to review the existing literature 
investigating the impact of maternal vitamin D status during pregnancy on a range 
of fetal and postnatal outcomes.
6.1 Fetal skeletal development
During pregnancy, the fetus relies on maternal supply and placental delivery of 
vitamin D and calcium for optimal development and function, particularly of the 
skeletal system [154]. Maternal vitamin D deficiency during pregnancy predisposes 
breast-fed infants to neonatal hypocalcemia and infantile rickets [155, 156]. It has 
been reported that maternal UV-B exposure in pregnancy is related to bone mineral 
content (BMC) and bone mineral density (BMD) at age 9.9 years independently of 
height and lean mass [157]. Further, winter newborns in Korea were found to have 
6% lower total body BMC, lower cord serum 25(OH)D and 1,25-dihydroxyvitamin 
D than summer newborns [158]. These results suggest that low maternal vitamin D 
concentrations due to limited UV-B exposure may exert direct effects on offspring 
bone mineral accrual.
The influence of maternal vitamin D status on bone outcomes has been investi-
gated in several observational studies at fetal [159–161], postnatal [162–164], and 
adult stages [115, 165–167]. Using data from a prospective longitudinal study, Mahon 
et al. observed that lower maternal 25(OH)D concentration was associated with the 
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greater femoral metaphyseal cross-sectional area at 19 weeks gestation and 34 weeks 
gestation. However, lower maternal 25(OH)D concentration was not related to fetal 
femur length [159]. In another prospective longitudinal study, Young et al. found a 
significant positive association between maternal 25(OH)D levels and fetal femur 
and humerus z-scores only when maternal calcium intake was <1050 mg/d [160]. It 
has also been reported that maternal serum 25(OH)D concentration, together with 
maternal height and adiposity, was significant predictors of femoral size [161]. In a 
cross-sectional study with a longitudinal follow-up, tibia BMC was 0.047 g/cm higher, 
and cross-sectional area was 12.3 mm2 larger in newborns with the first trimester and 
cord serum 25(OH)D above the median (42.6 nmol/L) compared with below median 
newborns [162]. In another study, Morley et al. found smaller knee-heel length in 
infants of mothers with low 25(OH)D levels (<28 nmol/L) in late pregnancy (28–
32 weeks of gestation) compared to babies whose mothers had higher concentrations 
[163]. Dror et al. reported no association between feto-maternal vitamin D status and 
early infant whole-body BMC. However, a large percentage of mothers in their study 
had adequate vitamin D status, which may have affected the results [164]. These 
observations suggest that maternal vitamin D status during pregnancy can influence 
fetal bone growth as early as the second trimester of pregnancy.
Emerging evidence suggests that the relationships between maternal vitamin 
D status and bone outcomes persist into childhood and beyond [115, 165, 166]. 
In a longitudinal study by Javaid et al., it was found that reduced concentration 
of maternal 25(OH)D during late pregnancy was associated with reduced whole-
body and lumbar-spine BMC in children at age 9 years. Besides, childhood bone 
mass was predicted by maternal use of vitamin D supplements and the estimated 
exposure to UV-B radiation during late pregnancy [165]. Zhu et al., in a study of 
341 mother and offspring pairs, found a positive association between maternal 
25(OH)D concentration and total body BMC and BMD in offspring at 20 years of 
age [115]. These results were confirmed in another study where maternal vitamin 
D deficiency (25(OH)D < 50 nmol/L) during pregnancy was associated with lower 
peak bone mass at 20 years [166]. In contrast to these studies, Lawlor and colleagues 
observed no relevant association between vitamin D deficiency in pregnant women 
and offspring’s BMC in late childhood [167]. In another study, compared to children 
born to mothers with high vitamin D status, tibial BMC was lower at birth in chil-
dren with low maternal vitamin D status, while BMC gain was greater, resulting in 
similar BMC at 14 months [168]. The evidence derived from observational studies, 
although conflicting, tends to suggest an association between vitamin D deficiency 
in pregnant women and reduced bone mineral accrual in the offspring, which may 
increase fracture risk in later life.
6.2  Birth anthropometry, small-for-gestational-age (SGA), and childhood 
growth
There is controversy regarding the relationship between maternal vitamin D sta-
tus and neonatal birth weight, with some studies reporting an association between 
reduced maternal vitamin D levels and lower neonatal birth weight [169–174], and 
others showing no association [175–178]. While some studies found no association 
between maternal vitamin D levels and other anthropometric birth outcomes such 
as length and head circumference [176–179], others suggested a nonlinear relation 
between 25(OH)D levels and head circumference [171, 174].
Inconsistencies in the literature have led several researchers to conduct 
meta-analyses to further clarify the association between maternal vitamin D 
concentrations and anthropometric outcomes in offspring. Four meta-analyses 
of observational studies have been published in recent years [45, 52, 180, 181]. In 
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the first study, Wei et al. carried out a meta-analysis on six studies and found that 
pregnant women with circulating 25(OH)D levels less than 50 nmol/L experi-
enced an about 1.5-fold increased risk of SGA [45]. These results were confirmed 
in another meta-analysis of 13 prospective cohort studies, in which a significant 
positive association was found between maternal vitamin D deficiency and risk of 
SGA infants (pooled odds ratio 1.58; 95% CI 1.14–2.22) in the random effects model 
[180]. Similar results were obtained in subgroup analyses by study quality (high vs. 
low), gestational week for blood sampling (first trimester vs. second trimester vs. 
mixed), cut-off vitamin D levels (<10 ng/mL vs. <15 ng/mL vs. <20 ng/mL), sample 
size (N > 1000 vs. N < 1000), adjustment for critical confounders (Yes vs. No), and 
method for measuring vitamin D (liquid chromatography with tandem mass spec-
trometry vs. others) [180]. There results suggest that maternal vitamin D deficiency 
may be associated with an increased risk of SGA infants.
A meta-analysis conducted in 2013 showed that insufficient serum levels of 
25(OH)D in pregnant women was associated with increased risk of having SGA 
infants (pooled odds ratio 1.85; 95% CI 1.52–2.26) [52]. In terms of birth weight, 
the authors used data from four observational studies and found infants of moth-
ers with low 25(OH)D concentrations during pregnancy (<37.5 nmol/L) had 
lower birth weight (random weighted mean difference −130.9 g). However, no 
significant difference was observed between maternal vitamin D status and other 
anthropometric outcomes such as birth length and head circumference [52]. The 
most recent meta-analysis conducted by Tous et al. included 54 eligible stud-
ies and reported that vitamin D-deficient mothers (<30 nmol/L) had offspring 
with lower birth-weight (mean difference −87.82 g), head circumference (mean 
difference −0.19 cm), and a higher risk of SGA infants (odds ratio 1.59; 95% CI 
1.24–2.03) compared to mothers with concentrations ≥30 nmol/L. However, no 
difference was observed in terms of infants’ length [181]. The results also revealed 
a significant association between vitamin D insufficiency (<50 nmol/L) and 
increased risk of SGA (odds ratio 1.43; 95% CI 1.08–1.91). The authors found no 
significant differences in birth-weight and SGA between offspring born to moth-
ers with 25(OH)D concentrations <75 nmol/L and those born to mothers with 
25(OH) D concentrations ≥75 nmol/L [181]. Further, a meta-analysis of 13 inter-
ventional studies revealed that vitamin D supplementation during pregnancy was 
associated with significantly higher circulating 25(OH)D levels (mean difference: 
66.5 nmol/L), birth weight (mean difference: 107.6 g), and birth length (mean 
difference: 0.3 cm), when compared to the control group [182]. Neonates exposed 
to low levels of vitamin D in utero (<30 nmol/L) showed accelerated growth in 
length and weight during the first year of life to compensate for their small initial 
size [183, 184]. There results suggest that maternal vitamin D deficiency is associ-
ated not only with increased risk of SGA infants but also with lower birth-weight. 
However, more studies are required to draw a firm conclusion on the relationship 
between maternal vitamin D status and other anthropometric outcomes.
6.3 Offspring soft tissue body composition
A growing body of evidence suggests that maternal vitamin D status in preg-
nancy may play a part in the offspring adipogenesis [185–189]; however, not all 
studies are in agreement [190, 191]. Tint et al. conducted a study to examine the 
association between maternal 25(OH)D status at mid-gestation and neonatal 
abdominal adipose tissue (AT) compartments. The findings indicated an inverse 
liner correlation between maternal 25(OH)D and both superficial and deep sub-
cutaneous AT compartments measured by magnetic resonance imaging (MRI). 
In addition, compared to neonates born to mothers with 25(OH)D sufficiency 
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(>75.0 nmol/L), neonates with maternal 25(OH)D inadequacy had higher superficial 
and deep subcutaneous AT volumes, despite similar birth weight [185]. However, 
in a prospective observational study, Godang et al. reported a positive association 
between neonatal total body fat mass (FM) and umbilical cord plasma, but not 
maternal, 25(OH)D [190]. This was confirmed in another study where a positive 
correlation between cord blood 25(OH)D levels and neonatal percentage body fat 
was observed [192]. Using data from the Southampton Women’s Survey, Crozier 
et al. found that lower maternal vitamin D status at 34-week gestation was associated 
with lower FM in the offspring at birth but with greater FM at ages 4 and 6 years 
[186]. Similarly, a prospective pregnancy cohort conducted by Daraki et al. showed 
that offspring of mothers in the low 25(OH)D tertile (<37.7 nmol/L) had higher BMI 
and waist circumference at preschool age, compared with the offspring of women 
with higher 25(OH)D concentrations, and this relationship persisted at age 6 years 
[187]. Results from a recent prospective cohort conducted in 476 mother/infant 
dyads also demonstrated that reduced maternal 25(OH)D (first quartile compared 
to the fourth quartile) was associated with lower birth weight for gestational age 
z-scores (−0.43 units) but higher 1-year weight-for-length (0.78 units) and 3-year 
BMI z-scores (0.83 units) in offspring [188]. In another study, maternal deficit of 
25(OH) D (<50 nmol/L) was reported to be associated with increased risk of fetal 
overweight defined as abdominal circumference ≥90th percentile or either as the 
estimated fetal weight ≥90th percentile. Moreover, a significant association was 
found between deficit of 25(OH)D in pregnancy and increased risk of overweight 
in offspring at age 1 year. However, this association was attenuated at age 4 years 
[189]. In contrast to these studies, Ong and colleagues, in a mother-offspring cohort 
in Singapore, observed no significant associations between maternal vitamin D 
status and any of the adiposity outcomes (i.e., BMI and skinfold thickness) at birth 
or postnatally. This was partly explained by the low prevalence of severe maternal 
vitamin D deficiency in the studied population (mean maternal vitamin D concen-
tration of 81.3 nmol/L) [191]. These findings suggest that intrauterine exposure to 
low 25(OH)D concentrations may be linked to lower FM at birth but greater FM 
during childhood. A higher FM may also contribute to decreased 25(OH)D levels in 
obese individuals, partly due to the sequestration of vitamin D by AT [193].
A limited number of studies have investigated the influence of maternal vitamin 
D status on offspring lean mass or muscle strength [194, 195]. Using data from 
Mysore Parthenon Study, Krishnaveni et al. reported that Indian children born to 
vitamin D-deficient mothers (serum 25(OH)D < 50 nmol/L) had a smaller arm-
muscle area at ages 5 and 9.5 years in comparison with children born to mothers 
without deficiency. However, no difference in grip strength was observed between 
the offspring of mothers with and without vitamin D deficiency [194]. In contrast, 
a study conducted in 678 mother-child pairs showed that maternal serum 25(OH) D 
concentration in pregnancy was positively associated with height-adjusted hand 
grip strength but not muscle mass in offspring at 4 years of age [195]. These results 
suggest that low maternal vitamin D status may be associated with the smaller arm-
muscle area and lower muscle strength in the offspring. However, more observa-
tions are required to draw a firm conclusion on this matter.
6.4 Respiratory health
In humans, lung development starts in utero with the formation of two endo-
dermally derived lung buds and continues through childhood, adolescence, and 
early adulthood [196]. A growing body of evidence suggests that the origins of 
respiratory disorders such as asthma can be traced back to the fetal period when the 
lung is undergoing rapid development [197, 198]. It has been shown that vitamin D 
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the first study, Wei et al. carried out a meta-analysis on six studies and found that 
pregnant women with circulating 25(OH)D levels less than 50 nmol/L experi-
enced an about 1.5-fold increased risk of SGA [45]. These results were confirmed 
in another meta-analysis of 13 prospective cohort studies, in which a significant 
positive association was found between maternal vitamin D deficiency and risk of 
SGA infants (pooled odds ratio 1.58; 95% CI 1.14–2.22) in the random effects model 
[180]. Similar results were obtained in subgroup analyses by study quality (high vs. 
low), gestational week for blood sampling (first trimester vs. second trimester vs. 
mixed), cut-off vitamin D levels (<10 ng/mL vs. <15 ng/mL vs. <20 ng/mL), sample 
size (N > 1000 vs. N < 1000), adjustment for critical confounders (Yes vs. No), and 
method for measuring vitamin D (liquid chromatography with tandem mass spec-
trometry vs. others) [180]. There results suggest that maternal vitamin D deficiency 
may be associated with an increased risk of SGA infants.
A meta-analysis conducted in 2013 showed that insufficient serum levels of 
25(OH)D in pregnant women was associated with increased risk of having SGA 
infants (pooled odds ratio 1.85; 95% CI 1.52–2.26) [52]. In terms of birth weight, 
the authors used data from four observational studies and found infants of moth-
ers with low 25(OH)D concentrations during pregnancy (<37.5 nmol/L) had 
lower birth weight (random weighted mean difference −130.9 g). However, no 
significant difference was observed between maternal vitamin D status and other 
anthropometric outcomes such as birth length and head circumference [52]. The 
most recent meta-analysis conducted by Tous et al. included 54 eligible stud-
ies and reported that vitamin D-deficient mothers (<30 nmol/L) had offspring 
with lower birth-weight (mean difference −87.82 g), head circumference (mean 
difference −0.19 cm), and a higher risk of SGA infants (odds ratio 1.59; 95% CI 
1.24–2.03) compared to mothers with concentrations ≥30 nmol/L. However, no 
difference was observed in terms of infants’ length [181]. The results also revealed 
a significant association between vitamin D insufficiency (<50 nmol/L) and 
increased risk of SGA (odds ratio 1.43; 95% CI 1.08–1.91). The authors found no 
significant differences in birth-weight and SGA between offspring born to moth-
ers with 25(OH)D concentrations <75 nmol/L and those born to mothers with 
25(OH) D concentrations ≥75 nmol/L [181]. Further, a meta-analysis of 13 inter-
ventional studies revealed that vitamin D supplementation during pregnancy was 
associated with significantly higher circulating 25(OH)D levels (mean difference: 
66.5 nmol/L), birth weight (mean difference: 107.6 g), and birth length (mean 
difference: 0.3 cm), when compared to the control group [182]. Neonates exposed 
to low levels of vitamin D in utero (<30 nmol/L) showed accelerated growth in 
length and weight during the first year of life to compensate for their small initial 
size [183, 184]. There results suggest that maternal vitamin D deficiency is associ-
ated not only with increased risk of SGA infants but also with lower birth-weight. 
However, more studies are required to draw a firm conclusion on the relationship 
between maternal vitamin D status and other anthropometric outcomes.
6.3 Offspring soft tissue body composition
A growing body of evidence suggests that maternal vitamin D status in preg-
nancy may play a part in the offspring adipogenesis [185–189]; however, not all 
studies are in agreement [190, 191]. Tint et al. conducted a study to examine the 
association between maternal 25(OH)D status at mid-gestation and neonatal 
abdominal adipose tissue (AT) compartments. The findings indicated an inverse 
liner correlation between maternal 25(OH)D and both superficial and deep sub-
cutaneous AT compartments measured by magnetic resonance imaging (MRI). 
In addition, compared to neonates born to mothers with 25(OH)D sufficiency 
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(>75.0 nmol/L), neonates with maternal 25(OH)D inadequacy had higher superficial 
and deep subcutaneous AT volumes, despite similar birth weight [185]. However, 
in a prospective observational study, Godang et al. reported a positive association 
between neonatal total body fat mass (FM) and umbilical cord plasma, but not 
maternal, 25(OH)D [190]. This was confirmed in another study where a positive 
correlation between cord blood 25(OH)D levels and neonatal percentage body fat 
was observed [192]. Using data from the Southampton Women’s Survey, Crozier 
et al. found that lower maternal vitamin D status at 34-week gestation was associated 
with lower FM in the offspring at birth but with greater FM at ages 4 and 6 years 
[186]. Similarly, a prospective pregnancy cohort conducted by Daraki et al. showed 
that offspring of mothers in the low 25(OH)D tertile (<37.7 nmol/L) had higher BMI 
and waist circumference at preschool age, compared with the offspring of women 
with higher 25(OH)D concentrations, and this relationship persisted at age 6 years 
[187]. Results from a recent prospective cohort conducted in 476 mother/infant 
dyads also demonstrated that reduced maternal 25(OH)D (first quartile compared 
to the fourth quartile) was associated with lower birth weight for gestational age 
z-scores (−0.43 units) but higher 1-year weight-for-length (0.78 units) and 3-year 
BMI z-scores (0.83 units) in offspring [188]. In another study, maternal deficit of 
25(OH) D (<50 nmol/L) was reported to be associated with increased risk of fetal 
overweight defined as abdominal circumference ≥90th percentile or either as the 
estimated fetal weight ≥90th percentile. Moreover, a significant association was 
found between deficit of 25(OH)D in pregnancy and increased risk of overweight 
in offspring at age 1 year. However, this association was attenuated at age 4 years 
[189]. In contrast to these studies, Ong and colleagues, in a mother-offspring cohort 
in Singapore, observed no significant associations between maternal vitamin D 
status and any of the adiposity outcomes (i.e., BMI and skinfold thickness) at birth 
or postnatally. This was partly explained by the low prevalence of severe maternal 
vitamin D deficiency in the studied population (mean maternal vitamin D concen-
tration of 81.3 nmol/L) [191]. These findings suggest that intrauterine exposure to 
low 25(OH)D concentrations may be linked to lower FM at birth but greater FM 
during childhood. A higher FM may also contribute to decreased 25(OH)D levels in 
obese individuals, partly due to the sequestration of vitamin D by AT [193].
A limited number of studies have investigated the influence of maternal vitamin 
D status on offspring lean mass or muscle strength [194, 195]. Using data from 
Mysore Parthenon Study, Krishnaveni et al. reported that Indian children born to 
vitamin D-deficient mothers (serum 25(OH)D < 50 nmol/L) had a smaller arm-
muscle area at ages 5 and 9.5 years in comparison with children born to mothers 
without deficiency. However, no difference in grip strength was observed between 
the offspring of mothers with and without vitamin D deficiency [194]. In contrast, 
a study conducted in 678 mother-child pairs showed that maternal serum 25(OH) D 
concentration in pregnancy was positively associated with height-adjusted hand 
grip strength but not muscle mass in offspring at 4 years of age [195]. These results 
suggest that low maternal vitamin D status may be associated with the smaller arm-
muscle area and lower muscle strength in the offspring. However, more observa-
tions are required to draw a firm conclusion on this matter.
6.4 Respiratory health
In humans, lung development starts in utero with the formation of two endo-
dermally derived lung buds and continues through childhood, adolescence, and 
early adulthood [196]. A growing body of evidence suggests that the origins of 
respiratory disorders such as asthma can be traced back to the fetal period when the 
lung is undergoing rapid development [197, 198]. It has been shown that vitamin D 
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is involved in the process of maturation of the fetal lung including type II alveolar 
cells maturation and the alveolarization [199]. Currently, there are four meta-
analyses published within a 3-year period from 2016 to 2018, which examined the 
association between maternal 25(OH)D levels during pregnancy and the offspring’s 
respiratory conditions [200–203]. The first meta-analysis included eight studies 
on the association between maternal vitamin D status and childhood asthma or 
wheeze. This meta-analysis showed no statistical association between maternal 
vitamin D during pregnancy and risk of childhood asthma or childhood wheeze 
[200]. In contrast, the second meta-analysis included 15 prospective studies with 
12,758 participants and found a U-shaped relationship between 25(OH) D levels 
during pregnancy and risk of childhood asthma, with the lowest risk at approxi-
mately 70 nmol/L [201]. The third meta-analysis assessed the association of both 
cord blood and maternal 25(OH)D levels with the risk of offspring’s asthma, 
wheeze, and respiratory tract infections. The results revealed borderline significant 
inverse associations between in utero exposure to vitamin D and risk of asthma 
and wheeze, but not the risk of respiratory tract infections in offspring [202]. In 
the final and most recent meta-analysis, Pacheco-González et al. found an inverse 
association between prenatal exposure to 25(OH)D and the risk of respiratory tract 
infections. The authors also observed a positive borderline association between 
maternal or cord blood 25(OH)D levels and lung function at school age. However, 
no associations were found for asthma and wheeze [203]. The apparently conflict-
ing results of meta-analyses may be partly explained by differences in inclusion 
criteria, the number of studies, the characteristics of participants and the meth-
odology used. Further, the results of two other meta-analyses revealed that higher 
maternal intake of vitamin D was associated with lower odds of wheeze during 
childhood [204, 205]. Taken together, these results suggest the role of maternal 
vitamin D status as a protective factor for the development of offspring respiratory 
disorders.
6.5 Immunity and allergies
Some studies are suggesting that low maternal or cord blood 25(OH)D con-
centrations are associated with an increased risk of developing atopic disorders, 
including atopic dermatitis or eczema, allergic rhinitis, asthma, and food allergy 
[206–209]. A study conducted in 270 mother-child pairs showed that a higher 
cord blood 25(OH)D concentration was associated with reduced risk of eczema in 
children at 1 and 3 years of age. However, no significant associations were found 
between cord blood 25(OH)D concentration and the development of allergic rhini-
tis, allergic sensitization, or asthma [206]. In another study, cord serum 25(OH) D 
levels were found to be inversely associated with the risk of atopic dermatitis by 
the age of 5 years, but no association was reported with allergic rhinitis and asthma 
[207]. Chiu et al. observed a significant association between low cord blood 25(OH)
D levels and increased risk of milk sensitization but not eczema, allergic rhinitis, 
or asthma in early childhood [208]. In another study with the same authors, it was 
revealed that lower maternal 25(OH)D levels (<20 ng/ml) were associated with 
a higher prevalence of allergen sensitization before age 2, and higher maternal 
25(OH)D levels were associated with lower risk of eczema and asthma at age 4 
[209]. Wei et al. conducted a meta-analysis of prospective cohort studies to examine 
the association between maternal vitamin D status and childhood allergic diseases. 
They found an inverse association between maternal vitamin D status during preg-
nancy and risk of childhood eczema but not childhood asthma or wheeze [200]. 
However, a recent meta-analysis of observational studies reported no significant 
associations between 25(OH)D levels in cord blood at birth or maternal blood in 
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pregnancy and the risk of atopic disorders [203]. Taken together, these studies 
indicate that lower maternal 25(OH)D concentration may be associated with an 
increased risk of developing atopic disorders.
Here, we discuss the role of intrauterine vitamin D exposure on the risk of two 
common autoimmune diseases—type 1 diabetes and multiple sclerosis. Type 1 
diabetes mellitus is an autoimmune disease characterized by the destruction of the 
insulin-producing pancreatic β-cells of the Langerhans islets [210]. Staples et al. 
found an inverse association between annual ambient UV radiation exposure and 
prevalence of type 1 diabetes in Australia, which was suggested to be due to the role 
of UV radiation in vitamin D synthesis [211]. In a case-control study conducted in 
109 cases and 219 control women, it was observed that lower levels of vitamin D 
during pregnancy were associated with a higher risk of developing type 1 diabetes 
in offspring before 15 years of age [212]. In contrast, in another case-control study 
conducted in Finnish women, Miettinen et al. found no difference between serum 
25(OH)D levels during early pregnancy between mothers whose children later on 
developed type 1 diabetes, and mothers of healthy children [213]. Thorsen and col-
leagues showed that normal variation in maternal or neonatal 25(OH)D levels has 
no significant effect on the risk of childhood type 1 diabetes [214]. Jacobsen et al. 
also failed to find an association between 25(OH)D levels around the time of birth 
and the risk of developing type 1 diabetes before the age of 18 years [215]. As these 
studies found inconsistent results, more research is still needed before any conclu-
sions can be drawn on the relationship between maternal vitamin D status and risk 
of developing type 1 diabetes in offspring.
Multiple sclerosis (MS) is an autoimmune disease, in which the immune system 
attacks the myelin sheaths surrounding nerve cells [216]. Accumulating evidence 
suggests an association between the month of birth and risk of MS [217–219], pos-
sibly due to variation in UV exposure, which in turn determines maternal vitamin 
D levels during pregnancy. In support of this hypothesis, Munger et al. reported 
that maternal vitamin D deficiency (<30.0 nmol/L) during early pregnancy was 
associated with increased risk of MS (almost 2-fold) in the offspring compared 
with women with normal 25(OH)D levels [220]. A nested case-control study 
demonstrated that exposure to high 25(OH)D levels during the years preceding 
disease onset was associated with decreased risk of MS in the offspring. However, 
no decrease in risk of MS was observed in the offspring exposed to high levels 
of 25(OH)D in utero (≥75 vs. <75 nmol/L) [221]. Nielsen et al. also carried out 
a matched case-control study and found an association between lower levels of 
25(OH)D in neonates and increased risk of MS [222]. However, in another popula-
tion-based case-control study conducted in Sweden, Ueda et al. failed to find such 
as association [223]. These results suggest that exposure to low levels of 25(OH)D 
prenatal and in early postnatal life may act as a risk factor for developing MS.
6.6 Offspring brain development and function
A growing body of evidence suggests that low maternal 25(OH)D levels during 
pregnancy are associated with impaired neurodevelopmental and neurocognitive 
outcomes during infancy and childhood [117, 224–228]; however, not all studies 
are in agreement [229, 230]. In this regard, several studies have shown a significant 
association between suboptimal maternal vitamin D status and reduced language 
developmental outcomes in the offspring [224–226].
Accumulating evidence also suggests a link between maternal vitamin D levels 
and the risk of developing neuropsychiatric disorders such as attention deficit 
hyperactivity disorder (ADHD) [231, 232], autism spectrum disorder (ASD) 
[233–236], and schizophrenia [237]. Results from a prospective pregnancy cohort 
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is involved in the process of maturation of the fetal lung including type II alveolar 
cells maturation and the alveolarization [199]. Currently, there are four meta-
analyses published within a 3-year period from 2016 to 2018, which examined the 
association between maternal 25(OH)D levels during pregnancy and the offspring’s 
respiratory conditions [200–203]. The first meta-analysis included eight studies 
on the association between maternal vitamin D status and childhood asthma or 
wheeze. This meta-analysis showed no statistical association between maternal 
vitamin D during pregnancy and risk of childhood asthma or childhood wheeze 
[200]. In contrast, the second meta-analysis included 15 prospective studies with 
12,758 participants and found a U-shaped relationship between 25(OH) D levels 
during pregnancy and risk of childhood asthma, with the lowest risk at approxi-
mately 70 nmol/L [201]. The third meta-analysis assessed the association of both 
cord blood and maternal 25(OH)D levels with the risk of offspring’s asthma, 
wheeze, and respiratory tract infections. The results revealed borderline significant 
inverse associations between in utero exposure to vitamin D and risk of asthma 
and wheeze, but not the risk of respiratory tract infections in offspring [202]. In 
the final and most recent meta-analysis, Pacheco-González et al. found an inverse 
association between prenatal exposure to 25(OH)D and the risk of respiratory tract 
infections. The authors also observed a positive borderline association between 
maternal or cord blood 25(OH)D levels and lung function at school age. However, 
no associations were found for asthma and wheeze [203]. The apparently conflict-
ing results of meta-analyses may be partly explained by differences in inclusion 
criteria, the number of studies, the characteristics of participants and the meth-
odology used. Further, the results of two other meta-analyses revealed that higher 
maternal intake of vitamin D was associated with lower odds of wheeze during 
childhood [204, 205]. Taken together, these results suggest the role of maternal 
vitamin D status as a protective factor for the development of offspring respiratory 
disorders.
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Some studies are suggesting that low maternal or cord blood 25(OH)D con-
centrations are associated with an increased risk of developing atopic disorders, 
including atopic dermatitis or eczema, allergic rhinitis, asthma, and food allergy 
[206–209]. A study conducted in 270 mother-child pairs showed that a higher 
cord blood 25(OH)D concentration was associated with reduced risk of eczema in 
children at 1 and 3 years of age. However, no significant associations were found 
between cord blood 25(OH)D concentration and the development of allergic rhini-
tis, allergic sensitization, or asthma [206]. In another study, cord serum 25(OH) D 
levels were found to be inversely associated with the risk of atopic dermatitis by 
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D levels and increased risk of milk sensitization but not eczema, allergic rhinitis, 
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[209]. Wei et al. conducted a meta-analysis of prospective cohort studies to examine 
the association between maternal vitamin D status and childhood allergic diseases. 
They found an inverse association between maternal vitamin D status during preg-
nancy and risk of childhood eczema but not childhood asthma or wheeze [200]. 
However, a recent meta-analysis of observational studies reported no significant 
associations between 25(OH)D levels in cord blood at birth or maternal blood in 
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a matched case-control study and found an association between lower levels of 
25(OH)D in neonates and increased risk of MS [222]. However, in another popula-
tion-based case-control study conducted in Sweden, Ueda et al. failed to find such 
as association [223]. These results suggest that exposure to low levels of 25(OH)D 
prenatal and in early postnatal life may act as a risk factor for developing MS.
6.6 Offspring brain development and function
A growing body of evidence suggests that low maternal 25(OH)D levels during 
pregnancy are associated with impaired neurodevelopmental and neurocognitive 
outcomes during infancy and childhood [117, 224–228]; however, not all studies 
are in agreement [229, 230]. In this regard, several studies have shown a significant 
association between suboptimal maternal vitamin D status and reduced language 
developmental outcomes in the offspring [224–226].
Accumulating evidence also suggests a link between maternal vitamin D levels 
and the risk of developing neuropsychiatric disorders such as attention deficit 
hyperactivity disorder (ADHD) [231, 232], autism spectrum disorder (ASD) 
[233–236], and schizophrenia [237]. Results from a prospective pregnancy cohort 
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conducted in 487 mother-child pairs revealed that children born to mothers in the 
high 25(OH)D tertile (>50.7 nmol/l) had decreased risk of developing ADHD-like 
symptoms at 4 years of age, compared to children of women in the low 25(OH) D 
tertile (<38.4 nmol/l) [231]. In another prospective study conducted in 1650 
mother-child pairs, Morales et al. found an inverse association between maternal 
circulating levels of 25(OH)D in pregnancy and risk of developing ADHD-like 
at ages 4–5 years [232]. Using a case-control design study, Chen and colleagues 
reported that low maternal first-trimester serum levels of 25(OH)D was associ-
ated with increased odds of ASD diagnosis at age 3–7 years in the offspring [233]. 
Another study also found an increased risk of ASD in children who were born to 
mothers with vitamin D deficiency at mid-gestation [234]. In a large population-
based cohort of mothers and their children, gestational vitamin D deficiency was 
associated with a continuous measure of autism-related traits at 6 years [235]. 
Magnusson et al. also observed a relationship between maternal vitamin D defi-
ciency and risk of ASD with, but not without, intellectual disability [236]. Further, 
it has been demonstrated that low maternal vitamin D levels are associated with 
increased risk of schizophrenia within the subgroup of black but not white individ-
uals [237]. Although more robust studies needed, these results highlight the impor-
tance of maternal vitamin D status in offspring brain development and function.
7.  The association of maternal vitamin D status and child vitamin D 
status
Several lines of evidence suggest that there is a strong association between 
maternal 25(OH)D levels during pregnancy and newborn 25(OH)D concentrations 
at birth or in the early neonatal period [238–242]. Novakovic et al. reported that 
maternal circulating 25(OH)D levels were the most significant regulator of neonatal 
circulating vitamin D concentrations, even over the impact of genetic factors [243]. 
In another study, maternal characteristics explained 12.2%, and maternal 25(OH)D 
concentrations explained 32.1% of the neonatal vitamin D variance [13]. These results 
were confirmed in a systematic review reporting the range of correlation coefficients 
between maternal and newborn 25(OH)D concentrations, by region: European 
0.42–0.95, America 0.68–0.97, Western Pacific 0.19–0.85, South-East Asian 0.78–0.81, 
and Mediterranean 0.03–0.88 [106]. Therefore, since maternal vitamin D status in 
pregnancy is an important determinant of neonatal 25(OH)D concentrations, atten-
tion should be given not only to vitamin D-deficient pregnant women, but also to 
their newborns, especially if they are exclusively breast-fed [244].
8. Policy and best practices (supplementation/education)
Vitamin D deficiency is very prevalent across the globe among pregnant women 
[245]. The range of recommended vitamin D from during pregnancy varies from 
200 to 4000 IU/d worldwide. The American Pregnancy Association stated that 
pregnant women are recommended to have (100 μg/d) of vitamin D intake to 
reduce the risk of premature birth and infections which is a considerably higher 
amount of vitamin D compared to the recommended intake of 10 μg/d for women 
[246]. A daily intake of 600 IU is suggested during pregnancy in China to have 
healthy and balanced fetal growth [247]. In the United Kingdom, it is advised to 
have a maternal vitamin D intake of 400 IU/d. Switzerland follows the IOM dietary 
recommended nutrient intake. For pregnant/lactating women who are at risk of 
vitamin D deficiency, the advised vitamin D is 1500–2000 IU/d, and for women, 
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without deficiency, the recommended intake is 600 IU [248]. The ministry of 
health of New Zealand recommended 200 IU/d dietary intake of vitamin D [249]. 
Vitamin D requirements are higher among pregnant women (average 400 IU/d), 
and it is very important to maintain optimum serum level of vitamin D during 
maternity and for the fetus growth.
WHO encourages receiving vitamin D from a healthy and balanced diet [250]. 
Some recent studies suggest vitamin D food fortification can work as a means to 
improve vitamin D status among the overall population, which can benefit preg-
nant women as well [251]. Currently, Canada, United States, India, and Finland 
had a vitamin D food fortification policy. In North America, the foods that are 
naturally enriched by vitamin D, such as fatty fish, are quite expensive and are 
not readily available to the general population. A majority of vitamin D intake 
comes from fortified food in North America. The United States has a voluntary 
fortification policy, and Canada has both voluntary and mandatory fortification 
policies for specific foods. In the United States, milk including fluid, acidified, 
cultured, skimmed powder, evaporated milk (1.05 μg/100 g), soy-based beverages 
(1.25 μg/100 g), soy products (2.23 μg/100 g), margarine (8.3 μg/100 g), butter 
alternatives spread (8.25 μg/100 g), cheese alternatives spread (6.25 μg/100 g), 
yogurt (2.22 μg/100 g), fortified fruit juice (2.5 μg/240 mL), meal replacement 
products (2.5 μg/40 g), cheese products (2.02 μg/30 g), and enriched ready to eat 
cereal (8.75 μg/100 g), rice, cornmeal, noodle, macaroni (2.25 μg/100 g), farina 
(8.75 μg/100 g), and instant formula (1–25 μg/100 kcal) are vitamin D forti-
fied [252]. Mandatory fortified products in Canada are margarine (1.5 μg/10 g), 
infant formulas (10 μg /L), milk (powder, sterilized, flavored, skim, evaporated) 
(2.5 μg/250 mL), meal replacements (5% of DV/55 g), soy beverages, and soy 
beverage products (1.5–3 μg/250 mL) [253]. Some recent studies have shown a 
high prevalence of vitamin D inadequacies despite the mandatory fortification. 
The Department of Health, the Government of Canada, recently announced that 
vitamin D fortification levels need to be increased to alleviate the risk of rickets in 
children and osteomalacia in adults. It proposed that by the end of December 2022, 
vitamin D level in cow’s milk, and goat’s milk will be increased to 2 μg/100 ml (cur-
rent range 0.9–1.2 μg/100 ml) and in margarine, it will be increased 26 μg/100 g 
(current range 13.3–17.5 μg/100 g) [254]. Fluid milk (2.5 μg/250 mL) and mar-
garine (2 μg/10 g) are also fortified in Finland that had helped the general Finish 
population to improve vitamin D status. Similar to the United States, Canada forti-
fication policy, edible oil, margarine (0.55 μg/10 g), cow’s milk (1.25 μg/250 mL), 
and ready to eat cereals (5 μg/1/2-¾ cups) are fortified in Australia [255]. Similar 
approaches can be adopted by other countries to improve vitamin D inadequacy 
among pregnant women as well as the general population.
Supplement intake can also play an important role in improving vitamin D status 
among pregnant and lactating women. A recent study assessing maternal vitamin 
D inadequacies showed that vitamin D supplementation of ≤2000 IU/d minimizes 
the chance of neonatal mortality [256]. Taking a vitamin D supplement may also 
reduce the risk of PET, GDM, and low birth weight during pregnancy [257]. The 
current WHO guideline recommends 200 IU/d of vitamin D supplement intake 
among pregnant women with vitamin D deficiency to reduce the risk of PET, low 
birth weight, and preterm birth [258]. In Turkey, free supplementation of vitamin 
D (1200 IU/d) is provided to all women from early pregnancy to 6 months after 
delivery [259]. In Canada, pregnant women are suggested to take a vitamin D 
supplement of 400–600 IU/d [260]. A similar vitamin D supplementation intake 
approach (400 IU/d) is followed in New Zealand as well during pregnancy The 
United Kingdom Health Department provides free vitamin D supplementation to 
pregnant women and newborn children and recommends taking 10 μg (400 IU) of 
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conducted in 487 mother-child pairs revealed that children born to mothers in the 
high 25(OH)D tertile (>50.7 nmol/l) had decreased risk of developing ADHD-like 
symptoms at 4 years of age, compared to children of women in the low 25(OH) D 
tertile (<38.4 nmol/l) [231]. In another prospective study conducted in 1650 
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reported that low maternal first-trimester serum levels of 25(OH)D was associ-
ated with increased odds of ASD diagnosis at age 3–7 years in the offspring [233]. 
Another study also found an increased risk of ASD in children who were born to 
mothers with vitamin D deficiency at mid-gestation [234]. In a large population-
based cohort of mothers and their children, gestational vitamin D deficiency was 
associated with a continuous measure of autism-related traits at 6 years [235]. 
Magnusson et al. also observed a relationship between maternal vitamin D defi-
ciency and risk of ASD with, but not without, intellectual disability [236]. Further, 
it has been demonstrated that low maternal vitamin D levels are associated with 
increased risk of schizophrenia within the subgroup of black but not white individ-
uals [237]. Although more robust studies needed, these results highlight the impor-
tance of maternal vitamin D status in offspring brain development and function.
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Several lines of evidence suggest that there is a strong association between 
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maternal circulating 25(OH)D levels were the most significant regulator of neonatal 
circulating vitamin D concentrations, even over the impact of genetic factors [243]. 
In another study, maternal characteristics explained 12.2%, and maternal 25(OH)D 
concentrations explained 32.1% of the neonatal vitamin D variance [13]. These results 
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pregnancy is an important determinant of neonatal 25(OH)D concentrations, atten-
tion should be given not only to vitamin D-deficient pregnant women, but also to 
their newborns, especially if they are exclusively breast-fed [244].
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pregnant women are recommended to have (100 μg/d) of vitamin D intake to 
reduce the risk of premature birth and infections which is a considerably higher 
amount of vitamin D compared to the recommended intake of 10 μg/d for women 
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healthy and balanced fetal growth [247]. In the United Kingdom, it is advised to 
have a maternal vitamin D intake of 400 IU/d. Switzerland follows the IOM dietary 
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without deficiency, the recommended intake is 600 IU [248]. The ministry of 
health of New Zealand recommended 200 IU/d dietary intake of vitamin D [249]. 
Vitamin D requirements are higher among pregnant women (average 400 IU/d), 
and it is very important to maintain optimum serum level of vitamin D during 
maternity and for the fetus growth.
WHO encourages receiving vitamin D from a healthy and balanced diet [250]. 
Some recent studies suggest vitamin D food fortification can work as a means to 
improve vitamin D status among the overall population, which can benefit preg-
nant women as well [251]. Currently, Canada, United States, India, and Finland 
had a vitamin D food fortification policy. In North America, the foods that are 
naturally enriched by vitamin D, such as fatty fish, are quite expensive and are 
not readily available to the general population. A majority of vitamin D intake 
comes from fortified food in North America. The United States has a voluntary 
fortification policy, and Canada has both voluntary and mandatory fortification 
policies for specific foods. In the United States, milk including fluid, acidified, 
cultured, skimmed powder, evaporated milk (1.05 μg/100 g), soy-based beverages 
(1.25 μg/100 g), soy products (2.23 μg/100 g), margarine (8.3 μg/100 g), butter 
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(2.5 μg/250 mL), meal replacements (5% of DV/55 g), soy beverages, and soy 
beverage products (1.5–3 μg/250 mL) [253]. Some recent studies have shown a 
high prevalence of vitamin D inadequacies despite the mandatory fortification. 
The Department of Health, the Government of Canada, recently announced that 
vitamin D fortification levels need to be increased to alleviate the risk of rickets in 
children and osteomalacia in adults. It proposed that by the end of December 2022, 
vitamin D level in cow’s milk, and goat’s milk will be increased to 2 μg/100 ml (cur-
rent range 0.9–1.2 μg/100 ml) and in margarine, it will be increased 26 μg/100 g 
(current range 13.3–17.5 μg/100 g) [254]. Fluid milk (2.5 μg/250 mL) and mar-
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and ready to eat cereals (5 μg/1/2-¾ cups) are fortified in Australia [255]. Similar 
approaches can be adopted by other countries to improve vitamin D inadequacy 
among pregnant women as well as the general population.
Supplement intake can also play an important role in improving vitamin D status 
among pregnant and lactating women. A recent study assessing maternal vitamin 
D inadequacies showed that vitamin D supplementation of ≤2000 IU/d minimizes 
the chance of neonatal mortality [256]. Taking a vitamin D supplement may also 
reduce the risk of PET, GDM, and low birth weight during pregnancy [257]. The 
current WHO guideline recommends 200 IU/d of vitamin D supplement intake 
among pregnant women with vitamin D deficiency to reduce the risk of PET, low 
birth weight, and preterm birth [258]. In Turkey, free supplementation of vitamin 
D (1200 IU/d) is provided to all women from early pregnancy to 6 months after 
delivery [259]. In Canada, pregnant women are suggested to take a vitamin D 
supplement of 400–600 IU/d [260]. A similar vitamin D supplementation intake 
approach (400 IU/d) is followed in New Zealand as well during pregnancy The 
United Kingdom Health Department provides free vitamin D supplementation to 
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vitamin D supplements during pregnancy and lactation [261]. Taking vitamin D 
enriched food and supplement can be advised to maintain optimum serum levels 
during pregnancy.
9. Conclusion
The existing evidence reveals the importance of adequate vitamin D status dur-
ing pregnancy for the mother, fetus, and child, although more studies are needed to 
clarify the exact mechanisms. In a situation where optimal vitamin D status cannot 
be achieved through diet and sun exposure, food fortification and supplementation 
seem to be proper approaches. Policies for vitamin D fortification vary across the 
globe, while more countries are recognizing the importance of vitamin D. The cur-
rent evidence indicates the need for vitamin D supplementation in pregnant women 
in a situation that fortification alone cannot address the needs [262]. To our knowl-
edge, only a few countries have free supplementation policies during pregnancy and 
early life. Effective systematic approaches by relevant agencies and governments are 
required to synthesize evidence-based recommendations for vitamin D supplemen-
tation during pregnancy and customize interventions considering cultural factors 
to ensure the optimal vitamin D status for pregnant women and their newborns.
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vitamin D supplements during pregnancy and lactation [261]. Taking vitamin D 
enriched food and supplement can be advised to maintain optimum serum levels 
during pregnancy.
9. Conclusion
The existing evidence reveals the importance of adequate vitamin D status dur-
ing pregnancy for the mother, fetus, and child, although more studies are needed to 
clarify the exact mechanisms. In a situation where optimal vitamin D status cannot 
be achieved through diet and sun exposure, food fortification and supplementation 
seem to be proper approaches. Policies for vitamin D fortification vary across the 
globe, while more countries are recognizing the importance of vitamin D. The cur-
rent evidence indicates the need for vitamin D supplementation in pregnant women 
in a situation that fortification alone cannot address the needs [262]. To our knowl-
edge, only a few countries have free supplementation policies during pregnancy and 
early life. Effective systematic approaches by relevant agencies and governments are 
required to synthesize evidence-based recommendations for vitamin D supplemen-
tation during pregnancy and customize interventions considering cultural factors 
to ensure the optimal vitamin D status for pregnant women and their newborns.
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Abstract
Vitamins and minerals are crucial for human health. Any deficiency can lead 
to major diseases; however, the most prevalent one is the vitamin D deficiency. 
Due to its high risk in the Middle East and Lebanon, besides its major effects, 
solutions to decrease this deficiency are taken nowadays. Vitamin D food 
fortification is the most popular solution taken now. Liposomes showed highest 
efficiency in vitamin D fortification. However, a study must be done in order 
to deduce the amounts needed in the targeted population. Therefore, before 
fortification starts, FDA regulations must be reviewed. Several foods succeeded 
in fortification with vitamin D and increasing its levels such as milk and ched-
dar cheese. Stability and flavors showed good results over fortification, while 
according to the odor, water sources showed more aroma depth than oil sources. 
The AOAC methods for vitamin D amount in fortified foods must be applied. 
Dietary 25(OH)D3 was 7.14-fold more effective at raising serum 25(OH)D than 
dietary vitamin D3.
Keywords: vitamin D, food fortification, health, FDA, Middle East and Lebanon
1. Introduction
Human body is a complex matrix that requires various components for its 
healthy functioning. Vitamins and minerals are crucial elements that are often 
obtained from one’s diet; these are referred to as micronutrients. Most of the latter 
are not produced by the human body and an unbalanced diet could inevitably lead 
to various nutrient deficiencies that could pose dramatic health risk for the human 
body that if severe enough could lead to death. Nutrient deficiency could be a direct 
effect of the changing eating patterns, but mostly due to poverty and lack of access 
to proper food especially in low- and middle-income societies. For this reason, 
studies and research were directed toward fortifying consumed food with vitamins 
that are most likely to be deficient and their deficiency could pose tremendous 
health problems. One of the most popular nutritional deficiencies in Lebanon and 
the Middle East is vitamin D deficiency. Due to the high frequency of vitamin D 
deficiency in Middle East and Lebanon, it is essential to find a product that is widely 
consumed among the population and provides a good source of vitamin D regard-
ing its stability. Dairy products are one of the most famous consumed foods in our 
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2. Nutrition and vitamins
2.1 Factors contributing to individual wellness
Healthy lifestyle improves individual strength, prevents certain illnesses, and 
maintains an advisable weight. Wellness incorporates physical, emotional, and spiri-
tual well-being (Figure 1). The concept of wellness is not an end point in a person’s 
life but rather an ongoing lifestyle. Diet and exercise are so linked to each other 
that they can be considered opposite sides of a coin. An individual’s nourishment is 
impacted by how much energy is used to perform daily exercises; meanwhile, physical 
activity directly affects the utilization of supplements in food. Consuming a nutri-
tious diet allows one to progressively perform strenuous exercises for longer durations 
and prompts an overall better feeling. On the other hand, an imbalanced food intake 
could lead to inactivity or, in extreme cases, cause severe medical issues [1].
2.2 Essential nutrients for health
Our daily consumed foods include bread, rice, dairy products, fruits, vegetables, 
and meats. Each of them is composed of various nutrients, which are each charac-
terized by its unique chemical composition. Each has its own function; however, 
they work together to complete body’s functions. Food nutrients are carbohydrates, 
proteins, fats, vitamins and minerals, and water. Fiber is likewise a fundamental 
part of our eating routine [2].
Macronutrients (carbohydrates, lipids, and proteins) are those that the body 
requires in huge quantities to give energy and maintain growth, whereas micro-
nutrients including vitamins and minerals are those nutrients required in lesser 
quantities to help normal health and body functions [1].
Figure 1. 
Factors contributing to individual wellness [1].
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2.2.1 Macronutrients
Macronutrients (carbohydrates, lipids, and proteins) are energy-providing 
nutrients [1].
• Carbohydrates: consist of the three main constituents: carbon, hydrogen, 
and oxygen. They are made of 3 groups: monosaccharides, disaccharides, 
and polysaccharides. Monosaccharides are single unit carbs such as glucose. 
Disaccharides are composed of two sugars connected together. An example of 
this class is lactose, which is known as milk sugar. Polysaccharides are those 
formed by more than two sugars and are generally more complex chains such 
as starch and dextrin [2].
• Fats: is an essential part of our body. Fat serves a vital role in protecting the 
cells and tissues of the essential organs in our body such as brain and heart. 
Food fats are composed of solid fats, fluid oils, fat-soluble vitamins, and 
cholesterol. Fats contain oxygen less than carbohydrates. Hence, 1 g of lipids 
gives the body more energy than carbohydrates (9 Cal/g of fat compared to 4 
Cal/g of carbohydrates) [2].
• Proteins: are huge natural compounds. Proteins, similar to starches and fats, 
contain carbon, hydrogen, and oxygen. Likewise, proteins contain around 16% 
nitrogen, which differentiates them from starches and fats. Proteins are used 
mainly for growth and development purposes [2].
2.2.2 Micronutrients
Nutrients required in little quantities to have healthy and normal body functions 
are “micronutrients” [1].
• Minerals: are inorganic elements that are not broken down by digestion, 
absorption, or heat. Minerals support with the regulation of body functions 
and are classified into major and trace minerals [1].
Minerals are needed for body-building; enhancing bones, teeth, and struc-
tural parts of soft tissues; muscle contraction; clotting of blood; and nerve 
stimuli [2].
• Vitamins: are organic compounds that assist in controlling physiological 
processes [1]. They engage in various activities throughout the entire body and 
help in the release of energy from the macronutrients [3].
2.2.3 Water
Water represents around 60 percent of the body weight. It is necessary for the 
use of food materials in the body and for disposal of food excess later on [2].
2.3 Vitamins
Vitamins (natural carbon-containing composites) adjust many of the body’s 
processes [1]. They are available in small amounts; however, they are essential 
for physiological functions as growth and development. Vitamins can work as 
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Vitamins A, D, E, and K are fat-soluble. They remain inside the fatty parts of 
foods and are absorbed along with dietary fat. Fat-soluble vitamins have  
good storage in the body since they are kept in the adipose tissues. Fat-soluble 
vitamin toxicity symptoms include hair, skin, bones, eye injuries, and anorexia 
nervosa [1].
2.3.2 Water-soluble vitamins
Fat-soluble vitamins include the B vitamin and ascorbic acid (vitamin C). They 
are distributed in many foods. Water-soluble vitamins are absorbed easily via the 
enteral tract straight into the blood and then into the cells. Water-soluble vitamins 
are not stored in large amounts, except vitamin B12. Thus, they should be eaten 
daily [1].
2.4 Vitamin deficiencies
Vitamin deficiency is the condition of a long-term lack of a certain vitamin. 
Most common and serious vitamin deficiencies are as follows [1]:
• Vitamin A, which leads to vision defect, impaired growth, and immunity
• Vitamin D, which leads to rickets, osteomalacia, or osteoporosis
• Vitamin K, which leads to coagulopathy and bone health impacts
• Vitamin B12, which leads to pernicious anemia, nerve damage, memory loss, 
and dementia
• Vitamin C, which mainly leads to Scurvy disease, fractures, and depression
3. Vitamin D
Vitamin D, known as the sunshine vitamin, is a real hormone delivered from 
body’s sterols by the photolytic activity of UV light on the skin [4]. It is a fat-soluble 
seco-steroid that may be either created within the skin from its precursor (7-dehy-
drocholesterol) by exposure to sunlight or offered from diet [5, 6]. Vitamin D with 
calcium, magnesium, and phosphorus plays a crucial role to support bones and 
teeth health [4].
3.1 Vitamin D sources
Vitamin D can be attained from foods as vitamin D3 (cholecalciferol) or as 
nutrient D2 (ergocalciferol). D3 is acquired from animal sources, while D2 is avail-
able in parasites and mushrooms irradiated with UVB [7]. Vitamin D approximate 
content in various foods is shown in Table 1 [8].
Since most foods contain low measurements of vitamin D (Table 1), fortifying 
common foods is becoming a trend and common practice nowadays. In addition, 
nutritional supplements are a reliable solution for compensation of the vitamin 
deficiency [4].
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3.2 Vitamin D needs and normal levels
The Food and Nutrition Board has set an adequate intake (AI) for vitamin D 
due to the inability to set a more precise RDA level because of the variability in sun 
exposure among individuals [9]. Recommendations for vitamin D instructed an AI 
for vitamin D of at least 500 IU/day (12.5 μg) and more than 1000 IU/day (25 μg) 
for those not exposed to enough sunlight [8].
International units are used to quantify vitamin D. 1 IU is equal to 25 metric 
weight unit of cholecalciferol, and 1 g of cholecalciferol is equal to 40 IU [7].
3.3 Metabolism and regulation
Metabolism of vitamin D occurs through different stages that includes hydrox-
ylation. Through these stages, vitamin ingested is transformed into its active form 
(Figure 2) [4].
Vitamin D synthesis starts when 7-dehydrocholesterol (cholesterol precursor 
found on skin) is visible to sunlight and then transformed to previtamin D [9, 10].  
7-Dehydrocholesterol is an intermediate precursor for vitamin D, it is found 
throughout the epidermis and dermis, and thus has the most elevated limit with 
respect to cholecalciferol synthesis [11].
The first step occurs when 7-dehydrocholesterol absorbs the UVB photons to 
convert them into previtamin D3. Then, photoisomerization occurs in order to 
covert previtamin D3 into vitamin D3 (cholecalciferol). However, it is not a problem 
since during delayed sun exposure previtamin D3 is converted into its inactive 
forms (lumisterol and tachysterol) [12].
Large portion of vitamin D reaches liver from lipoproteins or vitamin D–binding 
protein and is then transformed by hydroxylation to yield 25-OH-D3 [4]. 25-OH-D3 
is the major circulating type of vitamin D used by clinicians to evaluate vitamin 
D level, though it is latent and must be transformed to its active form (1α,25-
dihydroxyvitamin D) in the kidneys [13].
When calcium decreases in the body, parathyroid hormone is released leading to 
calcitriol synthesis increase (vitamin D active form: 1α,25(OH)2D) (Figure 3). Because 
of the hypocalcemia (declined blood calcium), PTH is released from parathyroid gland 
resulting in an increase in the hydroxylation of 25(OH)D3 to calcitriol. Then, calcitriol 
plays its role with PTH or by itself on its target tissues leading to an increase in serum 
calcium levels. Kidneys, bones, and intestines are the primary target tissues [8]:
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Calcitriol, 1,25 (OH)2 D3, synthesis and actions with parathyroid hormone (PTH) [8].
Figure 2. 
Sources, sites, and processing of vitamin D metabolites [10].
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3.3.1 Intestine
Increasing calcium and phosphorus absorption is the major role of calcitriol in 
the intestines. It works by the participation of calcitriol with cell membrane recep-
tors to improve calcium absorption [8].
3.3.2 Kidney
Calcitriol with the help of PTH increases calcium reabsorption in the distal renal 
tubule into the blood. Phosphorus released by the kidney is boosted and can result 
in lower serum phosphorus levels [8].
3.3.3 Bone
Regarding the bone, PTH plays its role with calcitriol for reabsorption increase 
of calcium and phosphorus from bone to reach normal blood calcium level. 
Osteoclasts catalyze calcium and phosphorus from bone. The net impact of this is to 
raise blood calcium and phosphorus levels [8].
3.4 Factors affecting vitamin D production
Vitamin D skin synthesis is negatively influenced by factors such as the  
following [6]:
• Season: winter season decreases the quantity of ultraviolet light reaching the 
skin, while summer season increases it.
• Skin pigmentation: dark pigments interfere with UV light entering the needed 
skin layer.
• Clothing: covering the skin leads to inadequate sunlight skin exposure.
3.5 Clinical manifestation of vitamin D levels
Calcidiol (25(OH)D) is the vitamin D metabolite that is estimated to identify a 
patient’s vitamin D status [14]:
• Vitamin D deficiency: 25(OH)D between 21 and 29 ng/mL
• Vitamin D lack: 25(OH)D < 20 ng/mL
• Normal vitamin D status: 25(OH)D > 30 ng/mL
• Vitamin D overproduction: 25(OH)D > 40–60 ng/mL
• Vitamin D toxicity: 25(OH)D > 150 ng/mL
However, females are at 3 times higher risk of having vitamin D deficiency 
compared to males. There is no relationship between the age and vitamin D  
levels in males, but in females, those having an age between 30 and 40 are at higher 
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3.6 Vitamin D transport
3.6.1 Transfer from chylomicrons to plasma
Practically, all consumed vitamin D is held in a nonesterified structure, which is 
believed to be associated with the outside of chylomicrons (lipoprotein particles). 
Vitamin D that is not moved in the plasma is taken up with chylomicron remainders 
by the liver, where it is then transferred to the same binding protein and discharged 
to the plasma [4].
3.6.2 Vitamin D–binding protein
Vitamin D is transferred in the plasma to a great extent in association with 
protein, as other sterols, which is the vitamin D–binding protein (DBP) [4].
3.7 Vitamin D storage
Vitamin D storage in the liver is minimal, in contrary to other fat-soluble vita-
mins. Vitamin D levels do not go above 25 nmol per kg in the liver. Plasma calcidiol 
(25-hydroxyvitamin D) is the storage form of vitamin D, which has a half-life of 
3 weeks [11]. Long-standing admission of vitamin D inside the physiological range 
induces storage in fat tissues and most likely in other tissues of clinical importance [16].
3.8 Vitamin D toxicity
Vitamin D toxicity is incredibly uncommon; however, it can occur by unplanned 
or purposeful ingestion of unreasonably high portions. Portions of more than 
50,000 IU every day raise levels of 25-hydroxyvitamin D to more than 150 ng for 
each milliliter (374 nmol/L) as well as hypercalcemia and hyperphosphatemia. 
Portions of 10,000 IU of vitamin D3 every day for as long as 5 months do not 
cause toxicity [13]. Excessive exposure to sunlight represents no danger of toxicity 
through overproduction of endogenous cholecalciferol [8].
When calcium plasma concentrations reach 2.75–4.5 mmol/L, vitamin D toxicity 
causes several symptoms such as nausea, appetite loss, cramps, and diarrhea, and 
in more severe cases, it causes hypercalcemia. When plasma calcium levels exceed 
3.75 mmol/L, hypertensive encephalopathy occurs due to the contraction of smooth 
muscles. Hypercalcemia and expanded vitamin D levels lead to soft tissue calcifica-
tion (kidneys, heart, and lungs) [11].
4. Vitamin D deficiency
The most popular and worldwide deficiency currently is vitamin D deficiency 
[17]. It is a worry for public health and has several acute and chronic impacts. It 
results from wrong lifestyle starting in predominance obesity and inadequate sun 
exposure [18].
4.1 Vitamin deficiency
Living with a lifestyle that is inadequate in any food group will result in a vita-
min deficiency. A vitamin deficiency results in different diseases and disorders. The 
clinical signs and symptoms are the final stage in hypovitaminosis [4].
Stages of vitamin deficiency are as follows:
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1. Marginal deficiency
• Stage I—depletion of vitamin stores
• Stage II—cellular metabolic changes
2. Observable deficiency
• Stage III—clinical defects
• Stage IV—morphological changes
During marginal deficiency, there is only depletion of vitamin stores and its 
effect on cells. This depletion cannot be recognized without chemical or biochemical 
testing, which shows the stores’ concentrations. However, in observational defi-
ciency, the signs and symptoms appear and morphological changes take place [4].
4.2 Vitamin deficiency causes and effects
Vitamin D deficiency is caused by the following [13]:
1. Decreased synthesis in the skin: due to creams, aging, and skin pigment, the 
vitamin D3 synthesis will be reduced.
2. Decreased bioavailability: obesity and malabsorption diminish the availability 
of vitamin D3.
3. Breastfeeding: decreased amount of vitamin D in human milk can lead to vita-
min D deficiency when the child is exclusively breastfed.
4. 25-hydroxyvitamin D diminished synthesis: vitamin D malabsorption caused 
by liver failure results in 25-hydroxyvitamin D diminished synthesis.
5. 1,25 dihydroxy vitamin D diminished synthesis: decreased phosphorus excre-
tion and decreased serum levels of 1,25-dihydroxyvitamin D are caused by 
chronic kidney diseases.
4.3 Manifestation of vitamin D deficiency
Vitamin D deficiency’s first stages include rickets and osteomalacia, whereas the 
final and long-term stages include osteoporosis in which there are chronic changes [19].
4.3.1 Rickets
Vitamin D deficiency in children leads to rickets. Rickets is classified by bone min-
eralization loss [8]. This occurs due to deficiency in both vitamin D and calcium [7]. 
Consequently, the bones twist due to their inability to hold the body, stand, or walk [3].
4.3.2 Osteomalacia
As rickets occur in children, osteomalacia occurs in adults [4]. Osteomalacia 
is the result of the demineralization of bones [7]. In the case of osteomalacia, 
nonmineralized bones are much more than mineralized bones. Consequently, the 
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3.6 Vitamin D transport
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patient will have muscular weakness, bone tenderness, and pain and will be at 
higher risk of fractures [4].
The decreased ability to produce vitamin D3 in elderly due to the decrease in 
7-dehydrocholesterol in the skin results in osteomalacia also. Therefore, vitamin D 
is essential for preventing and treating osteomalacia in elderly [7].
4.3.3 Osteoporosis
Osteoporosis is the result of inability to synthesize or get enough vitamin D from 
sunlight and food. This results in bone calcium loss and thus fractures [3]. It is due to 
multiple causes as aging, weakened vitamin D digestion, and decreased estrogen levels. 
It is widely seen in elderly, postmenopausal women, and those taking steroids [4].
4.4 Vitamin D deficiency prevention steps
Vitamin D deficiency can in fact be prevented by different methods. These can 
include the following [13]:
• Expose body to sun or ultraviolet radiation for the needed time.
• Ingestion of 400–100 IU/day for kids and 800–1000 IU for grown-ups.
• Control serum phosphate in case of kidney disease.
• Sustaining maintenance level.
4.5 Vitamin D deficiency in Middle East and Lebanon
International Osteoporosis Foundation (IOF) study showed that almost all 
countries have 25(OH)D3 levels beneath 30 ng/ml, while South Asia and Middle 
East have levels beneath 10 ng/ml [19].
The most widely seen medical issue in Middle East and North Africa is vitamin 
D deficiency. This results in diseases and disorders and most widely osteomalacia. 
Results showed 50–90% 25(OH)D3 deficiency, and these patients have levels below 
20 or 30 nmol/ml [15].
Results showed higher rates of vitamin D deficiency in Lebanon especially Beirut 
regions as 57.86% were deficient using a cut-off of 20 ng/ml [15].
Females are 3 times more prone to have hypovitaminosis D. An investigation on 
Lebanese grown-up population has demonstrated that hidden ladies had just about 3 
times more incidence of extreme hypovitaminosis D than nonhidden subjects [15].
Results verified that females are at more risk to have vitamin D deficiency. 
Besides, hidden ladies are 3 times more at risk than nonhidden ladies [15].
5. Vitamin D fortification
5.1 Food fortification basic principles
Fortification is the process of supplementing food with needed nutrients for 
their health benefits and in order to prevent diseases as defined by the Codex 
General Principles [20].
Fortification levels differ from one nation to another according to different 
factors. These factors include the dimension of enrichment, the bioavailability of 
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the fortificants, and the range of fortified consumed foods. Fortification can be 
achieved by adding a single nutrient (such as the addition of iodine to the salt), or 
by adding a blend of nutrients [20].
The general medical advantages of fortification include the following [20]:
• Prevention of micronutrient deficiency
• Correction of a micronutrient deficiency
• Achieving the health benefits of a nutrient (for example, there is some proof 
to recommend that a diet full in selected antioxidants may aid in preventing 
cancer and different disorders.)
5.2 Vitamin D fortification history
In order to prevent or defend rickets, humans usually used one teaspoon of 
cod liver oil daily (1 teaspoon has 10 μg = 400 IU of vitamin D). Vitamin D food 
fortification started in the 1940s in the US and other nations such as Britain. In 
the beginning, vitamin D was supplemented to milk and then to other foods and 
beverages. However, in the 1950s, events of hypercalcemia appeared, and an adjust-
ment was done for fortifying foods with vitamin D. As a result of that, few side 
effects of hypercalcemia had been seen in newborn children in the former German 
Democratic Republic, where babies were enriched with discontinuous portions of 
15 mg (600,000 IU) of vitamin D as a push to defend rickets. In these newborns, 
serum 25(OH)D levels increased to a few hundred nmol/L [17].
5.3 Vitamin D3 fortification forms
Various techniques for fortification of foods with vitamin D were accomplished. 
In a study done for the evaluation of fortifying cheddar cheese with vitamin D 
methods, vitamin D3 was supplemented by: addition of a water-soluble emulsion, 
crystalline liposoluble vitamin D, or water-soluble vitamin D multilamellar lipo-
somes [21]. Results showed better recovery of vitamin D3 in liposomes than that 
in homogenized cream and water-dissolved emulsions. Similar results were shown 
in commercial water and fat-soluble types of vitamin D3 in delivering an evenly 
dispersed concentration of vitamin D3 in prepared cheddar [22].
Vitamin D3 was fortified into a cheddar-like matrix, yogurt, or dessert in 
either a crystalline or an emulsified structure. The emulsified structure was more 
stable in cheddar over a three-month storage period at 4°C, with roughly 6% of 
the crystalline vitamin D3 lost under these conditions, while the two types of 
vitamin D3 were stable in yogurt and dessert with storage for the normal shelf life 
of the items [23].
5.4 Data required for determination of vitamin D fortification levels
Vitamin D fortification levels determination requires the following [24]:
1. Survey about the quality of the diet and amount of ingested nutrient in a target 
population
2. Average sun exposure adequacy in accomplishing vitamin D adequate levels
3. The recent vitamin D levels in the country
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When the fortification program is achieved, supervising and assessments should 
continue to get better data and higher effectiveness [24].
5.5 Factors affecting vitamin D food fortification
Vitamin D food fortification is affected by factors such as availability of fortifi-
cants and suitable vehicles for the fortificant [24]:
1. Availability of mechanical experience in producing D2 and D3.
2. Having a good capacity for raising 25-hydroxyvitamin D blood  
concentration.
3. Having different formulas that suit all foods: the fat-rich items and fat-poor 
foods. For example, a formula of dry preserved vitamin D is found and has 
benefits as it contains antioxidant that defends the strength of vitamin D for 
extended time, yet within the appearance of minerals.
4. Having the proper vehicle for fortification:
a. Widely consumed food must be used as fortification vehicle, financially 
available, and consumed all through the year.
b. The fortification vehicle must ensure an even scattering by economical 
technologies.
c. Vitamin D bioavailability in fortified items, for example, milk, milk 
powder, and cheddar.
d. Vitamin D fortification vehicle must have negligible olfactory impact.
5.6 FDA regulations
FDA authorizes the use of nutrients as supplements and additives after enough 
scientific safety reviews. The additive must be used under the law to stay in the safe 
side. Several studies were done to set a law for the use of vitamin D and its safety [25].
Vitamin D is available in different structures. The two main structures are vita-
mins D2 and D3. Vitamin D is certified and commonly identified as safe (GRAS) to 
be used in food, with the following exact conditions [25].
FDA authorized adding vitamin D to infant formulas, calcium-fortified foods 
and beverages, breakfast cereals, certain cheese and cheese products, soy beverages, 
and milk and milk products [25] (Table 2).
Category of food Maximum levels in food (as served)
Breakfast cereals 350 IU/100 g




Maxim levels of vitamin D in foods [25].
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The IOM (Institute of Medicine) specified the maximum allowed daily intake as 
UL of a supplement that represents safety of conflicting impacts when the supple-
ment is ingested over delayed time [25].
5.7 Foods fortified with vitamin D
The USA began vitamin D milk fortification in 1930s. In the USA, vitamin D 
food fortification is optional. They focus on food vehicle and the practical and 
dimensional use in order to avoid fortification above what is recommended by the 
FDA. The addition of vitamin D commonly in conjunction with calcium is usually 
to several foods including orange juice, breakfast grains, rice, and soy milk [24].
Vitamin D widely used concentration is 100 IU per serving. The consumption of 
foods that have been fortified with vitamin D significantly increased 25(OH)D blood 
levels. The average personal intake of almost 11 μg/day (440 IU/day) from fortified 
foods (range 120–1000 IU/day) raised 25(OH)D levels by 7.7 ng/mL. Said relation cor-
relates to a 0.5 ng/mL rise in 25(OH)D for every 40 IU (1 μg) ingested/day calories [24].
5.7.1 Milk
A couple of studies have researched the long impact of additional vitamin 
D3 on the initial vitamin D load of milk. Hollis in his article “Vitamin D and Its 
Metabolites in Human and Bovine Milk” demonstrated a 10-fold rise of vitamin D3 
consumption from 100 to 1000 μg/d and contributed a 7·5-fold rise in vitamin D3 
levels of the milk and a 2-fold rise in 25(OH)D3 [26].
5.7.2 Eggs
Two frequently used strategies to fortify eggs with vitamin D are: increasing 
sunlight exposure and supplementing bird diet with vitamin D. It is proved that 
eggs that were exposed to light have higher vitamin D3 content. Browning and 
Cowieson verified the effectiveness of diet enrichment with vitamin in increasing 
both vitamin D3 and 25(OH)D3. However, Browning, Cowieson, and Duffy verified 
that addition of 25(OH)D3 had positive impact on 25(OH)D3 level of the egg yolk. 
Thus, within a diet, 25(OH)D3 could be consumed straightforwardly by hens with 
no exchange to vitamin D3 within the circulation [26].
5.7.3 Cheddar cheese
It is verified that vitamin D is stable during pasteurization, manufacturing, and 
maturing. It is evenly distributed in the cheddar and does not influence the flavor. 
The positive part is that vitamin D has the same effect in supplements and in cheddar 
matrix. The disadvantage in fortifying cheddar with vitamin D is the loss in the whey-
ing off step. However, it is solved by decreasing the whey load before manufacturing 
and the use of ultrafiltration (UF) [27]. Ganesan proved vitamin D stability over a 
9-month maturity period while using typical types of vitamins. The use of UF to ched-
dar milk results in little yet considerable reductions in vitamin D losses in whey [28].
5.7.4 Bread
Bread is a widely consumed food item; it is prepared from flour and water by 
baking, as well as nongrain material such as nuts, fats, raisins, and nutrients to 
improve the nutritional quality of the meal eaten. Vitamin D can be added during 
different stages (fermentation, baking, and storage). It is verified that 60 min is the 
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reasonable time for dough fermentation, since when raising the fermentation time, 
oxidation of vitamin occurs [5].
5.8 Stability, odors, and off-flavors
In the USA, milk is commonly enriched with vitamin D with an amount of 
400 IU per quart. Vitamin D fortification occurs before pasteurization step, and the 
liquid milk shelf life is usually 1 year at room temperature and in dark [29].
5.8.1 Stability
The stability of vitamin D throughout production and storage in dairy and milk 
products is verified, as well as its stability in high temperature short time handling 
and storage without light and acid [29].
Vitamin D loses its stability in some conditions. It decreases in acidic media as 
it transforms into its inactive form isotachysterol, or by heating to a temperature 
above 150°C in the presence of air [27]. However, it is stable at temperatures below 
zero, at 4–8°C, at 25°C, and during cooking at 200°C [24].
In the study of elevating vitamin D3 under two different conditions, high 
temperature processed decreased fat milks (increased temperature/decreased time, 
pasteurized at 73°C for 15 s, and ultra-heat treated, purified at 138°C for 2 s) and 
reduced fat yogurt (purified at a temperature of 85°C for a half hour), it is verified 
that the amount of vitamin D does not decrease during preparation [30]. In addition 
to that, it was stable during storage and has no effect on sensory qualities [23].
Banville found that vitamin D3 fortification in cheddar in the liposome form 
decreased after 3–5 months of maturing and lost its stability [21]. It is shown also 
that vitamin D3 has stability in nonfat foods such as in squeezed orange (storage 
for 30 days at 4°C) [31]. Both vitamin D3 and vitamin D2 showed their stability in 
fortified squeezed orange [32].
5.8.2 Flavor
Even at maximal level of fortification (1200 IU), there were no flavor differences 
in vitamin D–fortified milk. This shows that increasing the concentration of vita-
min D is better to improve the nutritional quality and increase vitamin D amount 
ingested and do not influence the liquid milk flavors [29].
5.8.3 Odors
Odors were affected by vitamin D fortification, as they give rancid oil and painty 
odor. However, it is shown that the aroma depth is way more in water source than 
that in oil source. In oil sources, the aroma depth is lesser due to the oil matrices 
found that defend oxidation. After vitamin D oxidation occurs, aldehydes are found 
in the product [29].
5.9 Measurement of vitamins D2 and D3 in foods
The Association of Official Analytical Chemists (AOAC) International, which 
set up authority and “legally defensible analytic” strategies in the United States, has 
approved the accompanying chemical techniques for the examination of vitamin D 
in foods [23]:
Method 980.26: vitamin D in multivitamin preparations
Method 981.17: vitamin D in fortified milk and milk powder
89
Nutritional Considerations of Vitamin D Deficiency and Strategies of Food Fortification
DOI: http://dx.doi.org/10.5772/intechopen.89612
Method 982.29: vitamin D in mixed feeds, premixes, and pet foods
Method 992.26: vitamin D3 in ready-to-feed milk-based infant formula
Method 995.05: vitamin D in infant formulas and enteral products (for tube 
feeding)
Method 2002.05: cholecalciferol (vitamin D3) in selected foods (fortified milk, 
infant formula, gruel, margarine, and cooking and fish oil)
The AOAC strategies recorded above are alike on a basic level. Every strategy 
includes four key advances [23]:
1. A digestion step to break down the food matrix (alkaline saponification)
2. An extraction step for the separation of vitamin D from the food matrix
3. A clean-up step, to isolate vitamin D from other food components
4. Quantitative detection by HPLC with UV
However, these strategies are time-, work-, and expert-consuming. Besides that, 
they are allowed only for restricted items (generally dairy), and not suitable for 
nonfat items in certain countries. The AOAC techniques target vitamin D3, and not 
vitamin D2, that might be available either normally or as a fortificant [23].
Instrumental techniques for the analysis of vitamin D in foods incorporate [23]:
• partition by high-pressure liquid chromatography (HPLC),
• detection by ultraviolet absorption (UV), and
• diode array detection (DAD) or mass spectrometry.
The accompanying approach was created, approved, and used to survey vitamin 
D3 levels in Danish pork and dairy items [33, 34]:
1. Homogenization and addition of vitamin D2 internal standard
2. Digestion by alkali saponification for 45 min in a boiling water bath
3. Extraction with petroleum ether: diethyl ether
4. Clean-up with silica solid-phase extraction columns
5. Purification with semipreparative HPLC (amino + silica columns, normal phase)
6. Detection by reverse-phase HPLC with DAD
5.10 Vitamin D fortification efficacy
It is verified that the oral use of 25(OH)D3 is efficient in rising plasma 25(OH)
D levels [26]. The common level of vitamin intake range is between 10 and 20 μg/d. 
Cashman in his study gave adults (mean age of 57 years) 20 μg vitamin D3 or 
20 μg 25(OH)D3 for those having with serum 25(OH)D of 28·9 nmol/l in winter. 
The results showed after 2.5 months treatment an increase in both vitamin D3 
and 25(OH)D3. Jetter in his study provided fit postmenopausal ladies with 20 μg 
25(OH)D3 or 20 μg vitamin D3 for about 4 months over the winter. The results 
showed better effectiveness of 25(OH)D3 than that of dietary vitamin D3 [26].
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reasonable time for dough fermentation, since when raising the fermentation time, 
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Results showed better effectiveness for 25(OH)D3 in absorption and increas-
ing the plasma levels. In addition to that, 25(OH)D3 is better for human health as 
Bischoff Ferrari et al. proved a decline in systolic blood pressure and enhancements 
in a few markers of immunity in healthy postmenopausal ladies. Also, 25(OH)D3 
supplementation corrected the excess bone turnover, improved plasma lipid level 
rise in HDL cholesterol, and diminished LDL-cholesterol in osteopenic and dyslip-
idemic postmenopausal ladies [26].
6. Conclusion
After referring to various studies considering fortifying foods and dairy products 
with vitamin D, it is proven that dairy product vitamin D fortification is an effective 
strategy to diminish the prevalence and incidence of vitamin D deficiency among 
populations. This is because this method is cost-effective regarding its positive effect 
on public health and its impacts with minimal sensorial changes including flavor 
and order. Dairy products have been shown to be a suitable food type to be forti-
fied with vitamin D. Milk and many cheese products, and yogurt are fortified with 
vitamin D and have shown to be stable and an effective source of vitamin D, and this 
is why we can consider other types of dairy products to be fortified with vitamin D 
like Labneh, in which further research will be done in order to test for stability of 
vitamin D and the most appropriate form to be used in it. According to the appropri-
ate form of vitamin D used in dairy products, liposomes of vitamin D are effective 
for cheddar cheese fortification. This method proves the effectiveness and liposomes 
of food fortification that has been followed for years, a strategy that tremendously 
leads to decreasing the burden of nutrition deficiency among populations especially 
in developing countries. In fact, public awareness stays a must in promoting educa-
tion about vitamin D deficiency, its symptoms, risk factors, and causes.
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An Evidence-Based Review of 
Efficacy and Safety of Dietary, 
Natural Supplements and Sunlight 
in Vitamin D Deficiency
Jenson Mak
Abstract
There have been recent concerns about the propensity of calcium and vitamin D 
supplementation to cause cancer. In osteoporotic patients, this has led to increasing 
recommendations advocating the replacement of calcium supplementation with 
dietary or other means. Around the world, the problem of vitamin D deficiency 
remains, being a large contributor of rickets and osteomalacia in the developing 
world and osteoporosis in post-menopausal women and people dependent on long-
term corticosteroid treatment. We review the alternatives of vitamin D supplemen-
tation through dietary, other natural supplements as well as sunlight therapy, in an 
evidence-based manner. We will also review the safety aspect of each modality.
Keywords: vitamin D deficiency, osteoporosis, rickets, bone health, diet,  
natural supplements
1. Introduction
Vitamin D is a fat-soluble vitamin utilised by human beings for normal bone 
development; maintenance by increasing the absorption of calcium, magnesium 
and phosphate; as well as potential pleiotropic effects on the prevention of cancer, 
heart disease, autoimmune disease, type 2 diabetes and depression [1].
A circulating level of 25-hydroxyvitamin D greater than 30 ng/mL (50 nmol/L) 
is considered a healthy level of vitamin D to maintain. About 1 billion people in the 
world have vitamin D deficiency, ranging from children (leading most notably to 
rickets), pregnant and lactating women, certain racial groups, post-menopausal 
women and the elderly (leading to osteoporosis) [2].
Vitamin D deficiency arises from multiple causes including inadequate dietary 
intake and inadequate exposure to sunlight. About 50–90% of vitamin D is 
absorbed through the skin via sunlight, whilst the rest comes from the diet.
Vitamin D clinical trials have increased over the past decade. Despite these trials, 
studies (including meta-analyses) have provided inconsistent conclusions. Some 
meta-analyses make the assumption that vitamin D is a pharmacological agent, 
and not as a nutrient. Bolland [3, 4] and Zhao’s [5] findings suggest that vitamin D 
supplementation does not prevent fractures or falls (and in fact one study suggested 
it may contribute to falls in community-dwelling older women at higher dosages [6], 
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or have clinically meaningful effects on bone mineral density, and suggested ‘little 
justification to use vitamin D supplements to maintain or improve musculoskeletal 
health’). A recent umbrella review did conclude that most RCTs have been carried 
out in populations that are not vitamin D deficient and, because of this, possible 
beneficial effects from vitamin D supplementation cannot be excluded [7].
Further, complementary medicine supplementation receives less stringent 
regulation for approval to the general public. For example, in Australia, vitamin D 
or other supplements which claim that it ‘may’ improve bone health and general 
well-being are approved on the Therapeutic Goods Administration as an ARTG [8] 
compared with vitamin D as a medication.
Given the urgent need for the general population, clinicians and consumers 
will benefit from the latest evidence for vitamin D supplementation (through diet, 
extraneous supplementation and sunlight therapy), including its efficacy and 
potential harm (Figure 1).
2. Epidemiology
Vitamin D deficiency is a major global public health problem in all aged groups, 
particularly in the Middle East. There is striking lack of data in infants, children 
and adolescents worldwide and in most countries of South America and Africa [9]. 
Figure 1. 
In many countries, there is an abundance of sunlight throughout the entire year. Ironically, the sun-protective 
messages for the primary prevention of skin cancers become stronger than those of the moderate benefits of 
sunlight.
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Of concern, even in countries where there is sun exposure all year-round, reports of 
deficiency is common in infants (90% in Turkey, 46% in black Americans, 96% in 
Kuwait and 99% in Indian), in children (58% in Belgium, 72% in Malaysia and 95% 
in Afghanistan), in adolescents (50% of non-whites in Canada, 46% in China and 
45% in the United Arab Emirates) and in adults (52% of women in New Zealand, 
97% in 62% in Korea and 77% in Brazil).
3. Pathophysiology
Vitamin D is crucial in calcium and vitamin D metabolism, as its absence 
around 15% of dietary calcium and 60% of phosphorus is absorbed. 
1,25-Dihydroxyvitamin D interacts with the vitamin D receptor which increases 
Figure 2. 
Vitamin D Metabolism (From Horlick [10]).
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the intestinal calcium absorption to 40% and phosphorus to 80% (Figure 2, [10]). 
Vitamin D is transformed for activation through two hydroxylations in the body. 
Among the metabolic products or modified versions of vitamin include calcitriol 
(1,25-dihydroxyvitamin D3); the active form of vitamin D, with a 15-hour half-life; 
and calcifediol (25-hydroxyvitamin D3) with a 15-day half-life [10]. Vitamin D is 
bounded to specific receptors located throughout the body. Whilst serum 25(OH)
D levels do not indicate the amount of vitamin D stored in body tissues, it is the best 
indicator of vitamin D status.
When the level was 30 ng/mL or less, there was a significant decrease in 
intestinal calcium absorption that was associated with increased parathyroid 
hormone [10]. Further, there is strong support from reports that maternal vitamin 
D deficiency leads to overt bone disease (congenital rickets) from before birth to 
post-natal life [11]. Throughout the world, there has been widespread debate as to 
the serum 25(OH)D concentrations associated with deficiency (e.g. rickets), for 
optimal bone health and optimal overall health, and most cut points have not been 
developed by an agreed mutual scientific process. The US Institute of Medicine 
concluded that individuals are at risk of vitamin D deficiency at serum 25(OH)D 
concentrations <30 nmol/L (<12 ng/mL). However, some individuals are potentially 
at risk for inadequacy even at levels ranging from 30 to 50 nmol/L (12–20 ng/mL). 
The committee agreed with sufficient levels at ≥50 nmol/L (≥20 ng/mL) and that 
50 nmol/L is the serum 25(OH)D level that covers the majority of needs of the 
population (97.5%) [12].
Further, hypovitaminosis D in its mild but especially in severe forms can 
exacerbate symptomatic hypocalcaemia following intravenous bisphosphonate 
(zoledronic acid) [13]. Even though this is rare, associated hypocalcaemia may be 
life-threatening and require immediate resuscitation and evaluation, often requir-
ing hospitalisation to prevent additional morbidity and mortality risk from tetany, 
refractory hypotension, seizures or arrhythmias. Therefore it makes good sense to 
optimise vitamin D levels prior to administration of these agents [14].
Vitamin D toxicity can occur when blood 25(OH)D levels are 88 ng/mL or 
greater [15]. Symptoms may include sleepiness, vomiting, weakness, headache, 
nausea and constipation, and acute toxicity may cause hypercalcaemia and 
hypercalciuria.
4. Evidence-based review
Whilst there have been several treatment guidelines published, they are con-
sensus-based rather than evidence-based [16–19]. This review seeks to address this 
issue and identify any gaps in research for vitamin D replacement, listing the types 
available including dietary, other supplementation and sunlight, for bone health 
(rickets, osteoporosis) as well as to address safety and efficacy in an evidence-based 
manner.
Systematic search of MEDLINE, CINAHL and EMBASE for articles published 
rom September 2015 to August 2019 and the Cochrane Database of Systematic 
Reviews (most recent issue searched—Issue 2, 2019) was conducted by the author. 
Randomised controlled trials, meta-analyses and reviews of all aspects of vitamin D 
supplementation in humans were reviewed. Articles pertaining to osteoporosis in a 
specific condition (e.g. epilepsy) were excluded.
All studies were reviewed independently by the author, who recorded individual 
study results, and an assessment of study quality and treatment conclusions was 
made according to evidence-based protocols.
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Out of a total of 211 articles from PUBMED for vitamin D supplementation and 
osteoporosis, we found 22 articles satisfying the research criteria. Out of a total of 
54 articles from PUBMED for vitamin D supplementation and rickets, we found 22 
articles satisfying the research criteria. Of the 76 reviews from Cochrane Database 
of Systematic Reviews, there were 4 suitable review articles [20–23].
5. Vitamin D replacement in diet
Human beings require and source vitamin D from diet, dietary supplements and 
exposure to sunlight.
Whilst in particular for older people and those with restriction in diet, a diet rich 
in oily fish (which can theoretically improve 25-OHD levels and prevent vitamin D 
deficiency), in reality this is a challenge to achieve [24]. Only a few foods are a good 
source of vitamin D. These include fortified dairy products and breakfast cereals, 
fatty fish, beef liver and egg yolks.
Apart from the flesh of fatty fish (such as salmon, tuna and mackerel) and fish 
liver oils, very little foods contain vitamin D. Trace amounts of vitamin D can be 
found in egg yolks, cheese and beef liver. These foods contain vitamin D3 and its 
metabolite 25(OH)D3 [25]. Vitamin D2 is contained in some mushrooms [26, 27].
In the standard Western diet, fortified foods provide most of the vitamin D 
[26]. For example, US milk is fortified with 100 IU/cup. (In Canada, by law its milk 
is fortified with 35–40 IU/100 mL and its margarine at ≥530 IU/100 g.) However, 
other dairy products derived from milk, such as ice-cream and cheese, are gener-
ally not fortified. Some ready-to-eat cereals for breakfast often contain small 
amounts of added vitamin D, as do some brands of orange juice and yogurt. Some 
plant-based alternatives to mild (such as drinks made from oats, almond or soy) 
are sometimes fortified with vitamin D to the amount (about 100 IU/cup) found in 
fortified cow’s milk. Several countries of the developed world (e.g. United States, 
Canada and Australia) mandate the fortification of infant formula with vitamin 
D, 40–100 IU/100 kcal in the United States and 40–80 IU/100 kcal in Canada; 
however, this is not practical especially in those who breastfeed and those countries 
which do not mandate fortification of their milk formulas.
6. Sunlight for vitamin D replacement
Most people meet at least some of their vitamin D needs through exposure to 
sunlight [28]. Solar ultraviolet B radiation crosses the skin and converts 7-dehydro-
cholesterol to previtamin D3, which is rapidly converted to vitamin D3. Excessive 
sunlight exposure does not cause intoxication because any excess previtamin D3 or 
vitamin D3 is destroyed by sunlight, and in the skin there is reversible conversion to 
inactive sterols [24].
In residential aged care, practical attempts for therapeutic sunlight therapy have 
produced only mild 25(OH)D3 improvements and depended on the season of expo-
sure [29]. On a practical level, excessive exposure to ultraviolet is the primary cause of 
skin cancer, including squamous cell carcinoma, basal cell carcinoma and cutaneous 
malignant melanoma [30], so this is not a pragmatic approach from a public health 
perspective. Essentially, people with limited sun exposure require good dietary 
sources of vitamin D or take a supplement to achieve recommended intake levels.
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7. Natural supplements for vitamin D
In fortified foods and supplements, vitamin D is also available in two forms, 
vitamins D2 (ergocalciferol) and D3 (cholecalciferol), that differ in their side-chain 
structure only. Vitamin D2 is manufactured by the UV irradiation of ergosterol in 
yeast, and vitamin D3 is manufactured by the irradiation of 7-dehydrocholesterol 
from lanolin and the chemical conversion of cholesterol [10]. Both forms effectively 
raise serum 25(OH)D levels [28, 31]. It appears that at nutritional doses vitamins D2 
and D3 are equivalent, but at high doses vitamin D2 is less potent.
The recent increase in vitamin D interest by the general public has fuelled a big 
rise in sales of over-the-counter vitamin D preparations. Additionally, products 
with progressively increasing content of over-the-counter vitamin D preparations 
are becoming increasingly prevalent. Many types of pharmaceutical preparations 
for vitamin D supplementation are commercially available, including oily drops, 
capsules and tablets [31].
Individuals at high risk for deficiency should have a vitamin D blood test first; 
a dosage of up to 3000–4000 IU may be required to restore blood concentrations. 
In the Middle East and African countries, vitamin D doses ≥2000 IU/day may be 
needed to reach the target 25(OH)D level ≥20 ng/ml [32].
Whilst for pregnant women and children (1000 IU daily is safe) [33], there are 
very few concerns regarding vitamin D complications; in the elderly and especially 
those who are vitamin D replete, there has been some concerns about increased fall-
ing risks (especially at high doses) [34]. A 1-year, double-blind, randomised clinical 
trial conducted in Switzerland of 200 community-dwelling men and women 70 
years and older with a prior fall, randomised to receiving monthly 24,000 IU 
(low-dose), 60,000 IU of vitamin D3 and 24,000 IU of vitamin D3 plus 300 μg 
of calcifediol, found that the higher-dose groups  increased vitamin D levels more 
effectively but did not improve lower extremity function (over 12 months) and 
indeed increased fall incidence slightly [35]. Whilst this is not a cause for alarm, the 
study does confirm the popular scientific idiom ‘Too much of a good thing is bad 
thing’. Bischoff-Ferrari [36] advocates against regular high-dose bolus or monthly 
moderate doses of vitamin D for fracture prevention. Indeed Zhao [5] in a meta-
analysis of 33 randomised trials involving 51,145 participants found no benefit 
of supplements containing calcium, vitamin D or both compared with places in 
fracture prevention among community-dwelling older adults (over 50 years); 
however, it is noted that the research is limited by the lack of reporting of whether 
participants had osteoporosis, osteopenia or low bone mass, as well as participants 
mainly from Europe and the United States.
In contrast, research on vitamin D replenishment in the mild to moderate 
vitamin D-deficient elderly population following a hip fracture showed that a 
single loading dose of cholecalciferol (250,000 IU vitamin D3, the REVITAHIP 
(Replenishment of Vitamin D in Hip Fracture) strategy) or placebo, both receiving 
daily vitamin D (800 IU) and calcium (500 mg), was able to improve vitamin D 
levels and reduce falls (Figure 3) and pain levels [14]. The REVITAHIP investigators 
adopted a similar loading dose vitamin D followed by maintenance vitamin D at 
800 IU (and calcium) daily supplied to the participants, due to the very high rates 
of vitamin D deficiency noted in the HORIZON Recurrent Fracture study (observed 
in the first 385 patients [37]). The investigators found that virtually all participants 
in the active treatment group reached target vitamin D (>50 nmol/L) at weeks 2 and 
4 compared with the placebo group (Figure 4).
Interestingly, Smith [38], in a group of elderly women (mean age 66 years) 
with hypovitaminosis D (<50 nmol/L), demonstrated that vitamin D followed 
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a U-shaped curve on falls whether analysed by serum dose or serum 25(OH)D3 
levels. The investigators found no decrease in the incidence of falls on low vitamin 
D doses (400, 800 IU), a significant decrease in falls on medium doses (1600, 2400, 
3200 IU) (p = 0.020). Counterintuitively, Smith found no decrease on high doses 
(4000, 4800 IU) compared to placebo (p = 0.55). The rate of falls was 60% in the 
lowest quintile <25 ng/ml (<50 nmol/L), 21% in the low middle quintile 32–38 ng/
ml (80–95 nmol/L), 72% in the high middle quintile 38–46 ng/ml (95–115 nmol/L) 
and 45% in the highest quintile 46–66 ng/ml (115–165 nmol/L). A similar U-shaped 
pattern in the subgroup with a previous fall history was noted among the quintiles 
of 25(OH)D3 levels (Figure 5, [38]).
Conglomerating the results from Bischoff-Ferrari, Lyles, Smith and Mak, there 
does not appear to be any justification in having regular high-dose vitamin D supple-
ments at monthly intervals, due to the risk of vitamin D toxicity, hypercalcaemia 
and perhaps oversaturation of vitamin D receptors on skeletal muscles, leading to a 
propensity to falls. The author would recommend the REVITAHIP strategy of initial 
single loading dose bolus (250,000 IU) followed by regular 800 IU daily [14, 37], or 
24,000 IU monthly [35], supplementation but would recommend to be cautious with 
the Smith approach of medium daily dosages, probably up to 1600 IU daily without 
a bolus [38], for high-risk populations, and would support that larger monthly doses 
of 100,000 IU need further evaluation with respect to efficacy and safety.
Figure 3. 
REVITAHIP Active Vitamin D Protocol (initial 250,000 IU followed by 800 IU Vitamin D3 and 500 mg 
Calcium Daily at 4 weeks shows significance in reducing falls.
Figure 4. 
REVITAHIP Active Vitamin D Protocol (initial 250,000 IU followed by 800 IU Vitamin D3 and 500 mg Calcium 
Daily at 2, 4 and 26 weeks showed significant 25-OHD levels improvements compared with the placebo group.
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years and older with a prior fall, randomised to receiving monthly 24,000 IU 
(low-dose), 60,000 IU of vitamin D3 and 24,000 IU of vitamin D3 plus 300 μg 
of calcifediol, found that the higher-dose groups  increased vitamin D levels more 
effectively but did not improve lower extremity function (over 12 months) and 
indeed increased fall incidence slightly [35]. Whilst this is not a cause for alarm, the 
study does confirm the popular scientific idiom ‘Too much of a good thing is bad 
thing’. Bischoff-Ferrari [36] advocates against regular high-dose bolus or monthly 
moderate doses of vitamin D for fracture prevention. Indeed Zhao [5] in a meta-
analysis of 33 randomised trials involving 51,145 participants found no benefit 
of supplements containing calcium, vitamin D or both compared with places in 
fracture prevention among community-dwelling older adults (over 50 years); 
however, it is noted that the research is limited by the lack of reporting of whether 
participants had osteoporosis, osteopenia or low bone mass, as well as participants 
mainly from Europe and the United States.
In contrast, research on vitamin D replenishment in the mild to moderate 
vitamin D-deficient elderly population following a hip fracture showed that a 
single loading dose of cholecalciferol (250,000 IU vitamin D3, the REVITAHIP 
(Replenishment of Vitamin D in Hip Fracture) strategy) or placebo, both receiving 
daily vitamin D (800 IU) and calcium (500 mg), was able to improve vitamin D 
levels and reduce falls (Figure 3) and pain levels [14]. The REVITAHIP investigators 
adopted a similar loading dose vitamin D followed by maintenance vitamin D at 
800 IU (and calcium) daily supplied to the participants, due to the very high rates 
of vitamin D deficiency noted in the HORIZON Recurrent Fracture study (observed 
in the first 385 patients [37]). The investigators found that virtually all participants 
in the active treatment group reached target vitamin D (>50 nmol/L) at weeks 2 and 
4 compared with the placebo group (Figure 4).
Interestingly, Smith [38], in a group of elderly women (mean age 66 years) 
with hypovitaminosis D (<50 nmol/L), demonstrated that vitamin D followed 
101
An Evidence-Based Review of Efficacy and Safety of Dietary, Natural Supplements…
DOI: http://dx.doi.org/10.5772/intechopen.89598
a U-shaped curve on falls whether analysed by serum dose or serum 25(OH)D3 
levels. The investigators found no decrease in the incidence of falls on low vitamin 
D doses (400, 800 IU), a significant decrease in falls on medium doses (1600, 2400, 
3200 IU) (p = 0.020). Counterintuitively, Smith found no decrease on high doses 
(4000, 4800 IU) compared to placebo (p = 0.55). The rate of falls was 60% in the 
lowest quintile <25 ng/ml (<50 nmol/L), 21% in the low middle quintile 32–38 ng/
ml (80–95 nmol/L), 72% in the high middle quintile 38–46 ng/ml (95–115 nmol/L) 
and 45% in the highest quintile 46–66 ng/ml (115–165 nmol/L). A similar U-shaped 
pattern in the subgroup with a previous fall history was noted among the quintiles 
of 25(OH)D3 levels (Figure 5, [38]).
Conglomerating the results from Bischoff-Ferrari, Lyles, Smith and Mak, there 
does not appear to be any justification in having regular high-dose vitamin D supple-
ments at monthly intervals, due to the risk of vitamin D toxicity, hypercalcaemia 
and perhaps oversaturation of vitamin D receptors on skeletal muscles, leading to a 
propensity to falls. The author would recommend the REVITAHIP strategy of initial 
single loading dose bolus (250,000 IU) followed by regular 800 IU daily [14, 37], or 
24,000 IU monthly [35], supplementation but would recommend to be cautious with 
the Smith approach of medium daily dosages, probably up to 1600 IU daily without 
a bolus [38], for high-risk populations, and would support that larger monthly doses 
of 100,000 IU need further evaluation with respect to efficacy and safety.
Figure 3. 
REVITAHIP Active Vitamin D Protocol (initial 250,000 IU followed by 800 IU Vitamin D3 and 500 mg 
Calcium Daily at 4 weeks shows significance in reducing falls.
Figure 4. 
REVITAHIP Active Vitamin D Protocol (initial 250,000 IU followed by 800 IU Vitamin D3 and 500 mg Calcium 




Vitamin D is an essential fat-soluble hormone with multiple positive pleiotropic 
effects on the human bodies besides the optimisation on bone health. The evidence 
for ensuring high-risk groups such as pregnant women, children and those from the 
Middle East and African countries is vitamin D replete with either dietary, sunlight 
or combination with appropriate vitamin D supplements at moderate doses. For 
community-dwelling older adults with a history of falls, osteoporosis and/or frac-
tures, there is still evidence for a good safety profile for moderate dosages (either 
through an initial single-dose bolus followed by daily low-dose or regular moderate 
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(>500,000 IU bolus) or greater than 50,000 IU monthly given its possible increased 
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Figure 5. 
The rate of falls was 60% in the lowest quintile <25 ng/ml (<50 nmol/L), 21% in the low-middle quintile 32-38 
ng/ml (80-95 nmo/L), 72% in the high middle quintile 38-46 ng/ml (95-115 nmo/L) and 45% in the highest 
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history was noted amongst the quintiles of 25(OH)D3 levels [38].
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The cells of our body comprise calcitriol (1,25(OH) vitamin D2), the active form 
of vitamin D, an integral biological substance that has an impact on a large number 
of biological processes. While high prevalence of vitamin D deficiency is detected 
in population worldwide, the reports from sun-soaked countries like India are also 
alarming to note that the deficiency of vitamin D as high as 70 to 90% is observed 
leading to several chronic diseases in the majority of people. Deficiency of vitamin 
D is observed not only because of low levels of vitamin D in the diet, less exposure 
to sunlight, reduced cutaneous vitamin D synthesis, but also due to consumption 
of particular medicines, undue alcohol intake, and tobacco smoking. Vitamin D 
is known to affect estradiol, dopamine, and pro-inflammatory cytokine levels, 
besides being involved in the regulation of mechanisms pertaining to hormones like 
glucocorticoids. When vitamin D binds to vitamin D receptors (VDR) present in 
the central nervous system, it is noted to be responsible for the regulation of brain 
neuronal functions. Low 25-hydroxy vitamin D levels are found to have a higher 
incidence of various mood disorders. This review focusses on vitamin D receptors, 
VDR gene mutations, and pathophysiology causing vitamin D deficiency disorders.
Keywords: vitamin D, VDR receptors, mood disorders, deficiency, insufficiency, 
cognition
1. Introduction
Vitamin D is an integral biological substance used to maintain bone health pri-
marily, but it also plays its importance in several other biochemical pathways within 
the human body. Vitamin D, at the end of its metabolizing physiology, gets con-
verted into an active hormone metabolite of vitamin D, i.e., calcitriol (1,25(OH)2 
vitamin D), which binds to vitamin D receptors (VDR). Vitamin D enzymes present 
in the central nervous system are responsible for the regulation of cellular function 
in several tissues located in the body including brain neurons. Vitamin D comes in 
two main forms: the first form is vitamin D2 also known as ergocalciferol which is 
obtained from sources like mushrooms grown in UV light, dietary supplements, 
and fortified food, and the second form of vitamin D is vitamin D3 also known 
as cholecalciferol, obtained from oily fish and fish oil, liver, egg yolk, butter, and 
dietary supplements. Vitamin D2 and D3 are not equal when it comes to raising your 
vitamin D status. Both are effectively absorbed into the bloodstream. However, the 
liver metabolizes them differently. The liver metabolizes vitamin D2 into 25-hydroxy 
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1. Introduction
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marily, but it also plays its importance in several other biochemical pathways within 
the human body. Vitamin D, at the end of its metabolizing physiology, gets con-
verted into an active hormone metabolite of vitamin D, i.e., calcitriol (1,25(OH)2 
vitamin D), which binds to vitamin D receptors (VDR). Vitamin D enzymes present 
in the central nervous system are responsible for the regulation of cellular function 
in several tissues located in the body including brain neurons. Vitamin D comes in 
two main forms: the first form is vitamin D2 also known as ergocalciferol which is 
obtained from sources like mushrooms grown in UV light, dietary supplements, 
and fortified food, and the second form of vitamin D is vitamin D3 also known 
as cholecalciferol, obtained from oily fish and fish oil, liver, egg yolk, butter, and 
dietary supplements. Vitamin D2 and D3 are not equal when it comes to raising your 
vitamin D status. Both are effectively absorbed into the bloodstream. However, the 
liver metabolizes them differently. The liver metabolizes vitamin D2 into 25-hydroxy 
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vitamin D2 and vitamin D3 into 25-hydroxy vitamin D3. These two compounds 
are collectively known as calcifediol. The main circulating form of vitamin D is 
Calcifediol. The amount of Calcifediol can be determined by checking its blood 
levels in the body. However, vitamin D2 seems to yield less calcifediol than an equal 
amount of vitamin D3 [1, 2].
Vitamin D deficiency is prevalent worldwide. The knowledge of the causes of 
vitamin D deficiency and community affected by the same causes are prominent, 
and hence, differentiation in the therapy and supplementation of these popula-
tions is focused upon accordingly. Further, in India, the prevalence of vitamin D 
deficiency ranges from 40–90% in all age groups and high-risk groups alike, with 
the majority of study responses reporting 80–90% prevalence as reported by the 
National Center for Biotechnology Information (NCBI), India [3]. Vitamin D 
deficiency contributes to a high disturbance in the health/disease ratio and adds to 
the disease burden of the country [4, 5]. The daily requirement of the human body 
for vitamin D is not fulfilled by the dietary pattern of the Indian population, and 
hence, fortification of various foods with vitamin D is emphasized under the initia-
tives of various national programs [2].
Vitamin D deficiency can be defined as circulating 25(OH) vitamin D levels 
below 20 ng/ml, while vitamin D insufficiency is defined by circulating levels below 
32 ng/ml [3]. Vitamin D receptors are located in the bone, skeletal muscle, immune 
cells, and several other body tissues (including brain, prostate, breast, and colon). 
Deficiency of vitamin D hormone at its receptor site or the enzyme metabolizing 
site causes disturbed cell signalling, further indicating the increased risk of diseases 
like autoimmune diseases, cancer, tuberculosis, cardiovascular diseases, bone 
diseases, neurodegenerative diseases, and mood disorders, specifically discussed in 
this review. Low 25-hydroxyvitamin D levels less than 20 ng/ml are found to have a 
higher incidence of mood disorders consisting of premenstrual syndrome (PMS), 
seasonal affective disorder (SAD), non-specified mood disorder, and major depres-
sive disorder (MDD) [1].
The physiology of vitamin D in the human body involves both synthesizing and 
catabolizing pathways. Vitamin D is either absorbed by dietary intake or is synthe-
sized in the presence of ultraviolet B (UVB) rays ranging from 290 to 310 nm. In the 
epidermal layer of the skin, 7-dehydrocholesterol gets converted into pre-vitamin 
D3 in the presence of UVB rays, which further, under thermal reaction, forms 
vitamin D3 (also known as cholecalciferol). Vitamin D-binding proteins bind to 
vitamin D3, and by circulatory transport this protein-bound vitamin D3 reaches the 
liver, where it is further metabolized into 25(OH) vitamin D (calcifediol) and an 
inert form of vitamin D. Tightly regulated by parathyroid hormone (PTH), 25(OH) 
vitamin D converts into 1,25-dihydroxy vitamin D (also known as calcitriol), which 
is an active hormonal form of vitamin D in the kidneys and other extrarenal tissues. 
This active metabolite binds to vitamin D receptors to regulate the several tissue 
and cellular functions. When vitamin D deficiency occurs due to inadequate intake 
of vitamin D through diet or by application of excessive sun-protective agents, it 
causes dysfunctional regulation of glucocorticoid signalling which is known to 
be implicated in major depressive disorders and various other mood disorders, 
together with other body functioning disorders. It is reported to have elevated levels 
of glucocorticoid (a type of cortisol) for the patients of MDD [1, 6].
This review discusses sources of vitamin D, its association with different types 
of mood disorders in a different population, and its disease processes, together with 
the possible downstream molecular and genetic pathways associated with vitamin 
D deficiency and mood disorders. Further, this review focusses on the vitamin D 
deficiency causing mood disorders to the childbearing mothers and premenstrual 
syndrome to the ladies on the onset of their menses.
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2. Vitamin D status
Vitamin D status is determined by assessing serum levels of 25(OH) vitamin D 
after 3 months of a stable regimen of vitamin D intake. Serum 25(OH) vitamin D is 
used to measure vitamin D status because it is the major circulating form of vita-
min D and the most stable form of vitamin D. The National Health and Nutrition 
Examination Survey (NHANES) III data 8, which used a conservative measure of 
vitamin D deficiency {25(OH) vitamin D} levels <15 ng/mL, has reported 42.4% 
of African American women and 4.2% of white women are deficient in vitamin D 
during their childbearing years [2, 8, 9].
Toxic states (hypervitaminosis D) may occur when 25(OH) vitamin D levels 
supersede 100 ng/ml; however, in a study involving individuals diagnosed with 
multiple sclerosis treated with high doses of vitamin D, there was no evidence of 
toxicity found in individuals with 25(OH) vitamin D levels above 200 ng/ml [1].
3. Dietary recommendations of vitamin D
The dietary recommendations are largely based on bone health and assuming 
a minimal sun exposure of an individual under study. While the safe upper limit is 
set at 4000 international unit/day (IU/d) for healthy adults, for pregnant women, 
doses are higher than 6000 IU/d. Based on limited data from randomized controlled 
trials, some authors suggest that pregnant women can be supplemented with 
1000–2000 IU/d during the second and third trimesters, and a deficiency during 
pregnancy can be treated with daily doses of 4000 IU [5].
4. Synthesizing and metabolizing physiology of vitamin D
Vitamin D is a secosteroid hormone that is either absorbed by dietary intake 
or manufactured by the ultraviolet beam (UVB) rays ranging from 290 to 310 nm 
reaching the epidermis of the skin. In the presence of epidermal 7-dehydrocho-
lesterol, the absorbed vitamin D gets converted into pre-vitamin D3. Within the 
epidermis, a thermal reaction occurs to convert the pre-vitamin D3 into vitamin 
D3 also known as cholecalciferol [10, 11]. Vitamin D3 further, in process, moves 
to bind to the vitamin D-binding plasma proteins. Vitamin D3 is transported via 
vitamin D-binding proteins to the liver where it is metabolized into 25(OH) vitamin 
D (calcifediol) and an inert form of vitamin D. Calcifediol is tightly regulated by 
parathyroid hormone and converts it into 1,25-dihydroxy vitamin D also known 
as calcitriol [1]. Calcitriol is the active form of vitamin D, which binds to VDRs 
in the intestines, bones, and kidney and other extrarenal tissues to enhance the 
absorption of calcium from the intestines, promotes calcium deposition in bones, 
and decreases parathyroid hormone concentrations (PTH) [3, 6]. In the process, 
calcitriol binds to vitamin D receptors, the receptors from the nuclear receptor 
superfamily that regulates the cellular function in several tissues located in the body 
including brain neurons [1].
5. Challenges for estimation of serum vitamin D level
The estimation of calcitriol is very challenging as calcitriol (1,25(OH)2 vitamin D) 
has very short t1/2 and thus does not reflect long-term vitamin D status. Also, it is 
observed that the total 25(OH) vitamin D is the most reliable marker for vitamin D 
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status which measures both vitamin D-binding protein (DBP)-bound and free 
25(OH) vitamin D. In the light of widespread variation in measured results and 
divergent results in response to vitamin D supplementation, there is a need for a 
distinct method for estimation of vitamin D levels. Further, free 25(OH) vitamin D 
levels may vary according to genotype and single nucleotide polymorphisms (SNPs) 
in the DBP gene for which the assays are still not well established [5].
6. Prevalence of vitamin D deficiency
Vitamin D receptors are traced throughout the brain explaining the role 
of vitamin D in psychosomatic disorders, and it was found to have an equivocal call 
for vitamin D deficiency and depression going hand in hand [12].
Vitamin D insufficiency/deficiency is a worldwide problem, affecting all ages and 
races. Optimal 25(OH) vitamin D concentrations for skeletal health are >30 ng/ml. 
Serum 25(OH) vitamin D concentrations are generally lower in blacks than in whites 
and people who avoid exposing them to the sun. The increased use of sunscreens is 
hypothesized to increase the prevalence of vitamin D deficiency. Older adults, as a 
result of hyperparathyroidism related to renal insufficiency, tend to require more 
vitamin D to achieve adequate levels of 25(OH) vitamin D. As a result of the change 
in the definition of adequate concentrations, the prevalence of vitamin D defi-
ciency is higher than previously thought. The prevalence of vitamin D deficiency 
among older men and women living in the United States and Europe ranges from 
40–100%. The National Health and Nutrition Examination Survey from 2000 to 
2004 found that ~25% of men >50 years of age and 30–35% of women >50 years 
of age had 25(OH) vitamin D concentrations <0.001. Two studies performed in 
Colorado and Georgia found that despite reported consumption of more than the 
required daily intake of vitamin D (400–600 IU/d), the prevalence of vitamin D 
insufficiency (defined as <32 ng/mL and < 20 ng/ml, respectively) among commu-
nity-dwelling older adults (mean age, 77.8 and 77.0 years, respectively) ranged  
from 36.7 to 74.0% [3].
7. Vitamin D receptor
7.1 VDR in the brain
Vitamin D receptors are present on the nervous system tissues and cells espe-
cially dopaminergic nerves. In the momentary phase of cerebral development, 
vitamin D may act like a neurosteroid hormone in the areas of neurotransmission, 
neuroprotection, and neuroimmunomodulation. Vitamin D receptors belong to a 
hybrid class of nuclear receptor superfamily, which gets activated by vitamin D, a 
neurosteroid hormone that plays its major role in the nervous system by following 
mechanisms of differentiating, regulating Ca2+ ions, homeostasis, modulation of 
neurotrophins, and release and activation of key brain hormones and enzymes for 
neurotransmitter metabolism. VDR is a large molecular weight protein molecule 
weighing 50–60 kilodaltons, which consists of several functional binding domains, 
specifically and typically for all steroid hormones responsible for ligand binding, 
DNA binding, heterodimerization, nuclear localization, and ligand activation of 
transcriptional factors [13].
VDR detection in the brain tissue has been studied by enzyme-linked immuno-
sorbent assay (ELISA) and immunohistochemistry to understand the localization of 
nuclear ligand binding sites for the transcription of phenotypic characters [14].
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7.1.1 VDR gene location
Two important points of consideration for the production of the active form 
of vitamin D are 1,25(OH)2 vitamin D3, a vitamin D receptor, and an enzyme 1 
α-hydroxylase, which are found in the adult human brain. Identification of both 
the receptor and the enzyme were done in neuronal and glial cells in a regional 
and layer-specific pattern. The equivalent distribution of VDR regions and 
1α-hydroxylase enzyme regions together with their frequent discrete distribution is 
found in layers and subregions of brain tissue [15].
7.1.2 Expression of VDR
Expression of VDR has been documented in tissues, including the brain, heart, skel-
etal muscle, breast, prostate, colon, activated macrophages, skin, and the areas prone 
to tumor expression with any devised mutation. The age factor is known to dominantly 
decrease the VDR expression. Many in vitro studies with human and animal cells have 
observed the expression of not only VDRs but also an enzyme, 1α-hydroxylase, which 
is expressed in most of the body tissues and cells, specifically in the kidneys. Therefore, 
it appears that these cells locally produce the active form of vitamin D by a regulated 
mechanism, in a paracrine fashion, to be used in various cellular and physiological 
functions. This structures the strong biologic basis for the association between serum 
vitamin D concentrations and extra-skeletal physiology [15].
7.1.3 VDR gene mutations
VDR gene mutations have been characterized by altered behavior of VDR null 
mutant mice. A study revealed anxiety-like behavior with decreased exploration 
when the VDR mutant mice were subjected to anxiety evaluation [16]. Another study 
focusing on the investigation of anxiety parameters in VDR mutant mice demon-
strated unaltered spatial memory, olfaction, gustation, and hedonic responses [17].
VDR gene mutation is considered to influence the working of vitamin D hor-
mone, which is essential for the growth and differentiation of a variety of organs, 
including the complete central nervous system. Many studies have suggested the 
crucial role of vitamin D in the brain, inducing many CNS genes. Inhibition of 
brain neurotransmission can be seen by VDR gene mutation causing modulation 
of neuroprotection, neurotrophins release, and activity of key neurotransmitter 
metabolism enzymes [16].
7.1.4 Regulation of normal brain neurotransmitters by normal VDR gene
The active form of vitamin D, i.e., calcitriol has a fast and strong ligand binding 
to their respective receptors located in the bone, brain, and breast tissues, as well as 
in immune cells [6]. The upregulation of transient receptor potential (TRP) vanilloid 
calcium-selective cation channels, such as TRPV5 and TRPV6, is done by positive induc-
tion of vitamin D. Vitamin D regulated channels may express the role of the hormone by 
potential modulation of sensory pathways representing several cellular sensors respond-
ing to temperature, touch, pain, osmolarity, taste, and other stimuli [17].
7.1.5 VDR immunoreactivity
The immunohistochemical study depicted the distribution of the VDR in 
multiple brain regions inclusive of neuronal and glial cells and other regions of the 
substantia nigra in the normal functioning human brain. Further, it also revealed 
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the presence of the VDR and 1α- hydroxylase in the human brain and confirmed the 
cell expression for either the receptor or the activating enzyme in neuronal or glial 
origin [14, 15].
8. Effect of vitamin D on mood and cognition
Vitamin D receptors and the 1α-hydroxylase enzyme have been isolated and 
found in the regions of the cerebral cortex and cerebellum, suggesting the conver-
sion of calcifediol into an active form of vitamin D, i.e., calcitriol in the brain for 
a local cellular response [3, 18]. Several studies discuss the deficiency of vitamin 
D in the body at its targeted ligand binding sites due to less sunlight exposure or 
sun blockage, vitamin D receptor mutation causing phenotypic-conformational 
changes at the ligand binding site, and insufficient vitamin D-fortified diet, all 
causing major or minor mood disorders and illustrate the effectiveness of vitamin D 
or sunlight therapy (phototherapy), gene therapy, or supplemented vitamin D diet 
therapy for the treatment of depression and other mood disorders, demonstrating 
the associations between 25(OH) vitamin D concentrations and mood alone or 
mood and cognition in adults of all ages, including pregnant women, older adults, 
and targeted vitamin D-deficient population globally [3, 10].
9. Mood disorders
Vitamin D receptor mutant gene leads to the translation of mutant mRNA into 
defective vitamin D receptor proteins. Normal VDR is responsible for the regulation 
of glucocorticoid signalling, which, in this case, gets dysfunctional due to vitamin D 
deficiency. Dysfunctional glucocorticoid signalling is majorly implicated in several 
mood disorders like major depressive disorders, seasonal affective disorders, etc. 
Glucocorticoid, a type of cortisol, is seen to be increased in MDD and decreased in 
bone disorders. According to the recent diagnostic and statistical manual of mental 
disorders (DSM-IV), a major depressive disorder is diagnosed or said to be present 
when a person exhibits at least five of the following symptoms during 2 weeks, most 
of the day or nearly every day:
• Depressed mood
• Loss of interest or pleasure in daily activities
• Significant weight loss or gain
• Insomnia or hypersomnia
• Psychomotor agitation or retardation
• Fatigue or loss of energy
• Feelings of worthlessness or inappropriate guilt
• Diminished ability to concentrate or make decisions, problem with attention 
and cognition
• Recurrent suicidal thoughts with or without a plan [1]
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Genes are encoding for vitamin D3, 25-hydroxylase, and 1α-hydroxylase 
(CYP27B1), where CYP27B1 are the enzymes that metabolize vitamin D3 into cal-
ciferol hormones, which is further involved in brain functions. These are expressed 
in neurons and glial cells presenting VDR. Calciferol hormone, being a neuroactive 
compound, regulates the behavioral functions such as anxiety, hyperactivity, and 
depression. Hypovitaminosis is a deficient condition that is found to be associated 
with an increased risk of multiple sclerosis, seasonal affective disorder, schizo-
phrenia, Parkinson’s disease, and Alzheimer’s disease. Vitamin D deficiency could 
also be associated with autism, explained by a piece of indirectly related evidence. 
Furthermore, mood and cognitive performance appear to be dependent on plasma 
vitamin D level to some extent [19].
10. Types of vitamin D-deficient mood disorders
10.1 Seasonal affective disorder
Prevalence of seasonal affective disorder is seen when the vitamin D stored in 
the body are low with prominent seasonal changes. The disorder occurs during a 
particular time of a year where the sun exposure to the skin decreases leading to 
vitamin D deficiency, and the symptoms of the disorder can be resumed spontane-
ously on sun exposure. The individuals suffering from seasonal affective disorder 
have typically reported depression-like symptoms mostly in the winter months, 
where the levels of intensity of sunlight and photoperiod were predominately 
reduced [19–21]. Studies in the United Kingdom estimated the prevalence of SAD 
between 2.4 and 3.5%. The etiology of this disorder has not been fully elucidated, 
but the mechanisms leading to SAD are understood and linked to reduced sun-
light exposure and daylight length. SAD is led via an eye-brain-endocrine system 
pathway or a skin-vitamin D causal pathway. In the mammalian population, the 
first stage of in vivo vitamin D synthesis necessitates the irradiation of skin by 
UVB light, dependently showing the lower vitamin D serum levels in the winter 
months than that in summer months. It has been also postulated that at cellular 
or subcellular levels, vitamin D can directly influence the endocrine system of 
our body via ligand binding on vitamin D receptors present in the entire central 
nervous system of a human body [21]. A prospective, randomized controlled trial 
was conducted in a group of 15 subjects with SAD to postulate the hypothesis of 
the association of vitamin D deficiency and seasonal affective disorder in which 
eight subjects received 100,000 IU of vitamin D and seven subjects received 
phototherapy. The Hamilton Depression Scale, Structured Interview Guide for the 
Hamilton Depression Rating Scale, Seasonal Affective Depression version (SIGH-
SAD), and the SAD-8 depression scale were administered for the evaluation at two 
stages of treatment, i.e., first at onset of treatment and second after one month 
of the therapy. Also, intervention therapy was used to measure serum levels of 
25-hydroxyvitamin D (25-OH D) planned in a gap of 1 week before and after the 
intervention. Improvement in all subjects was seen with the one’s receiving vitamin 
D. Depression scale measure had no significant results for the phototherapy [1, 22].  
Major improvement was seen in both the abovementioned groups, and this 
improvement in 25(OH)D was intertwiningly associated with the improvement in 
depression scale score. Hence, it is evident that vitamin D supplementation has an 
important role in the treatment of SAD [10, 13, 14].
In order to understand the seasonality of mood change, it is integral to understand 
the seasonal changes in photoperiod to hypothesize the most vitamin D-deficient 
mood disorders. Many biological techniques are utilized for detecting photoperiod. 
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the presence of the VDR and 1α- hydroxylase in the human brain and confirmed the 
cell expression for either the receptor or the activating enzyme in neuronal or glial 
origin [14, 15].
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changes at the ligand binding site, and insufficient vitamin D-fortified diet, all 
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and targeted vitamin D-deficient population globally [3, 10].
9. Mood disorders
Vitamin D receptor mutant gene leads to the translation of mutant mRNA into 
defective vitamin D receptor proteins. Normal VDR is responsible for the regulation 
of glucocorticoid signalling, which, in this case, gets dysfunctional due to vitamin D 
deficiency. Dysfunctional glucocorticoid signalling is majorly implicated in several 
mood disorders like major depressive disorders, seasonal affective disorders, etc. 
Glucocorticoid, a type of cortisol, is seen to be increased in MDD and decreased in 
bone disorders. According to the recent diagnostic and statistical manual of mental 
disorders (DSM-IV), a major depressive disorder is diagnosed or said to be present 
when a person exhibits at least five of the following symptoms during 2 weeks, most 
of the day or nearly every day:
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• Significant weight loss or gain
• Insomnia or hypersomnia
• Psychomotor agitation or retardation
• Fatigue or loss of energy
• Feelings of worthlessness or inappropriate guilt
• Diminished ability to concentrate or make decisions, problem with attention 
and cognition
• Recurrent suicidal thoughts with or without a plan [1]
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In order to understand the seasonality of mood change, it is integral to understand 
the seasonal changes in photoperiod to hypothesize the most vitamin D-deficient 
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For example, initiation of the behavioral changes such as migration patterns and 
breeding behavior is conserved in many species, primates, and humans which are 
evident with changes in season and intensity of sunrays. Further, the scientists 
pointed out that the regulation of circadian phase shift is located in the suprachias-
matic nucleus (SCN) of the hypothalamus. The SCN has been shown to be involved 
in seasonal affective mood disorders. Further it was also presented that the SCN has 
an inhibitory action to the hypothalamic–pituitary–adrenal (HPA) axis and that this 
action can be altered by vitamin D dietary and supplementation restrictions [23].
10.2 Major depressive disorders
Major depressive disorder is a type of depressive disorder that is most likely to 
observe an association between vitamin D deficiency and anxio-depressive dis-
orders. This association can be demonstrated with a parallel comparison between 
the motor and behavioral disorders observed in animal models of depression 
and VDR-KO mice [13]. Several theories are suggesting seasonal mood swings in 
humans. The binding of vitamin D on the ligand binding site of VDR present on the 
hypothalamic core (which plays a crucial role in mood regulation) can be witnessed 
to have a link between several seasonal changes in photoperiod and seasonal mood 
swings. Epidemiological data are coherent with such a cross-linking hypothesis. 
As an instance, the evidence is suggestive that the established low serum 25(OH) 
vitamin D2 concentrations are closely related to the active experience of mood 
disorders in 80 subjects aging 65 years and older. Many studies have demonstrated 
that significant lower serum 25(OH) vitamin D2 and 1,25(OH)2 vitamin D3 concen-
trations are observed in depressive sample subjects than healthy controlled subjects. 
Indirect confirmation was made by studying the association between depression 
and osteoporosis in around 4000 women aged 67 years [15]. Nevertheless, these 
results can also be mitigated and potentially related to functional impairment and 
physical inactivity, both of which reasons to increase with osteoporosis and have an 
independent correlative associated with depression [16].
Various clinical trials support the theory of the efficacy of vitamin D supple-
mentation on mood disorders by varied sources like vitamin D-fortified diet, sun-
soaking, etc. [17]. Improvement in depression scale experiments was noted, and the 
improvements were associated with vitamin D supplementation technique, while 
not much improvement was observed with the phototherapy technique. It is specifi-
cally prescribed to have at least 800 IU daily dose of vitamin D which plays a major 
decisive role in mood disorder case studies [4, 22, 24].
10.3 Premenstrual syndrome
Premenopausal women face one of the most common disorders known as 
premenstrual syndrome. Up to 20% of reproductive-aged women are affected in 
the range of moderate-to-severe premenstrual syndrome and is associated with 
significant levels of mood impairment. Irritability, mood swings, anxiety, depres-
sion, breast tenderness, bloating, and headaches are some of the most common 
symptoms included in PMS. Women are reported to have a depressed mood during 
the last week of the luteal phase which resides within for few days from the onset 
of menses [9]. Many studies have postulated that blood serum calcium levels and 
vitamin D levels are lower in women with PMS and that vitamin D supplementation 
and calcium supplementation may reduce the severity of the symptoms [25].
It is hypothesized that the dysregulation of calciotropic hormone is seen to be a 
major provocative factor in premenstrual syndrome. The severity of the symptoms 
of PMS is directly linked to calcium homeostasis, regulated directly by vitamin D 
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and parathyroid hormone as the key factors. However, low dietary vitamin D intake 
and inhibited induction of parathyroid hormone have been directly associated with 
the development of premenstrual symptoms [8].
10.4 Postpartum depression (PPD)
Vitamin D insufficiency is common in its most vulnerable pregnant popula-
tion, and several studies have demonstrated the association of diminished levels 
of 25(OH) vitamin D with depressive symptoms [4]. Further, the diagnosis of 
low levels of 25(OH) vitamin D in maternal serum during pregnancy is associated 
with a higher incidental risk of postpartum depressive symptoms [26, 27]. Serum 
25(OH) vitamin D levels for pregnant and postpartum women with major depres-
sive episode, beginning within the first 4 weeks after childbirth, can be influenced 
by a multitude of factors like age, race/ethnicity, marital status, type of insurance, 
educational level, feeding type, and others. In addition, the season that accounts 
for the amount and strength of UVB exposure, i.e., photoperiod and vitamin D 
supplementation, also are found to be responsible for the episodes of major depres-
sion [28]. Vitamin D supplementation during pregnancy increases maternal serum 
25(OH) vitamin D levels and thereby ensures higher availability for the offspring 
neuronal development. Vitamin D levels can also be inversely associated with 
infertility parameters, preeclampsia, blood glucose, bacterial vaginosis, primary 
caesarean section, and postpartum depression, but direct correlation is seen in 
pregnancy associated with breast cancer [28, 29].
The core symptoms of PPD are similar to that of any major depressive disorder 
like depressed mood or loss of interest in normal activities, sleep and appetite dis-
turbances, loss of energy, feelings of guilt, and suicidal thoughts. Hence, the diag-
nosis of PPD becomes challenging as the sleep pattern changes and weight changes 
are also often observed in the normal postpartum period. It is further also exhibited 
that the lower maternal 1,25(OH)2 vitamin D levels have been found to be associ-
ated with higher levels of postpartum depressive symptoms as per the Edinburgh 
Postpartum Depression Scale scores. The promising results were observed by only 
one randomized clinical trial wherein the assessment was done by administration of 
high-dose vitamin D therapy in depressed subjects [6, 7].
Following birth in the first few days, the lower levels of 25(OH) vitamin D are 
reported for a greater risk of postnatal depressive symptoms and are also linked to 
serum vitamin D level in the second trimester of pregnancy. Further, the association 
of low 25(OH) vitamin D level was established with a continuous enhancing risk of 
reported level of symptoms that may indicate any one type of mood disturbance. 
Thus, it is confirmed that adequate intake of vitamin D is essential during pregnancy 
not only for the positive impact on the health and development of the offspring 
but also is a way to protect against postpartum mood disturbance in mothers [26]. 
Also, estrogen supplementation and vitamin D therapies have beneficiary effects on 
inflammatory response and related factors in women suffering from PPD [6, 29, 30].
When accounting the cortisol levels and hypothalamic–pituitary–adrenal axis 
reactivity in postpartum women, during the third trimester, maternal cortisol levels 
reach approximately three times that of nonpregnant levels. While the basal levels 
of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone, and 
cortisol are high, the HPA axis reactivity to stressful stimuli is dampened in late 
pregnancy. Furthermore, while the baseline cortisol levels return to normal within a 
couple of days after parturition, the hyporesponsiveness of HPA axis is found to be 
persistent in breastfeeding women [6].
The HPA axis hyperactivation or hypoactivation has always been associated with 
depressive states. It has also been hypothesized that depression during pregnancy 
Vitamin D Deficiency
116
For example, initiation of the behavioral changes such as migration patterns and 
breeding behavior is conserved in many species, primates, and humans which are 
evident with changes in season and intensity of sunrays. Further, the scientists 
pointed out that the regulation of circadian phase shift is located in the suprachias-
matic nucleus (SCN) of the hypothalamus. The SCN has been shown to be involved 
in seasonal affective mood disorders. Further it was also presented that the SCN has 
an inhibitory action to the hypothalamic–pituitary–adrenal (HPA) axis and that this 
action can be altered by vitamin D dietary and supplementation restrictions [23].
10.2 Major depressive disorders
Major depressive disorder is a type of depressive disorder that is most likely to 
observe an association between vitamin D deficiency and anxio-depressive dis-
orders. This association can be demonstrated with a parallel comparison between 
the motor and behavioral disorders observed in animal models of depression 
and VDR-KO mice [13]. Several theories are suggesting seasonal mood swings in 
humans. The binding of vitamin D on the ligand binding site of VDR present on the 
hypothalamic core (which plays a crucial role in mood regulation) can be witnessed 
to have a link between several seasonal changes in photoperiod and seasonal mood 
swings. Epidemiological data are coherent with such a cross-linking hypothesis. 
As an instance, the evidence is suggestive that the established low serum 25(OH) 
vitamin D2 concentrations are closely related to the active experience of mood 
disorders in 80 subjects aging 65 years and older. Many studies have demonstrated 
that significant lower serum 25(OH) vitamin D2 and 1,25(OH)2 vitamin D3 concen-
trations are observed in depressive sample subjects than healthy controlled subjects. 
Indirect confirmation was made by studying the association between depression 
and osteoporosis in around 4000 women aged 67 years [15]. Nevertheless, these 
results can also be mitigated and potentially related to functional impairment and 
physical inactivity, both of which reasons to increase with osteoporosis and have an 
independent correlative associated with depression [16].
Various clinical trials support the theory of the efficacy of vitamin D supple-
mentation on mood disorders by varied sources like vitamin D-fortified diet, sun-
soaking, etc. [17]. Improvement in depression scale experiments was noted, and the 
improvements were associated with vitamin D supplementation technique, while 
not much improvement was observed with the phototherapy technique. It is specifi-
cally prescribed to have at least 800 IU daily dose of vitamin D which plays a major 
decisive role in mood disorder case studies [4, 22, 24].
10.3 Premenstrual syndrome
Premenopausal women face one of the most common disorders known as 
premenstrual syndrome. Up to 20% of reproductive-aged women are affected in 
the range of moderate-to-severe premenstrual syndrome and is associated with 
significant levels of mood impairment. Irritability, mood swings, anxiety, depres-
sion, breast tenderness, bloating, and headaches are some of the most common 
symptoms included in PMS. Women are reported to have a depressed mood during 
the last week of the luteal phase which resides within for few days from the onset 
of menses [9]. Many studies have postulated that blood serum calcium levels and 
vitamin D levels are lower in women with PMS and that vitamin D supplementation 
and calcium supplementation may reduce the severity of the symptoms [25].
It is hypothesized that the dysregulation of calciotropic hormone is seen to be a 
major provocative factor in premenstrual syndrome. The severity of the symptoms 
of PMS is directly linked to calcium homeostasis, regulated directly by vitamin D 
117
Association of Vitamin D Deficiency and Mood Disorders: A Systematic Review
DOI: http://dx.doi.org/10.5772/intechopen.90617
and parathyroid hormone as the key factors. However, low dietary vitamin D intake 
and inhibited induction of parathyroid hormone have been directly associated with 
the development of premenstrual symptoms [8].
10.4 Postpartum depression (PPD)
Vitamin D insufficiency is common in its most vulnerable pregnant popula-
tion, and several studies have demonstrated the association of diminished levels 
of 25(OH) vitamin D with depressive symptoms [4]. Further, the diagnosis of 
low levels of 25(OH) vitamin D in maternal serum during pregnancy is associated 
with a higher incidental risk of postpartum depressive symptoms [26, 27]. Serum 
25(OH) vitamin D levels for pregnant and postpartum women with major depres-
sive episode, beginning within the first 4 weeks after childbirth, can be influenced 
by a multitude of factors like age, race/ethnicity, marital status, type of insurance, 
educational level, feeding type, and others. In addition, the season that accounts 
for the amount and strength of UVB exposure, i.e., photoperiod and vitamin D 
supplementation, also are found to be responsible for the episodes of major depres-
sion [28]. Vitamin D supplementation during pregnancy increases maternal serum 
25(OH) vitamin D levels and thereby ensures higher availability for the offspring 
neuronal development. Vitamin D levels can also be inversely associated with 
infertility parameters, preeclampsia, blood glucose, bacterial vaginosis, primary 
caesarean section, and postpartum depression, but direct correlation is seen in 
pregnancy associated with breast cancer [28, 29].
The core symptoms of PPD are similar to that of any major depressive disorder 
like depressed mood or loss of interest in normal activities, sleep and appetite dis-
turbances, loss of energy, feelings of guilt, and suicidal thoughts. Hence, the diag-
nosis of PPD becomes challenging as the sleep pattern changes and weight changes 
are also often observed in the normal postpartum period. It is further also exhibited 
that the lower maternal 1,25(OH)2 vitamin D levels have been found to be associ-
ated with higher levels of postpartum depressive symptoms as per the Edinburgh 
Postpartum Depression Scale scores. The promising results were observed by only 
one randomized clinical trial wherein the assessment was done by administration of 
high-dose vitamin D therapy in depressed subjects [6, 7].
Following birth in the first few days, the lower levels of 25(OH) vitamin D are 
reported for a greater risk of postnatal depressive symptoms and are also linked to 
serum vitamin D level in the second trimester of pregnancy. Further, the association 
of low 25(OH) vitamin D level was established with a continuous enhancing risk of 
reported level of symptoms that may indicate any one type of mood disturbance. 
Thus, it is confirmed that adequate intake of vitamin D is essential during pregnancy 
not only for the positive impact on the health and development of the offspring 
but also is a way to protect against postpartum mood disturbance in mothers [26]. 
Also, estrogen supplementation and vitamin D therapies have beneficiary effects on 
inflammatory response and related factors in women suffering from PPD [6, 29, 30].
When accounting the cortisol levels and hypothalamic–pituitary–adrenal axis 
reactivity in postpartum women, during the third trimester, maternal cortisol levels 
reach approximately three times that of nonpregnant levels. While the basal levels 
of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone, and 
cortisol are high, the HPA axis reactivity to stressful stimuli is dampened in late 
pregnancy. Furthermore, while the baseline cortisol levels return to normal within a 
couple of days after parturition, the hyporesponsiveness of HPA axis is found to be 
persistent in breastfeeding women [6].
The HPA axis hyperactivation or hypoactivation has always been associated with 
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and postpartum depression may have different pathogenesis; the first is found to 
be dejected with hyperactivity in the HPA axis and the second being atypical. The 
activity of the HPA axis is usually reduced in seasonal affective disorder, atypical 
depression, and PPD, which could point to a similar pathologic mechanism in all the 
three conditions mentioned. Furthermore, the physiological excess production of 
CRH at the end of pregnancy leads to a transient downregulation of hypothalamic 
CRH postpartum, which could possibly lead to an elevated risk for depression. 
Indeed, the hypothesis of PPD being related to hypoactivation of the HPA axis has 
been substantiated by a number of studies where women with PPD display lower 
baseline or reduced HPA responsiveness than controls, although conflicting data are 
available. In addition, women with a history of PPD appear to have increased levels 
of corticotropin-releasing hormone which further stimulates the dependent cortisol 
response in the experimental conditions of pregnancy. PPD can also be predicted by 
increased stress-induced cortisol levels or CRH levels [6, 20].
Together with SAD, PPD has also been classified, under the depressive states 
characterized by hypoactivation of the HPA axis. Increased serum concentrations 
of biomarkers detecting the inflammatory response, for example, IL-6, a pro-
inflammatory cytokine with a variety of endocrine and metabolic actions, have 
been observed in major depressive conditions. In this, IL-6 interacts with the HPA 
axis, and the interacted complex has significant higher serum levels in women 
with postpartum depressive symptomatology. Conclusively, vitamin D affects 
monoamine functional groups, the HPA axis, and immune responses to stress and 
symptom production [20, 38].
10.5 Aging depressive symptoms
Aging depressive symptoms are noticed for both hypervitaminosis D3 and hypo-
vitaminosis D3, which leads to premature aging of fibroblast growth factor 23 (FGF-
23) that is emerging as a significant mediator/hormone for early aging symptoms, 
and its FGF-23 effects are dominated by vitamin D-mediated excess of calcitriol. 
The early aging phenotypic features include thin skin, intestinal atrophy, spleen 
atrophy, muscle atrophy, weight loss, short life prognosis, osteoporosis, and athero-
sclerosis. There is a tight physiological regulation of 24-hydroxylase, the hormonal 
form of vitamin D3, which can be modulated by physiological serum concentrations 
of calcidiol. This regulation of hormonal form of vitamin D3 explains the develop-
ment of aging depressive symptoms [31]. However, some intoxications occur during 
the early period of synthesis and distribution of vitamin D3 with its substitution/
fortification. After the Second World War, the children in many parts of Europe 
were administered with extremely high oral doses of vitamin D3 and suffered from 
hypercalcemia, nephrocalcinosis, early aging, cardiovascular complications, and 
early death, supporting the possibility of hypothesizing that the hypervitaminosis 
D3 can accelerate aging symptoms [19, 24, 31].
Calciferol hormone insufficiency may accelerate the risk of diseases of CNS. A 
recent study postulated that the hypovitaminosis D3, also famously known as 
vitamin D deficiency, may cause premature or immature aging of cognitive func-
tions. Thus, both a lack and an excess of calciferol hormones enhance aging in major 
dependency [32]. Initial events affect the genome, causing telomere shortening 
or accumulation of DNA damages, which are modulated by the tumor suppressor 
protein, p53. Hormonal forms of vitamin D3 appear to control the basic mechanisms 
of aging and related diseases [19].
The hypothesis of the role of vitamin D in aging is considered based on three 
axial parameters, namely, calciferol hormone serum concentrations, risk of disease, 
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and onset of aging. The former two parameters are seen based on lower and higher 
values, and the latter parameter is seen as the typical or premature onset of aging. It 
is observed that both low and high action of calciferol hormones trigger premature 
aging, including diseases of CNS. Hence, an optimal serum concentration appears 
to delay aging [19].
10.6 Suicidal attempts due to vitamin D deficiency
Significant lower levels of vitamin D are seen in patients with suicidal tenden-
cies than both non-suicidal depressive patients and healthy control individuals. 
Deficiency of vitamin D was found in 58% of cases of all the reported cases of 
suicides, compared to around 30% cases found for the healthy controlled cases and 
the non-suicidal depressed patient cases [33–35].
Accumulating studies indicate that a dysregulated immune system could be a 
contributing factor to depression and possibly specifically to suicidal tendency. 
Direct evidence of causality comes both from animal models, where induction 
of peripheral inflammation is known to lead to depressive changes, and from the 
so-called cytokine-induced depression in humans, where treatment with inter-
ferons (IFN) of patients with hepatitis increases the risk for development of both 
depression and suicidal tendency [32]. Thus, an indirect proportional relationship 
between serum vitamin D concentration and inflammatory cytokines is seen to be 
established, i.e., the lower the vitamin, the higher are the levels of the inflamma-
tory cytokines IL-6 and IL-1β in the blood. The future prospective must be seen to 
compare vitamin D levels between other groups of psychiatric patients and groups 
of patients with personality disorders [7, 34, 36].
10.7 Schizophrenia
A study conducted in the year 2006 on the psychiatric population to understand 
the association between lower plasma levels of 25(OH) vitamin D3 and mood 
disorders revealed that all 82 subjects were suffering from psychiatric disorders. 
Further, 53 patients were suffering from mood disorders, and the remaining 29 
patients were diagnosed with schizophrenia. All these patients were found to have 
low vitamin D3 plasma concentration which confirms the significant association 
of low vitamin D3 plasma concentration with mood disorders and related disease 
symptoms. Additionally, significant hypovitaminosis D was also witnessed in 
mood disorders like major depression, bipolar disorder, and dysthymia than with 
schizophrenia [37]. Also, according to one of the neurodevelopmental hypothesis 
of schizophrenia, it was revealed that the prenatal vitamin D deficiency in a mother 
could be a high-risk factor for schizophrenia in an offspring [24].
10.8 Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder is an early-onset, chronic, a neurodevel-
opmental disease characterized by attention deficit, hyperactivity, and impulsivity 
mostly in children, affecting nearly 2–18% of children worldwide, and is found to 
be one of the most common psychiatric disorders in childhood stage [32]. Learning 
like basic skills can be affected in childhood and can also cause various psycho-
logical and social interaction problems in children and the adult population. The 
neurotransmitters like dopamine (DA) and noradrenaline (NA) play a crucial role 
in maintaining attention, concentration, motivation, awareness, and cognition. 
With the major role of vitamin D in cerebral function, it might have a direct role 
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atrophy, muscle atrophy, weight loss, short life prognosis, osteoporosis, and athero-
sclerosis. There is a tight physiological regulation of 24-hydroxylase, the hormonal 
form of vitamin D3, which can be modulated by physiological serum concentrations 
of calcidiol. This regulation of hormonal form of vitamin D3 explains the develop-
ment of aging depressive symptoms [31]. However, some intoxications occur during 
the early period of synthesis and distribution of vitamin D3 with its substitution/
fortification. After the Second World War, the children in many parts of Europe 
were administered with extremely high oral doses of vitamin D3 and suffered from 
hypercalcemia, nephrocalcinosis, early aging, cardiovascular complications, and 
early death, supporting the possibility of hypothesizing that the hypervitaminosis 
D3 can accelerate aging symptoms [19, 24, 31].
Calciferol hormone insufficiency may accelerate the risk of diseases of CNS. A 
recent study postulated that the hypovitaminosis D3, also famously known as 
vitamin D deficiency, may cause premature or immature aging of cognitive func-
tions. Thus, both a lack and an excess of calciferol hormones enhance aging in major 
dependency [32]. Initial events affect the genome, causing telomere shortening 
or accumulation of DNA damages, which are modulated by the tumor suppressor 
protein, p53. Hormonal forms of vitamin D3 appear to control the basic mechanisms 
of aging and related diseases [19].
The hypothesis of the role of vitamin D in aging is considered based on three 
axial parameters, namely, calciferol hormone serum concentrations, risk of disease, 
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and onset of aging. The former two parameters are seen based on lower and higher 
values, and the latter parameter is seen as the typical or premature onset of aging. It 
is observed that both low and high action of calciferol hormones trigger premature 
aging, including diseases of CNS. Hence, an optimal serum concentration appears 
to delay aging [19].
10.6 Suicidal attempts due to vitamin D deficiency
Significant lower levels of vitamin D are seen in patients with suicidal tenden-
cies than both non-suicidal depressive patients and healthy control individuals. 
Deficiency of vitamin D was found in 58% of cases of all the reported cases of 
suicides, compared to around 30% cases found for the healthy controlled cases and 
the non-suicidal depressed patient cases [33–35].
Accumulating studies indicate that a dysregulated immune system could be a 
contributing factor to depression and possibly specifically to suicidal tendency. 
Direct evidence of causality comes both from animal models, where induction 
of peripheral inflammation is known to lead to depressive changes, and from the 
so-called cytokine-induced depression in humans, where treatment with inter-
ferons (IFN) of patients with hepatitis increases the risk for development of both 
depression and suicidal tendency [32]. Thus, an indirect proportional relationship 
between serum vitamin D concentration and inflammatory cytokines is seen to be 
established, i.e., the lower the vitamin, the higher are the levels of the inflamma-
tory cytokines IL-6 and IL-1β in the blood. The future prospective must be seen to 
compare vitamin D levels between other groups of psychiatric patients and groups 
of patients with personality disorders [7, 34, 36].
10.7 Schizophrenia
A study conducted in the year 2006 on the psychiatric population to understand 
the association between lower plasma levels of 25(OH) vitamin D3 and mood 
disorders revealed that all 82 subjects were suffering from psychiatric disorders. 
Further, 53 patients were suffering from mood disorders, and the remaining 29 
patients were diagnosed with schizophrenia. All these patients were found to have 
low vitamin D3 plasma concentration which confirms the significant association 
of low vitamin D3 plasma concentration with mood disorders and related disease 
symptoms. Additionally, significant hypovitaminosis D was also witnessed in 
mood disorders like major depression, bipolar disorder, and dysthymia than with 
schizophrenia [37]. Also, according to one of the neurodevelopmental hypothesis 
of schizophrenia, it was revealed that the prenatal vitamin D deficiency in a mother 
could be a high-risk factor for schizophrenia in an offspring [24].
10.8 Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder is an early-onset, chronic, a neurodevel-
opmental disease characterized by attention deficit, hyperactivity, and impulsivity 
mostly in children, affecting nearly 2–18% of children worldwide, and is found to 
be one of the most common psychiatric disorders in childhood stage [32]. Learning 
like basic skills can be affected in childhood and can also cause various psycho-
logical and social interaction problems in children and the adult population. The 
neurotransmitters like dopamine (DA) and noradrenaline (NA) play a crucial role 
in maintaining attention, concentration, motivation, awareness, and cognition. 
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in the etiopathogenesis of ADHD in children and young adolescence. Further, 
vitamin D is also responsible for the regulatory synthesis of neurotrophic factors 
such as neurotrophin (NT), NT 3 and NT 4, nerve growth factor (NGF), and glial 
cell line-derived neurotrophic factor (GDNF), known to be significantly involved 
in cell differentiation and survival. Thus, ADHD is etiopathologically connected to 
vitamin D deficiency. In initial years of growth and development of life, vitamin D 
deficiency or extensive insufficiency can be harmful to neuronal development and 
function, resulting in stimulation of neurogenesis [7, 10].
11. Conclusion
To summarize, vitamin D deficiency is associated with several types of mood 
disorders involving various molecular and genetic mechanisms related to vitamin D 
receptors and VDR gene. The VDR gene mutation alters vitamin D binding capac-
ity to vitamin D receptor, preventing vitamin D activation into calcitriol which 
regulates synthesis of neurotrophic factors. Failing to maintain these neurotrophic 
factors in the presence of vitamin D deficiency leads to cerebral dysfunction and 
thereby contributes to mood disorder symptoms. Further, vitamin D deficiency 
is also associated with cognitive reasoning and mind disturbance that trigger off 
mood disorders like major depressive disorders, seasonal affective disorder, suicidal 
tendency, postpartum depression to the childbearing mothers, premenstrual syn-
drome to the ladies on the onset of their menses, ADHD, schizophrenia, and aging 
depressive symptoms. Futures studies and clinical trials can also be structured to 
establish a better understanding of the effects of the vitamin D deficiency on several 
mood disorders, behavioral disorders, and cognition.
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vitamin D is also responsible for the regulatory synthesis of neurotrophic factors 
such as neurotrophin (NT), NT 3 and NT 4, nerve growth factor (NGF), and glial 
cell line-derived neurotrophic factor (GDNF), known to be significantly involved 
in cell differentiation and survival. Thus, ADHD is etiopathologically connected to 
vitamin D deficiency. In initial years of growth and development of life, vitamin D 
deficiency or extensive insufficiency can be harmful to neuronal development and 
function, resulting in stimulation of neurogenesis [7, 10].
11. Conclusion
To summarize, vitamin D deficiency is associated with several types of mood 
disorders involving various molecular and genetic mechanisms related to vitamin D 
receptors and VDR gene. The VDR gene mutation alters vitamin D binding capac-
ity to vitamin D receptor, preventing vitamin D activation into calcitriol which 
regulates synthesis of neurotrophic factors. Failing to maintain these neurotrophic 
factors in the presence of vitamin D deficiency leads to cerebral dysfunction and 
thereby contributes to mood disorder symptoms. Further, vitamin D deficiency 
is also associated with cognitive reasoning and mind disturbance that trigger off 
mood disorders like major depressive disorders, seasonal affective disorder, suicidal 
tendency, postpartum depression to the childbearing mothers, premenstrual syn-
drome to the ladies on the onset of their menses, ADHD, schizophrenia, and aging 
depressive symptoms. Futures studies and clinical trials can also be structured to 
establish a better understanding of the effects of the vitamin D deficiency on several 
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Abstract
Approximately 90% of the elderly population in the western countries has at 
least a mild to moderate vitamin D hypovitaminosis. Besides the well-known func-
tion of vitamin D in calcium homeostasis, it has been recently found that several 
enzymes and receptors involved in its homeostasis are expressed in the nervous 
system and brain suggesting also an important role in the brain homeostasis. 
Interestingly, epidemiological and clinical studies found reduced vitamin D level 
associated with an increased risk of several neurodegenerative disorders. In this 
chapter, we focus on a potential link between vitamin D and Alzheimer’s disease, 
Parkinson’s disease, multiple sclerosis, prion disease, and motor neuron disease. 
Epidemiological studies were summarized, an overview of the known potential 
underlying pathomolecular mechanisms are given, and results from clinical stud-
ies dealing with vitamin D supplementation were presented. As an outlook, recent 
literature suggesting an impact of vitamin D on autism spectrum disease, depres-
sion, and schizophrenia are briefly discussed. In conclusion, the identification of an 
abundant vitamin D metabolism in the brain and the tight link between the increas-
ing number of several neurological and mental disorders emphasize the need of 
further research making a clear recommendation of the intake and supplementation 
of vitamin D in a growing elderly population.
Keywords: vitamin D hypovitaminosis, Alzheimer’s disease, Parkinson’s disease, 
multiple sclerosis, prion disease, neuropsychiatric diseases
1.  Introduction: relationship between vitamin D and neurodegenerative 
diseases
The secosteroid vitamin D3 was identified in the year 1928 by Adolf Windaus 
and colleagues. Its synthesis starts in the skin based on 7-dehydrocholesterol 
through extraneous cause of ultraviolet B radiation in a spectrum of 290–315 nm 
wavelengths. Via the vitamin D-binding protein, it is transported in the blood to the 
liver where the 25-hydroxylase CYP2R1 hydroxylates vitamin D3 to 25-hydroxyvi-
tamin D3 (25(OH)D3). Because of its serum half-life of weeks, this 25-hydroxyl-
ated form of vitamin D3 is clinically measured as an indicator for the patients’ 
vitamin D3 level [1, 2]. The active form of vitamin D3, 1,25-dihydroxyvitamin D3 
(1α,25(OH)2D3) or calcitriol, is synthesized in the kidney by the 1α-hydroxylase 
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CYP27B1. To a limited extent, vitamin D3 can also be taken up with diet as well as 
vitamin D2 (ergo-calciferol), which is largely found in food.
Calcitriol can perform its genomic actions via vitamin D receptor (VDR) bind-
ing. Hence this undergoes a conformational change and forms a complex with the 
retinoid X receptor (RXR) which interacts with the vitamin D response element 
(VDRE) to regulate the expression of numerous genes. Because of this ability of 
transcriptional modulation, vitamin D has influence on various cellular processes, 
for example, the mitochondrial function by maintaining the mitochondrial respira-
tory chain activity [3]. Dysfunctional mitochondria will normally be removed by 
autophagy, a process that is also promoted by vitamin D [4]. Damaged mitochon-
dria could induce inflammation. Vitamin D is able to downregulate the expression 
of pro-inflammatory cytokines such as the tumor necrosis factor-α (TNF-α) or 
interleukin-6 (IL-6), thereby reducing inflammation [5]. Additionally to these 
cellular processes, vitamin D antagonizes oxidative stress by enhancing the expres-
sion of antioxidants and thereby reduces levels of reactive oxygen species (ROS) 
[6]. Furthermore the expression of the voltage sensitive L-type Ca2+ channels is 
suppressed by vitamin D to regulate intraneural calcium [7, 8]. Vitamin D also plays 
a role in DNA-related cellular processes, for example, epigenetic changes. These 
are influenced on the one hand by oxidative stress which is regulated by vitamin 
D, as described before, and on the other hand by histone methylation which is 
also modulated by vitamin D due to its influence on the transcription of key DNA 
demethylases [9, 10].
Based on the fact that up to 90% of the elderly population is suffering from 
a vitamin D hypovitaminosis because of a homebound lifestyle and the reduced 
ability of their skin to generate vitamin D3, the idea arose to analyze the impact of a 
vitamin D deficit on the abovementioned cellular processes which are all involved 
in ageing [11]. Moreover, ageing is a risk factor for neurodegenerative disorders. 
Michael J. Berridge published a very detailed article 2 years ago reviewing the 
influence of vitamin D deficiency on ageing and age-related diseases. He figured 
out that hypovitaminosis D promotes those ageing-related processes, for example, 
due to a decline of mitochondrial respiration or the electron transport chain. This 
dysfunction leads to an increase in oxidative stress and inflammation, main drivers 
of ageing. Furthermore, he describes elevated Ca2+ levels in neurons during ageing 
which are accompanied by a decline in cognition. This observation can be restored 
by vitamin D due to its ability to reduce the levels of Ca2+. Additionally, telomere 
shortening, a DNA-related process that is involved in ageing, is reported to be 
decreased by vitamin D [12]. Those upregulated ageing processes under vitamin 
D-deficient conditions in the elderly population could further lead to age-related 
disorders like dementia or declines in cognition.
A relationship between vitamin D and age-related cognitive disorders was 
further strengthened by the findings that vitamin D and its metabolites are able 
to cross the blood-brain barrier. Early research reported the presence of vitamin 
D metabolism intermediates and products in human cerebrospinal fluid [13]. 
Furthermore, due to the presence of the metabolizing hydroxylases in the brain, the 
active form of this hormone-like secosteroid can be synthesized in the human brain. 
The additive existence of the VDR in neuronal and glial cells suggests that vitamin 
D might influence functioning of the central nervous system (CNS) [14]. As 
mentioned earlier, the VDR-mediated nuclear functions of 1,25(OH)2D3 influence 
cellular processes, for example, immune modulation and cell growth or differentia-
tion. Those biological systems have also an impact on maintaining the function 
of the brain. Annweiler et al. reported increased risks of cognitive disorders for 
patients with 25(OH)D3 serum concentrations lower than 10 ng/ml [15]. Vitamin 
D influences the structure of the brain, like changes in volume and vasculature as 
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well as its metabolism [16]. Furthermore, in vivo studies using offspring of vitamin 
D-deficient rats could show that vitamin D plays an important role in the devel-
oping brain [17]. Eyles et al. give a detailed overview in their review over all the 
different animal studies that have been made in this context. One exemplary finding 
is that rats with a vitamin D deficiency during their development have impairments 
in their adult behavior [18].
In a retrospective study from 2007, Przybelski and colleagues reported that 
serum 25(OH)D3 can be positively associated with increased cognitive function 
[19]. Consistent finding results from a prospective cohort study in older adults that 
showed a vitamin D hypovitaminosis (levels <30 ng/mL) in 68% of the participants 
and moreover that these ones have lower baseline cognitive function and increased 
decline over the 4 years of follow-up [20]. In the same year, another prospective 
study including 1185 women also pointed out an association of higher plasma 
25(OH)D3 levels and better cognitive performance [21]. A meta-analysis showed 
that participants with insufficient vitamin D levels have a 2.4-fold increased risk 
of cognitive impairments than those with sufficient levels [22]. In line with this, 
further systematic reviews and meta-analysis support an association between 
hypovitaminosis D and declined cognitive functions [23, 24]. Additionally, some 
longitudinal studies suggest a link between low serum 25(OH)D3 levels and cog-
nitive performance. Toffanello et al. reported decreasing scores at Mini-Mental 
State Examination (MMSE) in participants having serum 25(OH)D3 levels below 
75 nmol/L in their 4.4-year follow-up study including 1927 elderly subjects [25]. 
One year later, Miller et al. published a vitamin D-associated accelerated decline in 
cognitive performance in their study of a multiethnic cohort of older adults [26]. 
In line with these data, a more recent clinical study in the elderly US population 
(3325 participants) reported that low serum levels of vitamin D3 are linked to an 
enhanced risk of cognitive impairment [27].
Due to the suggested role of vitamin D in brain function, several studies examin-
ing the effect of dietary supplemented vitamin D exist. Animal studies and epide-
miological studies generate biological evidences for a relationship between vitamin 
D levels and brain health. Latimer et al. could show that a 6-month supplementa-
tion of vitamin D improves cognitive function in a rat model of aging [28]. One 
study from Annweiler and colleagues in the year 2010, including 5596 women with 
a mean age of 80.5 years, concluded that higher weekly dietary vitamin D intake is 
associated with better cognitive performance in older adults [29]. In line with this, 
a current cross-sectional and longitudinal study describes a significant association 
between serum vitamin D levels below 30 nmol/L and reduced general cognitive 
performance [30].
Unlike those animal and epidemiological findings, clinical studies using ran-
domized controls examining the role of vitamin D in individuals without any form 
of dementia show heterogeneous data [31–34]. In general, it should not be disre-
garded that differences in clinical intervention studies might be because included 
participants who already had sufficient vitamin D levels at baseline could mask 
the benefit of supplementation on cognitive function. To prevent this, it would be 
beneficial including exclusively participants affected by a hypovitaminosis D at the 
baseline measurement. These inconclusive data also support the idea of individually 
adjusted supplementation protocols for each patient. Furthermore, methodological 
differences between the studies, for example, duration, form, and dose of vitamin 
D supplementation, have to be considered. A current study from Pettersen et al. 
[35] considered these abovementioned methodological pitfalls by administering 
4000 IU/day of vitamin D3 for 18 weeks to healthy adults and by baseline as well as 
endpoint measurements of serum 25(OH)D3 levels. Furthermore, they were able 
to distinguish between the two cognitive domains, verbal and visual memory, with 
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several cognitive tests. High doses of vitamin D enhanced visual memory, while 
low doses (400 IU/day) improved verbal memory. As summarized by the authors, 
there seems to be a small positive effect of vitamin D3 supplementation on executive 
functioning, despite the outlined limitations (modest sample size with wide range 
of ages, no true placebo group) [35]. Recently, Aspell et al. give a well elaborated 
overview over a possible supporting role of vitamin D in cognitive function in age 
[36]. In the following chapter, we will present the results of current available studies 
examining the impact of vitamin D supplementation on brain-related disorders for 
each neurodegenerative disease itself. Up to this date, also the nutrition research 
field examines the influence of dietary components on brain health. In a recent 
review from Moore et al., the authors describe a potential protective role for vitamin 
D among others [37].
2. Alzheimer’s disease
Alzheimer’s disease (AD) can be described as a multifactorial, metabolic disease 
as this disease is characterized by impairments in multiple cellular processes. For 
example, AD pathology includes alterations in the sequential proteolytic processing 
of the amyloid precursor protein (APP) which results in the formation of neuro-
toxic Aβ plaques, in the phosphorylation of the microtubule-associated protein Tau, 
in lipid and energy metabolism, and in inflammation. Among others, AD patho-
genesis is influenced by lipophilic vitamins [38].
Epidemiological studies indicate a relationship between vitamin D deficiency 
and AD. A systematic review and meta-analysis concluded that patients affected by 
AD have lower levels of serum 25(OH)D3 than healthy controls [39]. Furthermore 
the level of vitamin D is shown to be significantly reduced in the cerebrospinal fluid 
of AD patients [40]. Another meta-analysis from Shen and colleagues shows that 
vitamin D hypovitaminosis (25(OH)D3 level < 50 nmol/L) is associated with a 21% 
increased risk of AD [41]. Different results were obtained by a study, measuring 
serum level of 25(OH)D3 via radioimmunoassay in patients with MCI or diag-
nosed dementia compared to healthy controls. Analysis of the cognitive perfor-
mance showed significant differences between these groups. Vitamin D levels of 
65.2 ± 17.9 nmol/L for controls, 61.4 ± 18.8 nmol/L for MCI, and 65.0 ± 20.3 nmol/L 
for AD were reported in this study; however the differences in vitamin D con-
centrations between these groups were not statistically significant. Interestingly, 
the authors show that approximately 12% of the MCI and AD patients used some 
kind of vitamin D supplementation, whereas only 5% of healthy controls did so. 
Furthermore, 80% of the MCI patients, 50% of the AD patients, and 62% of the 
control individuals regularly used nutritional supplements, which could have influ-
enced the results as discussed by the authors. In conclusion, the authors comment 
that their “findings cannot exclude the possibility that targeted vitamin supplemen-
tation can act as a modifying measure, although it is less likely that vitamin intake 
can prevent dementia onset” [42].
Several longitudinal studies provide homogeneous results indicating that a 
deficiency in serum 25(OH)D3 is linked to a greater risk and incidence of dementia 
and AD [43–47]. A current prospective study analyzed 25(OH)D3 level, cognitive 
decline, and incidence of dementia in 916 patients for 12 years and reported a more 
pronounced cognitive decline and a threefold increased risk of AD in individuals 
with hypovitaminosis D [48].
In line, a study from 2018 analyzing the serum vitamin D level in AD patients 
described decreased levels in various stages of AD. Additionally, the authors 
indicate 25(OH)D3 as significant predictor for severe AD and argue for vitamin D 
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supplementation in AD patients [49]. Moreover, Wang et al. recently reported a 
delayed onset of psychotic symptoms when vitamin D was used in AD patients and 
suggest variations in vitamin D-influenced genes as biomarkers for those individu-
als who can have a benefit from supplementation [50].
These studies consistently indicate a link between insufficient dietary intake of 
vitamin D and cognitive diseases like AD. However, these studies did not address 
the question whether vitamin D deficiency is a cause and thus risk factor for AD or 
a consequence of this neurodegenerative disease mediated by accompanying dietary 
and behavioral changes. Some more evidence of a causal relationship between 
hypovitaminosis D and AD was achieved by Mendelian randomization (MR) 
studies that use genetic associations on inherited alleles unaffected by confound-
ing factors or disease progression. It was reported that two polymorphisms in the 
VDR gene are associated with AD risk in patients younger than 76 years [51]. A 
subsequent meta-analysis including six AD studies also revealed this relationship 
[52], as well as an earlier study using genotyping of 213 participants [53]. Wang 
et al. also provide this genetic evidence and could further generate functional data 
indicating a link between the VDR and the genetic AD risk [54]. Furthermore, the 
study of Mokry and colleagues supports genetically decreased vitamin D levels 
as causal risk of AD, by analyzing the effect of single-nucleotide polymorphisms 
(SNPs) involved in vitamin D metabolism on 25(OH)D3 levels and the risk of AD in 
more than 56,000 participants [55]. A recently published MR study from Larsson 
and colleagues including 17,008 AD cases and 37,154 controls reported an inverse 
association between 7 SNPs related to elevated vitamin D3 levels with AD, in which 
2 of them were significant [56]. A study creating a vitamin D synthesis risk score 
analyzing more than 1000 Swedish men in a follow-up of 18 years is controversially 
discussed as this study revealed no link between baseline vitamin D status and the 
long-term risk of dementia [57].
Concerning clinical studies, randomized placebo-controlled trials analyzing the 
effect of vitamin D supplementation on AD risk and progression are still missing. 
However, recently nonrandomized studies showed positive findings about that 
relationship. A current study reported improvements in the cognitive status of MCI 
patients (n = 16) in an 18-month follow-up after 6 months of vitamin D supple-
mentation. Additionally, vitamin D supplementation protected lymphocytes from 
oxidative stress [58].
In contrast to the missing clinical trials, several animal and cell culture studies 
underline a causal relationship between vitamin D and AD. One study described an 
increased neurogenesis and enhanced cognition after feeding a transgenic mouse 
model of AD (5xFAD mouse model) with a daily dose of 500 IU/kg vitamin D 
for 5 months [59]. Additionally, animal and cell culture studies allow analyzing 
combination therapies, for example, a supplementation of both vitamin D and 
resveratrol. This resulted in an improvement of cognitive function and reduced 
levels of Aβ42 in the hippocampus along with decreased tau phosphorylation in the 
parietal cortex of a mouse model with AD-related memory impairment [60]. In 
line, a novel study from 2019 reported an improvement of the AD-related pathol-
ogy in 5xFAD mice after intravenous injection of vitamin D-binding protein which 
was loaded on a biocompatible polymer (PLGA) [61]. Especially cell culture and 
animal-based studies are indispensable for clarifying the molecular mechanisms 
of vitamin D action in neurodegenerative diseases. They revealed that vitamin 
D exerts its protective effects via VDR-related, genomic, as well as non-genomic 
actions directed to processes like Aβ metabolism, neurogenesis, immune modula-
tion, and neuronal calcium homeostasis. A study from Landel et al. examined the 
transcriptome of 5xFAD mice after 5 months of vitamin D3 supplementation and 
reported a large number of differentially expressed genes. The authors suggest an 
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several cognitive tests. High doses of vitamin D enhanced visual memory, while 
low doses (400 IU/day) improved verbal memory. As summarized by the authors, 
there seems to be a small positive effect of vitamin D3 supplementation on executive 
functioning, despite the outlined limitations (modest sample size with wide range 
of ages, no true placebo group) [35]. Recently, Aspell et al. give a well elaborated 
overview over a possible supporting role of vitamin D in cognitive function in age 
[36]. In the following chapter, we will present the results of current available studies 
examining the impact of vitamin D supplementation on brain-related disorders for 
each neurodegenerative disease itself. Up to this date, also the nutrition research 
field examines the influence of dietary components on brain health. In a recent 
review from Moore et al., the authors describe a potential protective role for vitamin 
D among others [37].
2. Alzheimer’s disease
Alzheimer’s disease (AD) can be described as a multifactorial, metabolic disease 
as this disease is characterized by impairments in multiple cellular processes. For 
example, AD pathology includes alterations in the sequential proteolytic processing 
of the amyloid precursor protein (APP) which results in the formation of neuro-
toxic Aβ plaques, in the phosphorylation of the microtubule-associated protein Tau, 
in lipid and energy metabolism, and in inflammation. Among others, AD patho-
genesis is influenced by lipophilic vitamins [38].
Epidemiological studies indicate a relationship between vitamin D deficiency 
and AD. A systematic review and meta-analysis concluded that patients affected by 
AD have lower levels of serum 25(OH)D3 than healthy controls [39]. Furthermore 
the level of vitamin D is shown to be significantly reduced in the cerebrospinal fluid 
of AD patients [40]. Another meta-analysis from Shen and colleagues shows that 
vitamin D hypovitaminosis (25(OH)D3 level < 50 nmol/L) is associated with a 21% 
increased risk of AD [41]. Different results were obtained by a study, measuring 
serum level of 25(OH)D3 via radioimmunoassay in patients with MCI or diag-
nosed dementia compared to healthy controls. Analysis of the cognitive perfor-
mance showed significant differences between these groups. Vitamin D levels of 
65.2 ± 17.9 nmol/L for controls, 61.4 ± 18.8 nmol/L for MCI, and 65.0 ± 20.3 nmol/L 
for AD were reported in this study; however the differences in vitamin D con-
centrations between these groups were not statistically significant. Interestingly, 
the authors show that approximately 12% of the MCI and AD patients used some 
kind of vitamin D supplementation, whereas only 5% of healthy controls did so. 
Furthermore, 80% of the MCI patients, 50% of the AD patients, and 62% of the 
control individuals regularly used nutritional supplements, which could have influ-
enced the results as discussed by the authors. In conclusion, the authors comment 
that their “findings cannot exclude the possibility that targeted vitamin supplemen-
tation can act as a modifying measure, although it is less likely that vitamin intake 
can prevent dementia onset” [42].
Several longitudinal studies provide homogeneous results indicating that a 
deficiency in serum 25(OH)D3 is linked to a greater risk and incidence of dementia 
and AD [43–47]. A current prospective study analyzed 25(OH)D3 level, cognitive 
decline, and incidence of dementia in 916 patients for 12 years and reported a more 
pronounced cognitive decline and a threefold increased risk of AD in individuals 
with hypovitaminosis D [48].
In line, a study from 2018 analyzing the serum vitamin D level in AD patients 
described decreased levels in various stages of AD. Additionally, the authors 
indicate 25(OH)D3 as significant predictor for severe AD and argue for vitamin D 
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supplementation in AD patients [49]. Moreover, Wang et al. recently reported a 
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als who can have a benefit from supplementation [50].
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long-term risk of dementia [57].
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However, recently nonrandomized studies showed positive findings about that 
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patients (n = 16) in an 18-month follow-up after 6 months of vitamin D supple-
mentation. Additionally, vitamin D supplementation protected lymphocytes from 
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In contrast to the missing clinical trials, several animal and cell culture studies 
underline a causal relationship between vitamin D and AD. One study described an 
increased neurogenesis and enhanced cognition after feeding a transgenic mouse 
model of AD (5xFAD mouse model) with a daily dose of 500 IU/kg vitamin D 
for 5 months [59]. Additionally, animal and cell culture studies allow analyzing 
combination therapies, for example, a supplementation of both vitamin D and 
resveratrol. This resulted in an improvement of cognitive function and reduced 
levels of Aβ42 in the hippocampus along with decreased tau phosphorylation in the 
parietal cortex of a mouse model with AD-related memory impairment [60]. In 
line, a novel study from 2019 reported an improvement of the AD-related pathol-
ogy in 5xFAD mice after intravenous injection of vitamin D-binding protein which 
was loaded on a biocompatible polymer (PLGA) [61]. Especially cell culture and 
animal-based studies are indispensable for clarifying the molecular mechanisms 
of vitamin D action in neurodegenerative diseases. They revealed that vitamin 
D exerts its protective effects via VDR-related, genomic, as well as non-genomic 
actions directed to processes like Aβ metabolism, neurogenesis, immune modula-
tion, and neuronal calcium homeostasis. A study from Landel et al. examined the 
transcriptome of 5xFAD mice after 5 months of vitamin D3 supplementation and 
reported a large number of differentially expressed genes. The authors suggest an 
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interaction of vitamin D with estrogen and insulin signaling to regulate the identi-
fied pathways [62]. Consistently, we could show that a deficit of vitamin D causes a 
dysregulation of numerous genes that are involved in multiple cellular processes like 
neurogenesis, inflammation, mitochondrial function, oxidative stress, signal trans-
duction, and APP homeostasis in brains of hypovitaminosis D mice [63]. In respect 
to the impaired APP homeostasis, several studies using primary cortical neurons or 
human neuroblastoma cell lines were able to show beneficial effects of vitamin D 
and its analogues on anabolism and catabolism of the neurotoxic Aβ peptide  
[64, 65]. In line with these findings, a vitamin D3-enriched diet leads to an increased 
Aβ clearance in mouse models of AD [66–68]. Consistent with the results of animal 
studies, Hooshmand et al. could demonstrate an association of increased plasma 
25(OH)D3 levels with higher concentrations of CSF Aβ1-42 in 75 patients, reflect-
ing a decreased Aβ1-42 aggregation in human brain parenchyma [69]. In contrast, a 
recent cross-sectional study failed to find significant associations between plasma 
vitamin D levels at baseline and Aβ load in different brain regions. But the authors 
themselves argue that those findings could be explained by an improper timing of 
measurements or rather no analysis over time or by a hypovitaminosis D-related 
cognitive decline independent of APP homeostasis [70]. The potential neuroprotec-
tive role of vitamin D3 is based on findings that it regulates the transcription of the 
neurotrophin nerve growth factor, glial-derived nerve factor, and neurotrophin 3 
which are important for neuronal survival [71–73]. Furthermore, the expression 
of the neuroprotective cytokine IL-34 was shown to be increased in dose- and 
time-dependent manner by calcitriol in neuroblastoma cells [74]. In respect to a 
relationship between vitamin D and neuronal calcium levels, a review describes a 
reduced autophagy due to impairments in calcium signaling as a consequence of 
hypovitaminosis D [6].
3. Parkinson’s disease
As one of the most common neurodegenerative diseases, Parkinson’s disease 
(PD) is characterized by the loss of dopamine-producing neurons in the substantia 
nigra pars compacta and typical Lewy bodies, aggregates of α-synuclein, provoking 
oxidative stress and further cell death, leading to impairments in cognition and 
behavior and to dysautonomia [75].
A number of epidemiological studies were able to indicate an association of 
vitamin D and PD. Several evidences exist that hypovitaminosis D is more frequent 
in PD patients [76, 77], and a cohort study with a 29-year follow-up reported a 
decreased risk of PD in individuals with higher vitamin D serum levels [78]. These 
findings are supported by the outcomes of recent studies describing significantly 
reduced levels of serum 25(OH)D3, daily vitamin D intake, and sunlight exposure 
in PD patients [79]. Besides significantly decreased serum 25(OH)D3 levels, also an 
association of vitamin D at baseline and disease motor severity after 36 months was 
observed in a recently published prospective observational study [80]. A clinical 
study found an inverse relationship between serum vitamin D concentrations and 
disease severity as well as an influence on balance function in PD patients [81]. A 
current study reported that vitamin D status of PD patients has no influence on 
nocturnal changes in blood pressure, a marker of cardiac autonomic dysfunction 
as non-motor symptom in PD [82]. However, the tight link between serum vitamin 
D concentrations and risk as well as severity of PD is also underlined by a recent 
systematic review and meta-analysis of Luo et al. [83].
PD is not only caused by environmental factors, for example, the vitamin D 
status, but also by genetic components. The first monogenetic mutation, which was 
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found to be associated with early onset familial PD, is located in the SNCA gene that 
encodes the α-synuclein protein [84]. A recent study was able to show an altered 
expression of Snca in brains of vitamin D-deficient mice, underlining a causal rela-
tionship between hypovitaminosis and PD [63]. Consistent with several previous 
publications, this is also supported by two recent studies analyzing SNPs in VDR 
and the vitamin D-binding protein. Besides the functional VDR polymorphism, 
FokI was reported to be associated with cognitive decline in PD and ApaI with the 
risk of PD, while vitamin D-binding protein gene was suggested as a risk factor 
for PD [85, 86]. In line with this, a double-blind, placebo-controlled intervention 
study from Suzuki and colleagues, including 114 PD patients, was able to reveal 
that supplementation of 1200 IU vitamin D3/day prevents disease progression in a 
VDR FokI genotype-dependent manner [87]. Moreover, high-dose supplementation 
of vitamin D (10,000 IU/day) resulted in significant improved balance measured 
via sensory organization test in PD patients with an age of 52–66 but not in older 
individuals [88].
To elucidate the underlying molecular mechanisms by which vitamin D exerts 
its potential beneficial role, animal and cell culture experiments were performed. 
Vitamin D3 seems to have a positive influence on synthesis and storage of dopamine 
in CNS by protecting against dopaminergic toxins such as 6-hydroxydopamine 
or hydrogen peroxide in rats [89]. This neuroprotective effect could be due to its 
ability to elevate the expression of the glial cell line-derived neurotrophic factor 
(GDNF) that influences the dopaminergic nigrostriatal system [90] and due to its 
antioxidative properties described before. Furthermore vitamin D3 administration 
was shown to prevent zinc-induced oxidative stress in substantia nigra of rat brain 
[91]. Oxidative stress and elevated intracellular-free calcium promote the aggrega-
tion of α-synuclein synergistically, and a recent study could show that the vitamin 
D3 analogue calcipotriol is able to induce the expression of calbindin-D28k, thereby 
inhibiting the calcium-mediated aggregation of α-synuclein in human neuroblas-
toma cells [92].
4. Multiple sclerosis
Multiple sclerosis (MS) is a multifactorial, chronic disease of the CNS character-
ized by demyelination, inflammation, and neurodegeneration.
Epidemiological studies indicate that genetic and environmental factors interact 
and influence the risk of MS, for example, several SNPs or environmental exposures 
like an infection with Epstein-Barr virus (EBV), vitamin D status, sunlight expo-
sure, or smoking. There is a high prevalence for MS in areas with low sun/ultraviolet 
sun exposure [93, 94], and this could be explained by vitamin D [95]. A study from 
Lucas and colleagues revealed that vitamin D and sun exposure are independent 
risk factors of CNS demyelination [96]. For an overview over environmental factors 
and MS, we suggest an article from Ebers GC [97]. Genetic predispositions which 
are associated with MS are found in genes of the immune system. The strongest 
correlation was found for genes of the major histocompatibility complex (MHC), 
especially the HLA genotype HLA-DRB1 [98]. Findings from Ramagopalan and 
colleagues suggest a direct functional link between known environmental risk fac-
tors, for example, vitamin D, and established genetic predispositions. The authors 
described the localization of a vitamin D response element on the promotor region 
of HLA-DRB1 and underlined its functional role by the finding that treatment with 
calcitriol results in an increased expression [99]. Later on this research group could 
show that mutations in the CYP27B1 gene, involved in vitamin D3 metabolism, 
are causative associated with the risk of MS [100]. Moreover, genetic variations 
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found to be associated with early onset familial PD, is located in the SNCA gene that 
encodes the α-synuclein protein [84]. A recent study was able to show an altered 
expression of Snca in brains of vitamin D-deficient mice, underlining a causal rela-
tionship between hypovitaminosis and PD [63]. Consistent with several previous 
publications, this is also supported by two recent studies analyzing SNPs in VDR 
and the vitamin D-binding protein. Besides the functional VDR polymorphism, 
FokI was reported to be associated with cognitive decline in PD and ApaI with the 
risk of PD, while vitamin D-binding protein gene was suggested as a risk factor 
for PD [85, 86]. In line with this, a double-blind, placebo-controlled intervention 
study from Suzuki and colleagues, including 114 PD patients, was able to reveal 
that supplementation of 1200 IU vitamin D3/day prevents disease progression in a 
VDR FokI genotype-dependent manner [87]. Moreover, high-dose supplementation 
of vitamin D (10,000 IU/day) resulted in significant improved balance measured 
via sensory organization test in PD patients with an age of 52–66 but not in older 
individuals [88].
To elucidate the underlying molecular mechanisms by which vitamin D exerts 
its potential beneficial role, animal and cell culture experiments were performed. 
Vitamin D3 seems to have a positive influence on synthesis and storage of dopamine 
in CNS by protecting against dopaminergic toxins such as 6-hydroxydopamine 
or hydrogen peroxide in rats [89]. This neuroprotective effect could be due to its 
ability to elevate the expression of the glial cell line-derived neurotrophic factor 
(GDNF) that influences the dopaminergic nigrostriatal system [90] and due to its 
antioxidative properties described before. Furthermore vitamin D3 administration 
was shown to prevent zinc-induced oxidative stress in substantia nigra of rat brain 
[91]. Oxidative stress and elevated intracellular-free calcium promote the aggrega-
tion of α-synuclein synergistically, and a recent study could show that the vitamin 
D3 analogue calcipotriol is able to induce the expression of calbindin-D28k, thereby 
inhibiting the calcium-mediated aggregation of α-synuclein in human neuroblas-
toma cells [92].
4. Multiple sclerosis
Multiple sclerosis (MS) is a multifactorial, chronic disease of the CNS character-
ized by demyelination, inflammation, and neurodegeneration.
Epidemiological studies indicate that genetic and environmental factors interact 
and influence the risk of MS, for example, several SNPs or environmental exposures 
like an infection with Epstein-Barr virus (EBV), vitamin D status, sunlight expo-
sure, or smoking. There is a high prevalence for MS in areas with low sun/ultraviolet 
sun exposure [93, 94], and this could be explained by vitamin D [95]. A study from 
Lucas and colleagues revealed that vitamin D and sun exposure are independent 
risk factors of CNS demyelination [96]. For an overview over environmental factors 
and MS, we suggest an article from Ebers GC [97]. Genetic predispositions which 
are associated with MS are found in genes of the immune system. The strongest 
correlation was found for genes of the major histocompatibility complex (MHC), 
especially the HLA genotype HLA-DRB1 [98]. Findings from Ramagopalan and 
colleagues suggest a direct functional link between known environmental risk fac-
tors, for example, vitamin D, and established genetic predispositions. The authors 
described the localization of a vitamin D response element on the promotor region 
of HLA-DRB1 and underlined its functional role by the finding that treatment with 
calcitriol results in an increased expression [99]. Later on this research group could 
show that mutations in the CYP27B1 gene, involved in vitamin D3 metabolism, 
are causative associated with the risk of MS [100]. Moreover, genetic variations 
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in the CYP24A1 gene, involved in catabolism of vitamin D, were found to play a 
pathogenic role in MS [101]. For detailed information about the results of several 
genome-wide association studies analyzing the genetic risk of developing MS, we 
recommend a recent publication from Baranzini and Oksenberg [102].
Clinical studies indicate that vitamin D influences MS development and disease 
activity including the risk of relapse, gray matter volume loss, and clinical course 
of MS. A prospective study from Munger et al. included participants from the US 
military personnel and reported a significantly decreased risk of MS with elevated 
levels of 25(OH)D3 [103]. Furthermore, a cross-sectional study described a link of 
serum 25(OH)D3 levels with both relapse rate and disability in MS patients [104]. In 
line with this, an association of reduced serum 25(OH)D3 levels with a higher risk of 
relapse in MS was reported in a prospective longitudinal study including 73 indi-
viduals with relapsing-remitting MS [105]. Consistent findings are obtained from 
a retrospective study describing an association of a 10 ng/ml increase in 25(OH)D3 
level with a 34% reduced relapse rate in pediatric-onset MS [106] and from a pro-
spective study reporting a 25(OH)D3 elevation of 10 nmol/L to be associated with a 
12% decreased risk of relapse in a cohort including 145 participants [107]. A 5-year 
longitudinal study from Mowry and colleagues using magnetic resonance imaging 
(MRI) as marker of disease activity provided evidences for a lower risk of develop-
ing new T2 lesions and gadolinium-enhancing lesions as well as reduced subsequent 
disability attended by an 10 ng/ml increase in 25(OH)D3 level [108].
As mentioned before in the context of AD, these clinical studies are not able to 
rule out the possibility of reverse causality. In this context MR studies are of great 
interest analyzing this potential causal relationship of vitamin D and MS risk. 
Mokry et al. identified four 25(OH)D3 level-associated SNPs in a large genome-wide 
association study for vitamin D, called SUNLIGHT, and performed an MR study to 
examine the influence of genetically reduced vitamin D3 levels on the odds of MS 
in a large genetic association study for MS. This leads to the finding that genetically 
reduced vitamin D3 levels are strongly linked to an elevated MS risk [109]. This 
thesis is furthermore supported by another novel MR study that described causal 
effects of decreased vitamin D3 levels on pediatric-onset MS [110]. A very recent 
study from Graves et al. provides evidence for a causal link between 25(OH)D3 and 
MS relapses in children. The authors indicate that a vitamin D genetic risk score 
(vitDGRS) can support the identification of patients at greater relapse risk [111].
The protective role of vitamin D could be exerted on the molecular level mainly 
due to its several potential immunomodulatory effects. These are summarized in 
a review from Smolders and colleagues. The authors pointed out that vitamin D 
causes a shift to an anti-inflammatory immune response and increased regulatory T 
cells as well as reduced pro-inflammatory helper cells like Th1 and Th17 selectively 
[112]. In line with this, a study from Munger et al. reported an overlap of genes 
associated with vitamin D3 and those associated with processes of immune regula-
tion. Furthermore they suggest the sphingosine-1-phosphate receptor-dependent 
migration of lymphocytes from secondary lymphoid tissue as potential vitamin D3-
mediated mechanism [113]. Additional evidences for the MS-underlying molecular 
mechanisms arise from a recent study using the L-type calcium channel antagonist 
nimodipine, showing decreased neurodegeneration in experimental autoimmune 
encephalomyelitis (EAE), a mouse model of MS. The authors reported calcium 
channel-independent, microglia-specific effects: induction of apoptosis, reduced 
levels of NO and ROS, as well as positive effects on remyelination [114].
Based on the results of all these studies demonstrating a causal link between 
vitamin D hypovitaminosis and the risk of MS, the role of vitamin D3 supple-
mentation in MS therapy was investigated. A study from Munger et al. reported 
an approximately 41% reduced relative risk of MS due to the supplementation of 
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400 IU vitamin D/day in two large cohorts of women [115]. Several following stud-
ies also describe beneficial effects of vitamin D3 supplementation on gadolinium-
enhancing lesions, relapses, and T-cell proliferation without unrequested calcemic 
side effects [116–118]. Inconsistent with these results, another study revealed no 
positive effect of high-dose vitamin D3 supplementation (20,000 IU/week) on 
course and activity of the disease, for example, the relapse risk. A possible explana-
tion for this finding could be individuals with high vitamin D3 levels in the placebo 
group. Furthermore the authors could not preclude that the used vitamin D dose 
was too low or that the sample size was too small [119]. In this context it should be 
mentioned that the individual vitamin D metabolism, which could be influenced 
by genetically mutations in the enzymes required for the anabolism and catabolism 
of vitamin D3 as discussed before, has to be analyzed since this would influence 
the response to identical supplemented doses of vitamin D in different individu-
als [120]. Subsequent studies were able to show a reduction in relapse rate after 
supplementation of vitamin D3 [121] and an improved cognitive performance [122]. 
Oral supplementation of 20,000 IU vitamin D3/week in a 96-week randomized 
double-blind placebo-controlled study in 68 MS patients results in reduced levels 
of anti-EBV nuclear antigen 1 (EBNA1) protein and fragment antibody [123]. A 
previous study could show a remarkable overlap of EBNA2 with VDR binding sites 
and thereby demonstrates a genetic argument for an interaction between genetic 
and environmental risk factors of MS [124]. A current study reports that long-term 
supplementation for several months with high doses of cholecalciferol results in 
a significantly promoted aggravation of clinical and histological EAE, but simul-
taneously they find a direct, anti-inflammatory, beneficial effect of vitamin D on 
lymphocytes of human and murine origin [125].
5. Prion diseases
Prion diseases are a group of neurodegenerative disorders whose pathology is 
caused by the conversion of the cellular prion protein (PrPC) into a misfolded form 
of the protein, called prion or “scrapie prion protein” (PrPSc), a proteinaceous, 
insoluble, infectious particle which is resistant to proteases and seems to act as tem-
plate for exponential transformation and further accumulation of prion proteins. 
One characteristic of prion diseases is their appearance by sporadic (spontaneously 
conversion, Jakob-Creutzfeldt disease), genetic (familial mutations in the prion 
protein gene, PRNP), or acquired (accidentally transmission or infection) mecha-
nisms [126].
A study on transgenic mice was able to identify a naturally occurring polymor-
phism in the human PRNP which is very rare but seems to completely prevent prion 
disease [127]. Up to this date, no clinical trial on human prion disease was success-
ful, and most of the analyzed chemical compounds failed as potential therapeutics 
because of their toxicity. A study from Suenaga and colleagues intended to identify 
compounds that interfere with the direct PrPC-PrPSc interaction by screening 
hydrophobic vitamins. The authors reported for the first time that vitamin D2 was 
able to interact with a truncated form of human recombinant PrPC leading to a 
reduced oligomerization in vitro. The absence of such an effect mediated by vitamin 
D3 could be due to structural differences between these two vitamin D forms. This 
study suggests vitamin D2 as suitable therapeutic candidate to target PrPC in the 
brain of patients with prion disease because of its direct inhibition of PrPC oligo-
merization, its blood–brain barrier permeability, and its safety compared to other 
synthetic compounds [128]. But apart from that, more studies, especially clinical 
trials, are essential to elucidate the relationship of vitamin D and prion diseases.
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400 IU vitamin D/day in two large cohorts of women [115]. Several following stud-
ies also describe beneficial effects of vitamin D3 supplementation on gadolinium-
enhancing lesions, relapses, and T-cell proliferation without unrequested calcemic 
side effects [116–118]. Inconsistent with these results, another study revealed no 
positive effect of high-dose vitamin D3 supplementation (20,000 IU/week) on 
course and activity of the disease, for example, the relapse risk. A possible explana-
tion for this finding could be individuals with high vitamin D3 levels in the placebo 
group. Furthermore the authors could not preclude that the used vitamin D dose 
was too low or that the sample size was too small [119]. In this context it should be 
mentioned that the individual vitamin D metabolism, which could be influenced 
by genetically mutations in the enzymes required for the anabolism and catabolism 
of vitamin D3 as discussed before, has to be analyzed since this would influence 
the response to identical supplemented doses of vitamin D in different individu-
als [120]. Subsequent studies were able to show a reduction in relapse rate after 
supplementation of vitamin D3 [121] and an improved cognitive performance [122]. 
Oral supplementation of 20,000 IU vitamin D3/week in a 96-week randomized 
double-blind placebo-controlled study in 68 MS patients results in reduced levels 
of anti-EBV nuclear antigen 1 (EBNA1) protein and fragment antibody [123]. A 
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a significantly promoted aggravation of clinical and histological EAE, but simul-
taneously they find a direct, anti-inflammatory, beneficial effect of vitamin D on 
lymphocytes of human and murine origin [125].
5. Prion diseases
Prion diseases are a group of neurodegenerative disorders whose pathology is 
caused by the conversion of the cellular prion protein (PrPC) into a misfolded form 
of the protein, called prion or “scrapie prion protein” (PrPSc), a proteinaceous, 
insoluble, infectious particle which is resistant to proteases and seems to act as tem-
plate for exponential transformation and further accumulation of prion proteins. 
One characteristic of prion diseases is their appearance by sporadic (spontaneously 
conversion, Jakob-Creutzfeldt disease), genetic (familial mutations in the prion 
protein gene, PRNP), or acquired (accidentally transmission or infection) mecha-
nisms [126].
A study on transgenic mice was able to identify a naturally occurring polymor-
phism in the human PRNP which is very rare but seems to completely prevent prion 
disease [127]. Up to this date, no clinical trial on human prion disease was success-
ful, and most of the analyzed chemical compounds failed as potential therapeutics 
because of their toxicity. A study from Suenaga and colleagues intended to identify 
compounds that interfere with the direct PrPC-PrPSc interaction by screening 
hydrophobic vitamins. The authors reported for the first time that vitamin D2 was 
able to interact with a truncated form of human recombinant PrPC leading to a 
reduced oligomerization in vitro. The absence of such an effect mediated by vitamin 
D3 could be due to structural differences between these two vitamin D forms. This 
study suggests vitamin D2 as suitable therapeutic candidate to target PrPC in the 
brain of patients with prion disease because of its direct inhibition of PrPC oligo-
merization, its blood–brain barrier permeability, and its safety compared to other 
synthetic compounds [128]. But apart from that, more studies, especially clinical 
trials, are essential to elucidate the relationship of vitamin D and prion diseases.
Vitamin D Deficiency
134
6. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects 
upper and lower motor neurons in the brain and spinal cord resulting in paralysis 
[129]. It is characterized, similar to the abovementioned vitamin D3-associated 
diseases, by oxidative stress, inflammation, mitochondrial dysfunction, and 
neurodegeneration [130].
Clinical studies result in inhomogeneous findings about a possible role of 
vitamin D on ALS. A retrospective study including 57 ALS patients reported neither 
significant differences in 25(OH)D3/D2 blood levels in comparison to 57 healthy 
individuals nor an improvement of the recorded clinical, ALS-related variables after 
oral supplementation of 100,000 IU of vitamin D3/week for 4 weeks and thereafter 
25,000 IU every 15 days compared to untreated participants. But as discussed by the 
authors, potential limitations of this study are its retrospective character and the 
sample size [131]. Two earlier studies also described an absent relationship between 
serum 25(OH)D3 levels and prognosis in ALS [132, 133]. A very recent study exam-
ined the outcome of supplementation of 50,000, 75,000, and 100,000 IU vitamin 
D3/month on motor dysfunction and clinical progression of ALS. After 6 months, 
they reported increased levels of serum 25(OH)D3 from approximately 14 ng/mL 
at starting point to approximately 40 ng/mL after supplementation of 75,000 and 
100,000 IU vitamin D3 monthly, but there were no statistically significant differ-
ences in the tested clinical ALS characteristics. As the authors mention, the sample 
size of 10–12 participants per group as well as the short duration of the follow-up 
study has to be taken into consideration [134].
In contrast to these findings, a study from Karam et al. reported vitamin D level 
less than 30 ng/mL for 81% of their patients with ALS and additionally improve-
ments in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) 
score after supplementation of 2000 IU vitamin D/day for 9 months in 20 partici-
pants [135]. In line, a subsequent study described a neuroprotective role for the 
biologically active form of vitamin D3 as well as a four-time accelerated decline 
and reduced expectation of life due to hypovitaminosis D [136]. These variable 
outcomes strengthen the need of further clinical studies with an adequate sample 
size to reach statistical power and follow-up period analyzing the effect of vitamin 
D3 on ALS. A first evidence of a genetic link between vitamin D3 and ALS arises 
from a study from Török and colleagues describing that a SNP in the VDR gene is 
associated with ALS [137]. Further suggestions of a potential role of the VDR in 
ALS derived from the finding that VDR-knockout mice have muscular and motor 
disruptions but no reduced cognitive performance [138].
In contrast to the ambiguous clinical studies, animal trials provide evidences for 
a positive effect of supplemented vitamin D3 on ALS. Studies from Gianforcaro and 
colleagues reported beneficial functions of high-dose dietary vitamin D3 supple-
mentation on the paw grip endurance and motor performance of transgenic G93A 
ALS mouse model while decreased performance of functional outcome in vitamin 
D3 deficient mice [139, 140].
In reference to the above itemized similarities in ALS characteristics with other 
neurodegenerative diseases, it is not remarkable that the molecular mechanisms of 
which vitamin D3 is suggested to have a beneficial influence on ALS are overlap-
ping. Vitamin D3 could decrease the elevated levels of TNF-α or IL-6 found in 
ALS patients [141] or influence calcium metabolism by regulating the expression 
of calcium-binding proteins, known to be impaired in ALS [142]. More detailed 
information can be found in the publications from Gianforcaro et al. and Long 
et al. [143, 144].
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7. Huntington’s disease
Up to this date, only a few studies are available examining a possible relationship 
between vitamin D3 and Huntington’s disease (HD), a neurodegenerative disorder 
characterized by impairments in cognition, motor behavior, and psychiatrics. HD 
is caused on molecular level by an expansion of an autosomal dominantly inher-
ited CAG trinucleotide repeat in the huntingtin (HTT) gene which is located on 
chromosome four in humans. This leads to the expression of a mutant huntingtin 
protein containing an abnormal long polyglutamine repeat [145]. The number of 
repeats is associated with the risk of developing HD [146]. A recent clinical review 
describes the consequences of mutant huntingtin on cellular level, including 
interferences in transcription and protein homeostasis as well as mitochondrial 
dysfunction and direct toxicity of the altered protein itself. This leads to a disrup-
tion in neuronal function and further cell death and neurodegeneration [147]. To 
our knowledge, there are no current epidemiological or clinical studies suggesting a 
relationship between vitamin D status and HD, just an explorative study from Chel 
and colleagues. They reported a high prevalence of deficient or insufficient serum 
vitamin D level (<50 nmol/L) in 28 individuals with manifest HD [148]. In line with 
this, a recent study on HD transgenic mice showed no effect on motor performance 
but a significantly prolonged lifespan after subcutaneous supplementation of 
12,000 IU vitamin D3 per kilogram weight [149]. Further evidences for an influ-
ence of vitamin D3 on HD arise from a recent publication of Seuter and colleagues 
analyzing the epigenome-wide effects of vitamin D in THP-1 human monocytes. 
They identified 165 physiologically important target genes after supplementation of 
1,25-dihydroxyvitamin D3 being one of them the HTT gene [150].
8. Neuropsychiatric diseases
Beside neurodegenerative disorders also neuropsychiatric diseases affect the 
nervous system, and therefore we would like to give a brief summary of recent 
studies analyzing a possible influence of vitamin D on autism spectrum disorders 
(ASD), depression, and schizophrenia. Epidemiological studies demonstrated 
an elevated prevalence for ASD in children born at higher latitudes [151] and in 
offspring of highly pigmented women [152] as well as lower vitamin D levels of 
children with autism [153]. Furthermore maternal, gestational hypovitaminosis D 
is associated with a higher ASD risk [154, 155]. Recent findings of strong associa-
tions of ASD with polymorphisms in the VDR or other genes involved in vitamin D3 
metabolism [156, 157] hypothesize vitamin D3 as environmental and genetic factor 
influencing ASD [158]. On the molecular level, cellular processes like oxidative 
stress or neuroinflammation were shown to play a role in ASD [159], and they could 
present a potential contact point for vitamin D3. In line with the abovementioned 
link between ASD and vitamin D, a vitamin D-deficient rat model revealed broad 
behavioral similarities between vitamin D-deficient models and ASD-associated 
behavior [160]. Treatment of an ASD rat model with high-dose vitamin D revealed 
significant protective effects [161]. In contrast to supplementation in animal trials, 
the first randomized controlled clinical study analyzing the daily supplementation 
of 300 IU vitamin D3/kg for 4 months on 109 children with ASD, resulting in sig-
nificant improvement of autism symptoms, was retracted 1 month ago [162]. This 
lets us conclude that vitamin D3 can be suggested as possible preventive treatment 
for the prevention of ASD, but more studies supplementing pregnant women and 
their children with adequate levels of vitamin D3 have to be performed.
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A potential link between vitamin D3 and depression is subject of current 
research, and for more detailed information about the potential role of vitamin D 
on major depressive disorder, we recommend a review from Casseb et al. [163]. 
A meta-analysis from Parker and colleagues concluded that there are increasing 
evidences for an influence of vitamin D on depression [164], and in line with this, 
another review also postulated hypovitaminosis D as risk factor for late-life depres-
sion [165]. Consistently, a very recent meta-analysis reported a negative association 
of serum 25(OH)D3 levels with the risk of depression [166].
A following cross-sectional study including 100 women in reproductive age also 
shows that the depression score inverse correlated with the vitamin D serum level 
[167]. Contradictorily, a supplementation with 1200 IU vitamin D for 12 months 
failed to have an influence on the prevention of depression in a very recent, 
randomized clinical trial including 155 participants having clinically relevant 
depressive symptoms [168]. Furthermore, a recent MR study from Libuda and 
colleagues indicates no causal relationship between both depressive symptoms and 
broad depression and vitamin D levels due to a missing association of six vitamin 
D-related SNPs with depression [169]. In summary, the current research investigat-
ing the role of vitamin D3 in depression is much less clear than other neurological 
disorders.
In respect to the chronic mental illness schizophrenia, it could be shown that 
hypovitaminosis D is common in patients [170]. This fits to the environmental 
risk factors that have been described for schizophrenia, like season of birth [171] 
and latitude [172]. Also a link between neonatal vitamin D levels and the schizo-
phrenia risk was reported [173]. A recent randomized, placebo-controlled study 
from Krivoy and colleagues examined psychosis severity, mood, cognition, and 
metabolic profile in 47 schizophrenia patients during an 8-week supplementation 
of 14,000 IU vitamin D/week. The authors described no significant effects on 
psychosis, mood, or metabolic status, but a trend to an improved cognitive function 
accompanied by significant elevated vitamin D levels in the supplemented group. A 
possible explanation for these findings, given by the authors, could be that a medi-
cal score that measures the symptom severity in schizophrenia patients decreased 
during the study in the placebo as well as in the treated group and could thereby veil 
the influence of supplemented vitamin D [174]. An actual study reported beneficial 
effects of supplementation of vitamin D3 in combination with probiotics in schizo-
phrenia patients [175]. Addressing the underlying molecular mechanism, vitamin 
D could perform its suggested beneficial actions via modulation of immune system 
and inflammation processes since it was reported that patients with chronic schizo-
phrenia have significantly elevated levels of TNF-α and IL-6 [176]. Furthermore, it 
could be shown that the expression of genes involved in the metabolism of vitamin 
D3 (VDR, CYP27B1, CYP24A1) is significantly elevated in peripheral blood of 
schizophrenic patients [177], indicating a potential causal relationship between 
vitamin D3 and schizophrenia, which should be the aim of future research.
9. Conclusion
In summary, in the current literature, several lines of evidence suggest a tight 
link between vitamin D3 and neurodegenerative diseases (see Table 1). Besides 
epidemiological studies, vitamin D deficiency influences several pathways associ-
ated with neurodegenerative diseases, which also indicates a causal link of hypovi-
taminosis D and AD, MS, and PD. As a consequence, vitamin D hypovitaminosis is 
broadly assumed to be a risk factor for these diseases. In addition, recent literature 
underlines a potential link between prion diseases, ALS, HD, and neuropsychiatric 
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diseases and reduced Vitamin D level; however, it has to be emphasized that many 
aspects of vitamin D remain obscure in these diseases. Therefore, further studies 
to clarify and judge a potential beneficial effect of vitamin D3 are needed to unravel 
the exact role of vitamin D in brain metabolism and neurodegenerative diseases. 
Especially determination of the individual serum 25(OH)D3 levels by appropriate 
methods like mass spectrometry and taking the individual patient’s competence to 
metabolize or form active vitamin D3 into consideration will help to avoid ambigu-
ous results. The fact that several prospective studies investigate a mixture of several 
different nutritional components makes it hard to trace the observed effects back to 
vitamin D in particular at the moment.
Interestingly some European countries, like Finland, already supplement 
vitamin D in general in food to prevent hypovitaminosis in the elderly population, 
and an optimal intake of 2000–4000 IU vitamin D or 10–20 min sunlight exposure 
per day is already recommended by experts, for example, at the Joint International 
Symposium Vitamin D in Prevention and Therapy and Biologic Effects of 
Light (2019). Further studies will help to validate the beneficial effects of these 
recommendations.
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diseases and reduced Vitamin D level; however, it has to be emphasized that many 
aspects of vitamin D remain obscure in these diseases. Therefore, further studies 
to clarify and judge a potential beneficial effect of vitamin D3 are needed to unravel 
the exact role of vitamin D in brain metabolism and neurodegenerative diseases. 
Especially determination of the individual serum 25(OH)D3 levels by appropriate 
methods like mass spectrometry and taking the individual patient’s competence to 
metabolize or form active vitamin D3 into consideration will help to avoid ambigu-
ous results. The fact that several prospective studies investigate a mixture of several 
different nutritional components makes it hard to trace the observed effects back to 
vitamin D in particular at the moment.
Interestingly some European countries, like Finland, already supplement 
vitamin D in general in food to prevent hypovitaminosis in the elderly population, 
and an optimal intake of 2000–4000 IU vitamin D or 10–20 min sunlight exposure 
per day is already recommended by experts, for example, at the Joint International 
Symposium Vitamin D in Prevention and Therapy and Biologic Effects of 
Light (2019). Further studies will help to validate the beneficial effects of these 
recommendations.
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Abstract
The aim of the present study was to focus on the effects of Vitamin D3 (VD3) 
supplementation (5.0 mg/kg, s.c.) on the NF-kB/p65, 17β-estradiol (17β-E2)/
VD3 receptors expression in the hippocampus in the long-term ovariectomized 
(OVX) rats treated with low dose of 17β-E2 (0.5 μg/rat, s.c.) submitted for the 
chronic unpredictable mild stress (CUMS) for 28 days. Sucrose preference (SPT), 
forced swimming (FST), and open-field (OFT) tests were conducted to estimate 
the anhedonia-/depression-like states. NF-kB/p65, 17β-E2/VD3 receptors levels in 
the hippocampus were evaluated by ELISA and Western blot assays. The findings 
demonstrated that VD3 at high dose (5.0 mg/kg, s.c.) in a combination with low 
dose of 17β-E2 decreased anhedonia in the SPT and depression-like behavior in the 
FST of the long-term OVX rats submitted to CUMS. VD3 (5.0 mg/kg) resulted in 
significant decreased levels of hippocampal NF-kB/p65 protein expression, as well 
as to the normalization of hippocampal 17β-E2/VD3 receptors levels in long-term 
OVX rats treated with 17β-E2 exposed to CUMS. In conclusion, VD3 (5.0 mg/kg, 
s.c.) in a combination with low dose of 17β-E2 had a synergic antianhedonic- and 
antidepressant-like effects in the adult female rats following long-term ovariectomy 
submitted to CUMS.
Keywords: vitamin D3, long-term ovariectomy, chronic unpredictable mild stress, 
NF-kB/p65, 17β-estradiol receptor, vitamin D3 receptors
1. Introduction
The menopausal transition is often associated with a multiplicity of manifesta-
tions, the most standard being neuropsychiatric [1, 2]. The role of ovarian hormones 
in affect-related disorders is of great interest for women transitioning through 
menopause [2, 3]. Mood disorders during menopause could partly be explained due 
to a loss of estrogen is known to have neuroprotective effects on brain [3]. Numerous 
experimental and clinical studies have documented that estrogen deficiency during 
menopause increases the susceptibility to mood disturbances, including anxiety 
[4–6]. There has been a discussion that menopausal hormonal therapy (MHT) may 
improve the symptoms of affective-related disorders or decrease the risk of develop-
ing these, yet some uncertainty still exist around this topic because as research has 
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also found that MHT does not entirely stop the development of affective-related 
symptoms [7].
Females going through menopause are at higher risk of developing Vitamin D 
(VD) deficiency due to a VD poor diet, restricted outdoor activity resulting in less 
sun exposure as well as a decreased capacity to produce enough calcitriol as a result 
of an age related decline in hydroxylation by the kidneys [8]. Our previous experi-
mental work has confirmed that hormonal profile in ovariectomized (OVX) female 
rodents is also characterized by VD deficiency or insufficiency [9, 10]. Traditional 
methods of affective-related disorders therapy, which also include antidepressants/
anxiolytics, are unfortunately of limited effectiveness [11]. Nutrient imbalance, 
especially VD3 deficiency, is considered as one of the critical causes, enabling the 
pathophysiological mechanisms for development of psychiatric disorders [12]. In 
the pathophysiological mechanisms of mood disorders, many trigger factors play a 
role, and it is argued that one of them could be a deficiency in VD3 [12].
VD3 deficiency has been proven to impact on the pathogenesis of various 
diseases, for example, autoimmune diseases, cardiovascular diseases, infections, 
osteoporosis, obesity, diabetes, and certain types of cancers [13–15]. A correlation 
between very low VD3 levels and numerous neuropsychiatric diseases and a correla-
tion between an impact of VD3 levels and normal brain functioning have also been 
found in recent studies [14–16]. VD receptors (VDRs) have been found present in 
the central nervous system [17], in the brain structures involved in processes of 
mood regulation (cingulate cortex, hippocampus, thalamus, and hypothalamus) 
[18]. In this line, it can be assumed that VD3 likely has humoral or neurohumoral 
activities in these brain structures. VD3 involves in the neurogenesis, neuroplas-
ticity, neuroprotection, and neuroimmunomodulation [19–21]. This fact creates 
a neurobiological basis to propose the involvement of VD in the mechanisms of 
neuropsychiatric disorders [22–26].
The neuroinflammation in the central nervous system is supposed to be one of 
the main trigger factors for the development of affective-related disorders [27, 28]. 
Taking this assumption into account, mood disturbances established in menopausal 
women might result from complex alterations in estradiol and VD3 levels, as well as 
neuroinflammation.
Nowadays, nuclear factor-kappa B (NF-κB) is postulated as the proinflamma-
tory transcription factor that controls proinflammatory cytokines expression and 
is involved in the mechanisms of many inflammatory and neuroinflammatory dis-
eases [29, 30]. NF-κB is triggered by stress and might mediate cellular responses to 
stressful life events, thereby critically involved in development of affective-related 
disorders [31–33]. The enhancement of NF-κB might induce the elevated produc-
tion of proinflammatory cytokines and diminished neurohormonal stress feedback 
[34]. Furthermore, NF-κB pathway is involved in antidepressant action of different 
psychotropic drugs that used for treatment of mood disorders [35]. Clinical studies 
using patients with mood disorders have shown that NF-κB levels are increased 
in the serum of such patients [35–37]. Using genetic and environmental model of 
depression, it was shown that the antidepressant effect of such pharmacological 
treatments was dependent on NF-κB-p65 acetylation [36, 37].
The hippocampus is one of the key structures of the brain, which plays a role in 
affective-related disorders [38]. Both estrogen and VD3 have been associated with 
the successful functioning of the hippocampus [1, 21, 25]. Basic and clinical studies 
have suggested that alterations in NF-kB/p65 signaling and in 17β-E2/VD3 receptors 
expression in the hippocampus, as well changes of serum estradiol/VD contents are 
very often registered at affective-related disorders [1, 23, 39]. Animal studies have 
documented that the impaired behavioral profile in OVX rats is correlated with 
increased NF-kB/p65 levels in the brain [40, 41].
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Recently, we found that VD3 (5.0 mg/kg, s.c.) reduced anhedonia and depres-
sion-like behavior of long-term adult ovariectomized (OVX) rats exposed to the 
chronic unpredictable mild stress (CUMS) in the sucrose preference (SPT) and 
forced swimming (FST), respectively [42]. However, the therapeutic effects of VD3 
in a combination with low dose of 17β-E2 in female rats with long-lasting decline 
of estrogens exposed to CUMS remain unknown. Furthermore, it is still unclear 
whether the antidepressant-like action of VD3 plus 17β-E2 application implicates 
NF-kB/p65 signaling pathway and modifications of 17β-E2/VD3 receptors expres-
sion in the hippocampus of long-term OVX adult rats with CUMS.
The current investigation was performed to clarify the antidepressant-like effect 
of a combination with VD3 plus low dose of 17β-E2 on a rat model of CUMS in the 
female rats with long-lasting decline of estrogens. Similar to previously published 
work [43], we used long-lasting estrogen deficiency caused by a post-ovariectomy 
period of 3 months. This animal model is widely utilized in preclinical behavioral 
research producing a menopausal-like state in women [44]. Such behavioral tests as 
sucrose preference (SPT), forced swimming (FST), and open-field (OFT) were car-
ried out to examine the depression-like behavior. NF-kB/p65, 17β-E2/VD3 receptors 
levels in the hippocampus and serum estradiol and VD concentrations were deter-
mined to assess the possible mechanisms of the VD3 effects on the depression-like 
behavior in long-term OVX rats given with low dose of 17β-E2 subjected to CUMS.
2. Materials and methods
2.1 Animals
A total of 49 Wistar rats of 3 months age, female sex (weighing 200–220 g) were 
purchased in this work. Animals were divided into experimental groups with access 
to rat standard food and water ad libitum. The female rats were placed under a 12 
light-dark scheme (light was given between 07:00 and 19:00 h) and room tempera-
ture (23 ± 2°C). All behavioral procedures and CUMS model were performed in 
compliance with the National research council’s guide for the care and use of labora-
tory animals and approved by the Ethical committee for experimental studies of 
I.P. Pavlov Institute of Physiology (statement No.: 1095/1/25.06.2012). Stress model 
of depression was conducted with minimal pain for all groups of rats.
2.2 Ovariectomy
Three months before CUMS procedure, sham operation and long-term total 
ovariectomy with general anesthesia (ketamine 70 mg/kg and xylazine 10 mg/kg, 
i.p.) were performed. Long-term period (3 months) elimination of female gonadal 
hormones was chosen as experimental model of menopause in women [44, 45]. The 
removal of ovaries was carried out accordingly to our method as prescribed earlier 
[43]. After surgery or sham-operation (SHAM), the ovariectomized (OVX) females 
were placed in home cage with free access to food and water. During 12 weeks, 
sham-operated and OVX females had a recovery. Following 3 months of surgery, 
experimental rats were randomly distributed to the groups for the chronic stress 
procedure, except for SHAM non-stressed control rats.
2.3 CUMS model
Chronic unpredictable mild stress (CUMS) paradigm is a valid and significant 
animal model of depression induced by stress procedure. This behavioral model 
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of depression state is strongly verified by both preclinical and clinical studies [46]. 
CUMS was made as described previously [47, 48]. The procedure included the expo-
sure to different and unpredictable stress factors that are randomly changed during 
experimental days [49]. These manipulations are 24 h food deprivation, 24 h water 
deprivation, wet bedding overnight, titled cage overnight, unpredictable shocks 
(15 mA, one shocks/20s, 10 s duration, 20 min), 5 min swimming at cold water 
(4°C), tail hanging, 1 min, clip tail for 1 min, reversal of light/dark cycle [47, 48]. All 
stress triggers were performed individually and continuously. To prevent habitu-
ation and to ensure the unpredictability of the stressors, all stress manipulations 
randomly made accordingly to experimental scheme, repeated throughout the 4 
weeks of CUMS protocol. The control SHAM females were placed in a separate room 
without any contact with the stressed groups of animals. These rats were maintained 
as undisturbed animals that are subjected only routine cage cleaning for 4 weeks. 
The total scheme of whole experiment is indicated on Figure 1.
2.4 Drugs
17β-E2, fluoxetine hydrochloride and VD3 as cholecalciferol were provided from 
Sigma Chemical Co. (St. Louis, MO, USA). The solution of female estrogen was 
prepared using sterile sesame oil. Vitamin D3 was dissolved in 95% ethanol and then 
aliquoted and remained at −80°C. The solution of cholecalciferol for the injection 
into the experimental groups was diluted in sterile water, resulting in a solvent 
of VD3 containing 2% ethanol. Fluoxetine hydrochloride was dissolved in sterile 
physiological saline. All drugs were injected subcutaneously (0.1 ml/rat) for the 
4 weeks during the CUMS procedure – 30 min before the daily stressor action – and 
throughout the period of the behavioral tests. All behavioral measurements were 
made 60 min after the last drug administration.
2.5 Groups of animals
All animals were randomly assigned to the six experimental groups (n = 7 in each): 
non-CUMS SHAM rats treated with solvent (control), SHAM rats exposed to CUMS 
treated with solvent, long-term OVX rats exposed to CUMS given with solvent, fluox-
etine as positive control (10.0 mg/kg/day), 17β-E2 (0.5 μg/rat/day, s.c.) or VD3 (5.0 mg/
kg/day, s.c.) in a combination with low dose of 17β-E2. In our preliminary studies, there 
were no significant differences between SHAM/OVX rats treated with physiological 
Figure 1. 
Timeline of chronic treatment. Female Wistar rats were divided into 6 groups – non-CUMS SHAM rats treated 
with solvent (control), SHAM rats submitted to CUMS treated with solvent, long-term OVX rats exposed to 
CUMS given with solvent, fluoxetine as positive control (10.0 mg/kg/day), 17β-E2 (0.5 μg/rat/day, s.c.) or VD3 
(5.0 mg/kg/day, s.c.) in a combination with low dose of 17β-E2.
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saline as solvent for fluoxetine and SHAM/OVX females treated with sterile water 
with 2% ethanol as solvent for VD3 or SHAM/OVX females treated with sesame oil as 
solvent for 17β-E2 in behavioral trials (data are not shown). Since, we did not found any 
differences between these experimental groups, the sesame oil as solvent for SHAM/
OVX females was used in the present work. The dose of VD3 and dose of 17β-E2 were 
based on our previous work on the behavioral effects of VD3 on depression-like behav-
ior of long-term OVX female rats submitted to CUMS [42, 43]. The dose of fluoxetine 
was utilized according to earlier studies demonstrating that the administration of 
fluoxetine decreases depressive-like behavior in rodents [42]. All drugs were injected 
subcutaneously (0.1 ml/rat) for the 4 weeks during the CUMS procedure – 30 min 
before the daily stressor action – and throughout the period of the behavioral tests. All 
behavioral measurements were made 60 min after the last drug administration.
2.6 Sucrose preference test
We performed SPT accordingly to our previous study [50, 51]. Before and after 
the initiation of the 4 weeks CUMS procedures, the experimental rats were sub-
jected to the sucrose preference test (SPT) [42, 51]. This test is set up as follows: fol-
lowing a training trial, the rats are subjected to a 24 h deprivation of food and water. 
On the next day, the rats have 1 hour access to one bottle with 200 ml of water and 
a similar amount of sucrose solution. The experimenter measures the percentage of 
the consumed sucrose solution and water volumes as a measure of sucrose prefer-
ence by calculating the value of the sucrose preference among all (sucrose plus 
water in mL) liquid consumption:
  %sucrose preference =  sucrose consumption   _________________________________   sucrose consumption + water consumption × 100  (1)
2.7 Forced swimming test
For testing of modifications of depression-like behavior, all groups of rats were 
submitted to the standard forced swimming test (FST) as described in earlier works 
(FST) [42, 43]. The three cylinders (60 cm tall and diameter 20 cm) were filled with 
23–25°C water up to a 30-cm depth. On the first day, rats were pre-tested during 15 min 
in cylinders. Then, rats were dried with papers and placed at their home cages till the 
next day. On the second day (testing trial), OVX females with CUMS were examined 
into the apparatus for 5 min. The following parameters were registered: (1) immobility 
time (floating in the water with only movements necessary to keep the head above 
water); (2) swimming time (active swimming movements around glass cylinder); 
(3) climbing time (active movements with forepaws directed toward the walls). For 
recording of these values, a video camera was installed above the apparatus.
2.8 Open field test
The measurements of the behavioral activity in the OFT were carried out in a 
similar way to the method which has been published in a previous study [43]. The 
rats were set in the center square of the OFT and tested for 5 min. Motor activity 
and rearing and grooming behavior were recorded for 300 s in the OFT apparatus 
using a video camera, and equipment was cleaned in-between sessions.
2.9 Biochemical measurements
All rats underwent a narcosis after behavioral trials, and approximately 5 ml 
samples of blood were drawn from the animals to be centrifuged at 4000 g for 
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CUMS was made as described previously [47, 48]. The procedure included the expo-
sure to different and unpredictable stress factors that are randomly changed during 
experimental days [49]. These manipulations are 24 h food deprivation, 24 h water 
deprivation, wet bedding overnight, titled cage overnight, unpredictable shocks 
(15 mA, one shocks/20s, 10 s duration, 20 min), 5 min swimming at cold water 
(4°C), tail hanging, 1 min, clip tail for 1 min, reversal of light/dark cycle [47, 48]. All 
stress triggers were performed individually and continuously. To prevent habitu-
ation and to ensure the unpredictability of the stressors, all stress manipulations 
randomly made accordingly to experimental scheme, repeated throughout the 4 
weeks of CUMS protocol. The control SHAM females were placed in a separate room 
without any contact with the stressed groups of animals. These rats were maintained 
as undisturbed animals that are subjected only routine cage cleaning for 4 weeks. 
The total scheme of whole experiment is indicated on Figure 1.
2.4 Drugs
17β-E2, fluoxetine hydrochloride and VD3 as cholecalciferol were provided from 
Sigma Chemical Co. (St. Louis, MO, USA). The solution of female estrogen was 
prepared using sterile sesame oil. Vitamin D3 was dissolved in 95% ethanol and then 
aliquoted and remained at −80°C. The solution of cholecalciferol for the injection 
into the experimental groups was diluted in sterile water, resulting in a solvent 
of VD3 containing 2% ethanol. Fluoxetine hydrochloride was dissolved in sterile 
physiological saline. All drugs were injected subcutaneously (0.1 ml/rat) for the 
4 weeks during the CUMS procedure – 30 min before the daily stressor action – and 
throughout the period of the behavioral tests. All behavioral measurements were 
made 60 min after the last drug administration.
2.5 Groups of animals
All animals were randomly assigned to the six experimental groups (n = 7 in each): 
non-CUMS SHAM rats treated with solvent (control), SHAM rats exposed to CUMS 
treated with solvent, long-term OVX rats exposed to CUMS given with solvent, fluox-
etine as positive control (10.0 mg/kg/day), 17β-E2 (0.5 μg/rat/day, s.c.) or VD3 (5.0 mg/
kg/day, s.c.) in a combination with low dose of 17β-E2. In our preliminary studies, there 
were no significant differences between SHAM/OVX rats treated with physiological 
Figure 1. 
Timeline of chronic treatment. Female Wistar rats were divided into 6 groups – non-CUMS SHAM rats treated 
with solvent (control), SHAM rats submitted to CUMS treated with solvent, long-term OVX rats exposed to 
CUMS given with solvent, fluoxetine as positive control (10.0 mg/kg/day), 17β-E2 (0.5 μg/rat/day, s.c.) or VD3 
(5.0 mg/kg/day, s.c.) in a combination with low dose of 17β-E2.
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saline as solvent for fluoxetine and SHAM/OVX females treated with sterile water 
with 2% ethanol as solvent for VD3 or SHAM/OVX females treated with sesame oil as 
solvent for 17β-E2 in behavioral trials (data are not shown). Since, we did not found any 
differences between these experimental groups, the sesame oil as solvent for SHAM/
OVX females was used in the present work. The dose of VD3 and dose of 17β-E2 were 
based on our previous work on the behavioral effects of VD3 on depression-like behav-
ior of long-term OVX female rats submitted to CUMS [42, 43]. The dose of fluoxetine 
was utilized according to earlier studies demonstrating that the administration of 
fluoxetine decreases depressive-like behavior in rodents [42]. All drugs were injected 
subcutaneously (0.1 ml/rat) for the 4 weeks during the CUMS procedure – 30 min 
before the daily stressor action – and throughout the period of the behavioral tests. All 
behavioral measurements were made 60 min after the last drug administration.
2.6 Sucrose preference test
We performed SPT accordingly to our previous study [50, 51]. Before and after 
the initiation of the 4 weeks CUMS procedures, the experimental rats were sub-
jected to the sucrose preference test (SPT) [42, 51]. This test is set up as follows: fol-
lowing a training trial, the rats are subjected to a 24 h deprivation of food and water. 
On the next day, the rats have 1 hour access to one bottle with 200 ml of water and 
a similar amount of sucrose solution. The experimenter measures the percentage of 
the consumed sucrose solution and water volumes as a measure of sucrose prefer-
ence by calculating the value of the sucrose preference among all (sucrose plus 
water in mL) liquid consumption:
  %sucrose preference =  sucrose consumption   _________________________________   sucrose consumption + water consumption × 100  (1)
2.7 Forced swimming test
For testing of modifications of depression-like behavior, all groups of rats were 
submitted to the standard forced swimming test (FST) as described in earlier works 
(FST) [42, 43]. The three cylinders (60 cm tall and diameter 20 cm) were filled with 
23–25°C water up to a 30-cm depth. On the first day, rats were pre-tested during 15 min 
in cylinders. Then, rats were dried with papers and placed at their home cages till the 
next day. On the second day (testing trial), OVX females with CUMS were examined 
into the apparatus for 5 min. The following parameters were registered: (1) immobility 
time (floating in the water with only movements necessary to keep the head above 
water); (2) swimming time (active swimming movements around glass cylinder); 
(3) climbing time (active movements with forepaws directed toward the walls). For 
recording of these values, a video camera was installed above the apparatus.
2.8 Open field test
The measurements of the behavioral activity in the OFT were carried out in a 
similar way to the method which has been published in a previous study [43]. The 
rats were set in the center square of the OFT and tested for 5 min. Motor activity 
and rearing and grooming behavior were recorded for 300 s in the OFT apparatus 
using a video camera, and equipment was cleaned in-between sessions.
2.9 Biochemical measurements
All rats underwent a narcosis after behavioral trials, and approximately 5 ml 
samples of blood were drawn from the animals to be centrifuged at 4000 g for 
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15 min at 4°C [43]. While doing so, the hippocampi of rats in the experimental 
group were dissected to be homogenized in cold lysis extraction buffer (0.2% 
sodium deoxycholate, 0.5% Triton X-100, 1% NP-40, 50 mM Tris-HCl pH 7.4, 
1 mM phenylmethylsulfonyl fluoride, 1 mM N-ethyl-maleimide, and 2.5 mM 
phenanthroline) [43]. After that, the hippocampal samples with the cold lysis 
buffer were sonicated for 15 s. Then, the hippocampi were centrifuged at 12,000 g 
for 15 min at 4°C. The Bradford method was used for the normalization of hippo-
campal supernatants to the total protein [52]. The serum samples and hippocampal 
protein normalized supernatants were stored at −80°C until the ELISA assays. The 
serum samples were used for the measurement of the 25-hydroxyvitamin D3 (25-
OH-VD3) and estradiol levels using a commercially available rat ELISA kits (Cusabio 
Biotech Co., Ltd., Wuhan, P.R. China) according to the manufacturer’s instructions. 
The sensitivity and detection range of the 25-OH-VD3 rat ELISA kits were 5.0 μg/l 
and 20–100 μg/l, respectively. The sensitivity and detection range of the estradiol 
rat ELISA kits were 4.0 pg/ml and 40–1500 pg/ml, respectively.
Hippocampal homogenates were used for the detection of the NF-kB/p65/p65, 
17β-E2/VD3 receptors levels by rat ELISA kits (Cusabio Biotech Co., Ltd., Wuhan, 
P.R. China) according to the manufacturer’s instructions. Briefly, 100 𝜇𝜇l of hip-
pocampal sample or standard was added to each well and incubated for 120 min 
at 37.0°C. Then, 100 𝜇𝜇l of anti-NF-kB/p65/p65, anti-17β-E2 receptor, and anti-VD3 
receptor antibodies were added to each different well and incubated for 60 min at 
37.0°C. After 3 times of washing, 100 𝜇𝜇l of HRP-avidin working solution was added 
to each well and incubated for 60 min at 37.0°C. Again, after 5 times of washing, 90 
𝜇𝜇l of tetramethylbenzidine solution was given to each different well and incubated 
for 15–30 min at 37.0°C. Then, 50 𝜇𝜇l of stop solution was added to each well to 
terminate the color reaction. The NF-kB/p65/p65, 17β-E2/VD3 receptors levels were 
measured using a MC Thermo Fisher Scientific reader (Thermo Fisher Scientific 
Inc., Finland) with an absorbance of 450 nm. The standard curve was used for the 
calculation of the relationship between the optical density and the NF-kB/p65/p65, 
17β-E2/VD3 receptors levels. The BDNF content is presented as pg/mg of tissue. 
The sensitivity and detection range of the NF-kB/p65 rat ELISA kit were 5.0 μg/
ml and 6.0–600 μg/ml, respectively. The sensitivity and detection range of the 
17β-E2 receptor rat ELISA kit was 0.39 pg/ml and 1.56–100 pg/ml, respectively. The 
sensitivity and detection range of the VD3 receptor rat ELISA kit was 5.8 pg/ml and 
23.5–1500 pg/ml, respectively. The assay exhibited no significant cross reactivity 
with other ligands. All samples were duplicated for the assay.
2.10 Western blots
Hippocampal tissues were homogenized in cold lysis buffer containing a protease 
inhibitor cocktail (Sigma-Aldrich, USA) for 1 h and centrifuged at 12,000 g at 4°C for 
20 min [42]. The protein content was evaluated by a Bio-Rad protein detector (Bio-
Rad, USA), and 100 μg of total protein from each sample was denatured with buffer 
(6.205 mM Tris-HCl, 10% glycerol, 2% SDS, 0.01% bromophenol blue, and 50 mM 
2ME) at 95°C for 5 min. The denatured proteins were separated on an SDS page 
(10% sodium dodecyl sulfate polyacrylamide gel) and forwarded to a nitrocellulose 
membrane (Amersham Biotech, USA). After that, the membranes were probed with 
anti-NF-kB/p65/p65, anti-17β-E2 receptor, anti-VD3 receptor (1:1000, Santa Cruz), 
and β-actin (1:1000; Sigma-Aldrich, USA) monoclonal antibodies for 2 h and sec-
ondary antirabbit antibodies (1:5000; Santa Cruz, USA) conjugated to horseradish 
peroxidase for 1 h. Bands were detected by 5-bromo-4-chloro-3-indolyl phosphate 
with a nitro blue tetrazolium kit (Abcam, China) as a chemiluminescent substrate. 
Signals were measured by an image analysis system (UVIdoc, Houston, TX, USA).
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2.11 Statistical analysis
All experimental data are expressed as the mean ± standard deviation of the 
mean. The treatment effects were determined with a one-way ANOVA followed by 
an LSD post hoc test using the Statistics Package for SPSS, version 16.0 (SPSS Inc., 
USA). A value of P < 0.05 was considered statistically significant.
3. Results
3.1  VD3 alters the body weight in the long-term OVX rats treated with 17β-E2 
exposed to CUMS
The body weights of long-term OVX rats subjected to CUMS and treated with 
17β-E2 in a combination with all investigated doses of VD3 are presented in Figure 2.
There was no difference in the initial body weight in all the experimental 
groups. Following 4 weeks, the body weight of SHAM rats with CUMS was 
significantly decreased compared to the control, non-CUMS SHAM group 
(Figure 2, F(1,34) = 72.66, P < 0.001). The body weight of long-term OVX 
rats with CUMS was significantly decreased compared to the non-CUMS/
CUMS SHAM groups (Figure 2, P < 0.001). Administration of 17β-E2 did not 
statistically enhance body weight of long-term OVX rats with CUMS compared 
to the non-CUMS control, CUMS OVX/SHAM groups (Figure 2, P > 0.001). 
However, there was a tendency to increase the body weight of long-term OVX 
Figure 2. 
VD3 corrects the body weight in the long-term OVX rats treated with 17β-E2 submitted to CUMS: (a) Prior 
to CUMS and (b) After CUMS. * – P < 0.05 versus the control group, # – P < 0.05 versus to the SHAM group 
with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the OVX group 
with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
Vitamin D Deficiency
158
15 min at 4°C [43]. While doing so, the hippocampi of rats in the experimental 
group were dissected to be homogenized in cold lysis extraction buffer (0.2% 
sodium deoxycholate, 0.5% Triton X-100, 1% NP-40, 50 mM Tris-HCl pH 7.4, 
1 mM phenylmethylsulfonyl fluoride, 1 mM N-ethyl-maleimide, and 2.5 mM 
phenanthroline) [43]. After that, the hippocampal samples with the cold lysis 
buffer were sonicated for 15 s. Then, the hippocampi were centrifuged at 12,000 g 
for 15 min at 4°C. The Bradford method was used for the normalization of hippo-
campal supernatants to the total protein [52]. The serum samples and hippocampal 
protein normalized supernatants were stored at −80°C until the ELISA assays. The 
serum samples were used for the measurement of the 25-hydroxyvitamin D3 (25-
OH-VD3) and estradiol levels using a commercially available rat ELISA kits (Cusabio 
Biotech Co., Ltd., Wuhan, P.R. China) according to the manufacturer’s instructions. 
The sensitivity and detection range of the 25-OH-VD3 rat ELISA kits were 5.0 μg/l 
and 20–100 μg/l, respectively. The sensitivity and detection range of the estradiol 
rat ELISA kits were 4.0 pg/ml and 40–1500 pg/ml, respectively.
Hippocampal homogenates were used for the detection of the NF-kB/p65/p65, 
17β-E2/VD3 receptors levels by rat ELISA kits (Cusabio Biotech Co., Ltd., Wuhan, 
P.R. China) according to the manufacturer’s instructions. Briefly, 100 𝜇𝜇l of hip-
pocampal sample or standard was added to each well and incubated for 120 min 
at 37.0°C. Then, 100 𝜇𝜇l of anti-NF-kB/p65/p65, anti-17β-E2 receptor, and anti-VD3 
receptor antibodies were added to each different well and incubated for 60 min at 
37.0°C. After 3 times of washing, 100 𝜇𝜇l of HRP-avidin working solution was added 
to each well and incubated for 60 min at 37.0°C. Again, after 5 times of washing, 90 
𝜇𝜇l of tetramethylbenzidine solution was given to each different well and incubated 
for 15–30 min at 37.0°C. Then, 50 𝜇𝜇l of stop solution was added to each well to 
terminate the color reaction. The NF-kB/p65/p65, 17β-E2/VD3 receptors levels were 
measured using a MC Thermo Fisher Scientific reader (Thermo Fisher Scientific 
Inc., Finland) with an absorbance of 450 nm. The standard curve was used for the 
calculation of the relationship between the optical density and the NF-kB/p65/p65, 
17β-E2/VD3 receptors levels. The BDNF content is presented as pg/mg of tissue. 
The sensitivity and detection range of the NF-kB/p65 rat ELISA kit were 5.0 μg/
ml and 6.0–600 μg/ml, respectively. The sensitivity and detection range of the 
17β-E2 receptor rat ELISA kit was 0.39 pg/ml and 1.56–100 pg/ml, respectively. The 
sensitivity and detection range of the VD3 receptor rat ELISA kit was 5.8 pg/ml and 
23.5–1500 pg/ml, respectively. The assay exhibited no significant cross reactivity 
with other ligands. All samples were duplicated for the assay.
2.10 Western blots
Hippocampal tissues were homogenized in cold lysis buffer containing a protease 
inhibitor cocktail (Sigma-Aldrich, USA) for 1 h and centrifuged at 12,000 g at 4°C for 
20 min [42]. The protein content was evaluated by a Bio-Rad protein detector (Bio-
Rad, USA), and 100 μg of total protein from each sample was denatured with buffer 
(6.205 mM Tris-HCl, 10% glycerol, 2% SDS, 0.01% bromophenol blue, and 50 mM 
2ME) at 95°C for 5 min. The denatured proteins were separated on an SDS page 
(10% sodium dodecyl sulfate polyacrylamide gel) and forwarded to a nitrocellulose 
membrane (Amersham Biotech, USA). After that, the membranes were probed with 
anti-NF-kB/p65/p65, anti-17β-E2 receptor, anti-VD3 receptor (1:1000, Santa Cruz), 
and β-actin (1:1000; Sigma-Aldrich, USA) monoclonal antibodies for 2 h and sec-
ondary antirabbit antibodies (1:5000; Santa Cruz, USA) conjugated to horseradish 
peroxidase for 1 h. Bands were detected by 5-bromo-4-chloro-3-indolyl phosphate 
with a nitro blue tetrazolium kit (Abcam, China) as a chemiluminescent substrate. 
Signals were measured by an image analysis system (UVIdoc, Houston, TX, USA).
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2.11 Statistical analysis
All experimental data are expressed as the mean ± standard deviation of the 
mean. The treatment effects were determined with a one-way ANOVA followed by 
an LSD post hoc test using the Statistics Package for SPSS, version 16.0 (SPSS Inc., 
USA). A value of P < 0.05 was considered statistically significant.
3. Results
3.1  VD3 alters the body weight in the long-term OVX rats treated with 17β-E2 
exposed to CUMS
The body weights of long-term OVX rats subjected to CUMS and treated with 
17β-E2 in a combination with all investigated doses of VD3 are presented in Figure 2.
There was no difference in the initial body weight in all the experimental 
groups. Following 4 weeks, the body weight of SHAM rats with CUMS was 
significantly decreased compared to the control, non-CUMS SHAM group 
(Figure 2, F(1,34) = 72.66, P < 0.001). The body weight of long-term OVX 
rats with CUMS was significantly decreased compared to the non-CUMS/
CUMS SHAM groups (Figure 2, P < 0.001). Administration of 17β-E2 did not 
statistically enhance body weight of long-term OVX rats with CUMS compared 
to the non-CUMS control, CUMS OVX/SHAM groups (Figure 2, P > 0.001). 
However, there was a tendency to increase the body weight of long-term OVX 
Figure 2. 
VD3 corrects the body weight in the long-term OVX rats treated with 17β-E2 submitted to CUMS: (a) Prior 
to CUMS and (b) After CUMS. * – P < 0.05 versus the control group, # – P < 0.05 versus to the SHAM group 
with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the OVX group 
with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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rats with CUMS compared to the OVX rats plus CUMS given with solvent. 
Supplementation with VD3 (5.0 mg/kg) plus 17β-E2 significantly prevented the 
reduction of the body weight of long-term OVX rats with CUMS (P < 0.001) 
compared to the OVX plus solvent or 17β-E2/SHAM rats exposed to CUMS 
(Figure 2, P < 0.001). This effect of co-administration of VD3 (5.0 mg/kg) plus 
17β-E2 was similar to the effect of the reference drug fluoxetine (10.0 mg/kg) in 
long-term OVX rats with CUMS.
3.2  VD3 increases sucrose preference in the long-term OVX rats treated with 
17β-E2 exposed to CUMS
Before the CUMS protocol, there was no significant difference among the 
experimental groups in the SPT (Figure 3). Following 28 days of the CUMS 
trials, the SHAM rats exhibited a decrease in sucrose preference when compared 
to the control non-CUMS SHAM group (P < 0.05). The sucrose preference in 
long-term OVX rats was significantly reduced compared to the non-CUMS/
CUMS SHAM rats (Figure 3, F(1,34) = 56.14, P < 0.05). Low dose of 17β-E2 
increased sucrose preference in long-term OVX rats with CUMS compared to the 
OVX group with CUMS plus solvent (Figure 3, P > 0.05). Treatment with VD3 at 
dose of 5.0 mg/kg plus 17β-E2, as well as fluoxetine, markedly increased sucrose 
Figure 3. 
VD3 increases sucrose preference in the long-term OVX rats treated with 17β-E2 submitted to CUMS:  
(a) Prior to CUMS and (b) After CUMS. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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consumption in the long-term OVX rats exposed to CUMS when compared to 
the OVX plus solvent or 17β-E2/SHAM rats submitted to the CUMS (Figure 3, 
P < 0.05).
3.3  VD3 decreases depression-like behavior in the forced swimming test of  
long-term OVX rats treated with 17β-E2 exposed to CUMS
CUMS produced a significant increase of the immobility time and decrease of 
swimming time in the long-term OVX compared to the non-CUMS/CUMS SHAM 
rats (Figure 4, F(1,34) = 52.84, F(1,76) = 68.89, F(1,76) = 26.12, respectively, 
Figure 4. 
VD3 decreased depression-like behavior in the forced swimming test of long-term OVX rats treated with 17β-E2 
submitted to CUMS: (a) immobility time, sec, (b) swimming time, and (c) climbing time, sec. * – P < 0.05 
versus the control group, # – P < 0.05 versus to the SHAM group with CUMS, $ – P < 0.05 versus to the OVX 
group with CUMS, and $$ – P < 0.05 versus to the OVX group with CUMS treated with 17β-E2. The data are 
presented as mean ± SD; n = 7 in each group.
Vitamin D Deficiency
160
rats with CUMS compared to the OVX rats plus CUMS given with solvent. 
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(Figure 2, P < 0.001). This effect of co-administration of VD3 (5.0 mg/kg) plus 
17β-E2 was similar to the effect of the reference drug fluoxetine (10.0 mg/kg) in 
long-term OVX rats with CUMS.
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17β-E2 exposed to CUMS
Before the CUMS protocol, there was no significant difference among the 
experimental groups in the SPT (Figure 3). Following 28 days of the CUMS 
trials, the SHAM rats exhibited a decrease in sucrose preference when compared 
to the control non-CUMS SHAM group (P < 0.05). The sucrose preference in 
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CUMS SHAM rats (Figure 3, F(1,34) = 56.14, P < 0.05). Low dose of 17β-E2 
increased sucrose preference in long-term OVX rats with CUMS compared to the 
OVX group with CUMS plus solvent (Figure 3, P > 0.05). Treatment with VD3 at 
dose of 5.0 mg/kg plus 17β-E2, as well as fluoxetine, markedly increased sucrose 
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VD3 increases sucrose preference in the long-term OVX rats treated with 17β-E2 submitted to CUMS:  
(a) Prior to CUMS and (b) After CUMS. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
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consumption in the long-term OVX rats exposed to CUMS when compared to 
the OVX plus solvent or 17β-E2/SHAM rats submitted to the CUMS (Figure 3, 
P < 0.05).
3.3  VD3 decreases depression-like behavior in the forced swimming test of  
long-term OVX rats treated with 17β-E2 exposed to CUMS
CUMS produced a significant increase of the immobility time and decrease of 
swimming time in the long-term OVX compared to the non-CUMS/CUMS SHAM 
rats (Figure 4, F(1,34) = 52.84, F(1,76) = 68.89, F(1,76) = 26.12, respectively, 
Figure 4. 
VD3 decreased depression-like behavior in the forced swimming test of long-term OVX rats treated with 17β-E2 
submitted to CUMS: (a) immobility time, sec, (b) swimming time, and (c) climbing time, sec. * – P < 0.05 
versus the control group, # – P < 0.05 versus to the SHAM group with CUMS, $ – P < 0.05 versus to the OVX 
group with CUMS, and $$ – P < 0.05 versus to the OVX group with CUMS treated with 17β-E2. The data are 
presented as mean ± SD; n = 7 in each group.
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P < 0.05). VD3 (5.0 mg/kg), as well as fluoxetine treatment, significantly reduced 
the immobility time and increased the swimming time in the long-term OVX 
treated with 17β-E2 compared to the OVX plus solvent or 17β-E2/SHAM with CUMS 
groups (Figure 4, P < 0.05).
3.4  VD3 changes the behavior in the open field test of long-term OVX rats 
treated with 17β-E2 exposed to CUMS
Following 28 days of CUMS protocol, there were no statistically significant 
differences for grooming activities between all the experimental groups of animals 
in the OFT (Figure 5, F(1,34) = 0.82, P > 0.05). The long-term OVX rats with CUMS 
Figure 5. 
VD3 alters the behavior in the open field test of long-term OVX rats treated with 17β-E2 submitted to CUMS. 
(a) Crossing, (b) rearing, and (c) grooming. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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showed a decreased number of rearings and crossings when they were compared 
to the non-CUMS/CUMS SHAM groups (Figure 5, F(1,34) = 14.14, P < 0.05). 
Administration of fluoxetine, 17β-E2, as well as treatment with VD3 significantly 
elevated the number of rearings and crossings in the long-term OVX rats with CUMS 
compared to the OVX/SHAM rats with CUMS plus solvent (Figure 5).
3.5  VD3 alters serum estradiol and VD3 levels in long-term OVX rats treated 
with 17β-E2 exposed to CUMS
The ELISA assay revealed decreased estradiol and VD3 concentrations in the 
long-term OVX rats with CUMS compared to the non-CUMS/CUMS SHAM 
groups (Figure 6, F(1,34) = 78.56, F(1,34) = 56.12, F(1,34) = 22.21, respectively, 
P < 0.05). Low dose of 17β-E2 induced increase of estradiol levels in the serum 
blood to some extent in the long-term OVX rats with CUMS, however, it was 
not statistically significant (P > 0.05). The co-administration of VD3 with 
17β-E2 significantly increased estradiol and VD3 concentrations in the long-
term OVX rats with CUMS compared to the OVX plus solvent or 17β-E2/SHAM 
with CUMS rats (Figure 6, P < 0.05). Fluoxetine did not change the serum 
Figure 6. 
VD3 alters serum estradiol and VD3 levels in long-term OVX rats treated with 17β-E2 submitted to CUMS.  
(a) estradiol, pg/ml and (b) 25-OH-VD3, μg/ml. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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P < 0.05). VD3 (5.0 mg/kg), as well as fluoxetine treatment, significantly reduced 
the immobility time and increased the swimming time in the long-term OVX 
treated with 17β-E2 compared to the OVX plus solvent or 17β-E2/SHAM with CUMS 
groups (Figure 4, P < 0.05).
3.4  VD3 changes the behavior in the open field test of long-term OVX rats 
treated with 17β-E2 exposed to CUMS
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in the OFT (Figure 5, F(1,34) = 0.82, P > 0.05). The long-term OVX rats with CUMS 
Figure 5. 
VD3 alters the behavior in the open field test of long-term OVX rats treated with 17β-E2 submitted to CUMS. 
(a) Crossing, (b) rearing, and (c) grooming. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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showed a decreased number of rearings and crossings when they were compared 
to the non-CUMS/CUMS SHAM groups (Figure 5, F(1,34) = 14.14, P < 0.05). 
Administration of fluoxetine, 17β-E2, as well as treatment with VD3 significantly 
elevated the number of rearings and crossings in the long-term OVX rats with CUMS 
compared to the OVX/SHAM rats with CUMS plus solvent (Figure 5).
3.5  VD3 alters serum estradiol and VD3 levels in long-term OVX rats treated 
with 17β-E2 exposed to CUMS
The ELISA assay revealed decreased estradiol and VD3 concentrations in the 
long-term OVX rats with CUMS compared to the non-CUMS/CUMS SHAM 
groups (Figure 6, F(1,34) = 78.56, F(1,34) = 56.12, F(1,34) = 22.21, respectively, 
P < 0.05). Low dose of 17β-E2 induced increase of estradiol levels in the serum 
blood to some extent in the long-term OVX rats with CUMS, however, it was 
not statistically significant (P > 0.05). The co-administration of VD3 with 
17β-E2 significantly increased estradiol and VD3 concentrations in the long-
term OVX rats with CUMS compared to the OVX plus solvent or 17β-E2/SHAM 
with CUMS rats (Figure 6, P < 0.05). Fluoxetine did not change the serum 
Figure 6. 
VD3 alters serum estradiol and VD3 levels in long-term OVX rats treated with 17β-E2 submitted to CUMS.  
(a) estradiol, pg/ml and (b) 25-OH-VD3, μg/ml. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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estradiol and VD3 levels in the long-term OVX rats exposed to CUMS (Figure 6, 
P > 0.05).
3.6  VD3 modulates hippocampal NF-kB/p65/p65 and 17β-E2/VD3 receptors 
levels in long-term OVX rats treated with 17β-E2 exposed to CUMS
CUMS significantly increased NF-kB/p65/p65 levels and decreased 17β-E2/VD3 
receptors concentrations in the hippocampus of SHAM rats compared to the non-
CUMS control (Figure 7, P < 0.05). CUMS produced a increase of hippocampal 
Figure 7. 
VD3 modulates hippocampal NF-kB/p65 and 17β-E2/VD3 receptors levels in long-term OVX rats treated with 
17β-E2 submitted to CUMS tested by ELISA. (a) NF-kB/p65/p65, μg/ml, (b) 17β-E2 receptor, pg/ml, and (c) 
VD3 receptor, pg/ml. * – P < 0.05 versus the control group, # – P < 0.05 versus to the SHAM group with CUMS, 
$ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the OVX group with CUMS 
treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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NF-kB/p65/p65 and decrease of 17β-E2/VD3 receptors levels in the long-term OVX rats 
compared to the non-CUMS/CUMS SHAM rats (Figure 7, F(1,34) = 28.44, P < 0.05).
Fluoxetine (10.0 mg/kg) decreased NF-kB/p65/p65 levels in the hippocampus of 
long-term OVX rats treated to CUMS compared to the OVX plus solvent/SHAM rats 
with CUMS (Figure 7, P < 0.05). Moreover, VD3 plus 17β-E2 reversed 17β-E2/VD3 
receptors levels and reduced NF-kB/p65 levels in the hippocampus of the long-term 
OVX rats compared to OVX plus solvent or 17β-E2/SHAM rats with CUMS (Figure 7, 
P < 0.05). Fluoxetine failed to modify 17β-E2/VD3 receptors levels in the long-term 
OVX rats exposed to CUMS (Figure 7, P > 0.05).
Western blotting analysis revealed that NF-kB/p65 protein levels in the hippocam-
pus of SHAM rats submitted to CUMS were higher compared to non-CUMS control 
Figure 8. 
VD3 modulates hippocampal NF-kB/p65 and 17β-E2/VD3 receptors expressions in long-term OVX rats with 
17β-E2 submitted to CUMS detected with western blotting treated. 1 – control SHAM, 2 – SHAM + CUMS + 
solvent, 3 – OVX + CUMS + solvent, 4 – OVX rats + CUMS + fluoxetine, 5 – OVX rats + CUMS + 17β-E2, and 
6 – OVX rats + CUMS + VD3 + 17β-E2. * – P < 0.05 versus the control group, # – P < 0.05 versus to the SHAM 
group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the OVX 
group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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OVX rats compared to OVX plus solvent or 17β-E2/SHAM rats with CUMS (Figure 7, 
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females (Figure 8, P < 0.05). NF-kB/p65 levels were increased in the hippocampus 
of long-term OVX rats with CUMS compared to the non-CUMS/CUMS SHAM 
rats (Figure 8, F(1,34) = 34.45, F(1,34) = 16.38, respectively, P < 0.05). Fluoxetine 
(10.0 mg/kg) resulted in significant reduced levels of hippocampal NF-kB/p65 protein 
expression in long-term OVX with CUMS compared to the OVX plus solvent/SHAM 
rats with CUMS (Figure 8, P < 0.05). Co-treatment with VD3 and 17β-E2 decreased 
NF-kB/p65 protein levels and increased 17β-E2/VD3 receptors protein expression in 
the hippocampus of the long-term OVX rats compared to OVX plus solvent or 17β-E2/
SHAM rats with CUMS (Figure 8, P < 0.05). Fluoxetine did not alter 17β-E2/VD3 
protein expression in the long-term OVX rats exposed to CUMS (Figure 8, P > 0.05).
4. Discussion
The present preclinical study analyzed the antidepressant-like effects of VD3 
(5.0 mg/kg, s.c.) in long-term adult OVX female rats given with low dose of 17β-E2 
subjected to the CUMS. A CUMS paradigm is a well-known experimental paradigm 
that has documented to consider as standard pathophysiological impairments in 
mood state linked to a clinical depressive disorders in humans [47–49]. In the pres-
ent work, the implications of NF-kB/p65 signaling pathway, as well as the 17β-E2/
VD3 receptors, in the mechanisms of VD3 activity in depression were tested regard-
ing to the affective-related condition of long-term adult OVX rats treated with low 
dose of 17β-E2 exposed to CUMS.
The results of this study showed that in the adult long-term OVX rats undergo-
ing CUMS, there were marked anhedonia-/depression-like behaviors, as assessed by 
SPT and LDT, respectively.
Moreover, long-term OVX rats exposed to CUMS exhibited decreased loco-
motor and rearing activities in the OFT. The ELISA assay clearly demonstrated 
lower estradiol and VD3 concentrations in adult long-term OVX rats subjected to 
CUMS. In addition, the increased NF-kB/p65 concentration/protein expression and 
decreased 17β-E2/VD3 receptors levels were found in the hippocampus of long-term 
OVX rats exposed to CUMS.
Administration of 17β-E2 failed to completely restore behavioral and biochemi-
cal parameters in the long-term OVX rats exposed to CUMS. Fluoxetine decreased 
anhedonia-like and depression-like states and decreased NF-kB/p65 levels in the 
hippocampus of the long-term OVX female rats exposed to CUMS. Data of litera-
ture have demonstrated that fluoxetine corrected depression-like profile of OVX 
rats in stress depression model [53]. The results of the study indicate that CUMS 
provokes marked behavioral, neurochemical, neurohormonal, and neuroinflamma-
tion alterations in adult OVX rats with long-lasting estrogens decline. Our data are 
in agreement with our recent data and other findings, which indicated that long-
term estrogen deprivation in female rodents subjected to a CUMS procedure results 
in a profound affective-like profile [54].
The most important findings of the present study is linked to the antidepressant-
like effects of VD3 in the long-term adult OVX rats treated with low dose of 17β-E2 
under conditions of CUMS. VD3 given with a dose of 5.0 mg/kg reversed anhe-
donia-like and depression-like states in the SPT/LDT paradigms in the long-term 
OVX rats treated with 17β-E2 subjected to CUMS, which was similar to the effects 
of the fluoxetine treatment. Moreover, the VD3 application reversed the behavioral 
impairments observed in the OFT in the long-term OVX rats supplemented with 
17β-E2 subjected to CUMS. Biochemical assays found that VD3 increased the serum 
VD3 and estradiol levels, as well decreased the hippocampal NF-kB/p65 content in 
the long-term OVX rats treated with 17β-E2 exposed to CUMS. Additionally, VD3 
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increased 17β-E2/VD3 receptors levels in the hippocampus of long-term OVX rats 
treated with 17β-E2 subjected to CUMS. Western blot analysis revealed that VD3 
reduced NF-kB/p65 and increased 17β-E2/VD3 protein expression in the hip-
pocampus of long-term OVX rats treated with 17β-E2 subjected to CUMS. These 
data suggest that VD3 attenuates the CUMS-produced behavioral impairments and 
normalized the serum VD3 and estradiol levels, as well NF-kB/p65 and 17β-E2/VD3 
production in the hippocampus of long-term OVX rats.
Inflammation is now recognized to be the one of the key components of affec-
tive-related development, with the NF-κB involved in both the early and late stages 
of the inflammatory processing [33, 41, 55]. NF-κB is the main transcriptional 
factor which controls the expression of various genes implicated in multiple cell 
functions and is triggered by different types of extracellular stimuli stimulated neu-
roinflammation [33, 34]. Deterioration of NF-κB signaling in the brain negatively 
influence on neuroplasticity and neuromorphology, as well as cognitive functions. 
However, NF-κB overstimulation is deleterious, and this detrimental effect can be 
reversed suppressing NF-κB signaling. That is why, NF-κB signaling is fundamental 
for normal brain function [36–39, 55]. The inhibition of neuroinflammation may 
be critical for the antidepressant action of VD3 that was noted in our study. The 
increased pro-inflammatory cytokines have been found repeatedly in both animals 
and depressed patients [37–39]. Clinical studies indicate that inhibition of neuroin-
flammation by nonsteroidal antiinflammatory drugs can attenuate depression-like 
behaviors in depressed rodents and humans [36–39]. The inhibitory effect of VD3 
on CUMS-induced increase in pro-inflammatory cytokines in the hippocampus 
of the long-term OVX rats is strongly in accordance with the neuroinflammation 
hypothesis of depression [39]. A better comprehension of NFκB-dependent mecha-
nisms in antidepressant action of VD3 needs further studies.
Based on our findings, it can be assumed that VD3 in the present study is impli-
cated in the modulation of NF-κB signaling in long-term OVX rats with CUMS. On 
the other hand, VD3 normalized 17β-E2/VD3 receptors levels in the hippocampus of 
long-term OVX rats treated with 17β-E2 subjected to CUMS. Such complex effects 
of VD3 on neuroinflammation and 17β-E2/VD3 receptors might promote a greater 
effect of combination of VD3 plus 17β-E2 than application only 17β-E2. This is the 
first study to show the action of VD3 in the behavioral and neuroinflammation and 
biochemical consequences of a CUMS in adult long-term OVX rats treated with low 
dose of 17β-E2. The inhibition of NF-kB/p65 activity by VD3 treatment is a promis-
ing fact of study for treatment of neuroinflammatory diseases that are associated 
with low levels of VD3. These results suggest an anti-inflammatory role for VD3, 
which may be one of the fundamental components of its activity.
Thus, the possible mechanism of VD3 action might be explained by the stimula-
tion of 17β-E2/VD3 receptors identified in the different brain structures involved 
in mood control [13–15]. The possible mechanisms of such action of VD3 in the 
long-term OVX rats can be connected with cross-talk protein-protein interactions. 
Moreover, VD alters the neuroinflammation response via NF-kB/p65 signaling at 
the affective-related state, thereby improving depression state [39, 55]. Low VD 
levels appear in the majority of postmenopausal women [52, 56, 57]. Therefore, VD 
supplementation may be very useful for treatment of mood disorders in postmeno-
pausal women with a low level of VD and supplemented with MHT. However, the 
exact role of VD supplementation in the prevention and treatment of mood disor-
ders associated with menopausal consequences has not been completely identified.
In conclusion, the present study supports evidence for repeated administra-
tion of VD3 in a chronic unpredictable stress model having an anti-anhedonia-like 
and antidepressant-like effects in long-term OVX adult rats treated with low dose 
of 17β-E2. Moreover, the biochemical and western blotting assays suggest the 
Vitamin D Deficiency
166
females (Figure 8, P < 0.05). NF-kB/p65 levels were increased in the hippocampus 
of long-term OVX rats with CUMS compared to the non-CUMS/CUMS SHAM 
rats (Figure 8, F(1,34) = 34.45, F(1,34) = 16.38, respectively, P < 0.05). Fluoxetine 
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the hippocampus of the long-term OVX rats compared to OVX plus solvent or 17β-E2/
SHAM rats with CUMS (Figure 8, P < 0.05). Fluoxetine did not alter 17β-E2/VD3 
protein expression in the long-term OVX rats exposed to CUMS (Figure 8, P > 0.05).
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implications of NF-kB/p65 and 17β-E2/VD3 production modulation in the antide-
pressant-like activity of VD3. Further studies should however explore the precise 
mechanism of VD3 action, due to the necessity of an improvement of therapies 
focusing on mood-repair in females with long-lasting estrogen deficiency.
5. Conclusions
This study demonstrated that VD3-induced antianhedonic- and antidepressant-
like effects in the adult female rats following long-lasting estrogens decline treated 
with low dose of 17β-E2 submitted to CUMS. Treatment with VD3 modulates 
NF-kB/p65 concentration/protein expression and 17β-E2/VD3 receptors levels in 
the hippocampus of long-term OVX rats exposed to CUMS treated with low dose of 
17β-E2. Our study yields new knowledge into the mechanisms by which VD3 affects 
to alleviate anhedonia- and depressive-like behaviors in female rodents with long-
term estrogen deficiency in stress model of depression.
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implications of NF-kB/p65 and 17β-E2/VD3 production modulation in the antide-
pressant-like activity of VD3. Further studies should however explore the precise 
mechanism of VD3 action, due to the necessity of an improvement of therapies 
focusing on mood-repair in females with long-lasting estrogen deficiency.
5. Conclusions
This study demonstrated that VD3-induced antianhedonic- and antidepressant-
like effects in the adult female rats following long-lasting estrogens decline treated 
with low dose of 17β-E2 submitted to CUMS. Treatment with VD3 modulates 
NF-kB/p65 concentration/protein expression and 17β-E2/VD3 receptors levels in 
the hippocampus of long-term OVX rats exposed to CUMS treated with low dose of 
17β-E2. Our study yields new knowledge into the mechanisms by which VD3 affects 
to alleviate anhedonia- and depressive-like behaviors in female rodents with long-
term estrogen deficiency in stress model of depression.
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Abstract
Obesity is a very common issue worldwide, and it is one of the risk factors for 
mortality. Several studies were done to identify the causes of this issue and to inves-
tigate factors that can affect this condition. Vitamin D is claimed to have an impact 
not only for maintaining bone health but also for having an association between 
its deficiency and obesity as some studies found that the concentrations of this 
vitamin are low in obese individuals. The suggested mechanisms and a discussion 
of the latest findings as well as the possibility of integrating supplementation in the 
treatment of obesity are covered in this book chapter. It was concluded that vitamin 
D deficiency is prevalent in many parts of the world and the supplements are an 
affordable option, but further studies are required to address different confounding 
factors that will result in clear data interpretation and will contribute to the future 
planning of health policies and guidelines used by healthcare professionals.
Keywords: vitamin D, deficiency, supplements, obesity, health, BMI
1. Introduction
Obesity is one of the most commonly observed health issues and can be defined 
as the condition in which there is an abnormal or excess fat accumulation in the 
body that can affect the health of an individual [1].
A measure of the obesity and other body weight status is the body mass index 
(BMI) which is a tool that uses the weight and the height of an individual. The 
weight is divided by the square of the height. If the BMI is 30 or more, the indi-
vidual will be considered obese. BMI provides a measure of obesity and overweight 
that is general for female and male adults from different age groups, but for children 
the age has to be taken into consideration. Due to its inconsistent representation 
and correspondence for the level of fat in various individuals, it should be used as a 
rough guide [1].
According to the World Health Organization (WHO), obesity is known to be 
high especially in developed countries (high-income countries), but recently it 
was observed to increase even in middle- and low-income countries as well which 
is a serious issue because obesity is one of the main risk factors for several seri-
ous chronic diseases that are noncommunicable diseases (NCDs) like respiratory 
diseases, cardiovascular diseases, diabetes, and cancers causing an estimated 38 
million deaths annually according to the WHO statistics [1].
According to the Global Health Observatory (GHO), data from the WHO sta-
tistics of the prevalence of obesity among adults aged 18+ (1975–2016) represented 
27.8% in the United Kingdom (UK) and 31.7% in the United Arab Emirates (UAE) 
among adults [1]. According to the National Health Survey, adult obesity in the UAE 
stands at 27.8% in 2019 [2]. Obesity is caused by several reasons, and one of them is 
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the imbalance between calories expended and calories consumed due to changes in 
physical activity and dietary patterns [3].
The prevalence of obesity was found to be due to several factors especially 
change in lifestyle habits besides the genetic contribution and other factors, and this 
indicates that certain healthcare awareness activities and certain interventions can 
help and contribute to overcome this issue [4].
Vitamin D is a very important vitamin and plays a role in the maintenance of bone 
tissues, the balance of phosphorus and calcium, as well as other cell functions [5].
During sunlight exposure, the skin is penetrated by ultraviolet B photons by 
which pre-vitamin D3 is isomerized into vitamin D3 by the body heat [6].
Although many controversies still exist suggesting that vitamin D is not con-
nected to any health condition and it is just a marker of general good health, there 
is also a good evidence of the relation between vitamin D level and malignancies as 
well as mental health, bone health, and other health issues [7].
Vitamin D has a vital role in maintaining good health, and its benefits or impor-
tance comes from its role in absorbing calcium and phosphorus from the gastro-
intestinal track, which is why it can be used to treat and prevent bone and muscle 
aches as well as chronic fatigue, teeth and dental problems, and osteoporosis [8].
Vitamin D deficiency contributes to many chronic metabolic and endocrine 
diseases [9, 10]. Vitamin D deficiency causes rickets and growth retardation and 
an enhanced risk of adult fractures [11, 12]. Obesity was found to be significantly 
associated with low calcium serum levels especially abdominal obesity [13, 14].
It is also associated with other conditions such as enhanced risk of common 
cancers, infectious conditions, cardiovascular diseases, and other diseases [15, 16].
In a recent study of 2018, it was observed that vitamin D supplements only 
increase bone density in adults with 25-hydroxyvitamin D ≤ 30 nmol/L, and the 
study suggested the implementation or use of supplements [17].
Vitamin D deficiency is connected as well to high myocardial diseases and 
cardiovascular risk; however, the way it works is yet to be investigated in further 
details [18]. A recent study held in 2018 showed a significant association between 
low plasma vitamin D levels and prevalence of hypertension. There was a statisti-
cally significant correlation between vitamin D deficiency and acute coronary 
syndrome [19].
On the other hand, a study found that the supplementation of calcium in addi-
tion to vitamin D did not diminish the danger of chronic heart disease or stroke and 
did not have an effect on the incident of hypertension [20, 21].
Several patients with low vitamin D level remain undetected, with bone chem-
istry values within the reference ranges, unless clinical suspicion is raised. Clinical 
suspicion based on history and awareness of risk factors should remain the gold 
standard for requesting vitamin D measurements [22].
2. Suggested mechanisms of action
The body obtains energy from the ingested food, and part of this energy is 
utilized to maintain the regular body activities while the other part can be stored 
in the adipose tissue that is able to sense the body energy state. When the body has 
excess energy compared to the demand, the adipose tissue starts to store the energy 
as triglyceride in the lipid droplets [23, 24].
The process of lipolysis in which the triglycerides get broken into free acids 
is activated by catecholamines by the cAMP signaling pathway which activates 
the protein kinase A. The hormone-sensitive lipase enzyme (HSL) that promotes 
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the translocation of lipid droplet which will lead to access to triglyceride stores is 
phosphorylated by protein kinase A [24, 25].
The activity of the proteins can be changed after being formed through a mecha-
nism called phosphorylation. A phosphate group which is provided by ATP is added 
to a protein by enzymes referred to as kinases [24].
When the body requires energy, lipolysis occurs. The adipose triglyceride lipase 
(ATGL) enzyme starts hydrolyzing the triglycerides into diacylglyceride. The 
diacylglyceride is then broken down into monoglyceride by the enzyme hormone-
sensitive lipase (HSL), and then the monoglyceride ester bond is cleaved to release 
glycerol [24, 26].
The lipid droplets in the fat-storing cells in adipose tissue are coated by a protein 
called perilipin which acts as a protective coat from the body’s natural lipases like 
hormone-sensitive lipase (HSL) that breaks triglycerides into glycerol and free 
fatty acids for use in metabolism during lipolysis. Phosphorylation of perilipin is 
important for the mobilization of fats in adipose tissue which is important for the 
regulation of lipid storage [27].
Insulin suppresses the enzyme hormone-sensitive lipase (HSL) and adipose 
triglyceride lipase (ATGL) as well because insulin enhances the amount of perilipin 
around the lipid droplets to prevent their access to triglycerides [24].
Vitamin D deficiency is known to occur due to several reasons and through 
several mechanisms, and one of the stated reasons is the low sun exposure due to 
decreased mobility due to obesity [14, 24].
Vitamin D is obtained from different sources taken up by the adipose tissue that 
was suggested to store this vitamin for conditions when the production is reduced. 
The levels of adipose tissue are inversely correlated with this vitamin level [28].
Several hypotheses were proposed to correlate obesity with vitamin D defi-
ciency, and few of which are due to low physical activities and other reasons which 
led to limited sun exposure. There was evidence that vitamin D storage, action, and 
metabolism influences adiposity, and an observational study had shown that there 
is an increased risk of deficiency among obese individuals, but detailed explained 
causes are not clear [29].
The hormonal form of vitamin D is (1,25 dihydroxyvitamin D), and besides its 
known action in the regulation of calcium level, the vitamin D hormone has many 
other activities such as the regulation of adipocytes [24].
Another hypothesis suggested that the level of vitamin D stimulation enzyme 
1-α-hydroxylase in the adipose cells may explain the greater local use of 25(OH)D.
Medical practitioners measure the level of this metabolite to identify a patient’s 
vitamin D status [30, 31]. 25-Hydroxyvitamin D (25(OH)D) is also known as cal-
cifediol, which is a prehormone produced in the liver by hydroxylation of vitamin 
D3 (cholecalciferol) by the enzyme cholecalciferol 25-hydroxylase. Vitamin D3 
gets converted into calcifediol, and this process takes approximately 7 days; then 
calcifediol is converted in the kidneys (by the enzyme 25(OH)D-1α-hydroxylase) 
into calcitriol (1,25-(OH)2D3), a secosteroid hormone that is the active form of 
vitamin D [32].
Variations in serum 25(OH)D and vitamin D reserves can be directly linked 
to the amount of subcutaneous body fat according to this hypothesis [10, 33]. 
However, in a cohort study, it was reported that this theory was not enough to 
address the relationship between vitamin D deficiency and obesity [10, 33].
The active form of vitamin D (1,25-dihydroxyvitamin D) can affect the free 
fatty acid mobilization from the adipose tissue [34]. Animal studies found that high 
doses of vitamin D can lead to elevation in energy expenditure because of uncou-
pling of oxidative phosphorylation in adipose tissues [35].
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It has also been suggested that the weather may contribute as obesity can result 
from an adaptive winter action and vitamin D obtained from the sun is limited 
during winter which can play a role in the tendency to elevate fat mass during cold 
weather [36].
Another theory for the correlation between obesity and vitamin D could be 
that vitamin D is stored in the adipose tissue, and, hence, perhaps the most likely 
explanation is that the bigger the storage capacity for this vitamin in obese people, 
the less the circulating [25(OH)D] concentrations in the blood [37].
Another suggested association was between genetic variants that imitate the 
impact of modifiable environmental exposure and the outcome of interest [38].
A genetic variant linked with lower 25(OH)D concentrations should be linked 
with BMI if lower vitamin intake is causally linked to obesity. The genetic associa-
tions are considered less subjected to confounding factors and socioeconomic and 
lifestyle factors as genotypes are invariant [39].
Different researches on vitamin D had been made based on the fact that several 
human cell types carry vitamin D receptor (VDR) which can contribute to several 
cell functions and regulation [40].
The role of vitamin D receptor (VDR) in the regulation of body energy in vivo 
was explained in previous studies, and it was observed that when these receptors 
were inhibited in some animal studies, several body tissues were affected, which 
made it difficult to interpret the data and make a clear correlation [24, 41]. Some 
studies suggested that 1.25(OH)D inhibits adipogenesis through actions modulated 
by vitamin D-dependent receptors, so the decrease in vitamin D can lead to exces-
sive differentiation of pre-adipocytes to adipocytes [10, 42].
It was observed in some studies that obese participants who were subjected to a 
dose of ultraviolet (UV-B) radiation showed a small response compared to normal-
weight participants [37, 40].
The detailed mechanism explaining how this vitamin might be kept in fat was 
not clearly mentioned, but although the previous mechanism is not detailed, it 
suggested that vitamin D is relatively tightly bound in tissue depots and not appro-
priately released to maintain the serum vitamin amount in the blood [40].
Several different levels of sun exposure are not a likely explanation for the 
link between adiposity and vitamin D deficiency as observed in some studies. 
Alternatively, it was suggested that extra fat holds the vitamin D metabolites and 
that the cholecalciferol is partially sequestered by the fat before being transported 
to the liver for the first hydroxylation [10, 37].
A study concluded that vitamin D serum levels were observed to be (53%) lower 
among obese participants. Some studies suggested that vitamin D deficiency can favor 
higher adiposity by promoting elevated parathyroid hormone levels and more calcium 
inflow into adipocytes which will increase lipogenesis through which acetyl-CoA is 
converted to triglyceride for storage in fat and packaged within lipid droplets [10, 43].
Identifying and understanding the mechanism beyond low vitamin D status in 
obesity has a great importance in deciding on appropriate vitamin D replacement 
doses for obese individuals [40].
However, further studies are required to clarify further the mechanism and the con-
founding factors that may interfere with the data interpretation such as physical activity, 
educational level, diet intake, secondary hyperparathyroidism, and other factors.
3. Vitamin D and obesity findings
Several studies were done to identify the causes of obesity and to investigate 
factors that can affect this condition. Vitamin D is claimed to have an impact not 
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only for maintaining bone health but also for having an association between its 
deficiency and obesity as some studies found that the concentrations of this vitamin 
are low in obese individuals.
Although many controversies still exist suggesting that vitamin D is not con-
nected to any health condition and it is just a marker of general good health, there 
is also a good evidence of the relation between vitamin D level and several health 
conditions [7].
It was observed in many studies including a meta-analysis study that vitamin D 
concentrations were linked to the decrease in the risk of occurrence of metabolic 
syndrome, diabetes, and cardiovascular diseases [10, 26].
Several studies have shown a positive correlation such as some observational 
studies that showed a correlation between vitamin D deficiency and obesity with no 
clear evidence for the detailed causes [9, 10, 44, 45].
Results of a meta-analysis study showed that the deficiency of this vitamin was 
linked with obesity regardless of the age of participants, and it was concluded that 
there was no significant correlation with age and many studies were held to assess 
the increasing risk of developing metabolic syndrome and other disorders like 
hypertension, excess weight, and cancer with vitamin D deficiency [9, 10, 46].
A recent meta-analysis study revealed as well no significant correlation with 
latitude or the development status of the country, so it can be concluded that it was 
found that the correlation between vitamin D deficiency and obesity is not affected 
by latitude, country status, or age, but a positive association between body mass 
index (BMI) and vitamin D deficiency was observed and due to the study designs 
included, it was difficult to clarify the underlying causes [7, 47].
It was concluded from some studies that investigated the relation between 
vitamin D status and body mass index that on the basis of a bidirectional genetic 
approach that reduces confounding, a bigger BMI leads to lower 25(OH)D and 
decreasing BMI is expected to reduce the prevalence of vitamin D deficiency. When 
obese and nonobese participants were given 50,000 IU of vitamin D orally or 
exposed to simulated sunlight, the results showed that the obese participants were 
able to increase the vitamin blood levels by no more than 50% compared with other 
participants, and this was explained that it is because the body fat sequesters the 
fat-soluble vitamin which makes obese individuals at higher risk [48, 49].
Similar results were observed in another study that the observed serum vitamin 
D3 levels in obese individuals were less than that in normal-weight individuals and 
blood vitamin D2 concentrations after the intake of 50,000 IU of vitamin D2 are 
inversely correlated with BMI [37].
Similarly, another study concluded that obesity is linked with a lower bioavail-
ability cutaneous synthesized vitamin D and dietary intake which was explained 
similarly to be due to the sequestration of vitamin D into the adipose tissue [50].
Similarly, other researches have shown that obese individuals tend to have lower 
blood concentrations of vitamin D3 and 25(OH)D3 than those with normal weights 
[51–53]. Several studies including epidemiological studies showed a high prevalence 
increased BMI and low vitamin D status [33, 54–59].
On the other hand, other researches revealed a weak correlation between 
vitamin D concentrations, and BMI a negative correlation between anthropometric 
variables and vitamin D level from different races and age groups [10, 47].
4. Integration of vitamin D in obesity treatment
Obesity is caused by many factors, but despite the genetic contribution, it was 
observed to occur mainly due to lifestyle habits, which indicates that it can be 
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It has also been suggested that the weather may contribute as obesity can result 
from an adaptive winter action and vitamin D obtained from the sun is limited 
during winter which can play a role in the tendency to elevate fat mass during cold 
weather [36].
Another theory for the correlation between obesity and vitamin D could be 
that vitamin D is stored in the adipose tissue, and, hence, perhaps the most likely 
explanation is that the bigger the storage capacity for this vitamin in obese people, 
the less the circulating [25(OH)D] concentrations in the blood [37].
Another suggested association was between genetic variants that imitate the 
impact of modifiable environmental exposure and the outcome of interest [38].
A genetic variant linked with lower 25(OH)D concentrations should be linked 
with BMI if lower vitamin intake is causally linked to obesity. The genetic associa-
tions are considered less subjected to confounding factors and socioeconomic and 
lifestyle factors as genotypes are invariant [39].
Different researches on vitamin D had been made based on the fact that several 
human cell types carry vitamin D receptor (VDR) which can contribute to several 
cell functions and regulation [40].
The role of vitamin D receptor (VDR) in the regulation of body energy in vivo 
was explained in previous studies, and it was observed that when these receptors 
were inhibited in some animal studies, several body tissues were affected, which 
made it difficult to interpret the data and make a clear correlation [24, 41]. Some 
studies suggested that 1.25(OH)D inhibits adipogenesis through actions modulated 
by vitamin D-dependent receptors, so the decrease in vitamin D can lead to exces-
sive differentiation of pre-adipocytes to adipocytes [10, 42].
It was observed in some studies that obese participants who were subjected to a 
dose of ultraviolet (UV-B) radiation showed a small response compared to normal-
weight participants [37, 40].
The detailed mechanism explaining how this vitamin might be kept in fat was 
not clearly mentioned, but although the previous mechanism is not detailed, it 
suggested that vitamin D is relatively tightly bound in tissue depots and not appro-
priately released to maintain the serum vitamin amount in the blood [40].
Several different levels of sun exposure are not a likely explanation for the 
link between adiposity and vitamin D deficiency as observed in some studies. 
Alternatively, it was suggested that extra fat holds the vitamin D metabolites and 
that the cholecalciferol is partially sequestered by the fat before being transported 
to the liver for the first hydroxylation [10, 37].
A study concluded that vitamin D serum levels were observed to be (53%) lower 
among obese participants. Some studies suggested that vitamin D deficiency can favor 
higher adiposity by promoting elevated parathyroid hormone levels and more calcium 
inflow into adipocytes which will increase lipogenesis through which acetyl-CoA is 
converted to triglyceride for storage in fat and packaged within lipid droplets [10, 43].
Identifying and understanding the mechanism beyond low vitamin D status in 
obesity has a great importance in deciding on appropriate vitamin D replacement 
doses for obese individuals [40].
However, further studies are required to clarify further the mechanism and the con-
founding factors that may interfere with the data interpretation such as physical activity, 
educational level, diet intake, secondary hyperparathyroidism, and other factors.
3. Vitamin D and obesity findings
Several studies were done to identify the causes of obesity and to investigate 
factors that can affect this condition. Vitamin D is claimed to have an impact not 
181
Vitamin D and Obesity
DOI: http://dx.doi.org/10.5772/intechopen.90181
only for maintaining bone health but also for having an association between its 
deficiency and obesity as some studies found that the concentrations of this vitamin 
are low in obese individuals.
Although many controversies still exist suggesting that vitamin D is not con-
nected to any health condition and it is just a marker of general good health, there 
is also a good evidence of the relation between vitamin D level and several health 
conditions [7].
It was observed in many studies including a meta-analysis study that vitamin D 
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Several studies have shown a positive correlation such as some observational 
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Results of a meta-analysis study showed that the deficiency of this vitamin was 
linked with obesity regardless of the age of participants, and it was concluded that 
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the increasing risk of developing metabolic syndrome and other disorders like 
hypertension, excess weight, and cancer with vitamin D deficiency [9, 10, 46].
A recent meta-analysis study revealed as well no significant correlation with 
latitude or the development status of the country, so it can be concluded that it was 
found that the correlation between vitamin D deficiency and obesity is not affected 
by latitude, country status, or age, but a positive association between body mass 
index (BMI) and vitamin D deficiency was observed and due to the study designs 
included, it was difficult to clarify the underlying causes [7, 47].
It was concluded from some studies that investigated the relation between 
vitamin D status and body mass index that on the basis of a bidirectional genetic 
approach that reduces confounding, a bigger BMI leads to lower 25(OH)D and 
decreasing BMI is expected to reduce the prevalence of vitamin D deficiency. When 
obese and nonobese participants were given 50,000 IU of vitamin D orally or 
exposed to simulated sunlight, the results showed that the obese participants were 
able to increase the vitamin blood levels by no more than 50% compared with other 
participants, and this was explained that it is because the body fat sequesters the 
fat-soluble vitamin which makes obese individuals at higher risk [48, 49].
Similar results were observed in another study that the observed serum vitamin 
D3 levels in obese individuals were less than that in normal-weight individuals and 
blood vitamin D2 concentrations after the intake of 50,000 IU of vitamin D2 are 
inversely correlated with BMI [37].
Similarly, another study concluded that obesity is linked with a lower bioavail-
ability cutaneous synthesized vitamin D and dietary intake which was explained 
similarly to be due to the sequestration of vitamin D into the adipose tissue [50].
Similarly, other researches have shown that obese individuals tend to have lower 
blood concentrations of vitamin D3 and 25(OH)D3 than those with normal weights 
[51–53]. Several studies including epidemiological studies showed a high prevalence 
increased BMI and low vitamin D status [33, 54–59].
On the other hand, other researches revealed a weak correlation between 
vitamin D concentrations, and BMI a negative correlation between anthropometric 
variables and vitamin D level from different races and age groups [10, 47].
4. Integration of vitamin D in obesity treatment
Obesity is caused by many factors, but despite the genetic contribution, it was 
observed to occur mainly due to lifestyle habits, which indicates that it can be 
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modified through some interventions or health awareness campaigns. The WHO 
has identified physical inactivity and unhealthy diet as one of the risk factors for 
noncommunicable diseases (NCDs), and it urges all efforts to contribute in reduc-
ing them to prevent deaths from NCDs [45].
Identifying and understanding the mechanism beyond low vitamin D status 
in obesity has a great importance in deciding the needed and required vitamin D 
replacement doses for obese individuals [40].
A study discussed the possibility of integrating vitamin D supplementation 
with current strategies, and it was suggested that the induction of adipocyte death 
through apoptosis is a very promising strategy to manage obesity [60–62].
When the adipocytes reach a maximum size, elevation in adipose tissue mass 
includes as well an elevation in adipocyte number. So, weight loss can result from 
not only a decrease in adipocyte size but also adipocyte number and can result 
in the loss of adipose tissue mass. The removal of adipocytes by a process called 
apoptosis decreases body fat and can contribute to the long-lasting control of 
weight loss [60–62]. The effects of the hormonal form of vitamin D, 1,25(OH)2D3, 
on apoptotic cell death are mediated through several signaling pathways on cellular 
calcium Ca2+ [60–62].
High calcium and vitamin D3 intake is linked to the stimulation of the calcium-
dependent apoptotic proteases in adipose tissue. The 1,25(OH)2D3-induced 
cellular calcium signal acts as an apoptotic initiator that directly recruits calcium-
dependent apoptotic effectors that are able of causing apoptosis in adipose tissue. 
It was observed that 1,25(OH)2D3 induces a prolonged elevation in intracellular 
calcium concentration (the apoptotic Ca2+ signal) and is also associated with low 
lipid accumulation in mature adipocytes [63].
Some studies revealed that vitamin D deficiency was closely associated with 
enhanced risk of major adverse cardiovascular diseases (CVD) [64, 65]. Some trials 
revealed a tendency toward a decrease in CVD risk with vitamin D supplementation 
as well, but the correlation was not significant [66]. Observational studies have 
indicated that high 25-hydroxyvitamin D [25(OH)D] levels were associated with a 
favorable serum lipid profile [67]. However, a solid rationale for such association 
is hard to identify unless there is an effect of vitamin D supplementation on serum 
lipids in placebo-controlled randomized trials. Unfortunately, the intervention 
studies gave different results ranging from positive to negative effect [67].
However, some randomized controlled trials (RCTs) studying the effect of 
supplementation on weight loss in overweight or obese people showed inconsistent 
results [68].
5. Conclusions
As long as vitamin D deficiency is prevalent in many parts of the world and the 
supplements are an affordable option, the deficiency of vitamin D may be a com-
mon and easily treatable risk factor for several health issues including obesity, but 
further studies are required to address different confounding factors and vari-
abilities especially prospective studies to study the causal relationship between the 
deficiency of this vitamin and obesity as well as focus on the safety as well as the 
required dose regimen. Strong well-structured studies with limited confounding 
factors that will result in clear data interpretation will contribute to the future plan-
ning of health policies and guidelines used by healthcare professionals.
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Abstract
Vitamin D (VD) is a molecule that can be synthesized directly in the humans’ 
body or enter the organism with food in the form of inactive precursors. To exert 
its biological action, VD undergoes two-stage hydroxylation (at the 25th and 1st 
position) catalyzed by cytochromes P450, the presence of which has already been 
shown in almost all tissues of the human body. The product of hydroxylation is 
hormone-active form of vitamin D–1,25(OH)2D. 1,25(OH)2D binds to specific 
vitamin D receptor (VDR) and regulates the expression of genes involved in bone 
remodeling (classical function) and genes that control immune response, hor-
mone secretion, cell proliferation, and differentiation (nonclassical functions). 
VD deficiency is prevalent around the globe and may be one of the key factors for 
diabetes development. The direct association between vitamin D deficiency and 
type 1 (T1D) and type 2 (T2D) diabetes has been proven. Detection of VDR in 
pancreas and adipose tissue, skeletal muscles, and immune cells allowed implying 
the antidiabetic role of vitamin D by enhancing insulin synthesis and exocytosis, 
increasing the expression of the insulin receptor, and modulating immune cells’ 
functions. This chapter summarizes data about relationship between VD insuffi-
ciency/deficiency and development of T1D and T2D, and their complications.
Keywords: cholecalciferol, vitamin D deficiency, vitamin D receptor, CYP27B1 
(1α-hydroxylase), type 1 diabetes mellitus, type 2 diabetes mellitus, immune response
1. Introduction
Vitamin D (VD) is a unique bioregulatory molecule as it can be synthesized 
in the skin in addition to its dietary sources. VD in its metabolically active form, 
1,25(OH)2D (calcitriol), is a secosteroid hormone produced after hepatic (at carbon 
atom 25) and, not exclusively, kidney (at carbon atom 1) hydroxylations. The well-
studied function of VD is associated with its ability to regulate metabolic processes 
in skeletal tissue by affecting mineralization, maintaining a balance between the 
formation and resorption of bone tissue, and thereby contributing to the preven-
tion of osteoporosis and the occurrence of fractures. In addition to being involved 
in calcium-phosphate metabolism, the variety of physiological effects of VD also 
extends to extra-skeletal tissues, since the vast majority of their species possesses 
vitamin D receptor (VDR). Furthermore, most of these tissues also express the 
cytochrome P450 enzyme, CYP27B1, responsible for converting 25-hydroxyvi-
tamin D (25OHD), the main circulating metabolite of VD, to hormonally active 
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1. Introduction
Vitamin D (VD) is a unique bioregulatory molecule as it can be synthesized 
in the skin in addition to its dietary sources. VD in its metabolically active form, 
1,25(OH)2D (calcitriol), is a secosteroid hormone produced after hepatic (at carbon 
atom 25) and, not exclusively, kidney (at carbon atom 1) hydroxylations. The well-
studied function of VD is associated with its ability to regulate metabolic processes 
in skeletal tissue by affecting mineralization, maintaining a balance between the 
formation and resorption of bone tissue, and thereby contributing to the preven-
tion of osteoporosis and the occurrence of fractures. In addition to being involved 
in calcium-phosphate metabolism, the variety of physiological effects of VD also 
extends to extra-skeletal tissues, since the vast majority of their species possesses 
vitamin D receptor (VDR). Furthermore, most of these tissues also express the 
cytochrome P450 enzyme, CYP27B1, responsible for converting 25-hydroxyvi-
tamin D (25OHD), the main circulating metabolite of VD, to hormonally active 
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form–1,25(OH)2D. 1,25(OH)2D through VDR controls the expression of both those 
genes that participate in mineral homeostasis and bone remodeling, and genes 
(about 500) that participate in various cellular pathways that affect physiological 
and cellular mechanisms, such as immunomodulation, hormone secretion, inhibi-
tion of cell proliferation, and induction of cell differentiation.
Recent epidemiological studies have indicated the association between VD 
deficiency and both type 1 (T1D) and type 2 (T2D) diabetes mellitus. Moreover, 
impaired glucose tolerance and diabetes have been shown to ameliorate in 
VD-deficient individuals after VD supplementation. Vitamin D deficiency, which 
may be a key factor for diabetes development, is prevalent around the globe, with an 
estimated one billion people being vitamin D deficient. The role of VD in diabetes 
became clearer after the discovery of VDR in the pancreas, adipose tissue, skeletal 
muscle cells, and immune cells, which indicates a regulatory effect of VD on glucose 
homeostasis. Vitamin D can directly enhance insulin synthesis and its release 
from pancreatic β-cells as well as increase the expression of the insulin receptor in 
peripheral tissues. It can also indirectly exert an antidiabetic effect by acting on 
cells of the immune system that secrete pro-inflammatory cytokines as mediators 
affecting weight gain, systemic inflammation (contributes to insulin resistance), 
and autoimmune-mediated destruction of pancreatic β-cells. These findings sug-
gested that VD deficiency probably has a causal relationship with diabetes mellitus. 
Some studies have also reported that VD deficiency was not the cause, but the result 
of diabetes. Regardless of whether this deficiency is one of the causes of diabetes or 
its consequence, it is obvious that low levels of VD are closely associated with poor 
regulation of diabetes and its complications; however, the extent of this relationship 
and its clinical relevance are not well established.
The aim of the present chapter is to summarize the latest evidence linking VD 
insufficiency/deficiency with the development of T1D and T2D and their compli-
cations. We also analyzed different intervention studies with VD supplements to 
determine their influence on glucose metabolism and delineated the underlying 
mechanisms. Previous reviews on the role of VD in diabetes mellitus have been 
published in recent years. Here, priority was given to the most recent and convinc-
ing available evidence.
2. Role of vitamin D in immune regulation and inflammatory responses
The first data concerning the potential role for VD and its active metabolite 
1,25(OH)2D in modulating the immune response were obtained as a result of the 
treatment of tuberculosis and leprosy caused by mycobacteria [1]. However, the 
mechanisms underlying these observations have been clarified more recently with 
several important discoveries: (1) the upregulation of CYP27B1 and VDR expres-
sion in activated human inflammatory cells, thus providing their ability both to 
produce 1,25(OH)2D in the site of inflammation and to respond to this hormon-
ally active metabolite; and (2) the participation of 1,25(OH)2D in modulating the 
multiple pathways of the innate and adaptive immune system. The influence of 
1,25(OH)2D on the different cell types of these immune system segments is outlined 
in Figure 1.
Innate immune response involves the activation of Toll-like receptors in mono-
cytes/macrophages as well as in a number of cells such as placenta trophoblasts, 
keratinocytes, and epithelial, intestinal, lung, and corneal cells, representing 
first-barrier defenses. VD affects innate immunity through its stimulatory action 
on the synthesis of defensin β2 and cathelicidin antimicrobial peptide (CAMP) 
upon Toll-like receptors’ activation. These low molecular weight host defense 
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antimicrobial peptides demonstrate a broad spectrum of activity against bacteria, 
viruses, and fungi in the immune cells and are also synthesized in a variety of other 
cell types [1]. CAMP is known to be a direct transcriptional target of VD, which is 
induced by binding of 1,25(OH)2D-VDR/retinoid X receptor (RXR) complex to 
the VD response elements (VDRE) in the gene promoter [2]. VD can also modulate 
innate immune system by increasing chemotaxis, autophagy, and phagolysosomal 
fusion of phagocytic cells. Notably, VD’s action on macrophages was established to 
be modulated by interleukins. In particular, VD increases the antimicrobial activity 
of macrophages formed after the IL-15 stimulus, while phagocytic macrophages do 
Figure 1. 
Vitamin D in immune modulation. 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D; 
IFN-γ, interferon-γ; ILs, interleukins; TGF-β, transforming growth factor β; Th1, type 1 T helper; Th2, type 2 
T helper; Th17, type 17 T helper; TNF-α, tumor necrosis factor-α; Treg, regulatory T cells.
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not respond to vitamin D after the IL-10 stimulus, regardless of their high phago-
cytic activity [1, 3].
Vitamin D shows an inhibitory action on the adaptive immune system, the 
responses of which include the ability of T and B lymphocytes to produce cytokines 
and immunoglobulins, respectively, to specifically combat antigens presented to 
them by macrophages and dendritic cells (DCs). Experimental studies have yielded 
encouraging results on the immunomodulatory effect of calcitriol on T helper 
(Th) cells. In particular, 1,25(OH)2D was shown to suppress the immune responses 
mediated by Th1 cells capable of producing such pro-inflammatory cytokines as 
IL-2, IL-6, interferon γ (IFN-γ), and tumor necrosis factor-α (TNF-α) [4]. The 
lack of IFN-γ prevents further antigen presentation to T lymphocytes and their 
recruitment, while lower IL-2 production impedes T lymphocyte proliferation 
and differentiation. It has been recently demonstrated that calcitriol also increases 
formation and activity of CD4+/CD25+ regulatory T cells (Treg) as seen by elevated 
FoxP3 and IL-10 expression [5]. Increased levels of IL-10 as well as other cytokines 
with anti-inflammatory properties, induced by calcitriol, block Th1 differentiation, 
thus shifting the balance from Th1 to Th2 cell phenotype [6]. Many of the effects of 
VD on Th1 cells, which were previously considered to be implicated in the patho-
genesis of several autoimmune diseases, can now be attributable, at least in part, 
to the inhibitory action of 1,25(OH)2D on the formation and activity of Th17 cells, 
producing IL-17 [5]. The overall impact of VD on Th cells is related to the suppres-
sion of antigen-presenting cells (APCs) of the innate immune system, including 
the most potent dendritic cells. This modulatory effect of 1,25(OH)2D induces a 
“tolerogenic state” associated with the differentiation of Treg cells, autoreactive T 
cell apoptosis, reduced production of inflammatory cytokines, and increased levels 
of the anti-inflammatory cytokines.
Chromatin immunoprecipitation assay revealed VDR binding to a VDRE in the 
proximal area of IL-10 promoter in antibody-producing cells of the immune system, 
or B-cells [7]. 1,25(OH)2D blocked the proliferation of activated B-cells and stimulated 
their apoptosis. It also inhibited maturation of activated B-cells into plasma cells and 
memory cells that is consistent with the inhibitory action of VD on the secretion of 
IgM and IgG [8]. Several observational trials showed an inverse relationship between 
serum IgE and 25OHD levels, while others indicated a positive correlation [9].
Due to the ability of VD to suppress the adaptive immune system, the role of 
VD deficiency and supplementation in inflammatory and autoimmune diseases 
acquires more comprehensive support. In a number of animal models, including 
autoimmune diabetes, inflammatory arthritis, experimental allergic encephalitis, 
and different mouse models of enterocolitis, calcitriol prevented the initiation and 
reduced the disease progression. However, despite strong experimental evidence, 
human studies are less convincing to prove a role for VD in the modulation of adap-
tive immune system of individuals affected by autoimmune diseases. In this respect, 
some trials have confirmed beneficial effect of VD on different inflammatory 
disease progression, inflammatory markers, and T cell subsets, whereas others have 
not shown any promising result [10, 11].
3.  Vitamin D in maintaining pancreatic β-cell function and regulating 
insulin sensitivity
As demonstrated in the previous section, VD is one of the key players in the 
control of immune homeostasis, and here, we will examine in more detail the 
molecular mechanisms, showing how inadequate VD status and inflammation can 
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contribute to pancreatic β-cell dysfunction and the formation of insulin resistance 
(IR). Comprehensive results of experimental and clinical studies have shown that 
vitamin D is a potential regulator of pancreatic β-cell survival, Ca2+ levels, insulin 
secretion, and insulin signaling (Figure 2).
Vitamin D plays an immunomodulatory role in preventing pancreatic β-cell 
dysfunction and death, via VDR, which is expressed along with Cyp27B1 in APCs, 
activated T cells, and islet pancreatic β-cells [12]. These effects have been demon-
strated in many studies of nonobese diabetic mice using 1,25(OH)2D or analogs. 
Conversely, 1,25(OH)2D-deficient mice showed a tendency to develop more aggres-
sive form of T1D, if the deficiency is present at an early age. The bioactive form of 
VD protects against the development of insulitis in the pancreas or reduces their 
Figure 2. 
Mechanisms of glucose homeostasis deregulation related to vitamin D deficiency status. Cyp27B1, 
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severity through a dual mechanism of action on both pancreatic β-cells and immune 
cells [13].
In pancreatic islets, 1,25(OH)2D decreases, as was shown in in vitro and in vivo 
experiments, the expression of pro-inflammatory cytokines (e.g., IL-6), which are 
involved in the pathogenesis of T1D, making β-cells less chemoattractive and less 
prone to inflammation [14]. This leads to a decrease in T-cell recruitment and infil-
tration, an increase in regulatory cells, and a delay in the autoimmune process. In 
addition, 1,25(OH)2D reduces the expression of MHC class I, leading to a decrease 
in the vulnerability of islet β-cells to the action of cytotoxic T lymphocytes [13, 14].
At the level of the immune system, 1,25(OH)2D inhibits the differentiation and 
maturation of DCs and promotes their apoptosis, preventing them from becom-
ing APCs, which is the first step in initiating an immune response. It has also been 
shown that 1,25(OH)2D restores suppressor cells, reduces cytokine formation by 
Th1 cells responsible for β-cell death, and shifts the immune response toward Th2 
cell activation, leading to more benign inflammatory response in pancreatic islets. 
1,25(OH)2D suppresses the formation of IL-6, a direct stimulator of Th17 cells 
involved in the pathogenesis of various autoimmune diseases, including T1D [15]. 
On the other hand, 1,25(OH)2D exerts an antiapoptotic effect on cytokine-induced 
apoptosis of pancreatic β-cells. It induces and maintains high protein levels of the 
A20 (anti-inflammatory protein; inhibits NF-κB signaling), leading to a decrease 
in nitric monoxide (NO) levels. In fact, NO is able to directly induce β-cell dysfunc-
tion and death, or indirectly may affect β-cell function through the induction of 
Fas expression. Fas is a transmembrane cell surface receptor and a member of the 
TNF receptor superfamily. Activation of these receptors occurs under the influ-
ence of inflammatory cytokines secreted by mononuclear cells that infiltrate islet 
cells. Reduction of the NO level leads to inhibition of all the above mechanisms 
and allows realizing cytoprotective effect on islet β-cells. The ability of 1,25(OH)2D 
to counteract the cytokine-induced expression of Fas in human pancreatic islets 
at both mRNA and protein levels, modulating the cell death signal cascades and 
preventing β-cell apoptosis, was established [16].
Several trials have reported that VD deficiency caused impairment of glucose-
mediated secretion of insulin in rat pancreatic β-cells, which was restored after VD 
supplementation. However, the results of clinical studies are not unambiguous as 
VD adequacy was not always associated with the improvement of insulin secretion. 
This stimulatory effect of VD is important for the prevention of T2D and may have 
different explanations. The bioactive form of VD is able to induce insulin secretion 
through direct binding of VDR-RXR complex to VDRE previously identified in the 
promoter of insulin gene in pancreatic β-cells [17]. In accordance with this finding, 
mice with a lack of functional VDR showed impaired insulin secretion after stimula-
tion with glucose [18]. It is noteworthy that VDRE can stimulate not only the tran-
scription of the insulin gene but also many other genes involved in the organization 
of the cytoskeleton, cell growth, differentiation, and survival of pancreatic β-cells.
In addition to genomic effects, rapid nongenomic mechanism of VD action 
appears to be involved in depolarization-stimulated insulin exocytosis by regulating 
intracellular Ca2+. This effect of calcitriol is realized through a membrane VDR-
mediated increase in the synthesis of inositol trisphosphate and phospholipase C 
that promotes the release of Ca2+ from endoplasmic reticulum and diacylglycerol-
mediated PKC activation. In turn, activated PKC phosphorylates the ATP-dependent 
K+ channels and L-type voltage-dependent Ca2+ channels. Ultimately, these effects 
lead to depolarization of the cytoplasmic membrane and the opening of Ca2+ L-type 
and T-type channels that increase intracellular Ca2+ level and, accordingly, insulin 
secretion [19]. Activation of PKA signaling pathways by calcitriol, apparently, is also 
involved in the regulation of L-type voltage-dependent Ca2+ channels.
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It has been suggested that increased intracellular Ca2+ induced by VD may 
enhance the expression of cAMP-responsive element-binding protein (CREB), 
responsible for maintaining efficient transcription of insulin gene and insulin 
exocytosis, as well as for the glucose sensing and pancreatic β-cell survival [20]. 
Increased expression of proteins involved in providing low resting Ca2+ level, such 
as calcium-binding proteins (parvalbumin, calbindin-D28k, and calbindin-D9k), 
plasma membrane Ca2+-ATPase, and Na+/Ca2+-exchanger, can be another mecha-
nism by which vitamin D affects insulin secretion [21]. Furthermore, preclinical 
studies have shown that VD improves β-cell function by reducing the excess activity 
of the renin-angiotensin-aldosterone system [22].
Optimal intracellular levels of Ca2+ are essential not only for the proper func-
tion of pancreatic β-cells but also for insulin-responsive tissues, including liver, 
adipose tissue, and skeletal muscles. Impaired regulation of extracellular and 
intracellular Ca2+ concentrations due to abnormal transduction of insulin signaling 
in target tissues may evoke dephosphorylation and decreased activity of glucose 
transporter-4 (GLUT-4), leading to a phenomenon known as peripheral insulin 
resistance. The results of several studies confirmed that VD deficiency is involved 
in the onset of IR. Moreover, an adequate VD level was shown to improve insulin 
resistance associated with T2D [23]. In addition to the effect of calcitriol on insulin 
sensitivity related to regulation of extracellular Ca2+ concentration and its influx 
into cells through cell membranes, the active metabolite of VD seems to be an 
inducer of insulin receptor expression, which in turn improves insulin sensitivity 
[23]. Another mechanism underlying the beneficial effects of calcitriol on insulin 
sensitivity is related to activation of the peroxisome proliferator-activated recep-
tor delta (PPARδ) [22]. Activated PPARδ, as a transcription factor, reduces fatty 
acids-evoked IR in adipose tissue and skeletal muscles. A secondary elevation of 
parathyroid hormone (PTH) in response to VD deficiency can also increase the 
concentration of intracellular Ca2+ in insulin-sensitive tissues and exacerbate IR 
by decreasing the number of GLUT1 and GLUT4 in the cell membranes of adipose 
tissue, liver, and muscle, thereby reducing glucose uptake [24].
An important endocrine and metabolic organ, playing a crucial role in glucose 
homeostasis and energy balance, is adipose tissue. This tissue is also the major site 
of VD storage in an organism that can sequestrate a fat-soluble prehormone and 
significantly decrease its level in blood circulation. It was found that VD exerts an 
important effect on the expression of genes implicated in promoting adipogenesis 
and adipose tissue remodeling. VDR is expressed in adipocytes in early stages of 
adipogenesis and mediates inhibitory effect of calcitriol on adipocyte differentia-
tion through Wnt/β-catenin and mitogen-activated protein kinase (MAPK) signal-
ing pathways [25]. Suppressive action of 1,25(OH)2D on transcription factors, such 
as PPARγ and CAAT/enhancer-binding protein α (C/EBPα), alters the expression 
of numerous genes involved in lipolysis, lipogenesis, secretion of adipokines, 
insulin sensitivity (via GLUT4 expression), and transfer of fatty acids across the 
membrane [26].
The association between obesity, IR, and VD deficiency is a subject of intense 
research. A characteristic feature of hypertrophic enlargement of adipose tissue 
is elevated release of pro-inflammatory cytokines (TNF-α, IL-6, IL-8, MCP1, and 
resistin) by adipose-resident macrophages and activated T lymphocytes, whereas 
secretion of adiponectin, an anti-inflammatory and insulin-sensitizing bioregula-
tory molecule, by adipocytes is reduced [27]. Thus, one of the harmful conse-
quences of obesity is impaired secretion of adipokines and systemic inflammation, 
which coexists with IR and favors the development of T2D as a key contributing 
factor. VD is known to protect against IR associated with inflammation by modu-
lating the function of immune cells and secretion of adipokines (adiponectin and 
Vitamin D Deficiency
194
severity through a dual mechanism of action on both pancreatic β-cells and immune 
cells [13].
In pancreatic islets, 1,25(OH)2D decreases, as was shown in in vitro and in vivo 
experiments, the expression of pro-inflammatory cytokines (e.g., IL-6), which are 
involved in the pathogenesis of T1D, making β-cells less chemoattractive and less 
prone to inflammation [14]. This leads to a decrease in T-cell recruitment and infil-
tration, an increase in regulatory cells, and a delay in the autoimmune process. In 
addition, 1,25(OH)2D reduces the expression of MHC class I, leading to a decrease 
in the vulnerability of islet β-cells to the action of cytotoxic T lymphocytes [13, 14].
At the level of the immune system, 1,25(OH)2D inhibits the differentiation and 
maturation of DCs and promotes their apoptosis, preventing them from becom-
ing APCs, which is the first step in initiating an immune response. It has also been 
shown that 1,25(OH)2D restores suppressor cells, reduces cytokine formation by 
Th1 cells responsible for β-cell death, and shifts the immune response toward Th2 
cell activation, leading to more benign inflammatory response in pancreatic islets. 
1,25(OH)2D suppresses the formation of IL-6, a direct stimulator of Th17 cells 
involved in the pathogenesis of various autoimmune diseases, including T1D [15]. 
On the other hand, 1,25(OH)2D exerts an antiapoptotic effect on cytokine-induced 
apoptosis of pancreatic β-cells. It induces and maintains high protein levels of the 
A20 (anti-inflammatory protein; inhibits NF-κB signaling), leading to a decrease 
in nitric monoxide (NO) levels. In fact, NO is able to directly induce β-cell dysfunc-
tion and death, or indirectly may affect β-cell function through the induction of 
Fas expression. Fas is a transmembrane cell surface receptor and a member of the 
TNF receptor superfamily. Activation of these receptors occurs under the influ-
ence of inflammatory cytokines secreted by mononuclear cells that infiltrate islet 
cells. Reduction of the NO level leads to inhibition of all the above mechanisms 
and allows realizing cytoprotective effect on islet β-cells. The ability of 1,25(OH)2D 
to counteract the cytokine-induced expression of Fas in human pancreatic islets 
at both mRNA and protein levels, modulating the cell death signal cascades and 
preventing β-cell apoptosis, was established [16].
Several trials have reported that VD deficiency caused impairment of glucose-
mediated secretion of insulin in rat pancreatic β-cells, which was restored after VD 
supplementation. However, the results of clinical studies are not unambiguous as 
VD adequacy was not always associated with the improvement of insulin secretion. 
This stimulatory effect of VD is important for the prevention of T2D and may have 
different explanations. The bioactive form of VD is able to induce insulin secretion 
through direct binding of VDR-RXR complex to VDRE previously identified in the 
promoter of insulin gene in pancreatic β-cells [17]. In accordance with this finding, 
mice with a lack of functional VDR showed impaired insulin secretion after stimula-
tion with glucose [18]. It is noteworthy that VDRE can stimulate not only the tran-
scription of the insulin gene but also many other genes involved in the organization 
of the cytoskeleton, cell growth, differentiation, and survival of pancreatic β-cells.
In addition to genomic effects, rapid nongenomic mechanism of VD action 
appears to be involved in depolarization-stimulated insulin exocytosis by regulating 
intracellular Ca2+. This effect of calcitriol is realized through a membrane VDR-
mediated increase in the synthesis of inositol trisphosphate and phospholipase C 
that promotes the release of Ca2+ from endoplasmic reticulum and diacylglycerol-
mediated PKC activation. In turn, activated PKC phosphorylates the ATP-dependent 
K+ channels and L-type voltage-dependent Ca2+ channels. Ultimately, these effects 
lead to depolarization of the cytoplasmic membrane and the opening of Ca2+ L-type 
and T-type channels that increase intracellular Ca2+ level and, accordingly, insulin 
secretion [19]. Activation of PKA signaling pathways by calcitriol, apparently, is also 
involved in the regulation of L-type voltage-dependent Ca2+ channels.
195
Vitamin D Deficiency and Diabetes Mellitus
DOI: http://dx.doi.org/10.5772/intechopen.89543
It has been suggested that increased intracellular Ca2+ induced by VD may 
enhance the expression of cAMP-responsive element-binding protein (CREB), 
responsible for maintaining efficient transcription of insulin gene and insulin 
exocytosis, as well as for the glucose sensing and pancreatic β-cell survival [20]. 
Increased expression of proteins involved in providing low resting Ca2+ level, such 
as calcium-binding proteins (parvalbumin, calbindin-D28k, and calbindin-D9k), 
plasma membrane Ca2+-ATPase, and Na+/Ca2+-exchanger, can be another mecha-
nism by which vitamin D affects insulin secretion [21]. Furthermore, preclinical 
studies have shown that VD improves β-cell function by reducing the excess activity 
of the renin-angiotensin-aldosterone system [22].
Optimal intracellular levels of Ca2+ are essential not only for the proper func-
tion of pancreatic β-cells but also for insulin-responsive tissues, including liver, 
adipose tissue, and skeletal muscles. Impaired regulation of extracellular and 
intracellular Ca2+ concentrations due to abnormal transduction of insulin signaling 
in target tissues may evoke dephosphorylation and decreased activity of glucose 
transporter-4 (GLUT-4), leading to a phenomenon known as peripheral insulin 
resistance. The results of several studies confirmed that VD deficiency is involved 
in the onset of IR. Moreover, an adequate VD level was shown to improve insulin 
resistance associated with T2D [23]. In addition to the effect of calcitriol on insulin 
sensitivity related to regulation of extracellular Ca2+ concentration and its influx 
into cells through cell membranes, the active metabolite of VD seems to be an 
inducer of insulin receptor expression, which in turn improves insulin sensitivity 
[23]. Another mechanism underlying the beneficial effects of calcitriol on insulin 
sensitivity is related to activation of the peroxisome proliferator-activated recep-
tor delta (PPARδ) [22]. Activated PPARδ, as a transcription factor, reduces fatty 
acids-evoked IR in adipose tissue and skeletal muscles. A secondary elevation of 
parathyroid hormone (PTH) in response to VD deficiency can also increase the 
concentration of intracellular Ca2+ in insulin-sensitive tissues and exacerbate IR 
by decreasing the number of GLUT1 and GLUT4 in the cell membranes of adipose 
tissue, liver, and muscle, thereby reducing glucose uptake [24].
An important endocrine and metabolic organ, playing a crucial role in glucose 
homeostasis and energy balance, is adipose tissue. This tissue is also the major site 
of VD storage in an organism that can sequestrate a fat-soluble prehormone and 
significantly decrease its level in blood circulation. It was found that VD exerts an 
important effect on the expression of genes implicated in promoting adipogenesis 
and adipose tissue remodeling. VDR is expressed in adipocytes in early stages of 
adipogenesis and mediates inhibitory effect of calcitriol on adipocyte differentia-
tion through Wnt/β-catenin and mitogen-activated protein kinase (MAPK) signal-
ing pathways [25]. Suppressive action of 1,25(OH)2D on transcription factors, such 
as PPARγ and CAAT/enhancer-binding protein α (C/EBPα), alters the expression 
of numerous genes involved in lipolysis, lipogenesis, secretion of adipokines, 
insulin sensitivity (via GLUT4 expression), and transfer of fatty acids across the 
membrane [26].
The association between obesity, IR, and VD deficiency is a subject of intense 
research. A characteristic feature of hypertrophic enlargement of adipose tissue 
is elevated release of pro-inflammatory cytokines (TNF-α, IL-6, IL-8, MCP1, and 
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factor. VD is known to protect against IR associated with inflammation by modu-
lating the function of immune cells and secretion of adipokines (adiponectin and 
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leptin). It has been reported in numerous trials using animal models and in several 
human observational studies that higher VD levels are accompanied by lower 
inflammatory markers including TNF-α, IL-6, and C-reactive protein in healthy 
persons, and in those with inflammation-associated diseases, such as arterioscle-
rosis, inflammatory polyarthritis, and diabetes [28]. As for adipokines, positive 
correlation was shown between VD and adiponectin, and inverse correlation 
between VD and leptin [29]. Finally, VD by targeting mitochondrial respiratory 
functions through multiple mechanisms also attenuates oxidative stress and exerts 
key beneficial effects on controlling inflammation, impaired energy metabolism, 
and cell apoptosis. However, this topic is beyond the scope of this chapter. Vitamin 
D functions associated with the regulation of β-cell function and insulin sensitivity 
are summarized in Figure 2.
4. Vitamin D deficiency and type 1 diabetes mellitus
Type 1 diabetes mellitus is an autoimmune disorder caused by the progressive 
T-cell-mediated destruction of insulin-producing β-cells in the pancreas. T1D is 
commonly diagnosed in childhood and young adults, who are ultimately at risk 
of the long-term complications of diabetes [30]. This autoimmune condition is 
characterized by a state of hypoinsulinaemia and insulin-like growth factor (IGF-1) 
deficiency. T1D is triggered by a combination of both genetic and environmental 
factors including viral infections, dietary antigens, disruption in the gut microbiota, 
and VD deficiency [31].
Data regarding the presence of VDR in immune cells (B- and T-lymphocytes) 
and their ability to produce hormonally active form of VD locally, which acts on 
immune cells in auto-/paracrine manner, give the evidence that VD is an important 
regulator of multiple pathways of innate and adaptive immunity. In addition to 
immune-modulating properties, VD seems to play a role in the regulation of insulin 
secretion from β-cells. Respectively, VD insufficiency/deficiency is frequently 
reported to be associated with immunological disorders such as T1D, multiple 
sclerosis, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, 
inflammatory bowel disease, hepatitis, asthma, and respiratory infections [32]. 
The link between the state of VD deficiency and T1D is a latter-day considerable 
area of interest; however, the presence of the clear association and especially causal 
relationship between low VD status and the occurrence of T1D still remains disput-
able and controversial.
Most of the international epidemiological and clinical studies have provided 
evidence to this causal relationship primarily in children. It has been reported 
previously that low 25OHD concentrations are fairly prevalent in the UK children 
with T1D [33]. Moreover, it has been shown that genetic factors affecting the VD 
metabolic pathway during the pregnancy can be related to the development of 
T1D. Another study emphasized that the fetal environment, including maternal 
VD metabolism, may be one of those factors that can lead to the early onset of T1D 
in Finnish children [34]. The study of VD level and its associated factors in Korean 
youth with T1D showed that serum 25OHD and 1,25(OH)2D levels were lower in 
T1D cases than in healthy controls [35]. Nevertheless, in other cross-sectional study 
of subjects in Seoul National University Children’s Hospital, there was no signifi-
cant difference in the frequency of VD deficiency or serum 25OHD level between 
healthy and pediatric T1D patients [36].
There is much less data available regarding adult patients with T1D. It has 
been observed that the serum concentration of VD is negatively associated with 
IR in adult diabetic patients recruited in Poland [37]. In Algerian population, the 
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link between VD deficiency and an increased risk of T1D was also found [38]. In 
contrast, there was no difference reported between Turkish adult T1D patients and 
healthy controls according to their vitamin D levels [39]. The exact reason for these 
conflicting results is unclear; thus, we can assume that the interplay of genetic, 
nutritional, and environmental factors seems to affect the circulating level of VD 
status marker (25OHD) in adult T1D patients.
The cellular and molecular mechanisms underlying the VD deficiency in 
patients with TID deserve further thorough and comprehensive study. More 
recently, in addition to measuring the level of 25OHD, increased attention has been 
paid to new experimental directions, in particular, the investigation of the state 
of the VD auto-/paracrine system, including the following key components: VDR, 
CYP27B1, and 24-hydroxylase (CYP24A1).
Different genetic factors including mutations are known to modify serum 
25OHD concentration. Several single nucleotide polymorphisms (SNPs) in the 
metabolic pathway of VD contribute as the genetic component to VD status. There 
is a set of studies dedicated to the associations between T1D and mutations related 
to VD metabolism genes such as VD-binding protein (VDBP), VDR [34, 40, 41], 
and CYP24A1. Moreover, polymorphisms in CYP2R1 gene encoding the enzyme 
involved in 25-hydroxylation of VD were also shown to be associated with a higher 
risk of T1D. Thus, polymorphisms in VD metabolism genes may contribute to 
susceptibility to T1D in Korean children [35]. Another study linked T-cell prolifera-
tion with VDBP level and reported higher levels and frequencies of serum anti-DBP 
antibodies in patients with T1D vs. healthy controls. This study postulated that 
VDBP, which was shown to be expressed in cells of pancreatic islets, can act as an 
autoantigen in T1D [42]. Furthermore, it has been reported that lower maternal 
third trimester VDBP levels and cord blood VDBP levels have been associated 
with a higher risk of T1D in offspring [43, 44]. At the same time, there is a lack of 
studies related to the investigation of the role of CYP27B1 in immune cells, such as 
monocytes, macrophages, and T-cells, which could shed light on the involvement 
of impaired VD metabolism in the pathogenesis and/or prevention of T1D. Thus, 
as VD biosynthesis and its signaling are regulated by genes encoding the VDR and 
enzymes of VD activation/catabolism, their polymorphisms may significantly alter 
the bioavailability and specific effects of VD metabolites.
Taken together, these data point to a role of VD deficiency in increasing the risk 
of T1D progression that provides the basis for further prospective studies on devel-
oping guidelines for vitamin D intake to prevent VD deficiency in patients with T1D 
and to treat this disease.
Since VD is considered a potential diabetes risk modifier, more studies appear 
to evaluate the role of vitamin D as an adjunctive therapy in improving glycemic 
control. The recent international study revealed that the majority of participants 
in Finland, Germany, and Sweden (97–99%) and 50% in the US receiving VD 
supplements during infancy demonstrated a reduced risk of T1D [45]. In another 
clinical trial, patients with T1D and low 25OHD concentrations were treated with 
different doses of cholecalciferol once daily for 3 months depending on their VD 
status, and as a result, it has been established that cholecalciferol can potentially 
improve the glycemic control [33]. Recent studies have shown favorable changes 
in HbA1c, C-peptide, insulin dose, and insulin sensitivity in VD-supplemented 
patients; therefore, cholecalciferol is increasingly attracting attention as a potential 
additional therapy in patients with T1D. In a double-blinded randomized controlled 
trial, which included Indian children with T1D, oral VD supplementation was used 
for six months in addition to insulin therapy. It has been proven that VD treatment 
may serve as an adjuvant to insulin therapy for children with T1D due to its effect 
on augmenting residual β-cell function and improving insulin secretion [46]. Some 
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for six months in addition to insulin therapy. It has been proven that VD treatment 
may serve as an adjuvant to insulin therapy for children with T1D due to its effect 
on augmenting residual β-cell function and improving insulin secretion [46]. Some 
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representative studies on mechanisms of VD action in T1D described a beneficial 
effect of its supplementation on regulatory T-cells, with an increase in their per-
centage [47], suppressive capacity [48], and reduced progression to undetectable 
C-peptide.
However, some other studies have not demonstrated a beneficial effect of VD 
supplementation in preventing/improving the course of T1D or its complications. 
The prospective Environmental Determinants of Diabetes in the Young (TEDDY) 
Study demonstrated no benefit of maternal VD supplementation during pregnancy 
on the risk of islet autoimmunity in the offspring [49]. According to the review 
[32], there was no beneficial impact of VD supplementation on β-cell function, 
HbA1c levels, or insulin requirement.
The reason for these conflicting results is unclear. Nevertheless, we can presume 
the presence of a plethora of factors that may affect the results. Differences in 
study design, seasonal differences, stages in the progression of diabetes, ethnic 
origin of the populations, age and gender of patients may contribute. Therefore, 
further randomized controlled trials with a larger sample of patients are needed to 
gain more insight into the relationship between VD and T1D and to investigate VD 
replacement in preventing T1D.
The life expectancy of T1D patients has increased substantially during the last 
decades due to the availability of exogenous insulin, though it is still shorter than 
that of healthy people and associated with the development of chronic complica-
tions. Traditionally, the diabetic complications have been classified as either 
microvascular (retinopathy, nephropathy, and neuropathy) or macrovascular 
(cardiovascular disease, cerebrovascular accidents, and peripheral vascular dis-
ease). Although intensive glycemic control significantly reduced the incidence of 
microvascular and macrovascular manifestations, the majority of patients with T1D 
are still developing these outcomes. Most clinical trials related to the influence of 
VD supplementation on diabetes-associated complications have been performed in 
patients with T2D. To date, a limited number of experimental and clinical trials are 
available regarding the effect of VD on complications associated with T1D.
Diabetic ketoacidosis, which is the most dangerous and life-threatening com-
plication of mainly T1D that results from insulin deficiency or excess of adrenaline 
or cortisol, is found to be associated with low VD level. VD is known to protect 
against viral and bacterial infections, which were shown to be triggering factors for 
diabetic ketoacidosis [50]; as a result, VD supplementation can become an integral 
part of diabetic ketoacidosis prevention and management. Nephropathy is another 
well-characterized complication of T1D, resulting in proteinuria and urinary loss 
of micronutrients. It has been previously found that the dietary supplements may 
modulate VD balance, attenuate polyuria, proteinuria, and renal hypertrophy 
in experimental T1D [51]. In addition, it has been reported that VD may reduce 
diabetic nephropathy not only by improving blood glucose and insulin levels but 
also by modulating hexosamine pathways in kidneys [52]. More recently, it has 
been shown that 1,25(OH)2D may improve diabetic cardiomyopathy in T1D rats by 
modulating autophagy through the β-catenin/TCF4/GSK-3β and mTOR pathway 
[53]. Several studies have also demonstrated an association between low VD levels 
and diabetic peripheral neuropathy. Since VD is a well-known neurosteroid, a 
possible beneficial effect of its supplementation on preventing diabetic peripheral 
neuropathy can be assumed; nevertheless, further studies are needed.
Type 1 diabetes mellitus is a secondary cause of osteoporosis, characterized 
by reduced bone mass and disturbed bone microarchitecture. Patients with T1D 
have increased fracture risk that may be determined by the low 25OHD levels. 
Diabetic retinopathy, advanced cortical cataracts, and diabetic neuropathy are 
the risk factors for increased number of falls and, as a result, fracture because of 
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visual impairment and alterations in balance [54]. Replacement of VD along with 
calcium has been found to improve the bone mineral density in children with T1D; 
therefore, an adequate calcium level and VD supplementation are important for the 
prevention of T1D-associated osteoporosis [55].
According to available experimental and clinical data, new recommendations 
for T1M patients have been developed including obligatory assessment of serum 
25OHD level and prescription of personalized doses of vitamin D in order to avoid 
the development of T1M complications or at least detain its progression.
5. Vitamin D deficiency and type 2 diabetes mellitus
Type 2 diabetes mellitus, formerly known as adult-onset diabetes, is a complex 
chronic metabolic disorder that has become one of the most serious public health-
care problems worldwide. According to the data of the World Health Organization, 
2.2 million people died from diabetes in 2012 and 1.6 million people died in 2015, 
and diabetes is expected to be the 7th cause of death by 2030. The incidence of 
T2D is estimated to account for 90% of all diabetes cases. T2D is characterized by 
dysfunction of pancreatic β-cell, systemic inflammation, and hyperglycemia due to 
insufficient insulin production, insulin action, or both [56]. A high diabetes-associ-
ated concentration of glucose in the blood over an extended period can cause heart 
disease, diabetic retinopathy, renal failure, poor blood circulation in the limbs, and, 
as a consequence, amputations.
T2D mainly develops as a result of the summation of genetic, environmental, 
and other risk factors [57]. To date, an increased risk of developing T2D in monozy-
gotic twins with a statistical reliability of about 96% has been convincingly shown. 
Moreover, the risk of developing this disease in children from diabetic parents is 
40% higher than in the offspring of healthy parents. T2D is now regarded as an 
endocrine-metabolic disease of a polygenic nature. About 75 loci have already been 
identified, damage to the sequences of which can be directly associated with the risk 
of developing T2D. These genes encode proteins with very different functions, such 
as ion channels (KCNJ11; potassium inwardly rectifying channel, subfamily J, and 
member 11), various transcription factors (TCF7L2, transcription factor 7-like 2), 
receptors (IRS1, insulin receptor substrate 1; MTNR1B, melatonin-receptor gene; 
and PPARγ2), growth factors (IGF2BP2, insulin-like growth factor two binding 
protein 2), as well as CDKN2A (cyclin-dependent kinase inhibitor 2A), HHEX 
(hematopoietically expressed homeobox protein), and FTO (fat mass and obesity-
associated protein) [58–60].
Despite the growing body of data on the relationship between the risk of devel-
oping T2D and certain genes, improper food behavior and the sedentary lifestyle 
are still considered the key reasons for the development of the disease. In a number 
of experimental and clinical studies, VD has been shown to exhibit various non-
skeletal properties that significantly regulate glucose metabolism. Furthermore, 
human studies have clearly revealed an inverse association between vitamin D 
status and the prevalence of T2D. It was found in numerous observational studies 
that the concentration of 25OHD negatively correlates with deteriorated glucose 
homeostasis, IR, and impaired β-cell function [61]. Low blood serum 25OHD levels 
were associated with the negative changes in a number of metabolic parameters, 
indicative of IR, including BMI (body mass index), HOMA-IR (homeostatic model 
assessment for IR), TG (triglycerides), HDL (high-density lipoproteins), LDL 
(low-density lipoproteins), TC (total cholesterol), and HbA1c [62]. More recently, 
large-scale epidemiological studies have been carried out as for the dependence of 
the risk of T2D developing on the availability of VD. VD deficiency has been shown 
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oping T2D and certain genes, improper food behavior and the sedentary lifestyle 
are still considered the key reasons for the development of the disease. In a number 
of experimental and clinical studies, VD has been shown to exhibit various non-
skeletal properties that significantly regulate glucose metabolism. Furthermore, 
human studies have clearly revealed an inverse association between vitamin D 
status and the prevalence of T2D. It was found in numerous observational studies 
that the concentration of 25OHD negatively correlates with deteriorated glucose 
homeostasis, IR, and impaired β-cell function [61]. Low blood serum 25OHD levels 
were associated with the negative changes in a number of metabolic parameters, 
indicative of IR, including BMI (body mass index), HOMA-IR (homeostatic model 
assessment for IR), TG (triglycerides), HDL (high-density lipoproteins), LDL 
(low-density lipoproteins), TC (total cholesterol), and HbA1c [62]. More recently, 
large-scale epidemiological studies have been carried out as for the dependence of 
the risk of T2D developing on the availability of VD. VD deficiency has been shown 
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to be widespread in both men and women in different age groups among Saudi 
citizens, and this was accompanied by hyperglycemia in 90 percent of patients [63]. 
T2D patients studied in India also showed VD deficiency of varying severity in 77% 
of subjects [64]. The association between a low serum of 25OHD concentration and 
an increased risk of developing T2D can be partially explained by an increase in fat 
mass. A study of serum 25OHD in patients with T2D from the urban area of Cairo 
with limited exposure to the sun and overdressing habit revealed a decrease of its 
level by 13% compared with the control. Depleted level of the prohormone has been 
found to be related to a higher risk of insulin resistance [65].
However, as it turned out, not all studies confirmed a decrease in VD contents in 
patients with T2D. Using the method of high-performance liquid chromatography 
in tandem with mass spectrometry, significantly higher levels of VD were demon-
strated in patients with T1D and T2D in comparison with the control group [66].
Overall, most of the data presented here suggest a pivotal role of VD in the 
regulation of insulin secretion and confirm that the decreased insulin sensitivity at 
target organs may be attributable to VD inadequacy [67]. The relationship between 
VD deficiency and IR could be realized at the level of modulation of immune 
processes and inflammation, since VD deficiency is associated with an increase in 
inflammatory markers. In addition, genetic polymorphisms of VD-related genes 
such as VDR, CYP2R1, and CYP27B1 may predispose to impaired glycemic control 
and T2D [68].
As we mentioned earlier, VD mediates its biological activity through VDR, 
which belongs to the family of steroid hormone receptors. Many VDR gene SNPs 
have been identified to be related to T2D, in particular to insulin synthesis and 
release [69]. The most reported VDR SNPs associated with diabetes are Fok1, Bsm1, 
Taq1, and Apa1. Recently, the study of these polymorphisms is becoming increas-
ingly popular because their detection can be a reliable diagnostic characteristic in 
determining the risk of T2D development. The association between VDR poly-
morphisms and abdominal obesity has shown that patients with Bsm1 and Apa1 
polymorphisms have low vitamin D status, which is accompanied by an increase 
in the concentrations of TC, LDL, and TG [69]. The results of another study show 
that body weight and BMI were significantly associated with polymorphisms Bsm1 
and Taq1, while Bsm1 strongly correlated with elevated HbA1c level. The frequency 
of the heterozygous genotype of the Bsm1 polymorphism was significantly greater 
in type 2 diabetics than in controls [70]. A study of this parameter in a group of 
patients with T2D from India revealed that it was Taq1 and Bsm1 polymorphisms 
that were closely associated with diabetes [71]. Thus, it can be concluded that the 
detection of different types of VDR gene polymorphisms is a reliable prognostic 
parameter for the risk of T2D. In addition, the type of polymorphism appears to be 
race-specific.
Despite a large amount of data on the association of CYP27B1 polymorphisms 
with the risk of T1D, the effect of different SNP variants of this gene in the develop-
ment of T2D is unclear to this day [72, 73].
While the closest relationship between VDR polymorphism in T2D has long 
been established, the discovery of the effect of CYP2R1 gene polymorphisms on 
the risk of developing this disease was a real step forward. Among a large group of 
tested SNPs of CYP2R1 gene, only two of them showed reliable association with the 
incidence of T2D. However, none of the tested polymorphisms were independently 
associated with serum 25OHD levels [74].
The effect of VD supplementation on glucose metabolism in patients with 
T2D remains controversial. It was shown that replenishing VD deficiency with 
high doses of cholecalciferol helped to reduce non-HDL cholesterol and caused 
significant normalizing changes in metabolic parameters of glucose homeostasis 
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(fasting glucose and serum insulin) and a decrease in oxidative stress and DNA 
damage [75, 76]. VD supplementation also caused an increase in insulin secretion 
and insulin sensitivity in T2D patients [77]. Nevertheless, some research groups 
did not find any effect, or only a slight decrease in fasting plasma glucose and an 
improvement in IR were seen. Basically, patients with VD deficiency and impaired 
glucose tolerance at baseline demonstrated these latter effects [68].
In addition to the ability of VD to reduce the risk of T2D, an adequate level of 
this vitamin in the body is also important for correcting diabetes-related pathologies 
such as retinopathy, nephropathy, neuropathy, and secondary osteoporosis caused 
by diabetes. Moreover, patients with already diagnosed T2D also have a risk of devel-
oping VD deficiency, in particular, due to the progression of nephropathy caused by 
diabetes [78]. Serum 25OHD was shown to be significantly reduced in patients with 
diabetic nephropathy [79]. Thus, the relationship between VD deficiency and the 
incidence of type 2 diabetes and related complications is likely to be bilateral.
Continuing the discussion on diabetic complications, we may note that vitamin 
D deficiency correlates with the risk of diabetic retinopathy. However, the reliable 
establishment of this relationship is problematic due to a number of limiting factors: 
cross-sectional structure, small sample size, ethnic variation, and heterogeneity in 
criteria that do not contribute to the identification of VD deficiency. Nevertheless, 
at least two state-of-the-art meta-analyses of observational studies indicate that D 
hypovitaminosis among T2D patients is associated with a significantly increased 
risk of diabetic retinopathy [80, 81].
A meta-analysis of data on the relationship between VD deficiency and the 
development of diabetes-induced neuropathy also revealed a strong correlation. 
Recovery of insulin secretion, increasing insulin sensitivity of target tissues, and 
reducing the inflammatory response have been proposed as potential mechanisms 
for improving the clinical manifestations of diabetic neuropathy following VD 
supplementation [82]. Furthermore, several independent studies have established 
serum 25OHD levels to predict cardiovascular complications or to assess the 
possible protective role of VD intake in patients with T2D. Diabetic patients with 
25OHD < 36 nmol/L manifested approximately 21% higher risk for developing 
macrovascular disease [83].
There is no doubt that achieving normal levels of 25OHD is an important factor 
in preventing the onset of T2D or for eliminating the complications associated with 
the disease. However, at the moment, the question of the VD dosage and duration of 
the complex therapy of patients with T2D remains unresolved. Based on interven-
tional trials, it can be postulated that the VD dose needs to be more than 2000 IU 
per day to raise blood 25OHD levels above 80 nmol/L, which is considered to be 
sufficient to reduce the risk of T2D [84]. However, the results of a double-blinded, 
placebo-controlled, randomized trial with 4000 IU of VD did not improve HbA1c 
or OGTT (oral glucose tolerance test)-based indices of β-cell function or insulin 
secretion in patients with stable T2D. The ambiguity of the results may be due to 
the following factors: the baseline 25OHD concentration was too high (<27 ng/mL), 
whereas a significant reduction in HbA1c and fasting glucose after VD supplemen-
tation was reported only among patients with baseline 25OHD < 20 ng/mL; VD may 
have no detectable effect in persons with well-controlled diabetes (good glycemic 
control, HbA1c-6.6%); and/or metformin treatment, which may have masked a 
small effect of VD supplementation [85]. These data indicate the need for indi-
vidual VD therapy for each patient with a risk of development or with an already 
established diagnosis of T2D. When choosing this type of therapy, it is necessary to 
take into account the initial level of 25OHD in the patient’s blood, changes in this 
level during therapy, as well as the presence of other drugs in the treatment regimen 
that can affect the manifestation of the beneficial effects of VD.
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A two-way relationship between VD status and T1D and T2D can be argued. At 
the moment, it seems undeniable that there is a causal association between the risk 
of diabetes mellitus development and numerous polymorphisms in genes respon-
sible for metabolism (CYP2R1 and CYP27B1) and signaling (VDR) of VD. Despite 
the fact that diabetes mellitus is a multifactorial disease, and it is unlikely that 
VD deficiency is the main cause of this pathology, there is no doubt that it may 
be used in the complex treatment of diabetes mellitus and its complications. The 
importance of more comprehensive and randomized clinical trials to determine the 
therapeutic role of vitamin D in preventing the progression of glucose intolerance in 
groups at high risk of developing T2D should be noted.
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Vitamin D and Cardiovascular 
Disease: The Final Chapter?
Jeremy I. Purow and Seth I. Sokol
Abstract
Vitamin D deficiency is globally prevalent and has been associated with the 
pathogenesis and complications of cardiovascular disease (CVD) and its risk fac-
tors. Defining these relationships has been challenging, and the clinical applications 
of vitamin D screening and supplementation for CVD risk prevention and modi-
fication have only recently become clearer. Most of the available evidence includes 
large observational studies and smaller randomized trials that scarcely evaluate CV 
outcomes as primary endpoints. Additionally, these studies include methodological 
inconsistencies, making it difficult to ascertain the benefits of vitamin D supple-
mentation. However, more recently, randomized trials have been conducted which 
utilize CVD outcomes as primary endpoints, while assessing the effects of high dose 
vitamin D supplementation on CV health. Despite observational evidence as well 
as a conventional consensus that vitamin D supplementation improves CV health, 
these studies suggest that vitamin D supplementation likely has no benefit in this 
regard, at least in the follow-up period and populations evaluated.
Keywords: vitamin D deficiency, cardiovascular disease, endothelial function, 
hypertension, heart failure, renal disease, prevention, vitamin D
1. Introduction
Cardiovascular disease (CVD) is the most common cause of death in the devel-
oped world and is forecasted to be the leading cause of death and morbidity in 
developing countries by 2020 [1]. According to the American Heart Association, 
9.0% (24.3 million in 2016) of adults (≥20 years of age) in the United States live 
with CVD (including coronary heart disease, heart failure, and stroke). This num-
ber increases to 48.0% when including hypertension [2]. CVD is a multifactorial 
disease that includes a complex interplay between genetics, environmental factors, 
and risk factors.
Despite effective measures for control and modification of traditional risk 
factors, a significant amount of risk remains. Therefore, the identification of 
easily modifiable novel risk factors has been heavily investigated over the past few 
decades.
In addition to the well-known relationship between vitamin D and bone health, 
there has been considerable interest of the possible linkage between vitamin D and 
CV health due to the expression of the vitamin D receptor (VDR) on cardiomyo-
cytes and vascular cells [3, 4]. Vitamin D plays an extensive role in the regulation of 
numerous pathways implicated in CVD pathogenesis. Interestingly, various studies 
note that CVD events are higher in the winter months, a time when vitamin D 
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levels are known to be at their lowest due to lack of sunlight [5, 6]. A similar trend 
is noted in certain populations with poor cutaneous vitamin D production, such as 
African Americans, who are more prone to developing hypertension and CV disease 
[6]. Lastly, low vitamin D levels (<20 ng/mL) have been independently linked to 
increased morbidity and mortality [7, 8]. Although convincing, this evidence does 
not demonstrate causality, but supports a hypothesis for further study.
Prior to 2017, randomized controlled trials had mostly relied on surrogate 
or secondary endpoints for CV risk reduction. Study methodologies have been 
heterogeneous, and results have often been conflicting. In the absence of results 
from these trials, regular supplementation has not been recommended for CV risk 
modulation. Despite the lack of recommendations, use of vitamin D supplements 
for this purpose had risen dramatically.
However, more recent trials have been conducted that have assessed CV risk 
reduction as a primary endpoint. These trials have given researchers and clinicians 
a better understanding of the effects of vitamin D supplementation and whether it 
should be indicated to reduce the risk of developing CVD [9, 10].
The following chapter will discuss the prevalence of vitamin D deficiency, 
describe vitamin D synthesis and metabolism, and provide an overview on the 
biologic plausibility and current state of the evidence linking vitamin D to CV 
health and disease.
2. Vitamin D deficiency
Vitamin D deficiency is found in 30–50% of the general population, and preva-
lence estimates suggest that more than 1 billion people worldwide are vitamin D 
insufficient or deficient [4, 11].
Vitamin D deficiency is indicated by serum levels of 25(OH)D < 20 ng/mL [4]. 
Serum levels >30 ng/mL are likely optimal for bone health, but some studies have 
shown benefits with lesser values. Parathyroid hormone (PTH) suppression appears 
to plateau at levels between 30 and 40 ng/mL [12]. There has been no agreement 
on optimum 25(OH)D levels required for purported health benefits beyond skel-
etal health. One study suggested that 25(OH)D levels below 11–14 ng/mL signify 
increased CVD risk [13]. Levels in the range of 21–29 ng/mL are considered by some 
as insufficient, a definition that would label the majority of the U.S. population 
vitamin D insufficient [4].
The Endocrine Society does not recommend screening for vitamin D deficiency 
in individuals who are not at risk for it [12]. Many of the risk factors for vitamin 
D deficiency have been identified. Some of these include inadequate cutaneous 
synthesis stemming from insufficient sun exposure or dark skin pigmentation and 
inadequate dietary intake. Other noted risk factors include aging, obesity, renal 
disease, liver disease, disorders that affect fat absorption (e.g. celiac disease, inflam-
matory bowel diseases, types of bariatric surgery), increased catabolism due to 
medications (e.g. steroids, anticonvulsants etc.), and other hereditable (e.g. rickets) 
and acquired disorders (e.g. hyperthyroidism) [4].
3. Vitamin D metabolism
Vitamin D’s active form, 1a,25-dihydroxyvitamin D (1,25[OH]2D3) plays a criti-
cal role in influencing a myriad of metabolic pathways [14].
Natural sunlight exposure contributes to more than 90% of vitamin D 
(D3-cholecalciferol) production in humans [15]. UV-B irradiation absorbed by skin 
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keratinocytes triggers photolysis of 7-dehydrocholesterol (pro-vitamin D3) in the 
plasma membrane, which is then swiftly modified into vitamin D3 by heat [4, 16].
Dietary supply of vitamin D (D2-ergocalciferol) contributes to the remainder 
of the total amount of vitamin D in the body. Foods containing vitamin D include 
oily fish (salmon, sardines, and mackerel), cod liver oil, egg yolk, mushrooms, and 
fortified milk, orange juice, cereals, and cheese [11, 12].
D3 and D2 from the skin and diet, respectively, each undergo two sequential 
hydroxylation’s: 25-hydroxylation in the liver and then 1,25-dihydroxylation in the kid-
ney. In order to assess vitamin D status from oral intake and endogenous production, 
the primary metabolite of vitamin D, 25(OH)D, should be measured [11, 15, 17]. The 
hydroxylation of 25(OH)D to its biologically active form, 1,25(OH)2D3, is controlled 
by PTH [11, 18].
Most of the known biological effects of 1,25(OH)2D3 are mediated through the 
vitamin D3 receptor (VDR), part of the superfamily of nuclear hormone receptors, 
which mediates transcriptional gene regulation [19].
Over 200 genes are regulated by 1,25(OH)2D3. These include genes directly or 
indirectly responsible for renin and insulin production, anti-inflammatory cytokine 
release, proinflammatory cytokine suppression, and regulation of vascular smooth 
muscle cell (VSMC) and cardiomyocyte proliferation [11, 20].
1,25(OH)2D3 is also involved in non-genomic mediated intracellular signal-
ing, demonstrating immunomodulatory, antiproliferative, and pro-differentiative 
activities in experimental settings [19].
4. Biologic plausibility
Characterizing vitamin D deficiency as a primary risk factor for CVD is chal-
lenging due to the multitude of complex interacting pathways involving vitamin 
D. The vitamin D receptor is nearly ubiquitous in human cells including vascular 
smooth muscle cells (VSMC), endothelial cells, cardiac myocytes, juxtaglomeru-
lar, and most immune cells, all implicated in the pathogenesis and progression of 
CVD [11, 18].
Immune cells such as activated CD4+ and CD8+ T cells, B cells, neutrophils, 
macrophages, and dendritic cells are capable of converting 25OHD3 into 1,25OHD3, 
its active form. Moreover, 1,25 hydroxylase, the rate-limiting enzyme in this 
pathway, is present in activated macrophages [21–23]. Lastly, VSMC and endothelial 
cells also express 1,25 hydroxylase, suggesting that these cells have an autocrine 
mechanism allowing them to modulate the effects of vitamin D on the vasculature 
[24, 25].
Vitamin D has various direct and indirect effects on CV function. 1,25(OH)2D3 
directly modulates VSMC and expression of vascular endothelial growth factor via 
the VDR and CYP27B1 expression in VSMC’s and endothelial cells. 1,25(OH)2D3 
has an inhibitory effect on hypertrophy and proliferation of VSMC in vitro and 
in cultured cardiac myocytes. It also plays an important role in inflammation and 
thrombosis [21, 24]. In a swine model of atherosclerosis, vitamin D deficiency 
accelerated plaque progression by enhancing inflammation in epicardial adipose tis-
sue [26]. Inverse associations between vitamin D deficiency and thrombogenicity, 
vascular inflammation, and vascular calcification have been demonstrated [27–29].
Indirectly, the expression of renin in vivo is strongly regulated by vitamin D, 
and an inverse relationship between vitamin D levels and renin expression has been 
demonstrated experimentally [30–32]. 1,25(OH)2D3 binds to the renin promoter 
region and inhibits renin transcription [30]. VDR knockout mice were shown to 
have increased levels of renin and angiotensin II and, therefore, a higher prevalence 
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Vitamin D deficiency is indicated by serum levels of 25(OH)D < 20 ng/mL [4]. 
Serum levels >30 ng/mL are likely optimal for bone health, but some studies have 
shown benefits with lesser values. Parathyroid hormone (PTH) suppression appears 
to plateau at levels between 30 and 40 ng/mL [12]. There has been no agreement 
on optimum 25(OH)D levels required for purported health benefits beyond skel-
etal health. One study suggested that 25(OH)D levels below 11–14 ng/mL signify 
increased CVD risk [13]. Levels in the range of 21–29 ng/mL are considered by some 
as insufficient, a definition that would label the majority of the U.S. population 
vitamin D insufficient [4].
The Endocrine Society does not recommend screening for vitamin D deficiency 
in individuals who are not at risk for it [12]. Many of the risk factors for vitamin 
D deficiency have been identified. Some of these include inadequate cutaneous 
synthesis stemming from insufficient sun exposure or dark skin pigmentation and 
inadequate dietary intake. Other noted risk factors include aging, obesity, renal 
disease, liver disease, disorders that affect fat absorption (e.g. celiac disease, inflam-
matory bowel diseases, types of bariatric surgery), increased catabolism due to 
medications (e.g. steroids, anticonvulsants etc.), and other hereditable (e.g. rickets) 
and acquired disorders (e.g. hyperthyroidism) [4].
3. Vitamin D metabolism
Vitamin D’s active form, 1a,25-dihydroxyvitamin D (1,25[OH]2D3) plays a criti-
cal role in influencing a myriad of metabolic pathways [14].
Natural sunlight exposure contributes to more than 90% of vitamin D 
(D3-cholecalciferol) production in humans [15]. UV-B irradiation absorbed by skin 
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keratinocytes triggers photolysis of 7-dehydrocholesterol (pro-vitamin D3) in the 
plasma membrane, which is then swiftly modified into vitamin D3 by heat [4, 16].
Dietary supply of vitamin D (D2-ergocalciferol) contributes to the remainder 
of the total amount of vitamin D in the body. Foods containing vitamin D include 
oily fish (salmon, sardines, and mackerel), cod liver oil, egg yolk, mushrooms, and 
fortified milk, orange juice, cereals, and cheese [11, 12].
D3 and D2 from the skin and diet, respectively, each undergo two sequential 
hydroxylation’s: 25-hydroxylation in the liver and then 1,25-dihydroxylation in the kid-
ney. In order to assess vitamin D status from oral intake and endogenous production, 
the primary metabolite of vitamin D, 25(OH)D, should be measured [11, 15, 17]. The 
hydroxylation of 25(OH)D to its biologically active form, 1,25(OH)2D3, is controlled 
by PTH [11, 18].
Most of the known biological effects of 1,25(OH)2D3 are mediated through the 
vitamin D3 receptor (VDR), part of the superfamily of nuclear hormone receptors, 
which mediates transcriptional gene regulation [19].
Over 200 genes are regulated by 1,25(OH)2D3. These include genes directly or 
indirectly responsible for renin and insulin production, anti-inflammatory cytokine 
release, proinflammatory cytokine suppression, and regulation of vascular smooth 
muscle cell (VSMC) and cardiomyocyte proliferation [11, 20].
1,25(OH)2D3 is also involved in non-genomic mediated intracellular signal-
ing, demonstrating immunomodulatory, antiproliferative, and pro-differentiative 
activities in experimental settings [19].
4. Biologic plausibility
Characterizing vitamin D deficiency as a primary risk factor for CVD is chal-
lenging due to the multitude of complex interacting pathways involving vitamin 
D. The vitamin D receptor is nearly ubiquitous in human cells including vascular 
smooth muscle cells (VSMC), endothelial cells, cardiac myocytes, juxtaglomeru-
lar, and most immune cells, all implicated in the pathogenesis and progression of 
CVD [11, 18].
Immune cells such as activated CD4+ and CD8+ T cells, B cells, neutrophils, 
macrophages, and dendritic cells are capable of converting 25OHD3 into 1,25OHD3, 
its active form. Moreover, 1,25 hydroxylase, the rate-limiting enzyme in this 
pathway, is present in activated macrophages [21–23]. Lastly, VSMC and endothelial 
cells also express 1,25 hydroxylase, suggesting that these cells have an autocrine 
mechanism allowing them to modulate the effects of vitamin D on the vasculature 
[24, 25].
Vitamin D has various direct and indirect effects on CV function. 1,25(OH)2D3 
directly modulates VSMC and expression of vascular endothelial growth factor via 
the VDR and CYP27B1 expression in VSMC’s and endothelial cells. 1,25(OH)2D3 
has an inhibitory effect on hypertrophy and proliferation of VSMC in vitro and 
in cultured cardiac myocytes. It also plays an important role in inflammation and 
thrombosis [21, 24]. In a swine model of atherosclerosis, vitamin D deficiency 
accelerated plaque progression by enhancing inflammation in epicardial adipose tis-
sue [26]. Inverse associations between vitamin D deficiency and thrombogenicity, 
vascular inflammation, and vascular calcification have been demonstrated [27–29].
Indirectly, the expression of renin in vivo is strongly regulated by vitamin D, 
and an inverse relationship between vitamin D levels and renin expression has been 
demonstrated experimentally [30–32]. 1,25(OH)2D3 binds to the renin promoter 
region and inhibits renin transcription [30]. VDR knockout mice were shown to 
have increased levels of renin and angiotensin II and, therefore, a higher prevalence 
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of hypertension [32]. Thus, vitamin D is implicated in blood pressure regulation 
and myocardial thickening.
Another indirect effect of vitamin D on CVD is the regulation of matrix metal-
loproteinase 2 and 9 production. Increased metalloproteinases have been associated 
with cardiac fibrosis, hypertrophy and heart failure in mice [33, 34].
Vitamin D deficiency may also indirectly harm the CV system by inducing 
hyperparathyroidism, which may act upon parathyroid hormone (PTH) receptors 
within the blood vessel wall and the myocardium [35]. Multiple studies have been 
able to demonstrate an association between elevated PTH levels and hypertension, 
cardiac dysfunction and vascular disease [35, 36].
Lastly, hyperlipidemia has also been associated with vitamin D deficiency. This 
is likely a result of decreased transcriptional activity of the VDR, leading to the 
increase of hepatic cholesterol production [37].
5. The clinical evidence
Vitamin D deficiency is prevalent in CVD patients [11]. Most studies showing 
an association between inadequate 25OHD3 and poor outcomes in CV health are 
observational, hindering the establishment of a causal relationship. Furthermore, 
significant differences across studies hamper the ability to make valid and con-
sistent conclusions. These differences include varying definitions of vitamin D 
deficiency and lack of seasonal adjustment and properly defined CV outcomes. 
Further difficulties include the use of single baseline measurements of vitamin 
D (which may be an inaccurate assessment of overall vitamin D status), a poor 
understanding of the role of high PTH on CVD, and the use of other disease 
modulating drugs such as calcium and statins in active and placebo groups, which 
may affect study results.
However, newer studies implement clearly defined primary endpoints, differing 
frequencies of vitamin D supplementation, and a diverse cohort of participants. 
These studies allow for a clearer understanding of the effects of vitamin D supple-
mentation on CVD health.
6. Observational data
Several large-scale observational studies have been completed over the past 
decades. The NHANES III national cohort registry found a significant inverse 
relationship between 25(OH)D levels and all-cause mortality, but a non-significant 
association between 25(OH)D levels and CVD mortality [8].
In the Intermountain Heart Collaborative Study Group, significantly higher 
rates of diabetes, hyperten sion, hyperlipidemia, and peripheral vascular disease 
were found in those with serum 25(OH)D levels below 30 ng/mL. Additionally, 
low serum 25(OH)D levels were also linked to coronary artery disease, myocardial 
infarction (MI), heart failure, stroke and incident death [38].
In the Health Professionals Follow-up Study, men deficient in 25(OH)D (≤15 ng/
mL) had a higher risk of MI than men with sufficient levels (≥30 ng/mL) [39].
In contrast, other prospective studies have had discordant results. In the 
MIDSPAN family study, with a median follow up of 14.4 years, plasma levels of 
25OHD less than 15 ng/mL were associated with all-cause mortality, but not the risk 
of CV diseases [40].
Similiarly, in the MrOS Sleep Study, no relationship between circulating 25(OH)
D levels and risk of CVD events was found [41].
217
Vitamin D and Cardiovascular Disease: The Final Chapter?
DOI: http://dx.doi.org/10.5772/intechopen.90106
Additionally, in a study involving 746 patients undergoing coronary angiogra-
phy, no correlation was found between vitamin D levels (<20 ng/mL vs. >20 ng/mL) 
and the degree and severity of coronary artery disease [42].
7. Randomized controlled trials
Prior to 2017, most randomized interventional studies have assessed surrogate 
endpoints rather than hard CV outcomes. In the available studies, there has been 
considerable variation in defining baseline vitamin D status, assessing adequate 
vitamin D dosage, and ascertaining study outcomes.
In a double-blind, placebo controlled, randomized trial where elderly partici-
pants in the United Kingdom received vitamin D3 supplements of 100,000 IU every 
4 months for 5 years, no benefits on CVD outcomes were shown [43].
Additionally, in a systematic review of 18 randomized trials studying the 
efficacy of supplementation with vitamin D (with or without calcium) on various 
cardiometabolic outcomes, only four reported on incident CVD. There were no 
significant reductions in CVD risk found in these trials [44].
Postmenopausal women in the Women’s Health Initiative (WHI) receiving 
calcium carbonate (1000 mg/day) and vitamin D (400 IU/day) had no reduc-
tion in their risk of coronary events or stroke during the 7 year follow-up period. 
Treatment with calcium and vitamin D also had no effect on blood pressure reduc-
tion, hypertension development and coronary artery calcification. In the overall 
participant cohort, supplementation did not reduce the overall incidence of heart 
failure, yet some benefits were noted in participants considered to be at low risk for 
heart failure. Lastly, in a follow-up 4.9 years after the culmination of the study, no 
positive effects on CVD were found [45–49].
More recent studies on vitamin D supplementation have made use of well-
defined CV outcomes as primary endpoints. In 2017, the results of the Vitamin D 
Assessment study (VIDA), a randomized, double blinded, placebo-controlled study 
on the effects of high-dose, monthly vitamin D supplementation in the general 
population aged 50–84, were published. 5,110 patients were randomized to receive 
either an initial oral vitamin D dose of 200,000 IU followed by 100,000 IU monthly 
or placebo. Primary outcomes included incident CVD and death. Secondary out-
comes included MI, angina, heart failure, hypertension, arrhythmias, chronic isch-
emic heart disease, arteriosclerosis, stroke, and venous thrombosis. Additionally, 
pre-specified subgroup analysis for the primary endpoint was done for patients 
with vitamin D deficiency (<20 ng/mL) and established CVD. Results of the study 
showed that high doses of monthly vitamin D supplementation provided no benefit 
to CV health over placebo. However, the study is limited by a low event rate and 
decreased power, especially for subgroup analysis in those deficient at baseline. 
Supplementation was monthly, leaving the question of whether daily dosing may be 
better. Finally, the funding of the clinical trial only allowed for a median follow-up 
time of 3.3 years and, therefore, the long-term effects of high dose, monthly vitamin 
D supplementation remain in question [10].
Another recent placebo-controlled trial, known as the VITAL study, assessed the 
effects of more frequent vitamin D supplementation (2,000 IU of vitamin D and 
1 g of omega-3 per day) on CVD and cancer. The primary endpoint in the CV arm 
was major CV events, which included MI, stroke, and cardiac related death. 25,871 
subjects participated in the study and the median follow-up time was 5.3 years. The 
trial found that daily vitamin D supplementation had no benefit on CV health. The 
strengths of the study included daily vitamin D supplementation, longer follow-up 
times, and participant diversity [9].
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observational, hindering the establishment of a causal relationship. Furthermore, 
significant differences across studies hamper the ability to make valid and con-
sistent conclusions. These differences include varying definitions of vitamin D 
deficiency and lack of seasonal adjustment and properly defined CV outcomes. 
Further difficulties include the use of single baseline measurements of vitamin 
D (which may be an inaccurate assessment of overall vitamin D status), a poor 
understanding of the role of high PTH on CVD, and the use of other disease 
modulating drugs such as calcium and statins in active and placebo groups, which 
may affect study results.
However, newer studies implement clearly defined primary endpoints, differing 
frequencies of vitamin D supplementation, and a diverse cohort of participants. 
These studies allow for a clearer understanding of the effects of vitamin D supple-
mentation on CVD health.
6. Observational data
Several large-scale observational studies have been completed over the past 
decades. The NHANES III national cohort registry found a significant inverse 
relationship between 25(OH)D levels and all-cause mortality, but a non-significant 
association between 25(OH)D levels and CVD mortality [8].
In the Intermountain Heart Collaborative Study Group, significantly higher 
rates of diabetes, hyperten sion, hyperlipidemia, and peripheral vascular disease 
were found in those with serum 25(OH)D levels below 30 ng/mL. Additionally, 
low serum 25(OH)D levels were also linked to coronary artery disease, myocardial 
infarction (MI), heart failure, stroke and incident death [38].
In the Health Professionals Follow-up Study, men deficient in 25(OH)D (≤15 ng/
mL) had a higher risk of MI than men with sufficient levels (≥30 ng/mL) [39].
In contrast, other prospective studies have had discordant results. In the 
MIDSPAN family study, with a median follow up of 14.4 years, plasma levels of 
25OHD less than 15 ng/mL were associated with all-cause mortality, but not the risk 
of CV diseases [40].
Similiarly, in the MrOS Sleep Study, no relationship between circulating 25(OH)
D levels and risk of CVD events was found [41].
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Additionally, in a study involving 746 patients undergoing coronary angiogra-
phy, no correlation was found between vitamin D levels (<20 ng/mL vs. >20 ng/mL) 
and the degree and severity of coronary artery disease [42].
7. Randomized controlled trials
Prior to 2017, most randomized interventional studies have assessed surrogate 
endpoints rather than hard CV outcomes. In the available studies, there has been 
considerable variation in defining baseline vitamin D status, assessing adequate 
vitamin D dosage, and ascertaining study outcomes.
In a double-blind, placebo controlled, randomized trial where elderly partici-
pants in the United Kingdom received vitamin D3 supplements of 100,000 IU every 
4 months for 5 years, no benefits on CVD outcomes were shown [43].
Additionally, in a systematic review of 18 randomized trials studying the 
efficacy of supplementation with vitamin D (with or without calcium) on various 
cardiometabolic outcomes, only four reported on incident CVD. There were no 
significant reductions in CVD risk found in these trials [44].
Postmenopausal women in the Women’s Health Initiative (WHI) receiving 
calcium carbonate (1000 mg/day) and vitamin D (400 IU/day) had no reduc-
tion in their risk of coronary events or stroke during the 7 year follow-up period. 
Treatment with calcium and vitamin D also had no effect on blood pressure reduc-
tion, hypertension development and coronary artery calcification. In the overall 
participant cohort, supplementation did not reduce the overall incidence of heart 
failure, yet some benefits were noted in participants considered to be at low risk for 
heart failure. Lastly, in a follow-up 4.9 years after the culmination of the study, no 
positive effects on CVD were found [45–49].
More recent studies on vitamin D supplementation have made use of well-
defined CV outcomes as primary endpoints. In 2017, the results of the Vitamin D 
Assessment study (VIDA), a randomized, double blinded, placebo-controlled study 
on the effects of high-dose, monthly vitamin D supplementation in the general 
population aged 50–84, were published. 5,110 patients were randomized to receive 
either an initial oral vitamin D dose of 200,000 IU followed by 100,000 IU monthly 
or placebo. Primary outcomes included incident CVD and death. Secondary out-
comes included MI, angina, heart failure, hypertension, arrhythmias, chronic isch-
emic heart disease, arteriosclerosis, stroke, and venous thrombosis. Additionally, 
pre-specified subgroup analysis for the primary endpoint was done for patients 
with vitamin D deficiency (<20 ng/mL) and established CVD. Results of the study 
showed that high doses of monthly vitamin D supplementation provided no benefit 
to CV health over placebo. However, the study is limited by a low event rate and 
decreased power, especially for subgroup analysis in those deficient at baseline. 
Supplementation was monthly, leaving the question of whether daily dosing may be 
better. Finally, the funding of the clinical trial only allowed for a median follow-up 
time of 3.3 years and, therefore, the long-term effects of high dose, monthly vitamin 
D supplementation remain in question [10].
Another recent placebo-controlled trial, known as the VITAL study, assessed the 
effects of more frequent vitamin D supplementation (2,000 IU of vitamin D and 
1 g of omega-3 per day) on CVD and cancer. The primary endpoint in the CV arm 
was major CV events, which included MI, stroke, and cardiac related death. 25,871 
subjects participated in the study and the median follow-up time was 5.3 years. The 
trial found that daily vitamin D supplementation had no benefit on CV health. The 
strengths of the study included daily vitamin D supplementation, longer follow-up 
times, and participant diversity [9].
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A recent updated meta-analysis, including VITAL and VIDA, with a total of 
83,291 patients, indicated that vitamin D supplementation had no benefit on CV 
health. Only 4 of the 21 trials used CVD as a primary endpoint. It has also been 
shown that vitamin D supplementation provided no benefit toward the secondary 
endpoints of MI, stroke, CVD mortality, and all-cause mortality [50]. This meta-
analysis, though, lacks complete and specific patient level data and, therefore, 
subgroup analysis is difficult.
8. Hypertension
Low vitamin D status has been heavily linked to an increased prevalence of 
hypertension. A prospective examination of 1,211 non-hypertensive men, over a 
15 year follow-up period, demonstrated an inverse association between vitamin D 
levels and hypertension development [51].
In addition to the demonstrated link between low vitamin D levels and hyper-
tension development, the Framingham Offspring Study suggested that low vitamin 
D levels may also increase the risk associated with already existing hypertension, 
which may substantially augment the risk of future CV events [52].
Contrary to observational evidence, randomized controlled trials of vitamin 
D repletion have not shown significant changes in blood pressure in vitamin D 
deficient individuals with prehypertension or hypertension [53, 54].
In a randomized, double blind trial involving 283 black subjects given either pla-
cebo, 1,000, 2,000, or 4,000 IU/day of vitamin D for 3 months, significant modest 
reductions in systolic blood pressure were seen. Systolic blood pressure decreased 
by 0.2 mmHg for every 1 ng/mL increase in vitamin D, but no effect on diastolic 
pressure was demonstrated [55].
In VITdish, another small (N = 159) randomized, double-blind, placebo-con-
trolled trial, there was no effect of vitamin D supplementation on blood pressure 
or other markers of vascular health in older adults with systolic hypertension [56].
A 6 month study of vitamin D3 supplementation including patients with 
resistant hypertension showed similar results. Effects on left ventricular hyper-
trophy were also negligible, although the short follow-up may have limited this 
assessment [57].
In the VIDA study, with monthly high dose vitamin D supplementation, there 
were no significant differences between the vitamin D and placebo groups regard-
ing incident hypertension [10].
Lastly and likewise, in the VITAL study using high daily doses of vitamin D, 
hypertension incidence was not significantly different in the vitamin D and placebo 
groups [9].
9. Endothelial dysfunction
Vitamin D deficiency has been associated with endothelial dysfunction. A 
study involving 23 asymptomatic subjects demonstrated impaired brachial artery 
flow-mediated dilatation (FMD) in subjects with significant vitamin D deficiency. 
Improvement was seen with vitamin D repletion [58].
In contrast, there was no improvement in endothelial-dependent vasodilation 
with active treatment (ergocalciferol 50,000 IU/week) versus placebo in an 8 week 
trial in non-hypertensive, overweight, vitamin D deficient individuals [59].
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Similarly, a prospective placebo-controlled pilot study evaluated the effects of 
vitamin D repletion on endothelial function and inflammation in subjects with both 
vitamin D deficiency and coronary artery disease. The study was conducted over a 
12-week period in 90 subjects. No significant differences between the groups were 
found in reactive hyperemia index (using RH-PAT), blood pressure, and levels of 
hs-CRP, IL-6, IL-12, interferon gamma (INF-gamma), and CXCL-10 [60].
Additionally, in the Prospective Study of the Vasculature in Uppsala Seniors 
(PIVUS) (N = 852), vitamin D levels were positively related to endothelial-indepen-
dent vasodilation in women only. There were no significant relationships between 
vitamin D levels and indices of endothelium-dependent vasodilatation in both men 
and women [61].
Lastly, a recent systematic review including 31 trials and individual-level meta-
analysis (2,571 patients) assessed the relationship between vitamin D and various 
markers of vascular function. The analysis found that most vascular markers 
studied were not significantly effected by vitamin D supplementation [62].
10. Heart failure
The impact of vitamin D supplementation on patients with heart failure has not 
been the focus of large randomized trials.
The RECORD trial (Randomized Evaluation of Calcium Or vitamin D) was a 
trial designed for the secondary prevention of fractures in 5292 participants aged 
≥70 years (conducted between 1999 and 2002). Subjects received oral vitamin D3 
(800 IU/d) plus calcium (1,000 mg calcium carbonate/d), vitamin D3 alone, cal-
cium alone, or a placebo. An analysis of unpublished data from the trial, suggested 
that vitamin D supplementation may decrease heart failure events in the elderly. 
The trial had pre-specified CV endpoints of time to first cardiac failure, time to first 
MI, time to first stroke, and time to first composite outcome of cardiac failure, MI, 
or stroke. The trial, though, was not designed as a CV outcomes trial, and outcomes 
were not subject to an adjudication committee nor verified against medical records. 
Furthermore, significance for heart failure event reduction was reached only when 
off-trial data were used [63].
Several small placebo-controlled studies have been conducted to analyze the 
effects of vitamin D supplementation on differing endpoints in patients with heart 
failure. Results have been conflicting.
In a small randomized, double-blind, placebo-controlled trial (N = 105) in older 
adults with vitamin D deficiency (25-vitamin D < 20 ng/mL) and systolic heart 
failure, subjects were given 100,000 IU of oral vitamin D2 or placebo at baseline 
and 10 weeks. Functional outcomes, quality of life and biomarkers (B-type natri-
uretic peptide (BNP) and tumor necrosis factor (TNF alpha)) were measured at 
baseline, 10 and 20 weeks. BNP was significantly reduced in the active treatment 
group versus placebo, but TNF alpha was not. Despite reduced BNP levels, physical 
function, as measured by the 6-minute walk test and the timed get up and go test, 
did not improve. There was also no change in the Functional Limitations Profile 
measure in the active versus placebo group. A small, but significant worsening in 
quality of life with active treatment was noted, despite a non-significant increase in 
activity level, suggesting a chance finding [64].
Schleithoff et al. examined cytokine profiles with vitamin D3 supplementation in 
younger patients with heart failure. A dose of 2,000 IU per day reduced the pro-
inflammatory marker TNF-alpha levels and increased the anti-inflammatory cyto-
kine interleukin-10 levels, but no significant effects on BNP levels were seen [20].
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Similarly, a prospective placebo-controlled pilot study evaluated the effects of 
vitamin D repletion on endothelial function and inflammation in subjects with both 
vitamin D deficiency and coronary artery disease. The study was conducted over a 
12-week period in 90 subjects. No significant differences between the groups were 
found in reactive hyperemia index (using RH-PAT), blood pressure, and levels of 
hs-CRP, IL-6, IL-12, interferon gamma (INF-gamma), and CXCL-10 [60].
Additionally, in the Prospective Study of the Vasculature in Uppsala Seniors 
(PIVUS) (N = 852), vitamin D levels were positively related to endothelial-indepen-
dent vasodilation in women only. There were no significant relationships between 
vitamin D levels and indices of endothelium-dependent vasodilatation in both men 
and women [61].
Lastly, a recent systematic review including 31 trials and individual-level meta-
analysis (2,571 patients) assessed the relationship between vitamin D and various 
markers of vascular function. The analysis found that most vascular markers 
studied were not significantly effected by vitamin D supplementation [62].
10. Heart failure
The impact of vitamin D supplementation on patients with heart failure has not 
been the focus of large randomized trials.
The RECORD trial (Randomized Evaluation of Calcium Or vitamin D) was a 
trial designed for the secondary prevention of fractures in 5292 participants aged 
≥70 years (conducted between 1999 and 2002). Subjects received oral vitamin D3 
(800 IU/d) plus calcium (1,000 mg calcium carbonate/d), vitamin D3 alone, cal-
cium alone, or a placebo. An analysis of unpublished data from the trial, suggested 
that vitamin D supplementation may decrease heart failure events in the elderly. 
The trial had pre-specified CV endpoints of time to first cardiac failure, time to first 
MI, time to first stroke, and time to first composite outcome of cardiac failure, MI, 
or stroke. The trial, though, was not designed as a CV outcomes trial, and outcomes 
were not subject to an adjudication committee nor verified against medical records. 
Furthermore, significance for heart failure event reduction was reached only when 
off-trial data were used [63].
Several small placebo-controlled studies have been conducted to analyze the 
effects of vitamin D supplementation on differing endpoints in patients with heart 
failure. Results have been conflicting.
In a small randomized, double-blind, placebo-controlled trial (N = 105) in older 
adults with vitamin D deficiency (25-vitamin D < 20 ng/mL) and systolic heart 
failure, subjects were given 100,000 IU of oral vitamin D2 or placebo at baseline 
and 10 weeks. Functional outcomes, quality of life and biomarkers (B-type natri-
uretic peptide (BNP) and tumor necrosis factor (TNF alpha)) were measured at 
baseline, 10 and 20 weeks. BNP was significantly reduced in the active treatment 
group versus placebo, but TNF alpha was not. Despite reduced BNP levels, physical 
function, as measured by the 6-minute walk test and the timed get up and go test, 
did not improve. There was also no change in the Functional Limitations Profile 
measure in the active versus placebo group. A small, but significant worsening in 
quality of life with active treatment was noted, despite a non-significant increase in 
activity level, suggesting a chance finding [64].
Schleithoff et al. examined cytokine profiles with vitamin D3 supplementation in 
younger patients with heart failure. A dose of 2,000 IU per day reduced the pro-
inflammatory marker TNF-alpha levels and increased the anti-inflammatory cyto-
kine interleukin-10 levels, but no significant effects on BNP levels were seen [20].
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A recent randomized, controlled trial assessed the effects of 50,000 IU of 
weekly vitamin D or placebo for 6 months on various measures of physical perfor-
mance (primary endpoint: peak VO2; secondary endpoints: 6-Minute Walk test, 
timed get up and go test, isokinetic muscle strength) in patients with heart failure. 
The study failed to demonstrate any benefits, despite considerable increases in 
serum 25(OH)D levels in the active treatment group [65].
In VINDICATE, a double-blind, randomized, placebo-controlled trial, subjects 
with systolic dysfunction (ejection fraction (EF) ≤ 45%) and vitamin D deficiency 
(<20 ng/mL) were randomized to 4,000 IU of vitamin D3 or placebo. At 12 months, 
there was no significant difference in 6-minute walking distance (primary end-
point), but there was significant improvement in left ventricular (LV) systolic 
function and a reduction in LV end diastolic and end systolic diameter with active 
supplementation [66].
In the EVITA trial, 400 patients with heart failure were randomized to receive 
4,000 IU of vitamin D or placebo daily for 3 years. There was no benefit of supple-
mentation on the primary endpoint of all-cause mortality. Additionally, secondary 
endpoint analysis suggested that vitamin D supplementation was associated with an 
increased frequency of implantation of mechanical circulatory support [67].
11. Renal disease
Observational studies show that there are potential benefits to vitamin D 
supplementation in patients with chronic kidney disease (CKD). In a meta-analysis 
of some of these studies, it was determined that receiving treatment with any 
vitamin D derivative reduces all-cause mortality as well as CV mortality [68]. In 
another, more recent, meta-analysis of observational studies, it has been shown that 
vitamin D treatment may pose benefits toward reducing all-cause mortality and CV 
related mortality [69].
To further assess some of the available randomized, clinical trials for renal 
patients, a meta-analysis was done to test the efficacy of vitamin D supplementa-
tion in these patients. The 13 trials used for the meta-analysis showed no significant 
benefits for serious adverse CV events, all-cause mortality, or CV related mortality 
in CKD patients who supplemented with vitamin D. Unfortunately, there is a lack 
of patient level data relating to patients with CKD, making it difficult to draw any 
conclusions regarding the effects of vitamin D supplementation on CV health in 
this population [70].
In many of the previous studies in patients with CKD, the dosage of vitamin 
D has been limited in order to protect patients from developing hypercalcemia. 
Additionally, a lack of standardization in vitamin D formulations has made it 
especially difficult to compare results in different trials. Larger randomized tri-
als with well-defined primary outcomes need to be conducted in order to further 
define vitamin D’s effect on CVD in renal patients. In 2025, the SIMPLIFIED trial 
is expected to conclude and expectantly give insight into the effects of vitamin D 
supplementation on hard endpoints of all-cause mortality and CV related mortality 
in CKD patients [71, 72].
12. Conclusions
Epidemiologic, observational and laboratory evidence have implicated vitamin 
D deficiency in the pathogenesis and complications of CVD. This lent extensive 
biologic plausibility to the theory that vitamin D levels would be an effective target 
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for CVD prevention. However, like many other trials of vitamin supplementation, 
large randomized placebo-controlled trial data from the general population have 
refuted this theory. Therefore, vitamin D supplementation for the purpose of CVD 
prevention is not recommended for the general public.
13. Future directions
Based on the findings in the most recent clinical trials, it appears that the last 
chapter may have been written regarding the role of vitamin D for CVD prevention 
in the general population. However, many questions still remain and will likely 
fuel ongoing investigation and debate. Was the follow-up in these recent trials 
long enough? Do large trials randomizing by baseline vitamin D status need to be 
conducted since the mean vitamin D levels in VITAL and VIDA were both above the 
deficient threshold of 20 ng/mL? [9, 10]. Are there benefits to vitamin D repletion 
for heart failure outcomes? What is the true benefit of vitamin D repletion on CVD 
outcomes in the chronic kidney disease and dialysis population? These questions 
and others regarding both CVD and other chronic disease states will likely keep the 
book open on vitamin D for the foreseeable future.
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Abstract
Vitamin D has many and profound effects on the immune system. Vitamin D 
deficiency is known to be related to the development of autoimmune diseases. In 
particular, vitamin D deficiency is related to the development and the severity of 
rheumatoid arthritis (RA). RA develops in patients with vitamin D deficiency, and 
the activity of the disease is related to vitamin D deficiency. Vitamin D deficiency 
is also related to the development of systemic lupus erythematosus (SLE). SLE 
develops in patients with vitamin D deficiency, and the activity of the disease is also 
greater in patients with vitamin D deficiency. Vitamin D deficiency is also related to 
the development and the severity of multiple sclerosis. Vitamin D should be admin-
istered to patients with multiple sclerosis, and this seems to mitigate the symptoms 
of the disease and to prevent disease progression. Vitamin D deficiency is also 
observed in patients with inflammatory bowel disease and may be related to disease 
severity. Low vitamin D levels have also been observed in patients with autoimmune 
Hashimoto’s thyroiditis. Low vitamin D levels have been observed in patients with 
systemic sclerosis, especially in the diffuse form of the disease. Optimal vitamin 
D levels appear to be required for normal immune function and for the prevention 
and treatment of autoimmune diseases.
Keywords: vitamin D, autoimmunity, rheumatoid arthritis, systemic lupus 
erythematosus, multiple sclerosis, inflammatory bowel disease, autoimmune 
Hashimoto’s thyroiditis
1. Introduction
Vitamin D is a secosteroid hormone, which is known to be related to the regu-
lation of the musculoskeletal system. It affects calcium and phosphate metabo-
lism and is related to bone health. Recently, the extraskeletal effects of vitamin 
D are under intense research and have attracted the interest of the scientific 
community [1–6]. In particular, the relationship of vitamin D with the immune 
system is in the focus of scientific evaluation [7–9]. In the chapter herein, the 
effects of vitamin D on the immune system will be discussed, and the relation-
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2. Vitamin D and the immune system
The classic function of vitamin D is to enhance intestinal absorption of calcium 
by regulating several calcium transport proteins in the small intestine [4]. However, 
various cells express the vitamin D receptor (VDR) and the vitamin D activating 
enzyme 1-α-hydroxylase. Various cells of the immune system also express the VDR 
and harbor 1-α-hydroxylase [10, 11]. Thus, cells of the immune system respond 
to vitamin D and also activate vitamin D in a paracrine or autocrine fashion. The 
extra-renal 1-α-hydroxylase is not upregulated by PTH, and thus, production of 
1,25(OH)2D3 is dependent on concentrations of the substrate 25(OH)D3, and it 
may be regulated by inflammatory signals, such as lipopolysaccharide and cyto-
kines [12, 13]. Cells of the immune system, which express the VDR and harbor 
1-α-hydroxylase, are macrophages, T cells, dendritic cells, monocytes, and B cells 
(Figure 1) [9]. Vitamin D is involved in the regulation of the innate immunity as it 
enhances the defense system of the organism against microbes and other pathogenic 
organisms, and it modulates the adaptive immune system through direct effects on 
T-cell activation and on the phenotype and function of antigen-presenting cells, 
particularly dendritic cells.
2.1 Vitamin D and the innate immune system
The innate immune system is a first line of defense against infection. Vitamin 
D is a regulator of the innate immune system [1, 14]. The first data on the effect of 
vitamin D on the innate immune system have been generated on the treatment of 
diseases caused by mycobacteria, such as tuberculosis and leprosy [15–18]. Vitamin 
D has been used as a treatment of infections for more than 150 years. In 1849, 
Williams reported favorable results with the use of cod-liver-oil, an excellent source 
of vitamin D, in the treatment of patients with tuberculosis [19]. Fifty years later, 
Niels Finsen received the third Nobel Prize in Medicine for his description of using 
UV light, an effective method to increase vitamin D status, to treat lupus vulgaris, a 
cutaneous form of tuberculosis [20, 21]. Alfred Windaus contributed to the discov-
ery of the chemical structure of vitamin D2 and vitamin D3 found in cod-liver-oil and 
received the Nobel prize [22–24]. Thereafter, several groups used vitamin D2 and D3 
as a treatment for tuberculosis [22, 25]. Rook et al. [26] demonstrated in the 1980s 
that 1,25(OH)2D3 inhibited the proliferation of Mycobacterium tuberculosis in culture. 
Vitamin D enhances the production of defensin β2 and cathelicidin in response to 
infection by macrophages, monocytes, and keratinocytes [12]. Humans have only 
Figure 1. 
Cells of the immune system regulated in part by vitamin D.
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one cathelicidin, which is cleaved to form LL-37 [27]. Cells of the immune system 
including neutrophils and macrophages and cells lining epithelial surfaces that are 
constantly exposed to potential pathogens such as the skin, the respiratory, and the 
gastrointestinal tract produce cathelicidin [28–30]. Cathelicidin has broad antimi-
crobial activity against Gram-positive and Gram-negative bacteria, as well as certain 
viruses and fungi [31]. The killing mechanism of cathelicidin involves bacterial lysis 
by destabilizing cell membrane [32]. Treatment with 1,25(OH)2D3 upregulates cathe-
licidin mRNA in several cell lines. Thus, it appears that 1,25(OH)2D3 upregulates 
antimicrobial peptide production, primarily cathelicidin, on a variety of different 
cells [33]. Studies indicate that 25(OH)D3, the major circulating form of vitamin D 
to determine vitamin D status, is important for local production of 1,25(OH)2D3 to 
upregulate cathelicidin production in the skin and macrophages. Exposing human 
monocytes to pathogens increases the expression of both 1,25(OH)2D3 and VDR, 
thus increasing both the local production of 1,25(OH)2D3 and the ability of the cell 
to respond to it [12]. Since keratinocytes also possess 25-α-hydroxylase, UV light 
may directly stimulate cathelicidin production by providing the substrate 25(OH)
D3 directly from vitamin D3 produced within the skin [34, 35]. Macrophages also 
respond to vitamin D increasing their antimicrobial activity, however, heteroge-
neously [36, 37]. Macrophages formed after interleukin-15 stimulus respond to 
vitamin D increasing their antimicrobial activity, whereas macrophages formed after 
stimulation by interleukin-10 respond to vitamin D stimulus weakly.
Data regarding other infections also exist. Thus, children with low vitamin 
D status may be more prone to urinary tract infections due to low production of 
cathelicidin and defensin β2 [38, 39]. Also, adults with asthma may be less prone to 
infection after treatment with vitamin D due to increased production of cathelidicin 
and modulation of inflammatory cytokines [40, 41]. Low levels of vitamin D may 
be related to chronic obstructive pulmonary disease severity [42]. Vitamin D may 
increase resistance to HIV infection. Low levels of vitamin D have been associated 
with disease progression and mortality [43]. The ability of the immune cells to 
hydroxylate 25(OH)D3 locally suggests that in patients with infections, it may be 
better to administer 25(OH)D3 rather than hydroxylated metabolites to allow for 
local production and the feedback system to function.
2.2 Vitamin D and autoimmunity
The natural history of autoimmunity remains largely unknown. However, the 
theory is that both genetic susceptibility and environmental factors play a role in 
the development of clinical autoimmune disease. Vitamin D has known immuno-
modulatory effects on a wide range of immune cells, including T and dendritic cells 
[44, 45]. Each of these immune cells expresses VDR and produces the enzymes 
1-α-hydroxylase and 24-hydroxylase and is therefore capable of locally producing 
active 1,25(OH)2D3 [46–49]. Activation of CD4+ T cells results in a significant 
increase in VDR expression enabling regulation of many genes responsive to 
1,25(OH)2D3 [50]. 1,25(OH)2D3 suppresses T-cell receptor induced T cell prolifera-
tion and changes their cytokine expression. The overall shift is away from T helper 
Th1 phenotype toward a more tolerogenic Th2 response [51–53]. Vitamin D appears 
to directly inhibit Th1 cells and may additionally modulate a skewing toward a Th2 
response [54]. Th17 cells are a subset of CD4+ T cells involved in organ-specific 
autoimmunity playing a role in maintaining inflammation, which can lead to tissue 
damage. 1,25(OH)2D3 suppresses autoimmunity and tissue destruction by inhibit-
ing the Th17 response at several levels [55, 56]. Altogether, the evidence suggests 
an important role for vitamin D in influencing T-cell responses and in tempering 
inflammation and tissue damage.
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Vitamin D appears to have a direct effect on B cells and inhibits immunoglobulin 
production [57]. Additionally, differentiation of B cells is interrupted when exposed 
to 1,25(OH)2D3. 1,25(OH)2D3 also has effects on dendritic cells. Dendritic cells have 
important functions in maintaining both protective immunity and self-tolerance 
[58, 59]. Physiologic levels of 1,25(OH)2D3 inhibit maturation of dendritic cells and 
maintain an immature and tolerogenic phenotype with inhibition of activation 
markers such as MHC class II, CD40, and others and upregulation of inhibitory 
molecules [60, 61]. Thus, it appears that the maturational state of dendritic cells can 
be modulated by 1,25(OH)2D3, making it possible that the vitamin D status of an 
individual is likely to have important immunologic consequences.
3. Vitamin D and autoimmune diseases
There are several animal models of autoimmunity, in which disease could either 
be prevented or ameliorated with the administration of either 1,25(OH)2D3 or one 
of its analogues. These animal models are models of autoimmune encephalomy-
elitis, collagen-induced arthritis, type 1 diabetes mellitus, inflammatory bowel 
disease, autoimmune uveitis, and lupus [44, 56, 62–76]. These studies show that 
treatment with active vitamin D is effective in modulating immune function and 
ameliorating autoimmune disease. Vitamin D deficiency is a risk factor for the 
development of some autoimmune diseases, such as rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE), diabetes mellitus type 1, multiples sclero-
sis, inflammatory bowel disease, and Hashimoto’s thyroiditis [49, 69, 74, 77–85] 
(Figure 2). Additionally, vitamin D deficiency has been observed in patients with 
systemic sclerosis [86].
3.1 Vitamin D deficiency and rheumatoid arthritis
A meta-analysis showed that low vitamin D intake is associated with the 
development of RA [87]. Thereafter, several studies performed in various areas 
all over the world showed that vitamin D deficiency is observed in patients with 
RA and that vitamin D deficiency is associated with disease activity [78, 82, 83, 
88–97]. A meta-analysis of the good quality studies performed regarding the 
association between vitamin D deficiency and RA showed that vitamin D defi-
ciency is observed in RA patients significantly more than in a control group and 
that vitamin D levels are inversely correlated with disease activity, meaning that 
low vitamin D levels are associated with high-disease activity [98]. Moreover, an 
Figure 2. 
Autoimmune diseases related to vitamin D deficiency.
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association has been shown between VDR polymorphism and RA. Specifically, 
the Fokl F allele of the VDR may be a risk factor for the development of RA [99]. 
Further studies are needed to unravel the exact association between vitamin D 
deficiency and RA and to determine the best method of vitamin D supplementa-
tion and whether it may be used for the prevention of RA or for the best manage-
ment of the disease [77, 100]. In addition, it has been proposed that vitamin D may 
contribute to the management of pain in RA and may be used along with TNF-α 
inhibitors in RA treatment [77, 101].
3.2 Vitamin D deficiency and systemic lupus erythematosus
In SLE, the inflammatory milieu drives the development of T cells into proin-
flammatory pathways, defective function of Tregs, and survival and activation 
of B cells, which produce autoantibodies [78, 81]. Patients with systemic lupus 
erythematosus have lower 25(OH)D3 levels compared to controls, suggesting that 
vitamin D deficiency may be a risk factor for SLE [81, 84, 102–107]. The major-
ity of studies have also found higher SLE disease activity associated with lower 
levels of 25(OH)D3 [84, 103]. As patients with SLE have often photosensitivity 
and are advised to avoid direct sun exposure, detecting vitamin D deficiency and 
replacing 25(OH)D3 with oral supplementation is critical and may impact disease 
activity [108].
3.3 Vitamin D deficiency and type 1 diabetes mellitus
Type 1 diabetes mellitus is one of the most prevalent chronic diseases with 
onset in childhood and is the result of immune-mediated destruction of pancreatic 
insulin producing β cells. There appears to be a geographic variation in incidence 
following a gradient in latitude, which is the inverse of the global distribution of 
ultraviolet B irradiation, critical for the production of vitamin D within the skin 
[109]. Studies have shown higher incidence of vitamin D deficiency in patients with 
type 1 diabetes [110–113]. One environmental factor thought to be protective against 
the development of type 1 diabetes mellitus is early supplementation with vitamin D 
[114]. A number of large case control studies showed that the risk of type 1 diabetes 
mellitus was significantly reduced in infants who were supplemented with vitamin 
D compared to those who were not supplemented [115–117]. Additionally, a lower 
incidence of type 1 diabetes was observed in infants born to mothers who were 
administered cod liver oil during pregnancy [118]. A birth cohort study in Finland, 
now more than 50 years ago, evaluated the effects of vitamin D supplementation 
on rickets and the development of type 1 diabetes mellitus [85]. All women due to 
give birth in 1966 were enrolled. There was an 80% reduction in the risk for type 1 
diabetes mellitus in children having received >2000 IU vitamin D/day compared 
to those receiving less or not receiving supplementation with vitamin D. Evidence 
from both human and animal studies shows that vitamin D may be protective as far 
as the development of type 1 diabetes mellitus is concerned [68, 71, 76]. Thus, the 
administration of vitamin D may prevent diabetes mellitus type 1; however, once the 
destruction of pancreatic beta cells has taken place, it will not act therapeutically to 
reverse diabetes mellitus type 1.
3.4 Vitamin D deficiency and multiple sclerosis
Multiple sclerosis is characterized by inflammation, demyelination, axonal or 
neuronal loss, and astrocytic gliosis in the central nervous system, which can result 
in disability. Epidemiological studies have suggested that vitamin D insufficiency 
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may contribute to the risk of multiple sclerosis [62, 63, 75, 119, 120]. Moreover, 
several genetic studies in multiple sclerosis patients have shown that diverse abnor-
malities in vitamin D metabolism are related to the risk of the disease. It appears 
that vitamin D deficiency may interact with genetic and environmental protective 
and risk factors, such as the allele HLA BRB1*1501, infections, obesity, smok-
ing, and sexual hormones and may modulate the risk of the disease [63, 74, 80]. 
Thus, vitamin D deficiency may be a risk modulating factor for the development 
of multiple sclerosis. Vitamin D acts as an immunomodulatory factor affecting 
T and B lymphocytes, and it may exert neuroprotector and neurotrophic actions 
within the central nervous system. Several studies have shown that vitamin D 
supplementation exerts multiple beneficial immunomodulatory effects in multiple 
sclerosis [121–124]. On the contrary, a Cochrane review states that there appears to 
be no benefit from vitamin D supplementation in patients with multiple sclerosis; 
however, the level of evidence is very low [125]. Nevertheless, it should be noted 
that robust statistical models used in association studies have already predicted 
a favorable vitamin D effect reducing relapses by 50–70% [121]. There is little 
doubt that vitamin D exerts a beneficial action on multiple sclerosis, the inflam-
matory component in particular, less so the degenerative. Until more information 
becomes available, vitamin D supplementation of multiple sclerosis patients, using 
a moderate physiological dose essentially correcting their vitamin insufficiency, is 
recommended.
3.5 Vitamin D and inflammatory bowel disease
Vitamin D deficiency has been observed in patients with inflammatory bowel 
disease, Crohn’s disease, and ulcerative colitis [126]. It was found to be related 
to disease activity in Crohn’s disease and ulcerative colitis. Vitamin D supports 
the integrity of the intestinal barrier and is related to microbiota homeostasis in 
this cohort of patients [127, 128]. Thus, vitamin D may contribute to the preven-
tion of inflammatory bowel disease by supporting the integrity of the intestinal 
barrier, contributing to bacterial homeostasis and ameliorating disease progres-
sion via anti-inflammatory action. Vitamin D deficiency in inflammatory bowel 
disease is aggravated by decreased absorption of the vitamin via the gastrointes-
tinal tract [128].
3.6 Vitamin D deficiency and autoimmune Hashimoto’s thyroiditis
Studies have observed an association between autoimmune Hashimoto’s thyroid-
itis and low vitamin D levels [79, 129]. These studies have not observed low vitamin 
D levels in patients with Graves’ disease. A meta-analysis of 26 observational 
studies confirmed an association between vitamin D deficiency and autoimmune 
Hashimoto’s thyroiditis [130]. The aforementioned meta-analysis found that 
although there was heterogeneity between the results of the various studies per-
formed all over the globe, studies had similar results in populations from different 
countries and also in populations in different age ranges, in particular pediatric and 
adult populations.
3.7 Vitamin D deficiency and systemic sclerosis
Systemic sclerosis is a chronic, inflammatory, fibrotic disorder thought to be 
related to autoimmune etiology. Vitamin D deficiency has been observed in patients 
with systemic sclerosis [86, 131], especially in patients with the diffuse type of the 
disease [131].
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4. Optimal levels of 25(OH)D3
The molecule used to assess vitamin D sufficiency in a population is 25(OH)D3 
[9]. It appears that vitamin D has physiologic effects beyond those related to bone 
physiology and mineral homeostasis. It may be that the alarming prevalence of 
vitamin D deficiency observed all over the globe may be contributing to the devel-
opment of autoimmune diseases. Based on bone-related biomarkers such as intact 
parathyroid hormone, calcium absorption, and bone mineral density, maintaining a 
25(OH)D3 level of at least 32 ng/ml appears sufficient.
5. Conclusions
It appears that vitamin D is a potent immunomodulator. It has multiple and 
diverse effects on the immune system. In particular, it potentiates the innate 
immune response enhancing the production of cathelicidin from human mac-
rophages, monocytes, and keratinocytes, thus enhancing and potentiating the 
immune response against external pathogens. It affects the adaptive immune 
response shifting the phenotype of the adaptive immune response toward a more 
tolerogenic phenotype. Vitamin D deficiency is related to various autoimmune 
disorders. Vitamin D deficiency appears to be related to the development of RA and 
correlates with disease severity. Vitamin D deficiency is observed in patients with 
SLE. It was found to be related to disease severity and activity in some but not all 
studies. Vitamin D deficiency is observed in patients with multiple sclerosis, and 
vitamin D administration may ameliorate disease severity. Vitamin D deficiency 
is also observed in patients with inflammatory bowel disease, Crohn’s disease, and 
ulcerative colitis, and it is related to disease activity. Vitamin D contributes to the 
integrity of the intestinal barrier and bacterial homeostasis. In addition, vitamin D 
absorption is decreased making supplementation important. Vitamin D deficiency 
is also observed in patients with autoimmune Hashimoto’s thyroiditis. Vitamin D 
deficiency is found in patients with systemic sclerosis, especially the diffuse form 
of the disease. It appears that optimal levels of vitamin D are important for immune 
function and for the prevention of autoimmunity in the human organism.
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Vitamin D Deficiency in Renal 
Disease
Jean Jeanov Filipov and Emil Paskalev Dimitrov
Abstract
Vitamin D deficiency is highly prevalent in patients with renal disease. The 
abnormal vitamin D (VD) metabolism in chronic kidney disease (CKD) is a key fac-
tor for developing CKD-related mineral bone disease (CKD-MBD), which directly 
influences the survival of the CKD patients. The importance of VD is perhaps of 
greater value due to its pleiotropic effects that span beyond calcium-phosphorus 
metabolism (cancer protection, diabetes prevention, and renal protection). The aim 
of our chapter is to depict the clinical implications of VD deficiency in the setting 
of CKD, including VD pleiotropy in renal disease, and to propose the most adequate 
treatment suggested in the literature.
Keywords: vitamin D deficiency, chronic kidney disease, mineral bone disease, 
vitamin D pleiotropy, vitamin D supplementation
1. Introduction
Vitamin D (VD) deficiency is a growing problem worldwide [1]. Due to the 
wide distribution of the vitamin D receptor in human body, the effect of VD spans 
beyond calcium-phosphorus and bone metabolism—VD deficiency is associated 
with higher prevalence of hypertension, diabetes mellitus, and neoplasia [2]. As 
kidneys play an important role in the metabolism of VD, patients with chronic kid-
ney disease (CKD) are at increased risk for VD deficiency. The aim of our chapter 
is to demonstrate the clinical implications of vitamin D deficiency in CKD and 
to outline the possible treatment options in this group of patients. In our review, 
a stress is laid on clinical trials due to their greater relevance to everyday clinical 
practice, compared to in vitro and animal models.
2.  Definition: vitamin D deficiency, vitamin D sufficiency, chronic 
kidney disease
VD status is being evaluated via the serum level of 25-hydroxyvitamin D 
(25VD)—the metabolite formed in the first hydroxylation in the liver, due to its 
longer half-life (approx. 3 weeks), compared to the active metabolite 1,25-dihy-
droxyvitamin D (1,25VD) (4–6 hours). The best options for 25VD serum level 
evaluation methods are high performance liquid chromatography (HPLC) and 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). There are reports, 
discussing the use of free 25VD as indicator of VD status. However, in renal disease, 
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Vitamin D deficiency is highly prevalent in patients with renal disease. The 
abnormal vitamin D (VD) metabolism in chronic kidney disease (CKD) is a key fac-
tor for developing CKD-related mineral bone disease (CKD-MBD), which directly 
influences the survival of the CKD patients. The importance of VD is perhaps of 
greater value due to its pleiotropic effects that span beyond calcium-phosphorus 
metabolism (cancer protection, diabetes prevention, and renal protection). The aim 
of our chapter is to depict the clinical implications of VD deficiency in the setting 
of CKD, including VD pleiotropy in renal disease, and to propose the most adequate 
treatment suggested in the literature.
Keywords: vitamin D deficiency, chronic kidney disease, mineral bone disease, 
vitamin D pleiotropy, vitamin D supplementation
1. Introduction
Vitamin D (VD) deficiency is a growing problem worldwide [1]. Due to the 
wide distribution of the vitamin D receptor in human body, the effect of VD spans 
beyond calcium-phosphorus and bone metabolism—VD deficiency is associated 
with higher prevalence of hypertension, diabetes mellitus, and neoplasia [2]. As 
kidneys play an important role in the metabolism of VD, patients with chronic kid-
ney disease (CKD) are at increased risk for VD deficiency. The aim of our chapter 
is to demonstrate the clinical implications of vitamin D deficiency in CKD and 
to outline the possible treatment options in this group of patients. In our review, 
a stress is laid on clinical trials due to their greater relevance to everyday clinical 
practice, compared to in vitro and animal models.
2.  Definition: vitamin D deficiency, vitamin D sufficiency, chronic 
kidney disease
VD status is being evaluated via the serum level of 25-hydroxyvitamin D 
(25VD)—the metabolite formed in the first hydroxylation in the liver, due to its 
longer half-life (approx. 3 weeks), compared to the active metabolite 1,25-dihy-
droxyvitamin D (1,25VD) (4–6 hours). The best options for 25VD serum level 
evaluation methods are high performance liquid chromatography (HPLC) and 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). There are reports, 
discussing the use of free 25VD as indicator of VD status. However, in renal disease, 
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the ratio between free and total 25VD remained unchained; therefore, total 25VD is 
the indicator of VD status in CKD [3].
Generally, 25VD level has reverse association with parathyroid hormone (PTH) 
levels. In addition, higher 25VD is associated with higher calcium intestinal reab-
sorption. However, at 25VD ≥ 75 nmol/l, no reduction in PTH levels and no increase 
in calcium intestinal reabsorption occurs [4, 5]. Therefore, 25VD ≥ 75 nmol/l is 
regarded as a cut-off value for vitamin D sufficiency.
No generally accepted definition for VD deficiency exists, as authors choose cut-off 
value either serum 25VD of 25 nmol/L [6] or serum 25VD of 50 nmol/L [7]. However, 
target levels of 75 nmol/L are recommended, taking into consideration the clinical 
importance of mild VD insufficiency (25VD between 50 and 74.9 nmol/L) [7, 8].
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure 
or function, present for more than 3 months, with implications for health [one 
of the following: estimated glomerular filtration rate (eGFR) less than 60 ml/
min/1.73 m2,presence of proteinuria, structural abnormalities of the kidney 
detected on imaging, pathological findings detected on kidney biopsy, urine 
sediment pathology, electrolyte abnormalities due to tubular disorders, history of 
kidney transplantation] [9]. CKD patients are at increased risk for VD deficiency; 
therefore, they require VD screening [7].
3. Vitamin D metabolism in health and renal disease
3.1 VD metabolism in healthy subjects
VD is synthesized predominantly endogenously (approx. to 90% of the total 
VD in human body). In the skin, the ultraviolet light transforms 7-dehydroxycho-
lesterol (provitamin D) to pre-vitamin D, which under the influence of body tem-
perature spontaneously isomerizes to cholecalciferol (vitamin D3). Approximately, 
10% of total body VD is taken orally (vitamin D2, ergocalciferol, and cholecalcif-
erol). VD is transported via VD-binding protein to the liver, where it is hydroxyl-
ated to 25VD. The next step in VD activation is hydroxylation of 25VD by the 
enzyme 1α-hydroxylase (CYP27B1) to 1,25VD, which is the active VD metabolite. 
The process occurs predominantly in the renal tubules. In addition, non-renal 
CYP27B1 was detected in skin (basal keratinocytes and hair follicles), lymph nodes 
(granulomata), colon (epithelial cells and parasympathetic ganglia), pancreas 
(islets), adrenal medulla, brain (cerebellum and cerebral cortex), prostate epithe-
lial cells, and placenta (decidual and trophoblastic cells) [10], indicating the wider 
significance of the VD metabolites. Finally, 1,25VD is inactivated by the enzyme 
24-hydroxylaze.
1,25VD exerts its effect via the vitamin D receptor (VDR), which is detected in 
all human organs. 1,25VD binds to VDR, the complex forms a heterodimer with 
the receptor for retinoid X (RXR) within the nucleus. The 1,25VD-VDR-RXR 
complex binds to vitamin D reacting elements, modulating gene expression. The 
highest expression of VDR is detected in bones, small intestines, and parathyroid 
gland. VDR activation leads to influencing bone metabolism), increase of calcium 
and phosphate absorption, and PTH secretion suppression. However, due to the 
wider VDR distribution in human body, its activation is associated with effects 
beyond influencing calcium-phosphorus metabolism–renin-angiotensin system 
(RAS) suppression and cardiac hypertrophy prevention (myocardial VDR), diabe-
tes mellitus control (pancreatic VDR), and immune system modulation (VDR in 
the immune cells).
The above-mentioned stages of VD metabolism form the so called VD axis.
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3.2 VD metabolism in CKD
All levels of VD metabolism are significantly affected in renal disease.
Cholecalciferol synthesis is reduced in uremic skin. In addition, these patients 
are usually older, with reduced exposure to sunlight, which is additionally associ-
ated with poorer skin VD synthesis. What is more, oral VD intake is decreased due 
to protein intake reduction.
25VD is reduced in CKD due to reduced amount of its precursor, increased loss 
in nephrotic patients, and 25VD sequestration in adipose tissue due to higher rate of 
obesity in CKD patients [11, 12].
Even during the initial stages of CKD (eGFR below 60 ml/min/1.73 m2) due to 
reduced phosphate tubular excretion, higher levels of fibroblast growth factor 23 
(FGF-23) occur, which suppress CYP27B1 activity. Furthermore, phosphatemia and 
metabolic acidosis decrease enzyme activity too. In addition, 1,25VD levels in renal 
disease are reduced because of increased catabolism due to increased FGF-23 levels. 
Finally, the smaller number of functioning tubules is directly associated with lower 
1,25VD production in advanced CKD.
VDR is affected in CKD too. Low 1,25VD downregulates of VDR expression [13]. 
In areas of nodular growth in the parathyroid gland reduced VDR content is detected. 
In uremia, there is significant decrease in VDR-RXR binding to vitamin D reacting 
elements, as well as reduced RXR content in the parathyroid glands, explaining 
increased PTH levels without the presence of hypocalcaemia and hyperphosphatemia 
[14]. Hypocalcaemia in advanced CKD increases the parathyroid levels of calreticulin, 
a cytosolic protein that binds the DNA-binding domain of nuclear receptors, thus 
blocking VDR-mediated transactivation. Higher levels of inflammatory cytokines 
were found to be associated with impaired binding of VDR-RXR to vitamin D 
VD axis Healthy subjects In CKD
Cholecalciferol/ergocalciferol Skin synthesis from 
UV light or oral intake
• Reduced skin synthesis (age, 
uremia, reduced UV exposure)
• Reduced oral intake
25-hydroxyvitamin D(25VD) Hepatic synthesis 
(25-hydroxylase)
• Reduced amount of its precursor
• Increased loss in nephrotic 
patients
• 25VD sequestration in adipose 
tissue
1,25-dihydroxyvitamin D(1,25VD) Hydroxylation 




• Suppressed 1α-hydroxylase 
activity
• Reduced synthesis in renal tubules 
in advanced CKD
Vitamin D receptor(VDR) Widely spread 
in human body, 




In all other organs 
(pleiotropy)
• Downregulated expression (low 
1,25VD, hypocalcaemia)
• Impaired binding to VDRE 
(uremia, inflammatory cytokines, 
etc.)
• Reduced VDR content in parathy-
roid glands (hypertrophy)
CKD, chronic kidney disease; VDRE, vitamin D reacting elements; UV, ultraviolet.
Table 1. 
Vitamin D axis in health and in renal disease.
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are usually older, with reduced exposure to sunlight, which is additionally associ-
ated with poorer skin VD synthesis. What is more, oral VD intake is decreased due 
to protein intake reduction.
25VD is reduced in CKD due to reduced amount of its precursor, increased loss 
in nephrotic patients, and 25VD sequestration in adipose tissue due to higher rate of 
obesity in CKD patients [11, 12].
Even during the initial stages of CKD (eGFR below 60 ml/min/1.73 m2) due to 
reduced phosphate tubular excretion, higher levels of fibroblast growth factor 23 
(FGF-23) occur, which suppress CYP27B1 activity. Furthermore, phosphatemia and 
metabolic acidosis decrease enzyme activity too. In addition, 1,25VD levels in renal 
disease are reduced because of increased catabolism due to increased FGF-23 levels. 
Finally, the smaller number of functioning tubules is directly associated with lower 
1,25VD production in advanced CKD.
VDR is affected in CKD too. Low 1,25VD downregulates of VDR expression [13]. 
In areas of nodular growth in the parathyroid gland reduced VDR content is detected. 
In uremia, there is significant decrease in VDR-RXR binding to vitamin D reacting 
elements, as well as reduced RXR content in the parathyroid glands, explaining 
increased PTH levels without the presence of hypocalcaemia and hyperphosphatemia 
[14]. Hypocalcaemia in advanced CKD increases the parathyroid levels of calreticulin, 
a cytosolic protein that binds the DNA-binding domain of nuclear receptors, thus 
blocking VDR-mediated transactivation. Higher levels of inflammatory cytokines 
were found to be associated with impaired binding of VDR-RXR to vitamin D 
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reacting elements, contributing to vitamin D resistance in patients on hemodialysis 
[15]. Finally, hypocalcaemia in CKD suppresses the calcium-sensing receptor (CaSR) 
in the parathyroid glands, which in turn downregulates parathyroid VDR expression; 
use of calcimimetics upregulated VDR expression in rat models [16].
The VD axis in health and renal disease is depicted in Table 1.
4. Vitamin D deficiency: clinical implications in renal disease
The major mechanisms for abnormal VD metabolism and VD deficiency were 
outlined in the section above. Of particular importance is hyperphosphatemia, 
caused by initial renal damage, leading to higher FGF-23 levels, which in turn 
suppresses CYP27B1 activity and increases 1,25VD catabolism. Suboptimal VD 
levels are the basis of the abnormal calcium-phosphate metabolism in renal disease. 
Currently, the term CKD-associated mineral bone disorder (CKD-MBD) is used 
to define the wide spectrum of CKD-related abnormalities in calcium-phosphate 
metabolism, as their importance spans beyond bone health.
4.1 CKD-associated mineral bone disorder (CKD-MBD)
CKD-MBD comprises of three major aspects—biochemical abnormalities, bone 
changes, and vascular calcifications [17].
4.1.1 Biochemical abnormalities in CKD-MBD
The biochemical abnormalities in CKD-MBD represent the laboratory aspect 
of the disorder. These include calcium level (ionized or total), phosphate level, 
PTH, alkaline phosphatase (total or bone specific), and VD status (25VD). Other 
indicators, such as 1,25VD and FGF-23 are not measured routinely. The earliest 
changes occur in PTH and VD metabolites—the abnormal values for PTH, 25VD 
and 1,25VD are detected in eGFR<60 ml/min/1.73 m2, whereas abnormal calcium 
and phosphate levels are detected in eGFR below 40 and remain stable until 
eGFR<20 ml/min/1.73 m2 [18].
According to the current guidelines, testing for calcium, phosphate, PTH, and 
alkaline phosphatase should be initiated in eGFR<60 ml/min/1.73 m2; the frequency 
of laboratory evaluation should be based on the rate of CKD progression, the 
magnitude of abnormalities, and the evaluation of treatment’s effectivity. Similarly, 
25VD should be tested in patients with eGFR<60 ml/min/1.73 m2 and frequency of 
testing depends on baseline values and therapeutic interventions [17]. The timing 
and frequency suggested by Kidney Disease: Improving Global Outcomes (KDIGO) 
are summarized in Table 2.
4.1.2 Bone disorders in CKD-MBD
Bone involvement in CKD [renal osteodystrophy (ROD)] is of pivotal 
importance, as it is associated with bone fractures (asymptomatic or symptom-
atic), bleeding, chronic disability, poorer life quality, and higher mortality in 
renal disease. In children with CKD, it leads to growth retardation and skeletal 
deformities [17].
Several types of bone histological changes can be detected in CKD, according 
to three major histological indicators: turnover, mineralization, and volume. Bone 
turnover (T) is a parameter, corresponding to bone formation rate. It can be abnor-
mally low, normal, or very high and is best assessed via bone biopsy and tetracycline 
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labeling. Mineralization (M) is the second parameter. Normally, the osteoblasts lay 
down new collagen and direct mineralization of the matrix. This process is impaired 
in CKD, leading to thickened osteoid. Mineralization is measured by osteoid matu-
ration time and mineralization lag time. The osteoid maturation time is the osteoid 
width divided by the distance between labels per day. The mineralization lag time 
is the osteoid maturation time adjusted for the percentage of osteoid surface that 
has a tetracycline label. Mineralization is classified as normal and abnormal. Bone 
volume (V) sums up bone formation and resorption rates. It is generally accepted 
that bone volume is expressed as bone volume per tissue volume and is classified as 
low, normal, and high bone volume.
According to the TMV classification of bone histology in CKD, the following 
ROD categories are recognized [19]:
1. Adynamic bone disease (AD)—low-turnover bone disease with normal miner-
alization. Volume can be low, but in some patients with normal mineralization 
and low turnover, it will be normal. AD is usually associated with PTH over-
suppression, including overdose of VD analogs or calcitriol
2. Mild secondary hyperparathyroidism related bone disease (MHPTBD)—medi-
um-to high bone turnover, any bone volume, normal mineralization
3. Osteitis fibrosa (OF)—represents a more advanced form of high-turnover dis-
ease, compared to MHPT, any bone volume and normal mineralization
4. Osteomalacia (OM)—low-turnover bone with abnormal mineralization. The 
bone volume may be low to medium, depending on the severity and duration 
of the process and other factors that affect bone health
5. Mixed uremic osteodystrophy (MUO)—represents features of the above men-
tioned variants; for example, a combination of high-turnover, normal bone 
volume, with abnormal mineralization
In addition, age related/postmenopausal osteoporosis can be detected. 
Measurement of bone mineral density [by using dual-energy X-ray absorpti-
ometry (DXA)] is most informative in CKD stages 1–2; in these cases, low BMD 
is associated with osteoporosis and treatment is performed as in the general 
population. Patients with low BMD and CKD stages 3–5 are designated as having 
CKD-MBD with low BMD. Recent reports demonstrate that BMD testing can 
predict fracture risk in eGFR<60 ml/min/1.73 m2. The current KDIGO guidelines 
broaden the indications for BMD testing in CKD stages 3–5D to assess fracture 
risk, if it will have effect on treatment. Finally, normal histology is also possible 
[17, 20].
Indicator CKD stage 3 CKD stage 4 CKD stage 5 and on dialysis 
(CKD 5D)
Calcium and phosphorus 6–12 months 3–6 months 1–3 months
PTH and alkaline phosphatase Baseline 6–12 months 3–6 months
25-Hydroxyvitamin D Baseline Baseline Baseline
CKD, chronic kidney disease; PTH, parathyroid hormone.
Table 2. 
Suggested testing for biochemical indicators of CKD-MBD according to CKD stage.
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volume (V) sums up bone formation and resorption rates. It is generally accepted 
that bone volume is expressed as bone volume per tissue volume and is classified as 
low, normal, and high bone volume.
According to the TMV classification of bone histology in CKD, the following 
ROD categories are recognized [19]:
1. Adynamic bone disease (AD)—low-turnover bone disease with normal miner-
alization. Volume can be low, but in some patients with normal mineralization 
and low turnover, it will be normal. AD is usually associated with PTH over-
suppression, including overdose of VD analogs or calcitriol
2. Mild secondary hyperparathyroidism related bone disease (MHPTBD)—medi-
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3. Osteitis fibrosa (OF)—represents a more advanced form of high-turnover dis-
ease, compared to MHPT, any bone volume and normal mineralization
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bone volume may be low to medium, depending on the severity and duration 
of the process and other factors that affect bone health
5. Mixed uremic osteodystrophy (MUO)—represents features of the above men-
tioned variants; for example, a combination of high-turnover, normal bone 
volume, with abnormal mineralization
In addition, age related/postmenopausal osteoporosis can be detected. 
Measurement of bone mineral density [by using dual-energy X-ray absorpti-
ometry (DXA)] is most informative in CKD stages 1–2; in these cases, low BMD 
is associated with osteoporosis and treatment is performed as in the general 
population. Patients with low BMD and CKD stages 3–5 are designated as having 
CKD-MBD with low BMD. Recent reports demonstrate that BMD testing can 
predict fracture risk in eGFR<60 ml/min/1.73 m2. The current KDIGO guidelines 
broaden the indications for BMD testing in CKD stages 3–5D to assess fracture 
risk, if it will have effect on treatment. Finally, normal histology is also possible 
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Indicator CKD stage 3 CKD stage 4 CKD stage 5 and on dialysis 
(CKD 5D)
Calcium and phosphorus 6–12 months 3–6 months 1–3 months
PTH and alkaline phosphatase Baseline 6–12 months 3–6 months
25-Hydroxyvitamin D Baseline Baseline Baseline
CKD, chronic kidney disease; PTH, parathyroid hormone.
Table 2. 
Suggested testing for biochemical indicators of CKD-MBD according to CKD stage.
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It should be noted that histological findings differ according to renal replace-
ment type. In patients on hemodialysis OF and MUO are the most common find-
ings, in peritoneal dialysis–AD is detected in up to 50%, whereas in patients in CKD 
stages 3–5 not on dialysis the most common findings are OF and MUO. However, in 
the latter group, the highest percentage of normal histology is detected [20].
Bone biopsy is regarded as the golden standard for the precise diagnosis of the 
bone changes in CKD-MBD. Indications for bone biopsy are bone fractures, bone 
pain, unexplained hypercalcemia/hypophosphatemia, evaluation of the type of 
bone turnover (which may lead to treatment correction), and suspected aluminum 
toxicity. Planning antiresorptive treatment in eGFR<30 ml/min/1.73 m2 is currently 
not an indication for bone biopsy, as no evidence exists, linking bisphosphonate use 





Bone pain Bone pain
Calciphylaxis Calciphylaxis
Bone fractures Bone fractures




Vomiting, nausea, hypertension 
(hypercalcemia)





Serum calcium N in early stages
↓/N/↑ in advanced HTMBD
Early stages N/↑
Advanced stages—↑↑
Serum phosphate N in early stages
N to very high in advanced stages
Early stages N/↓
Advanced—↓/↑
BAP N in early stages
↑ in advanced HTMBD
Early stages N/↓
Advanced—↓
PTH N/↑ in early stages




Subperiosteal erosions—hands, clavicles, and 
pelvis
Fractures
Vertebral osteosclerosis Looser zones
Brown tumors Bone deformities
Extraskeletal calcifications Osteopenia and osteoporosis
Histology HTMBD LTMBD
OF, MHPTBD AD, OM
PTH, parathyroid hormone; BAP, bone specific alkaline phosphatase; N, normal; ↓, decreased; ↑, increased values; 
OF, osteitis fibrosa; MHPTBD, mild secondary hyperparathyroidism related bone disease; AD, adynamic bone 
disease; OM, osteomalacia.
Table 3. 
Clinical presentation, laboratory, radiologic and histologic findings in low turnover mineral bone disease 
(LTMBD) and high turnover mineral bone disease (HTMBD).
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of the procedure are pain, laborious procedure, time-consuming, and expensive 
histological evaluation, as well as insufficient histopathological expertise [21].
These limitations restrict the wide use of bone biopsy. Therefore, markedly elevated 
PTH and bone-specific alkaline phosphatase can be used in clinical practice to predict 
bone turnover in CKD-MBD. Thus, two types of mineral bone diseases are defined—
high turnover mineral bone disease (HTMBD) and low turnover mineral bone disease 
(LTMBD). In cases, in which clinical and laboratory data are inconclusive of the type of 
bone turnover, bone biopsy should be considered [17]. The clinical, laboratory, radio-
logical, and histological characteristics of the both entities are summarized in Table 3.
4.1.3 Vascular calcification in CKD-MBD
Vascular calcification (VC) is deposition of calcium phosphate in vascular tis-
sues. It presents with calcification of arterial media, intima, valves, and rarely with 
calcific uremic arteriolopathy (calciphylaxis). Normally, this occurs with aging. 
However, the process is accelerated in CKD and leads to increased mortality and 
morbidity. Initially, it was regarded as a finding in patients with end-stage renal 
disease (ESRD), but currently, it is detected in early CKD stages in adults and in 
children with ESRD, thus depicting a more complicated picture [22].
Patients with VC are regarded as having the highest risk for cardiovascular 
events. The diagnosis is based on abdominal lateral radiograph (vascular calcifica-
tions), echocardiogram (valvular calcifications), or computer tomography [17].
The association of VC with VD status in CKD is not well defined as contradicting 
reports exist. Two report demonstrate, that lower serum 1,25VD is associated with 
increased risk for and demonstrated that 25VD has no association with VC [23, 24]. 
As arterial stiffening is regarded as related pathology to VC in CKD, it should be 
noted that two recent interventional studies demonstrated improvement of endo-
thelial dysfunction in CKD patients after cholecalciferol supplementation [25–27]. 
Higher serum levels of 1,25VD and high doses of VD supplementation increased the 
risk for VC [23, 28], thus indicating the dual role of VD in vascular health.
Finally, the type of VD treatment may be important too. Generally, vitamin 
D analogs (VDA) demonstrate similar effectivity in reduction of PTH levels to 
calcitriol, with lower toxicity—lower rates of hypercalcemia and hyperphosphate-
mia, thus suggesting lower risk for supplementation-enhanced VC. Unfortunately, 
more trails are needed to evaluate the effect of different supplementation types 
on VC prevalence. In addition, new VDA are being evaluated in the treatment of 
CKD-MBD, with more expressed cardiac protection and less hypercalcemia and 
hyperphosphatemia than paricalcitol [29–31].
4.2 VD pleiotropy in renal disease
As mentioned above, the VDR and the enzyme CYP27B1 have wider distribution 
in the body and are being expressed in organs not involved in calcium-phosphate 
metabolism. This indicates a greater physiological importance of the VD axis, span-
ning beyond skeletal physiology. These extraskeletal properties are designated as 
pleiotropic effects of VD. In this sub-section, the current knowledge of VD pleiot-
ropy in CKD patients will be presented.
4.2.1 VD pleiotropy in CKD: proteinuria and CKD progression
Poorer VD status was associated with higher proteinuria and faster progres-
sion of CKD. In addition, VDR activation was found to slow CKD progression in 
immune and non-immune renal diseases.
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It should be noted that histological findings differ according to renal replace-
ment type. In patients on hemodialysis OF and MUO are the most common find-
ings, in peritoneal dialysis–AD is detected in up to 50%, whereas in patients in CKD 
stages 3–5 not on dialysis the most common findings are OF and MUO. However, in 
the latter group, the highest percentage of normal histology is detected [20].
Bone biopsy is regarded as the golden standard for the precise diagnosis of the 
bone changes in CKD-MBD. Indications for bone biopsy are bone fractures, bone 
pain, unexplained hypercalcemia/hypophosphatemia, evaluation of the type of 
bone turnover (which may lead to treatment correction), and suspected aluminum 
toxicity. Planning antiresorptive treatment in eGFR<30 ml/min/1.73 m2 is currently 
not an indication for bone biopsy, as no evidence exists, linking bisphosphonate use 





Bone pain Bone pain
Calciphylaxis Calciphylaxis
Bone fractures Bone fractures




Vomiting, nausea, hypertension 
(hypercalcemia)





Serum calcium N in early stages
↓/N/↑ in advanced HTMBD
Early stages N/↑
Advanced stages—↑↑
Serum phosphate N in early stages
N to very high in advanced stages
Early stages N/↓
Advanced—↓/↑
BAP N in early stages
↑ in advanced HTMBD
Early stages N/↓
Advanced—↓
PTH N/↑ in early stages




Subperiosteal erosions—hands, clavicles, and 
pelvis
Fractures
Vertebral osteosclerosis Looser zones
Brown tumors Bone deformities
Extraskeletal calcifications Osteopenia and osteoporosis
Histology HTMBD LTMBD
OF, MHPTBD AD, OM
PTH, parathyroid hormone; BAP, bone specific alkaline phosphatase; N, normal; ↓, decreased; ↑, increased values; 
OF, osteitis fibrosa; MHPTBD, mild secondary hyperparathyroidism related bone disease; AD, adynamic bone 
disease; OM, osteomalacia.
Table 3. 
Clinical presentation, laboratory, radiologic and histologic findings in low turnover mineral bone disease 
(LTMBD) and high turnover mineral bone disease (HTMBD).
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in the body and are being expressed in organs not involved in calcium-phosphate 
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ning beyond skeletal physiology. These extraskeletal properties are designated as 
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Poorer VD status was associated with higher proteinuria and faster progres-
sion of CKD. In addition, VDR activation was found to slow CKD progression in 
immune and non-immune renal diseases.
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In IgA nephropathy, human studies associated poorer VD status with poorer 
clinical outcomes [32]. In addition, calcitriol supplementation suppressed pro-
teinuria in IgA patients by activating the VDR and thus influencing cytokine and 
leukotriene metabolism [33].
Recent studies demonstrated the importance of VD axis in systemic lupus 
erythematosus (SLE) and lupus nephritis (LN). Poorer VD status correlated with 
higher SLE activity, whereas poorer VDR expression in renal tissue was linked to 
higher renal activity and more severe renal lesions in patients with LN [34, 35]. 
Podocyte autophagy is a key factor in renal involvement in LN. A recent study 
showed that poorer VD status correlated with higher podocyte autophagy activity 
and VD effectively suppressed it in LN, thus protecting podocytes from antibody-
mediated injury [36]. VD and VDR affect autophagy via different mechanisms: acti-
vating calcium-dependent intracellular kinases, downregulating mTOR expression, 
or upregulation of the cyclin-dependent kinase inhibitor p19INK4D [37].
However, VD has renoprotective effect in non-immune glomerular diseases too. 
In diabetic nephropathy (DN), both animal models and clinical trials demonstrate 
the negative correlation between low VD and the risk for DN and DN progression, 
as well as the beneficial effect of VD/VD analogs in reducing albuminuria, renal 
fibrosis, thus retarding disease progression [38, 39]. The effect can be explained with 
RAS suppression, suppression of inflammatory mediators [nuclear factor-kappa B 
(NF-κB), transforming growth factor-β(TGF-β)], suppressing the Wnt/β-catenin 
pathway, which is involved in epithelial to mesenchymal cell transition (EMT) in 
high glucose milieu, as well as upregulation of nephrin expression [39–41].
The mechanisms mentioned in DN (suppression of RAS, inflammation, EMT) 
are the basis of renal protection of VD in other renal diseases–in animal models and 
human clinical trials [33]. Additionally, an inverse correlation between VD status 
and proteinuria and blood pressure control in autosomal polycystic kidney disease 
(ADPKD) was reported, as well as reduction of proteinuria and hypertension on 
treatment with VDR agonist in experimental PKD. However, the findings are to be 
evaluated prospectively in interventional study in patients with ADPKD [42].
4.2.2 VD pleiotropy in CKD: autoimmunity, inflammation, and infection
The presence of VDR and CYP27B1 has been well recognized in the immune 
cells, which modulate their differentiation and proliferation. VD suppresses B-cell 
proliferation, modulates T-helper proliferation, favoring the T-helper type 2 sub-
type, thus suppressing inflammatory cytokine synthesis (IL17, IL21) and stimulat-
ing the production of anti-inflammatory ones (IL10). In addition, VD enhances the 
production of cathelicidin and β-defensin 2, as well as influences autophagy and 
apoptosis [33, 43]. All these properties of VD and VDR demonstrate the importance 
of VD axis in protective and pathological immunity.
4.2.2.1 VD and autoimmunity/inflammation
The role of VD in LN has been already discussed. Other studies, evaluating the 
VD–SLE association demonstrate that poorer VD is related to higher SLE activity 
in adults and children [44]. Different supplementation regimens also demon-
strated improvement in inflammatory markers, disease activity indices, decrease 
in T-helpers types 1 and 17 [44]. However, despite the different papers, reporting 
beneficial effect from VD, a recent study demonstrated increase of SLE activity 
after exposing patients to UV radiation, despite improvement in VD status [45]. 
Thus, the SLE-VD correlation still remains to be clarified.
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The rheumatoid arthritis (RA) and the inflammatory bowel disease (IBD) are 
diseases that influence kidney health by causing AA amyloidosis, which in turn 
progresses to ESRD. VD status was inversely associated with RA disease activity 
and RA-associated complications [46]. However, despite some reports, indicating 
beneficial effect of VD supplementation on T-helper 17 function, the results for VD 
supplementation currently are inconsistent [46, 47].
Several studies demonstrated lower VD status in patients with more aggressive 
IBD. However, the findings may be attributed to lower absorption of VD due to the 
active intestinal inflammation, especially in Crohn’s disease [48, 49]. Interventional 
studies also demonstrated the beneficial effect of VD supplementation in suppress-
ing pro-inflammatory markers in IBD. Yet, the importance of VD in IBD remains to 
be clarified [50, 51].
4.2.2.2 VD and infection
Infection is a well-recognized leading cause for death in CKD patients, especially 
those on dialysis. It was already mentioned that the VD axis plays a role in immunity 
by enhancing cathelicidin production. In dialysis patients, low cathelicidin levels were 
detected, which were associated with higher risk for infection and also modest corre-
lation to 1,25VD levels was discovered [52]. Interventional studies also demonstrated 
the decreased risk for infection in dialysis patients. VD supplementation reduced 
significantly the risk for hospitalization due to acute respiratory infections in hemo-
dialysis (HD) patients; in another study, VD supplementation decreased the risk for 
peritonitis in patients on peritoneal dialysis (PD) [53, 54]. A more recent study also 
demonstrated decrease in infection rates in dialysis patients treated with VDR analogs 
[55]. In contrast to these findings, Yildirim et al. failed to demonstrate a significant 
relation between VD status and inflammatory markers in CKD patients [56].
4.2.3 VD pleiotropy in CKD: neoplasia
An already mentioned paper demonstrated reduced malignancy-associated 
mortality in VDA-treated dialysis patients. However, the study did not evaluate 
the specific localization of the neoplasia, nor its histology [55]. Therefore, in this 
subsection, the most common malignant diseases will be reviewed and their asso-
ciation with VD. Unfortunately, the exact association between VD and neoplasia in 
CKD patients is not well evaluated, as CKD patients are usually excluded from large 
trials and registries [57].
4.2.3.1 Breast cancer
The reports evaluating the association between VD deficiency and breast cancer 
are inconsistent. The inverse association between breast cancer and VD, detected in 
several studies was not supported by more recent prospective studies. In addition, 
a controversy exists about the beneficial effect of VD supplementation on breast 
cancer risk and survival [44]. Unfortunately, the cited studies did not demonstrate 
data for CKD patients.
4.2.3.2 Colorectal cancer
Several studies demonstrate an inverse correlation between colorectal cancer 
and 25VD levels [58, 59]. The findings do not correspond to the results of a larger 
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The rheumatoid arthritis (RA) and the inflammatory bowel disease (IBD) are 
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progresses to ESRD. VD status was inversely associated with RA disease activity 
and RA-associated complications [46]. However, despite some reports, indicating 
beneficial effect of VD supplementation on T-helper 17 function, the results for VD 
supplementation currently are inconsistent [46, 47].
Several studies demonstrated lower VD status in patients with more aggressive 
IBD. However, the findings may be attributed to lower absorption of VD due to the 
active intestinal inflammation, especially in Crohn’s disease [48, 49]. Interventional 
studies also demonstrated the beneficial effect of VD supplementation in suppress-
ing pro-inflammatory markers in IBD. Yet, the importance of VD in IBD remains to 
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Infection is a well-recognized leading cause for death in CKD patients, especially 
those on dialysis. It was already mentioned that the VD axis plays a role in immunity 
by enhancing cathelicidin production. In dialysis patients, low cathelicidin levels were 
detected, which were associated with higher risk for infection and also modest corre-
lation to 1,25VD levels was discovered [52]. Interventional studies also demonstrated 
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significantly the risk for hospitalization due to acute respiratory infections in hemo-
dialysis (HD) patients; in another study, VD supplementation decreased the risk for 
peritonitis in patients on peritoneal dialysis (PD) [53, 54]. A more recent study also 
demonstrated decrease in infection rates in dialysis patients treated with VDR analogs 
[55]. In contrast to these findings, Yildirim et al. failed to demonstrate a significant 
relation between VD status and inflammatory markers in CKD patients [56].
4.2.3 VD pleiotropy in CKD: neoplasia
An already mentioned paper demonstrated reduced malignancy-associated 
mortality in VDA-treated dialysis patients. However, the study did not evaluate 
the specific localization of the neoplasia, nor its histology [55]. Therefore, in this 
subsection, the most common malignant diseases will be reviewed and their asso-
ciation with VD. Unfortunately, the exact association between VD and neoplasia in 
CKD patients is not well evaluated, as CKD patients are usually excluded from large 
trials and registries [57].
4.2.3.1 Breast cancer
The reports evaluating the association between VD deficiency and breast cancer 
are inconsistent. The inverse association between breast cancer and VD, detected in 
several studies was not supported by more recent prospective studies. In addition, 
a controversy exists about the beneficial effect of VD supplementation on breast 
cancer risk and survival [44]. Unfortunately, the cited studies did not demonstrate 
data for CKD patients.
4.2.3.2 Colorectal cancer
Several studies demonstrate an inverse correlation between colorectal cancer 
and 25VD levels [58, 59]. The findings do not correspond to the results of a larger 
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study, detecting no significant association between colorectal cancer and VD status 
[60]. Unfortunately, the data from interventional trails with VD supplementation 
also have conflicting result for the effect of VD on colorectal cancer prevention and 
survival improvement [44, 61]. Similarly to breast cancer, the data for the associa-
tion between colorectal cancer and VD status in renal patients is limited.
4.2.3.3 Other neoplasms
The results about the influence of VD on the risk for other malignancies are 
controversial. A large study (n = 70,563) evaluated the association of 25VD levels on 
the risk for prostate cancer, breast cancer, lung cancer, pancreatic cancer, colorectal 
cancer, ovarian cancer, and neuroblastoma. 25VD concentrations did not corre-
spond to the risk for any of the mentioned neoplasias. Therefore, the authors do not 
support the regular VD screening as an attempt for cancer prevention [62]. In addi-
tion, a large multicenter study in patients on hemodialysis also did not demonstrate 
significant association between total cancer prevalence and VD deficiency [63].
Multiple myeloma (MM) is a plasma cell disease that often presents with 
kidney manifestations. Several studies reported high rates of VD deficiency in MM 
patients and specific alleles for VDR were associated with higher risk for MM [64, 
65]. Lauter and Schmidt-Wolf established that lower VD levels were associated 
with more expressed plasma cell infiltration of the bone marrow. In this study, VD 
supplementation improved anemia, led to higher white blood cell and lower platelet 
count [66]. Yet, the risk for hypercalcemia should be taken into consideration when 
VD supplementation is applied in MM patients.
4.2.4 VD pleiotropy in CKD: diabetes mellitus, cardiovascular disease (CVD)
4.2.4.1 VD and diabetes mellitus
Basic science studies demonstrated improvement in glucose metabolism due 
to immunomodulatory effect (especially in diabetes type 1), improvement of β 
cell function by increase in insulin secretion, and decreasing insulin resistance by 
stimulating insulin receptor expression via activating the VDR. Other mechanisms 
such as RAS suppression and anti-inflammatory effect of VD were also taken into 
consideration. However, observational studies do not establish clear relationship 
between VD status and DM prevalence, as some studies support the association, 
whereas others do not [44]. Interventional trials also have conflicting results. 
Two recent prospective studies showed improvement in glucose metabolism after 
vitamin D supplementation was applied [67, 68]. Unfortunately, the studies did not 
evaluate patients with renal disease. Two interventional studies with paricalcitol 
failed to detect improvement in insulin resistance in patients CKD stages 3 and 4 
and in dialysis [69, 70].
4.2.4.2 VD and cardiovascular disease (CVD)
CVD is a leading cause for mortality in CKD. As VDR and 27CYPB1 are 
expressed in the cells of the cardiovascular system, it could be expected that the VD 
axis can play a beneficial role in cardio-vascular health. A possible cardioprotection 
can be explained with RAS suppression and anti-inflammatory effects; VDR activa-
tion can improve cardiac muscle cells contractility and modulate their proliferation 
and growth. In addition, VD can improve peripheral vascular health by affecting 
endothelial and smooth muscular cells too [71].
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Even though the association between VD deficiency and CVD has been recognized 
in the general population and in CKD, large randomized interventional studies failed 
to demonstrate improvement from VD supplementation in cardiovascular outcomes, 
cardiac structure, or function in CKD patients [72]. An improvement in blood pres-
sure control and endothelial function (as measured by brachial artery flow-mediated 
dilatation) was observed after VD supplementation in the general population; 
however, in CKD patients, no significant antihypertensive effect was detected [73]. 
Similarly, the results for the effect on VD supplementation on arterial stiffness and 
endothelial function are conflicting [72, 73]. Therefore, the use of VD in renal disease 
in order to improve cardiovascular events is currently not recommended [72].
4.2.5  VD pleiotropy in CKD: muscle health, cognitive function, peritoneal fibrosis, 
and anemia
4.2.5.1 Muscle health and cognitive function
In hemodialysis (HD) patients, a positive relationship between muscle strength 
and VD levels was detected, with optimal handgrip strength in 25VD above 30 ng/
ml (75 nmol/L). In ESRD patients, suboptimal VD was associated with lower quad-
riceps mass and increased risk for falls [74]. In addition, in PD patients, low 25VD 
was found to be the independent factor for global cognitive impairment due to the 
antioxidant and neuroprotective role of 1,25VD. This is of crucial importance, as 
PD is a home-based renal replacement therapy that needs adequate cognition and 
self-monitoring [75].
4.2.5.2 Anemia and peritoneal fibrosis
Treatment with VDA led to the improvement of anemia in ESRD patients. A pos-
sible mechanism is suppression of inflammation and direct stimulation of erythro-
poiesis. In addition, paricalcitol reduced PD-associated thickening of the peritoneum 
and prevented peritoneal fibrosis in animal models. However, recent study in PD 
patients did not detect any benefit from paricalcitol supplementation in preventing 
peritoneal remodeling. In contrast to these results, Kerschbaum et al. demonstrated 
protective effect of oral active VD against peritonitis in PD patients [33, 54, 76].
5. Vitamin D deficiency after kidney transplantation
Suboptimal 25VD is a commonly detected problem after kidney transplanta-
tion (KT) with prevalence above 80% of the kidney transplant recipients (KTRs). 
As KTRs are CKD patients, all mentioned factors, predisposing to impaired VD 
metabolism are valid for this cohort of patients, especially considering the fact that 
more than 50% of the KTRs have GFR<60 ml/min/1.73 m2. In addition, transplant-
specific factors influence VD synthesis: sun exposure avoidance due to the increased 
risk for skin malignancies, use of sun-protecting cosmetics (limiting further UV 
exposure), proteinuria after KT (increased loss in urine), higher prevalence of 
obesity after KT (reduced bioavailability), the presence of new onset diabetes after 
transplantation (NODAT) (by reducing intestinal absorption), use of steroids 
(increased 1,25VD catabolism), and calcineurin inhibitors (impaired 25VD liver 
synthesis) [77, 78]. Similarly to CKD in native kidneys, the VD-associated clinical 
implications after KT are categorized as post-transplant mineral bone disorder 
(PTMBD) and VD pleiotropy.
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stimulating insulin receptor expression via activating the VDR. Other mechanisms 
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vitamin D supplementation was applied [67, 68]. Unfortunately, the studies did not 
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failed to detect improvement in insulin resistance in patients CKD stages 3 and 4 
and in dialysis [69, 70].
4.2.4.2 VD and cardiovascular disease (CVD)
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expressed in the cells of the cardiovascular system, it could be expected that the VD 
axis can play a beneficial role in cardio-vascular health. A possible cardioprotection 
can be explained with RAS suppression and anti-inflammatory effects; VDR activa-
tion can improve cardiac muscle cells contractility and modulate their proliferation 
and growth. In addition, VD can improve peripheral vascular health by affecting 
endothelial and smooth muscular cells too [71].
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5. Vitamin D deficiency after kidney transplantation
Suboptimal 25VD is a commonly detected problem after kidney transplanta-
tion (KT) with prevalence above 80% of the kidney transplant recipients (KTRs). 
As KTRs are CKD patients, all mentioned factors, predisposing to impaired VD 
metabolism are valid for this cohort of patients, especially considering the fact that 
more than 50% of the KTRs have GFR<60 ml/min/1.73 m2. In addition, transplant-
specific factors influence VD synthesis: sun exposure avoidance due to the increased 
risk for skin malignancies, use of sun-protecting cosmetics (limiting further UV 
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obesity after KT (reduced bioavailability), the presence of new onset diabetes after 
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synthesis) [77, 78]. Similarly to CKD in native kidneys, the VD-associated clinical 
implications after KT are categorized as post-transplant mineral bone disorder 
(PTMBD) and VD pleiotropy.
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5.1 Post-transplant mineral bone disorder
Similarly to native kidneys, PTMBD consists of three aspects—biochemical 
abnormalities, bone involvement, vascular pathology and is associated with higher 
risk for fractures and death.
5.1.1 PTMBD: biochemical abnormalities
Significant changes occur in the biochemical indicators of calcium-phosphorus 
metabolism after KT. In the early post-transplant period, the fluctuations in the 
parameters are more pronounced as the graft function is rapidly changing. Due to 
the presence of functioning renal tubules and still high levels of PTH and FGF-23, 
hypophosphatemia and mild hypercalcemia are common. These changes usually 
normalize within months after KT as graft function stabilizes. Therefore, the 
current KDIGO guidelines recommend at least weekly testing for calcium and 
phosphorus immediately after KT [17]. FGF-23 and PTH rapidly decrease; however, 
PTH may be significantly elevated years after successful KT due to parathyroid cell 
hypertrophy. VD levels are low in the early post-transplant period; yet, suboptimal 
levels are very common later after KT [78].
In the late post-transplant period, current guidelines recommend the testing for 
calcium, phosphorus, PTH, and alkaline phosphatase to be performed according 
to the magnitude of the abnormalities, rate of progression of post-transplant CKD, 
and the presence of medical treatment. Practically, the timing is similar to patients 
with CKD stage 3–5 with native kidneys (see Table 2). 25VD should be tested at 
baseline and repeated testing should be performed according to the initial level and 
the presence of medical interventions. In our center, 25VD levels are monitored 
twice annually, taking into consideration its seasonal variations in the general popu-
lation. Thus, a significant deterioration of VD status in the winter/fall was detected, 
allowing adequate seasonal supplementation to be initiated.
5.1.2 PTMBD: bone disease
Post-transplant bone disease is commonly observed after KT and encompasses 
ROD, osteoporosis, bone fractures, and osteonecrosis. Deterioration in BMD occurs 
mainly during the first 12 months, though BMD loss persists at lower rates after the 
first post-transplant year. The etiology is multifactorial: pre-existing CKD-MBD, 
duration of dialysis and transplantation, poor graft function, hypogonadism, 
higher rates of diabetes after KT, suboptimal VD levels, and use of immunosup-
pressive agents. Of these, steroids are of particular importance as their cumulative 
and mean dose is associated with decreased bone formation and bone density. Some 
reports indicate that calcineurin inhibitors can rise PTH levels and increase the risk 
of osteoporosis, but the findings are not uniformly accepted [17, 79].
In KTRs, not only fracture prevalence is significantly increased compared to the 
general population, but also fracture-associated complications, including mortality, 
are more common in the post-transplant setting. Major fracture sites are the hip 
(usually osteoporosis-associated) and the ankle/foot (atypical for osteoporosis), 
which demonstrate that both ROD and osteoporosis play an important role in bone 
fragility [80].
The use of DXA–BMD measurement is getting more attention in native CKD, 
as a growing body of evidence demonstrates that it can predict fracture risk across 
CKD categories. To date, only one retrospective study, total hip DXA measurement 
after KT was associated with increased fracture risk. In addition, a recent prospec-
tive study had similar findings [81, 82]. Despite the insufficient evidence for KTRs, 
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KDIGO suggests the use of BMD testing in all stages of post-transplant CKD in 
KTRs with high risk for osteoporosis, if the measurement will have effect on treat-
ment. Bone biopsy can be considered to guide treatment [17].
5.1.3 PTMBD: vascular calcifications
VC is common after KT and is usually associated with pre-transplant uremia. 
In addition, most studies are semi-quantitative, thus making post-transplant VC 
progression assessment difficult. However, there are studies demonstrating a stop 
in progression or even improvement in VC in KTRs [83, 84]. Recognized risk factors 
for VC after KT are statin use, low 25VD levels, male sex, older age, and higher 
phosphate levels [85]. The data for the effect of immunosuppressive agents are 
conflicting. Mycophenolates proved to have protective effects against calcification, 
especially compared to steroids and calcineurin inhibitors; rapamycin suppressed 
smooth muscle cell proliferation, whereas everolimus impaired the vasoactive and 
antithrombotic function of the endothelium [86]. Therefore, more studies are 
needed in order to evaluate the effect of KT on VC.
5.2 VD pleiotropy after kidney transplantation
The graft survival at the tenth year after KT is significantly lower than the 
survival during the first 12 months. The explanation for these unsatisfactory results 
is poorer patient survival due to neoplasia, CVD, NODAT, calcineurin toxicity. It 
could be hypothesized that VD can improve graft and patient survival due to its 
pleiotropy. However, the trials in KTRs are small in number and in size, thus further 
research in this sphere is warranted.
5.2.1 VD pleiotropy after KT: proteinuria and renal protection
Observational studies linked poor VD status to poorer graft outcomes [86]. Our 
results also demonstrated that higher VD is associated with lower post-transplant 
proteinuria [87]. However, interventional studies did not fully support the VD–
graft function association. Cholecalciferol supplementation failed to demonstrate 
renoprotection in prospective study [88]. However, in a recent prospective placebo-
controlled study, paricalcitol ameliorated proteinuria in KTRs [89].
5.2.2 VD pleiotropy after KT: rejection
Observational studies demonstrated higher rates of acute rejection in VD defi-
cient KTRs [90]. Unfortunately, interventional studies did not find protective role 
of cholecalciferol supplementation on rejection prevalence [88]. Therefore, the role 
of VD in rejection prevention after KT is not fully understood and is under debate.
5.2.3 VD pleiotropy after KT: infection
Infection is a major cause for death after KT. Several recent reports established 
negative correlation between VD status and infection risk, especially for cytomega-
lovirus and BK virus infections in KTRs [91, 92]. However, our observational study 
showed no association between VD status and prevalence of urinary tract infections 
after KT [93]. Furthermore, the VITA-D study did not establish positive effect of 
cholecalciferol supplementation on infection risk [88]. A probable explanation for 
the discrepancies in the studies are the different types of infection evaluated (e.g. 
in the VITA-D study the total infection risk was assessed). Probably, a more specific 
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approach should be chosen and the infection risk for specific etiological agent and 
its association to VD should be analyzed.
5.2.4 VD pleiotropy after KT: malignancies
Despite the anti-neoplastic properties of VD in vitro and in animal models, the 
evidence for anti-malignancy effect of VD in CKD patients and KTRs is insufficient. 
Observational studies report conflicting results for the association between post-
transplant malignancies and VD status [86]. A recent study in our transplant center 
showed that VD-deficient KTRs had higher prevalence of non-cutaneous cancers [94]. 
A single center study established beneficial effect from active VD supplementation on 
post-transplant neoplasia rates [95]. The larger prospective, multicenter, double-blind, 
randomized, controlled study VITALE is currently being performed, which will evalu-
ate the effect of cholecalciferol supplementation on malignancy risk after KT [96].
5.2.5 VD pleiotropy after KT: NODAT
The major risk factors for NODAT are use of steroids and calcineurin inhibi-
tors. The data for VD-NODAT association are insufficient. The trial VITALE is to 
assess the effect of high and low doses cholecalciferol in VD–insufficient KTRs on 
NODAT prevalence [96].
5.2.6 VD pleiotropy after KT: cardiovascular disease
Marchal et al. established a significant association between lower 25VD and vascu-
lar calcification after KT [85]. However, a more recent study did not find a relationship 
between VD status and post-transplant hypertension and major CV events [97]. One 
of the aims of the already mentioned trial VITALE is to assess the effect of cholecalcif-
erol supplementation on blood pressure control and CVD rates in KTRs [96].
6. Treatment of vitamin D deficiency in renal disease
6.1 Treatment with cholecalciferol, ergocalciferol, calcitriol, VDA
Supplementation with cholecalciferol (vitamin D3), ergocalciferol (vitamin D2), 
or treatment with the active vitamin D calcitriol or VDA suppresses PTH in secondary 
hyperparathyroidism in CKD. As a first step, a correction of hypocalcemia, hyper-
phosphatemia, and suboptimal 25VD levels should be performed. In more advanced 
CKD-related secondary hyperparathyroidism calcitriol and VDA can be initiated. It 
should be noted that over-suppression of the parathyroid gland due to overdose of 
the VD treatment is a major cause for AD. Therefore PTH, as well as serum phosphate 
and calcium, should be regularly monitored. It should be noted that the optimal PTH 
values for dialysis patients are two times up to nine times the upper normal limit, 
whereas for patients not on dialysis the optimal range is not established. If trend for 
lowering/rising values is present, changes in treatment should be changed so that the 
negative trends be reverted [17]. Similarly, in KTRs cholecalciferol/calcitriol/VDA 
treatment should also take these trends into consideration.
6.1.1 Supplementation with cholecalciferol/ergocalciferol
In the general adult population, supplementation doses of VD at least 
600 IU daily; however, if improvement in VD status is needed, doses of at least 
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1500–2000 IU per day should be prescribed. The maximal dose VD without medical 
supervision should be 4000 IU daily. Cholecalciferol and ergocalciferol are equally 
effective [98]. The KDIGO guidelines recommend VD deficiency in CKD patients 
and in KTRs to be treated as in the general population. It is the initial therapeutic 
step, together with correction of hypocalcemia and hyperphosphatemia, as it effec-
tively suppresses PTH in CKD stages 3–5 not on dialysis. More aggressive approach 
is to be avoided as modest PTH elevation is regarded as adaptive mechanism in 
declining GFR [17].
6.1.2 Treatment with calcitriol and VDA
Calcitriol is naturally existing 1,25VD, whereas VDA are synthetic deriva-
tives of vitamin D2 (paricalcitol, doxercalciferol) and vitamin D3 (alfacalcidol, 
falecalcitriol, 22-oxacalcitriol). Despite the existing trials demonstrating positive 
effect of calcitriol/VDA on biochemical abnormalities, more recent studies do not 
demonstrate improvement in patient-centered end-points, such as left ventricular 
mass index and heart function; however, hypercalcemia was observed. Taking into 
account that modest PTH elevation is a possible adaptive response in CKD, the lack 
of significant clinical effects and higher risk for hypercalcemia, the use of calcitriol 
and VDA is not routinely recommended in CKD stages 3–5 not on dialysis. Their use 
is advocated in cases of severe and progressive secondary hyperparathyroidism and 
eGFR below 30 ml/min/1.73 m2 or dialysis patients [17].
The data for hypercalcemia rates in calcitriol and VDA are conflicting. Zand 
et al. demonstrated lower hypercalcemia prevalence in patients treated with parical-
citol; other reports established no difference in hypercalcemia between calcitriol 
and paricalcitol [29, 99].
6.1.3 Other therapeutic measures
Other measures, recommended by KDIGO that optimize VD treatment in CKD-
MBD are avoidance of hypercalcemia, reduction of phosphate serum levels, including 
phosphate dietary restriction, limitation of the use of calcium-based phosphate bind-
ers, calcium dialysate concentrations within the range of 1.25 and 1.50 mmol/l [17].
6.1.4 Novel agents
6.1.4.1 Calcifediol
Calcifediol is an oral 25-hydroxyvitamin D3. A study demonstrated reduction 
in PTH levels without changes in phosphate, calcium, and FGF-23 levels in CKD 
patients. In this chapter, patient-related outcomes were not assessed [100]. Further 
trials are needed to clarify the use of calcifediol in renal disease.
6.1.4.2 Vitamin K
Vitamin K plays a crucial role in vascular health. It serves as a cofactor for 
γ-glutamyl carboxylation, which converts glutamate into γ-carboxyglutamate (Gla). 
In vitamin K insufficiency, which is common in CKD, higher levels of desphosphor-
ylated-uncarboxylated matrix Gla-protein (MGP) are established, which are associ-
ated with VC, as MGP serves as calcification inhibitor. Vitamin K supplementation 
increases MGP carboxylation. What is more, VD supplementation upregulates MGP 
synthesis, whereas vitamin K suppressed 1,25VD-associated calcinosis [101, 102]. 
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Therefore, it can be hypothesized that vitamin K supplementation in CKD can be 
an adjuvant treatment to VD supplementation and will decrease its adverse effects. 
Further research of the efficacy and safety of vitamin K supplementation in CKD is 
needed.
7. Conclusion
VD deficiency in renal patients has been a burning issue in nephrology for many 
years. Yet, many questions remain unanswered. Of particular interest are the effect 
on VD treatment on clinical outcomes, especially death and cardiovascular events; 
VD-associated adverse events in CKD; VD pleiotropy in renal disease (random-
ized controlled prospective interventional studies are needed); the use of novel 
therapeutic agents should be further evaluated (vitamin K, new VDA, calcifediol). 
In addition, new biomarkers, evaluating bone health in CKD and new techniques, 
evaluating BMD and fracture risk may guide VD treatment more accurately. 
Therefore, new diagnostic and therapeutic strategies can be expected in the future.
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Therefore, it can be hypothesized that vitamin K supplementation in CKD can be 
an adjuvant treatment to VD supplementation and will decrease its adverse effects. 
Further research of the efficacy and safety of vitamin K supplementation in CKD is 
needed.
7. Conclusion
VD deficiency in renal patients has been a burning issue in nephrology for many 
years. Yet, many questions remain unanswered. Of particular interest are the effect 
on VD treatment on clinical outcomes, especially death and cardiovascular events; 
VD-associated adverse events in CKD; VD pleiotropy in renal disease (random-
ized controlled prospective interventional studies are needed); the use of novel 
therapeutic agents should be further evaluated (vitamin K, new VDA, calcifediol). 
In addition, new biomarkers, evaluating bone health in CKD and new techniques, 
evaluating BMD and fracture risk may guide VD treatment more accurately. 
Therefore, new diagnostic and therapeutic strategies can be expected in the future.
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